ANNUAL MEETING ABSTRACTS
Seattle: April 2 –7 Virtual Experience: April 24–26
What ’s
INSIDE Introduction This digital book lists 2022 Annual Meeting abstracts available in the following two formats in Seattle: Scientific Sessions: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes for question and answer with the author. Posters: A series of thematic abstract presentations in an electronic format. There will also be more than 470 abstracts exclusively presented as posters during the 2022 Annual Meeting Virtual Experience April 24-26. This digital book also lists these abstracts. To search a complete library of abstracts online, visit AAN.com/22Abstracts. To register for the meeting or to learn about all of the science, education, and networking opportunities at the 2022 Annual Meeting in Seattle or the distinct virtual experience, visit AAN.com/AM.
Annual Meeting Abstracts Seattle Scientific Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Sunday, April 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Monday, April 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Tuesday, April 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Wednesday, April 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Thursday, April 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Seattle Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Saturday, April 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Sunday, April 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Monday, April 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 Tuesday, April 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Wednesday, April 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Thursday, April 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 Virtual Experience Posters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
SCIENTIFIC SESSIONS Date Goes Here
Scientific Sessions are a group of abstracts covering a similar topic presented in an oral format. Presentations are 12 minutes in length with eight minutes for presentation and four minutes for questions and answers with the author.
Sunday, April 3 1:00 p.m.–3:00 p.m. PT
S1
Sleep: Want To Hear The Latest?
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. 2022 Sleep Science Award: This award recognizes distinguished academic contributions by neurologists to the field of sleep medicine or the contributions of non-neurologists to the interface area of sleep neurology. Recipient: Louis J. Ptacek, MD, San Francisco, CA 1:24 p.m. 2022 Wayne A. Hening Sleep Medicine Investigator Award: This award recognizes scientific contributions in sleep from promising young investigators. Recipient: John Kent Werner, Jr., MD, Bethesda, MD 1:36 p.m. S1.004 Longitudinal 123I-FP-CIT SPECT Imaging in Isolated REM Sleep Behavior Disorder–Toji Miyagawa, Scott Przybelski, Daniela Maltais, Hoon-Ki Min, Lennon Jordan, Timothy Lesnick, Michael H. Silber, Stuart McCarter, Erik Kent St. Louis, Jonathan Graff-Radford, David T. Jones, Rodolfo Savica, David S. Knopman, Ronald C. Petersen, Walter Kremers, Leah Kathleen Forsberg, Julie A. Fields, Tanis J. Ferman, Hugo Botha, Vijay K. Ramanan, Laura Andelman Allen, Kejal Kantarci, Val John Lowe, Bradley F. Boeve 1:48 p.m. S1.005 Acute blood biomarkers predict chronic insomnia trajectories following traumatic brain injury: A TRACK-TBI study–Jackie Gottshall, Bryson Hewins, Andrew Krystal, Jennifer Albrecht, Vincent F. Capaldi, Sonia Jain, Pratik Mukherjee, Ashlee McKeon, Michael Timothy Smith, Joseph T. Giacino, Raquel Gardner, Lindsay Nelson, Scott Graeme Williams, Jacob Collen, Shelly Sun, David Schnyer, Amy Markowitz, Ramon R. Diaz-Arrastia, Geoffrey Manley, Emerson Wickwire, John Kent Werner 2:00 p.m. S1.006 Poor sleep quality is associated with elevated exosomal inflammatory cytokines in warfighters with chronic mild TBI–Jackie Gottshall, Phorum Sheth, Josephine Pucci, Daniel Ian Brooks, Nora L. Watson, Ainslee Gabriel, Sara Mithani, Jacqueline J. Leete, Chen Lai, Bao-Xi Qu, Christina Devoto, Jessica Gill, Kimbra L. Kenney, John Kent Werner 2:12 p.m. S1.007 Impairment in Functioning and Quality of Life in Patients With Idiopathic Hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE)–Logan D. Schneider, Joanne Stevens, Aatif M. Husain, Diane Ito, Wayne Macfadden, Douglas S. Fuller, Phyllis C. Zee 2:24 p.m. S1.008 Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a Real-World Evidence Study–Rami Ben-Joseph, Ragy Saad, Jed Black, Elizabeth C. Dabrowski, Benjamin Taylor, Sophia Gallucci, Virend Somers 2:36 p.m. S1.009 Safety and pharmacodynamics of a single infusion of TAK-925 in adults with idiopathic hypersomnia–Emmanuel Mignot, Richard K. Bogan, Helene A. Emsellem, Nancy R. Foldvary-Schaefer, Melissa Naylor, Rachel Neuwirth, Todd J. Swick, Tina Olsson 2:48 p.m. S1.010 Good Night, Sleep Tight, Don’t Let the Sleep Disturbances Bite–Alexander Poulakis, Michael Ibarra, Jennifer Lin, Sullafa Kadura
S2
Behavioral Neurology
CME
2
1:00 p.m. 2022 Norman Geschwind Prize in Behavioral Neurology: This prize is awarded to an individual for outstanding research in the field of behavioral neurology. Recipient: Julio C. Rojas -Martinez, MD, PhD, San Francisco, CA 1:12 p.m. S2.002 Neuropsychological and neuropsychiatric traits among asymptomatic relatives from C9orf72 repeat expansion kindreds–Marie Ryan, Emmet Costello, Mark Heverin, Russell L. McLaughlin, Niall Pender, Orla Hardiman 1:24 p.m. S2.003 Economic Outcomes Associated with Behavioral Symptoms among Commercially Insured Patients with Dementia in the US–Rezaul Khandker, Farid Chekani, Kirti Mirchandani, Sreya Chakladar, Niranjan Kathe 1:36 p.m. S2.004 Tractography Examination of Dentato-rubro-thalamic Tract in Autopsyconfirmed Variants of Progressive Supranuclear Palsy.–Rodolfo Gabriel Gatto, Peter Martin, Farwa Ali, Heather Clark, Joseph Duffy, Rene Utianski, Hugo Botha, Mary M. Machulda, J. Eric Ahlskog, Dennis W. Dickson, Keith A. Josephs, Jennifer Louise Whitwell 1:48 p.m. S2.005 Patterns of CSF Biomarkers of Alzheimer’s Disease in Specialty Behavioral Neurology Practices–Wentao Li, Ronald C. Petersen, Alicia Algeciras-Schimnich, Joshua Bornhorst, Bradley F. Boeve, David T. Jones, Hugo Botha, Vijay K. Ramanan, David S. Knopman, Rodolfo Savica, Keith A. Josephs, Christine Cliatt Brown, Gregory S. Day, Neill R. Graff-Radford, Nilufer Taner, Bryan Keith Woodruff, Richard J. Caselli, Jonathan Graff-Radford 2:00 p.m. S2.006 Brain Metabolic Changes in the Presymptomatic Stage of Frontotemporal Dementia Associated with GRN Mutations–Dario Saracino, Leila Sellami, Hugo Boniface, Maxime Locatelli, Melanie Pelegrini-Issac, Aurélie Funkiewiez, Marion Houot, Daisy Rinaldi, Karim Dorgham, Florence Pasquier, Mathieu Chastan, Anne Hitzel, Jeremie Pariente, Amandine Pallardy, Eric Guedj, Mira Didic, Aurelie Kas, Marie-Odile Habert, Isabelle Le Ber 2:12 p.m. S2.007 Area Deprivation Index and Progression to Dementia–Maria Vassilaki, Jeremiah Aakre, Anna Castillo, Alanna Chamberlain, Patrick Wilson, Walter Kremers, Michelle M. Mielke, Yonas E. Geda, Mary M. Machulda, Rabe’ Alhurani, Jonathan Graff-Radford, Prashanthi Vemuri, Val John Lowe, Clifford R. Jack, David S. Knopman, Ronald C. Petersen 2:24 p.m. S2.008 Sex Differences in Cerebral Amyloid Angiopathy: The Role of Monocytes/ Macrophages–Carson Finger, Juneyoung Lee, Bharti Manwani 2:36 p.m. S2.009 PTSD, Depression, and Cognitive Performance in Military Service Members With and Without History of mTBI–Carolyn Parsey, Hyun Jin Kang, Jason Barber, Nancy Temkin, Christine MacDonald 2:48 p.m. S2.010 Towards Machine Learning-Based Cognitive Examination–Calvin William Howard
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
1
SCIENTIFIC SESSIONS Sunday, April 3 1:00 p.m.–3:00 p.m. PT
S3
Autoimmune Neurology 1: Mechanisms of Disease, Clinical Practice
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. S3.001 Coronavirus 2019: clinical and neuropathological aspects–David S. Younger 1:12 p.m. S3.002 Acute Neurological Inflammatory Diseases in Colombia: A Multi-center Observational Study from Zika outbreak to SARS-CoV-2 pandemic–Susana Carolina Dominguez Penuela, Martha Moyano, Jose Enrique Vargas Manotas, Jorge Andres Jimenez-Arango, Guillermo Gonzalez-Manrique, Jairo Francisco Lizarazo Nino, Jorge Angarita, Andres Felipe Zea-Vera, Reydmar Lopez, Daniela Zuluaga Lotero, David Orlando Acero-Garces, Maria Alejandra Garcia-Dominguez, Jose Miguel Enciso, Maria Fernanda Ramos Sanchez, Julie Benavides, Katherine V Claros, Jaime Quintero, Jonathan Urrego, Christian Rojas, Juan Pablo Rojas, Fernando Rosso, Gustavo Eduardo Ramos, Luis Carlos Quintero, Mario Llanos, Angela Catalina Vallejo Cajigas, Viviana Martinez, Beatriz Parra, Lyda Osorio, Carlos A. Pardo-Villamizar 1:24 p.m. S3.003 Reporting Rates of Encephalopathy Post-COVID-19 Vaccination: A Vaccine Adverse Event Reporting System (VAERS)–Kazim Jaffry, Kranthi Kiran Mandava, Mustafa Jaffry, Sanjana Rosario, Kamel Jedidi, Nizar Souayah 1:36 p.m. S3.004 Development of new or enlarging MRI lesions outside of attacks is rare in myelin oligodendrocyte glycoprotein antibody-associated disease–Stephanie Bridget Syc-Mazurek, Elia Sechi, John Chen, Padraig Morris, Karl Krecke, Steven Anthony Messina, Jan-Mendelt Tillema, Alfonso Sebastian Lopez, Claudia F. Lucchinetti, Nicholas L. Zalewski, Marina Buciuc, M. Tariq Bhatti, Sean J. Pittock, Eoin P. Flanagan 1:48 p.m. S3.005 Acute Symptomatic Seizures Secondary to Myelin Oligodendrocyte Glycoprotein Antibody-associated Disorder–Mayra Montalvo Perero, Jamal F. Khattak, Vyanka Redenbaugh, Yong Guo, Cristina Valencia Sanchez, Jan-Mendelt Tillema, Claudia F. Lucchinetti, John Chen, Andrew McKeon, Sean J. Pittock, Jeffrey W. Britton, Eoin P. Flanagan, Divyanshu Dubey 2:00 p.m. S3.006 Surveying the Clinical and Radiographic Heterogeneity of Pediatric Anti-MOGAssociated Disease–Jeffrey Russ, Elizabeth George, Alexandria Valdrighi, Camilla Lindan, Heather Early, Mark Mamlouk, Emmanuelle Waubant, Carla Marina Francisco, Yi Li 2:12 p.m. S3.007 Neuromyelitis Optica as an In-Vivo Model of Glymphatic System Alterations: An MRI Study–Laura Cacciaguerra, Antonio Carotenuto, Elisabetta Pagani, Marta Radaelli, Vittorio Martinelli, Massimo Filippi, Maria Assunta Rocca 2:24 p.m. S3.008 Evaluation of a Point-of-Care Diagnostic Test for Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder–Dylan R. Rice, Shuhei Nishiyama, Santiago Pardo, Ana Maria Maria Cabal Herrera, Michael Levy, Farrah J. Mateen 2:36 p.m. S3.009 Matched or Unique Cerebrospinal Fluid Oligoclonal Bands: Clinical Characteristics and Diagnostic Utility–Stefanie Jordan Rodenbeck, Justin Abbatemarco, Jason Tsun-Yin Poon, Suzanne Liu, M. Mateo Paz Soldan, John E. Greenlee, John W. Rose, Lisa Kay Peterson, Lisa Johnson, Stacey Clardy 2:48 p.m. S3.010 Potential Role of Variants of UNC13D in Pediatric Autoimmune CNS Disorders– Saba Jafarpour, Nusrat Ahsan, Jonathan Santoro
2
2022 AAN Annual Meeting
S4
Hot Topics in Headache Medicine
CME
2
1:00 p.m. S4.001 Identifying Factors Pertaining to Migraine-Related Internalized Stigma from a Novel Question Set: Results of the OVERCOME (US) study–Robert E. Shapiro, Robert A. Nicholson, Anthony J Zagar, Yongin Kim, Michael L. Reed, Dawn C. Buse, Eva Jolanda Muenzel, Sait Ashina, Eric M. Pearlman, Richard B. Lipton 1:12 p.m. S4.002 Impact of Monthly Headache Days on Migraine-Related Quality of Life: Results From the CaMEO Study–Richard B. Lipton, Patricia Pozo-Rosich, Serena Orr, Michael L. Reed, Kristina Fanning, Brett Dabruzzo, Dawn C. Buse 1:24 p.m. S4.003 Pre-pregnancy migraine and risk of adverse pregnancy outcomes–Alexandra Purdue-Smithe, Jennifer J. Stuart, Leslie V. Farland, Jae Hee Kang, Rebecca C. Burch, Janet Rich-Edwards, Kathryn Rexrode 1:36 p.m. S4.004 Characterizing Pre-headache (Prodrome) Features of Migraine Attacks: Results From the CaMEO Study–Todd J. Schwedt, Stephanie J. Nahas, Kristina Fanning, Janette Contreras-De Lama, Brittany L. Jordan, Michael L. Reed, Dawn C. Buse, Richard B. Lipton 1:48 p.m. S4.005 Assessing Sleep Quality in Children with Migraines: Implementation of Electronic Health Record Cue–Ezgi Saylam, Praveen Ramani, Brett James, Matthew Robert Savage, Supriya Jambhekar, Aravindhan Veerapandiyan 2:00 p.m. S4.006 Investigating the Roles of the Enzymes MAGL and ABHD6 in Headache Physiology via the KCl Model of Migraine–Aidan Levine, Erika Liktor-Busa, Seph Palomino, Raveena Parmar, Tally Largent-Milnes 2:12 p.m. S4.007 An Altered Pontine-Hypothalamic Functional Interplay Could Predict Migraine Disease Progression Over the Years–Roberta Messina, Paola Valsasina, Maria Assunta Rocca, Massimo Filippi 2:24 p.m. S4.008 Headache as an Early Symptom and Post-Acute Sequela of COVID-19 in Hospitalized COVID-19 Survivors–Teshamae Monteith, Alexandra Nicole Cocores, Mejgan Mukhtarzada, Natalia Rincon, Yensea Mayra Costas Encarnacion, Christina Kursewicz, Evie Sobczak, Emily Swafford, Daniel Samano, Tatjana Rundek, Ayham Alkachroum 2:36 p.m. S4.009 Relative Frequency, Healthcare Resource Utilization, and Costs of Diagnosed Drug-Induced Headache and Potential Acute Medication Overuse in Patients With Migraine–Anand R. Shewale, Jennifer Brandenburg, Kate Burslem, Richard B. Lipton, Jalpa Doshi 2:48 p.m. S4.010 Patient Experience of Telemedicine for Headache Care During the COVID-19 Pandemic: An American Migraine Foundation Survey Study–Chia-Chun Chiang, Rashmi B. Halker Singh, Nim Lalvani, Kenneth Shubin Stein, Deborah Henscheid Lorenz, Christine L. Lay, David W. Dodick, Lawrence C. Newman
SCIENTIFIC SESSIONS Sunday, April 3 3:30 p.m.–5:30 p.m. PT
S5
COVID and MS Basic Science
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. 2022 John Dystel Prize for Multiple Sclerosis Research: This award recognizes outstanding contributions to research that have led to breakthroughs in the understanding, prevention, treatment, or cure of MS. Recipient: Xavier Montalban, MD, PhD, FAAN, Barcelona, Spain 3:54 p.m. S5.003 An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders treated with Anti-CD20 Therapies–Tyler Lee Borko, Sean Selva, Ryan Baxter, Berenice Cabrera-Martinez, Cody Rester, Stefan Sillau, Daniel Pastula, Maite Sabalza, Iswariya Venkat, Jeffrey L. Bennett, Enrique Alvarez, Robert H. Gross, Anna Shah, Ryan Kammeyer, Timothy L. Vollmer, Ross Kedl, John Corboy, Elena Wen-Yuan Hsieh, Amanda Lee Piquet 4:06 p.m. S5.004 Bile Acids Metabolites as Predictors of long-term Multiple Sclerosis Progression–Marianna Cortese, Kjetil Bjornevik, Clary B. Clish, Gilles Edan, Mark S. Freedman, Hans-Peter Hartung, Xavier Montalban, Rupert Sandbrink, ErnstWilhelm Radue, Frederik Barkhof, Eva-Maria Wicklein, Ludwig Kappos, Kassandra L. Munger, Alberto Ascherio 4:18 p.m. S5.005 The Genetic Basis of Multiple Sclerosis Severity Suggests Central Nervous System Involvement–Adil Harroud 4:30 p.m. S5.006 Adaptive B-cell and T-cell responses to SARS-CoV-2 vaccination in patients with Multiple Sclerosis on disease modifying immunotherapy–Anna Tomczak, Julia Sumera, Yamuna Joseph, Danwei Wu, Jamie C. McDonald, Neda Sattarnezhad, Lucas Kipp, Christopher Lock, May Han, Jeffrey E. Dunn 4:42 p.m. S5.007 Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review and meta-analysis–Grace Gombolay, Monideep Dutt, William R. Tyor 4:54 p.m. S5.008 Impact of Multiple Sclerosis Disease-Modifying Therapies on Effectiveness of SARS-Cov-2 Vaccines: A Longitudinal Total Population Study of National Health Service (NHS) England–Afagh Garjani, Sameer Patel, Graham Law, Dhiren Bharkhada, Waqar Rashid, Alasdair Coles, Nikolaos Evangelou 5:06 p.m. S5.009 WITHDRAWN 5:18 p.m. S5.010 Glymphatic Impairment in Multiple Sclerosis: A New Pathological Mechanism Associated with Disease Burden–Antonio Carotenuto, Laura Cacciaguerra, Elisabetta Pagani, Paolo Preziosa, Maria Assunta Rocca, Massimo Filippi
S6
Cerebrovascular Disease: Diagnosis, Prediction and Population Health
CME
2
3:30 p.m. 2022 Alliance Award Founders: This award is designed to encourage clinical and translational research in neuroscience by physicians in clinical neurology training programs. Recipient: Ronda Lun, MD, Ottawa, ON, Canada 3:42 p.m. S6.002 Temporal Trends & Outcomes Of Hospitalizations For Epilepsy With Aneurysmal Subarachnoid hemorrhage–Parisha Bhatia, Varun Singh, Neena Viswanathan, Tejinder Singh, Tanushri Bhushan 3:54 p.m. S6.003 Sex Differences in the Delivery of Stroke Care via Telemedicine in a Large National Telestroke Practice–Johanna L. Morton, Kristina L. Boyd, Eric Anderson, Robert Jason Hallock 4:06 p.m. S6.004 Risk of Seizures after Posterior Reversible Encephalopathy Syndrome–Sarah Christine Parauda, Cenai Zhang, Setareh Salehi Omran, Andrew D. Schweitzer, Santosh Bhaskar Murthy, Alexander Merkler, Babak Navi, Hooman Kamel, Neal S. Parikh 4:18 p.m. S6.005 Adherence to Blood Pressure Guidelines Predicts Hospital Readmission After Acute Stroke: The Florida Stroke Registry–Oriana Tascione, Hannah Gardener, Carolina Gutierrez, David Z. Rose, Tatjana Rundek, Angus Jameson, Jose Gabriel Romano, Ralph L. Sacco, Sebastian Koch, Negar Asdaghi, Gillian L. Gordon-Perue 4:30 p.m. S6.006 Access to Mechanical Thrombectomy for Large Vessel Occlusion Stroke: An MT2020+ Report on Global Disparities–Kaiz Shabbar Asif, Nabeel Herial, Fadar Oliver Otite, Shashvat Desai, Santiago Ortega Gutierrez, Adam A. Dmytriw, Fawaz Al-Mufti, Priyank Khandelwal, Violiza A. Inoa, Siddharth Galav, Viktor Szeder, Tanzila Kulman, Gabor Toth, Alicia Clara Castonguay, Jennifer Potter-Vig, Victor C. Urrutia, Kaustubh S. Limaye, Hesham Masoud, Syed F. Zaidi, Dileep R. Yavagal 4:42 p.m. S6.007 Identification of early ischemia on non-contrast CT head using artificial intelligence–James Michael Hillis, Bernardo Canedo Bizzo, Romane Gauriau, Christopher Philip Bridge, John Kent Chin, Stuart Robert Pomerantz, Keith Dreyer, Katherine Patricia Andriole, Michael H. Lev, Ramon Gilberto Gonzalez 4:54 p.m. S6.008 Determinants and Outcomes of Cerebrovascular Disease in Patients with COVID-19 in the Philippines: An Analysis of 10881 Cases–Mario Bugay Prado, Roland Dominic Jamora, Marie Charmaine Cootauco Sy, Michelle Anlacan, Adrian Isidoro Espiritu 5:06 p.m. S6.009 The SPA prediction score for presence of intracranial aneurysms during follow-up screening in persons with a positive family history of subarachnoid hemorrhage–Charlotte Zuurbier, Romain Bourcier, Pacome Constant Dit Beaufils, Richard Redon, Hubert Desal, Stijntje Bor, Antti Lindgren, Gabriel Rinkel, Jacoba P. Greving, Ynte Ruigrok 5:18 p.m. S6.010 Novel Ischemic Stroke Treatment Protocol for Salvageable Penumbra in Acute Small Vessel Disease–Farah Yolanda Fourcand, Hemal Patel, Sean W. Scarpiello, Muhammad Nagy, Siddhart Kumar Mehta, Haralabos Zacharatos, Jawad F. Kirmani
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
3
SCIENTIFIC SESSIONS Sunday, April 3 3:30 p.m.–5:30 p.m. PT
S7
Epilepsy and Clinical Neurophysiology (EEG) 1
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. 2022 Dreifuss-Penry Epilepsy Award: This award recognizes physicians in the early stages of their careers who have made an independent contribution to epilepsy research. Recipient: Piero Perucca, MD, Heidelberg, Australia 3:42 p.m. S7.002 Combining Machine-detected EEG Epileptiform Abnormalities and Quantitative EEG Spectral Features Predicts Post Traumatic Epilepsy–Yilun Chen, Songlu Li, Hsin Yi Chen, Daniel Doherty, Alison Herman, Safa Kaleem, Kan Ding, Gamaleldin M. Osman, Christa Brittany Swisher, Christine Smith, Carolina B. Maciel, Ayham M. Alkhachroum, Jong Woo Lee, Monica B. Dhakar, Emily Jean Gilmore, Sacit Bulent Omay, Brian Edlow, M. Brandon Westover, Jennifer A. Kim 3:54 p.m. S7.003 Use of an Electronic Medical Record Alarm to Prevent Iatrogenic Interventions in Patients with Psychogenic Non-Epileptic Seizures–Serena Yin, Lydia Wolkiewicz, Bichum Ouyang, Elana Wagner, Sarah Abdel-Hadi, Adriana C. Bermeo Ovalle 4:06 p.m. S7.004 Real-Time & Passive Localization of the Epileptic Network based on SinglePulse Electrical Stimulation: Correlation with the standard of care and surgical outcomes UPMC HBM Lab–Tritan Joseph Plute, Rafeed Alkawadri 4:18 p.m. S7.005 Neurology resident epileptiform discharge identification training– a randomized controlled educational trial.–Fabio Augusto Nascimento E Silva, Jin Jing, Christopher Bentley Traner, Erik P. Duhaime, Jeremy Moeller, Michael Brandon Westover 4:30 p.m. S7.006 A Machine Learning Approach for Identifying Factors that Contribute to Seizure Freedom Following Temporal Lobectomy for Mesial Temporal Lobe Epilepsy– Sara Elizabeth Ratican, Seo Ho Song, George Zanazzi, Jennifer Hong 4:42 p.m. S7.007 Validation of a semi-automated method for tracking quality metrics in benzodiazepine-resistant status epilepticus–Benjamin Siegel, Mohammed Shahnawaz, Kathryn Coreil Elkins, Ammar Kheder, Evan Orenstein 4:54 p.m. S7.008 Seizure Detection Enabled by Information Theory on Human Intracortical Electroencephalography–Lisa Yamada, Tomiko Oskotsky, Paul Nuyujukian 5:06 p.m. S7.009 Network Analysis of Focal Seizure Dynamics Suggests a Possible Mechanism of Seizure Termination–Stefan Louis Sumsky, L John Greenfield 5:18 p.m. S7.010 Bilateral temporal lobe epilepsy: How many seizures are required in chronic ambulatory electrocorticography to estimate the laterality ratio?–Sharon Chiang, Joline M. Fan, Vikram Rao
4
2022 AAN Annual Meeting
S8
General Neurology: Clinical Treatment and Practice
CME
2
3:30 p.m. S8.001 Clinical Diversity of Patients with Neuronal Intranuclear Inclusion Disease– Tomoko Okamoto, Tasuku Ishihara, Masayuki Miyazaki, Ken Saida, Yuji Saitoh, Toshiyuki Yamamoto, Tadashi Tsukamoto, Yuko Saito, Noriko Sato, Naomichi Matsumoto, Yuji Takahashi 3:42 p.m. S8.002 Cipaglucosidase alfa/miglustat Versus alglucosidase alfa/placebo in Late-onset Pompe Disease (LOPD): PROPEL Study Subgroup Analyses–Tahseen Mozaffar, Drago Bratkovic, Barry Byrne, Jordi Diaz Manera, Pascal Lafort, Ans Van Der Ploeg, Mark Roberts, Benedikt Schoser, Antonio Toscano, Hai Jiang, Sheela Sitaraman, Mitchell Goldman, Jeff Castelli, Priya Kishnani 3:54 p.m. S8.003 HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy–David D. Adams, Ivajlo Tournev, Mark Taylor, Teresa Coelho, Violaine Plante-Bordeneuve, John L. Berk, Maria Alejandra Gonzalez Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Piera Obici, Chongshu Chen, Prajakta Badri, Seth Arum, John Vest, Michael J. Polydefkis 4:06 p.m. S8.004 Virtual vs In-person Neurological Exam Study (VINES) in Response to the COVID-19 Crisis and Beyond–Lauren Hophing, Tiffany Tse, Nicole Julia Naimer, Houman Khosravani, Charles Kassardjian, Sara Mitchell 4:18 p.m. S8.005 VA National TeleNeurology Program: Patient Characteristics and Access to Care–Steven S. Schreiber, Aditi Narechania, Heidi Watson, Brandon Edwards, Holly Martin, Linda S. Williams, Jayne R. Wilkinson 4:30 p.m. S8.006 Differential Associations of Kidney Function with Cerebral Gray and White Matter Tissue Health in Middle-Aged and Older Adults–Mei-jun Shu, Ding-Ding Zhang, Fei Han, Li-Xin Zhou, Jun Ni, Ming Yao, Shu-Yang Zhang, Li-Ying Cui, ZhengYu Jin, Yi-Cheng Zhu 4:42 p.m. S8.007 Longitudinal Evaluation of Neuro-PASC Symptoms–Jacqueline Shanley, Andrew Valenciano, Garrett Malloy Timmons, Visesha Kakarla, Annalise E. Miner, Torge Rempe, Jennifer Graves 4:54 p.m. S8.008 High Patient Satisfaction and Acceptability of Tele-Neurology Consultations at a Regional Tertiary Referral Hospital in Kenya During the COVID-19 Pandemic– Fazal Yakub, Jasmit Shah, Dilraj Singh Sokhi 5:06 p.m. S8.009 A Placebo-Controlled Phase I Study of NVG-291 in Healthy Subjects, Targeting CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPs)–Daniel D. Mikol, Betty Lawrence, Nana Collett, Judy Toews, Matvey Lukashev, Marc DePaul 5:18 p.m. S8.010 Neutralizing Antibody Conversion With Onabotulinumtoxina From Global Studies Across Multiple Indications In Nearly 30,000 Patient Records: A MetaAnalysis–Joseph Jankovic, Jean Carruthers, Markus Naumann, Terry Boodhoo, Swati Gupta, Mayssa Attar, Rita Singh, Irina Yushmanova, John Soliman, Mitchell F. Brin, Jie Shen
SCIENTIFIC SESSIONS Monday, April 4 1:00 p.m.–1:50 p.m. PT
S9
Neuromodulation and Alternatives to Reduce Opioid Use in Pain Management
1:00 p.m.–1:50 p.m. PT CME
0.75
1:00 p.m. 2022 Mitchell B. Max Award for Neuropathic Pain: This award recognizes an individual for outstanding work in the field of neuropathic pain for either a single contribution or for lifetime achievement. Recipient: John Markman, MD, FAAN, Rochester, NY 1:12 p.m. S9.002 Pramipexole Improves the Analgesic Properties of Low-dose Morphine in the Treatment of Acute Pain–Ryan Patton, Allison Mainhart, Stefan Clemens, Kori Brewer 1:24 p.m. S9.003 Repetitive Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial–Nilson Nogueira Mendes Neto, Poty Jales, Jessika Thais da Silva Maia 1:36 p.m. S9.004 Non-Invasive Brain Stimulation For Diabetic Neuropathic Pain–Persen Sukpornchairak, Krishnakant Shah Aka Khandelwal, Salim Hayek, Christopher Connor, Paola Gonzalez Mego, Gautham Chitturu, Ryan Tatton, Anisha Yarlagadda, Felipe Fregni, Uri Eden, Tim Wagner, Laura Dipietro, Ciro Ramos Estebanez
S10 Neuro-rehabilitation: Neuromodulation
CME
0.75
1:00 p.m. S10.001 At-Home Transcranial Direct Current Stimulation (tDCS) for Teleinterventions: Safety and Tolerability with Remote Supervision–Giuseppina Pilloni, Pamela Best, Allan George, Matthew Lustberg, Ibraheem Mirza, Lana Zhovtis Ryerson, Lauren B. Krupp, Leigh Elkins Charvet 1:12 p.m. S10.002 Evaluation of repetitive Transcranial Magnetic Stimulation as an adjunct to modified Constraint Induced Movement Therapy in improving Upper Limb Function in Children with Unilateral Cerebral Palsy aged 5 – 18 years - A Randomized Controlled Trial–Juhi Gupta, Sheffali Gulati, Upinderpal Singh, Atin Kumar, Prashant Jauhari, Biswaroop Chakrabarty, R M Pandey, Renu Bhatia, Suman Jain, Achal K. Srivastava 1:24 p.m. S10.003 Baseline presentation and goal setting for patients undergoing treatment for lower limb spasticity with abobotulinumtoxinA in routine practice. Data from the AboLiSh study–Alberto Esquenazi, Richard Zorowitz, Stephen Ashford, Francoise Calvi-Gries, Pascal Maisonobe, Simon Page, Jorge Jacinto 1:36 p.m. S10.004 Transcranial Direct Current Stimulation (tDCS) Enhanced Stroke Recovery and Cortical Reorganization–Timea M. Hodics, Alexander W. Dromerick, John Pezzullo, Karen Kowalske, Leonardo G. Cohen
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
5
SCIENTIFIC SESSIONS Monday, April 4 1:00 p.m.–3:00 p.m. PT
S11 ALS and Motor Neuron Disorders
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. 2022 Sheila Essey Award: An Award for ALS Research: This award recognizes an individual who has made significant research contributions in the search for the cause, prevention of, and cure for amyotrophic lateral sclerosis (ALS). Recipient: Matthew Colm Kiernan, PhD, FRACP, MBBS, Sydney, Australia 1:24 p.m. S11.003 Deciphering the Phenotype of ALS Patients with Intermediate ATXN2 PolyQ Expansion–Adriano Chio, Cristina Moglia, Antonio Canosa, Umberto Manera, Maura Brunetti, Salvatore Gallone, Ruth Chia, Jinhui Ding, J. Raphael Gibbs, Clifton Dalgard, Sandra D’Alfonso, Lucia Corrado, Fabiola De Marchi, Letizia Mazzini, Bryan Traynor, Andrea Calvo 1:36 p.m. S11.004 GBA Variants Influence Cognitive Status of ALS Patients–Adriano Chio, Maurizio Grassano, Cristina Moglia, Barbara Iazzolino, Laura Peotta, Salvatore Gallone, Maura Brunetti, Francesca Palumbo, Sara Cabras, Umberto Manera, Rosario Vasta, Bryan Traynor, Lucia Corrado, Sandra D’Alfonso, Letizia Mazzini, Andrea Calvo, Antonio Canosa 1:48 p.m. S11.005 Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer’s Disease: Integrated Clinical Trials Experience–Steven E. Arnold, Sabrina Paganoni, Suzanne Hendrix, Jessie Johnson, Samuel Dickson, Newman Knowlton, Jay W. Mason, Jamie Timmons, Machelle Manuel, Shide Badri, Patrick Yeramian, Merit E. Cudkowicz 2:00 p.m. S11.006 Unraveling the clinical and genetic spectrum of FUS-ALS–Maurizio Grassano, Andrea Calvo, Cristina Moglia, Antonio Canosa, Umberto Manera, Alessandro Bombaci, Giorgia Brodini, Giovanni De Marco, Bryan Traynor, Adriano Chio 2:12 p.m. S11.007 A Clinical Bulbar Assessment Scale for ALS/MND: Preliminary Validation–Gary L. Pattee, Jenenne Geske, Elizabeth Burton, Laura Ball 2:24 p.m. S11.008 Using mfn2 Knockout Zebrafish as a Novel Model of ALS–Kristi Russell, Jon Downie, Summer Gibson, Karla Patricia Figueroa, Mark B. Bromberg, Joshua Bonkowsky, Lynn Jorde, Stefan M. Pulst 2:36 p.m. S11.009 Clinical Outcomes in Primary Lateral Sclerosis: A Prospective Natural History Study–Eoin Finegan, Rangariroyashe Chipika, Stacey Li Hi Shing, Orla Hardiman, Peter Bede 2:48 p.m. S11.010 Accurate Test of Limb Isometric Strength (ATLIS) as an Outcome Measure in ALS and as a Marker of Upper Motor Neuron Involvement in Primary Lateral Sclerosis–Samuel Frank, Peggy Allred, Youstina Haidy Makary, Sophia Katherine Mostowy, Richard A. Lewis, Robert H. Baloh, Matthew Burford, Frank Diaz
6
2022 AAN Annual Meeting
S12 Neuroepidemiology
CME
2
1:00 p.m. 2022 Bruce S. Schoenberg International Award in Neuroepidemiology: This award salutes a promising young investigator from a developing country or Eastern Europe. Recipient: Adrian Isidoro Espiritu, MD, Manila, Philippines 1:24 p.m. S12.003 Incidence Trends of Early-Onset Parkinson’s Disease in Olmsted County, MN: 1976-2013.–Emanuele Camerucci, Aidan Mullan, Pierpaolo Turcano, Cole Daniel Stang, Delana Weis, Bradley F. Boeve, James H. Bower, J. Ahlskog, Rodolfo Savica 1:36 p.m. S12.004 Functional Status at 30 and 90 Days After Mild Ischemic Stroke–Hannah Gardener, Leo Armando Romano, Eric E. Smith, Iszet Campo-Bustillo, Yosef Khan, Sofie Tai, Ralph L. Sacco, Pooja Khatri, Heather Alger, Brian Mac Grory, Deepak Gulati, Navdeep Sangha, Karin E. Olds, Curtis G. Benesch, Adam Kelly, Scott Brehaut, Amit Kansara, Lee H. Schwamm, Jose Gabriel Romano 1:48 p.m. S12.005 Cost utility analysis of dabigatran and warfarin for stroke prevention among patients with Non-Valvular Atrial Fibrillation in India–Rajeswari Aghoram, Mathan Kumar S, Rajasulochana Subramania Raju, Sitanshu Sekhar Kar, Rakesh Aggarwal 2:00 p.m. S12.006 Characterization and Analysis of Neurologic Adverse Events Associated with COVID-19 Vaccination–Abhilasha Pankaj Boruah, Erica Westenberg, Abdul Hanif Khan Yusof Khan, Fan Kee Hoo, Alla Borisovna Guekht, Marianna Spatola, Ismael Calandri, Sunderraj Netravathi, Tissa Wijeratne, Elyce Warburton, Mohamed Fahmy Doheim, Carolin Pulickal, Jakin David Chen, Kiran Thakur, Nicholas Ravindra Mulchan, Vivian Ssonko, Lindsay Tetreault, James J. Sejvar, Simon Faissner, Jeyanthan Charles James, Jessica Hunter, David García-Azorín, Arina Tamborska, Maja Bresjanac, Guillermo Ruben Delgado-Garcia, Nina Singh, Betul Baykan, Hasim Gezegen, Nana Yaa Kyei-Frimpong, Andrea Winkler, Jennifer A. Frontera 2:12 p.m. S12.007 Comorbidity Phenotype Trajectories in Veterans Before and After Emergence of Epilepsy–Mary Jo Pugh, W. Curt LaFrance, Sidney Hinds, Alan R. Towne, Anne C. Van Cott, Christine B. Baca, Hamada Hamid Altalib, Chen-Pin Wang 2:24 p.m. S12.008 Incidence and Clinical Characteristics of Parkinson’s Disease Psychosis in a Population-based Incidence Cohort in Olmsted County, MN (2006-2015).–Emanuele Camerucci, Aidan Mullan, Gretchen Ahrens, Pierpaolo Turcano, Cole Daniel Stang, James H. Bower, Bradley F. Boeve, Rodolfo Savica 2:36 p.m. S12.009 Incidence of Creutzfeldt-Jakob Disease in the United States 1993-2014–Alison Seitz, Cenai Zhang, Alexander Merkler 2:48 p.m. S12.010 Selective ß2-Adrenoreceptor Agonists and Long-Term Parkinson’s Disease Risk–Julia Axiina Tuominen, Kjetil Bjornevik, Julia Romanowska, Magne Solheim, Trond Riise, Jannicke Igland
SCIENTIFIC SESSIONS Monday, April 4 1:00 p.m.–3:00 p.m. PT
S13 Epilepsy/Clinical Neurophysiology (EEG): Antiseizure Medications
3:30 p.m.–5:30 p.m. PT CME
2
1:00 p.m. S13.001 Real-world Study of Brivaracetam in the United States–Hina N. Dave, Jacqueline French, Hamada Hamid Altalib, Heidi L. Henninger, Roger J. Porter, Michael Gelfand, Melinda S. Martin, Prashant Dongre, Sami Elmoufti, Anne-Liv Schulz, Michael R. Sperling 1:12 p.m. S13.002 Pronounced Antiepileptic Activity of Darigabat, a Subtype-Selective GABAA Receptor Positive Allosteric Modulator, in the Mesial Temporal Lobe Model of Drug-Resistant Focal Epilepsy–Rachel Gurrell, Philip A. Iredale, Alexis Evrard, Venceslas Duveau, Celine Ruggiero, Corinne Roucard 1:24 p.m. S13.003 Effect of Steroids on cortical excitability in children with Encephalopathy with Status Epilepticus in Sleep (ESES): A TMS based longitudinal study–Gautam Kamila, Prashant Jauhari, Sheffali Gulati, Biswaroop Chakrabarty, Atin Kumar, Shobha Sharma, Suman Jain, Jeeva Sankar, R M Pandey 1:36 p.m. S13.004 Cenobamate Plasma Concentrations in Patients Reaching =50% or 100% Responder Rates for =12 Months: A Post-hoc Analysis–Stephen Greene, William E. Rosenfeld, Louis Ferrari 1:48 p.m. S13.005 Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up–Heather E. Olson, Ahsan Moosa Naduvil Valappil, Eva Rybak, Alex Aimetti, Joseph Hulihan, Elia Margarita Pestana Knight 2:00 p.m. S13.006 Efficacy of Cenobamate by Focal Seizure Subtypes: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study–William E. Rosenfeld, Louis Ferrari, Marc Kamin 2:12 p.m. S13.007 Preclinical Development of NRTX-1001, an Inhibitory Interneuron Cellular Therapeutic for the Treatment of Chronic Focal Epilepsy–Mansi Parekh, Philip Hampel, Marina Radoul, Eric Steven Sevilla, David Traver, Hannah Kim, Nathalie Picard, Andrew Adler, Luis Fuentealba, Jiayin Li, Adrian Bates, Daniel Cherkowsky, Marina Bershteyn, Yves Maury, Myriam M. Chaumeil, Catherine Priest, Cory Nicholas 2:24 p.m. S13.008 Maternal Symptomatic Toxicity and Oxcarbazepine Free Fraction during Pregnancy in Women with Epilepsy–Page B. Pennell, Angela K. Birnbaum, Charul Avachat, Sean Hwang, Laura A. Kalayjian, Elizabeth Gerard, Abigail G. Matthews, Carrie Brown, Kimford J. Meador 2:36 p.m. S13.009 Ganaxolone Significantly Reduces Major Motor Seizures Associated with CDKL5 Deficiency Disorder: A Randomized, Double-blind, Placebo-Controlled Phase 3 Study–Elia Pestana-Knight, Sam Amin, Timothy A. Benke, J. Helen Cross, Heather E. Olson, Tom Fleming, Scott Thomas Demarest, Nicola Specchio 2:48 p.m. S13.010 Interim Analysis of Long-Term Safety and Efficacy of FINTEPLA (fenfluramine) in Patients with Lennox-Gastaut Syndrome–Kelly G. Knupp, Ingrid E. Scheffer, Berten Ceulemans, Joseph Sullivan, Katherine C. Nickels, Lieven G. Lagae, Renzo Guerrini, Sameer M Zuberi, Rima Nabbout, Catherine Riney, Svetlana Shore, Anupam Agarwal, Michael Lock, Gail M Farfel, Bradley Galer, Arnold Gammaitoni, Ronald G. Davis, Antonio Gil-Nagel
S14 MS Therapeutics
CME
2
3:30 p.m. 2022 Alliance Award S. Weir Mitchell: This award is designed to encourage basic research in neuroscience by physicians in clinical neurology training programs. Recipient: Jean-Pierre René Falet, MD, CM, Montreal, QC, Canada 3:42 p.m. S14.002 Mediterranean Diet Score is Associated with Disability and Brain Atrophy in Multiple Sclerosis–Ilana B. Katz Sand, Kathryn Fitzgerald, Tali R. Sorets, Sarah Ann Levy, James F. Sumowski 3:54 p.m. S14.003 Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Patients With Relapsing Multiple Sclerosis: 18-Month Results– Jiwon Oh, Sana Syed, Atuyota Larry Orogun, Deborah Dukovic, Robert J. Fox 4:06 p.m. S14.004 Long-term Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis–Stephen L. Hauser, Anne H. Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Ann Nicholas, Sven G. Meuth, Paul Giacomini, Francesco Sacca, Ronald Zielman, Ayan Das Gupta, Jing Xi, Ratnakar Pingili, Roseanne Sullivan, Virginia De Las Heras Revilla, Wendy Su, Ludwig Kappos 4:18 p.m. S14.005 Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6-Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis–John F. Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey Alan Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary Raymond Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell 4:30 p.m. S14.006 The Role of Cerebellar Damage in Explaining Disability and Cognition in Multiple Sclerosis Phenotypes: A Multiparametric MRI Study–Raffaello Bonacchi, Alessandro Meani, Elisabetta Pagani, Olga Marchesi, Massimo Filippi, Maria Assunta Rocca 4:42 p.m. S14.007 Safety Profile Characterization of Evobrutinib in Over 1000 Patients from Phase II Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus–Hans Guehring, Daniel Wallace, Mark C. Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H. Kao, Xavier Montalban 4:54 p.m. S14.008 Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing forms of Multiple Sclerosis: Interim Analysis–Tarun Singhal, Kelsey Carter, John Ficke, Preksha Kukreja, Eero Rissanen, Gauruv Bose, Bonnie Glanz, Jonathan D. Zurawski, Steven Cicero, Maria K. Houtchens, Christopher Severson, Shipra Dubey, Bo Yeun, Brandon Brown, Rohit Bakshi, Harald Kropshofer, Tanuja Chitnis, Howard L. Weiner, Marina Ollervides Ziehn 5:06 p.m. S14.009 Effects of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis–Douglas L. Arnold, Colm Elliott, Xavier Montalban, Emily C. Martin, Yann Hyvert, Davorka Tomic 5:18 p.m. S14.010 MRI Activity versus Relapses as Markers of Disease Activity in SPMS: Data from Adelphi Real-World MS Disease Specific Programme and The Phase 3 EXPAND Study–Gavin Giovannoni, Emma Houchen, Lukas Sobisek, Himanshu Karu, Suzannah Ryan, Eddie Jones, Patricia Dominguez Castro, Vladimir Bezlyak, Daniela Piani Meier, Virginia De Las Heras Revilla, Carol Lines
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
7
SCIENTIFIC SESSIONS Monday, April 4 3:30 p.m.–5:30 p.m. PT
S15 Aging and Dementia 1
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. S15.001 Psychosis in Neurodegenerative Disease–Andrew Breithaupt, Georges Naasan, Suzie Shdo, Estrella Morenas Rodriguez, Lucia Lopez, Anna Karydas, Salvatore Spina, Lea Grinberg, William Seeley, Bruce L. Miller, Katherine P. Rankin 3:42 p.m. S15.002 Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of Amyotrophic Lateral Sclerosis.–Myrna Dominique, Krista Spiller 3:54 p.m. S15.003 African Locus Reduces the Effect of ApoE e4 Allele in Alzheimer’s Disease– Farid Rajabli, Gary W. Beecham, Hugh Hendrie, Olusegun Baiyewu, Adesola Ogunniyi, Sujuan Gao, Nicholas Kushch, Marina Lipkin Vasquez, Kara HamiltonNelson, Juan Young, Derek Dykxhoorn, Karen Nuytemans, Brian Kunkle, Liyong Wang, Fulai Jin, Xiaoxiao Liu, Briseida E. Feliciano Astacio, Alzheimer’s Disease Genetic Consortium, Clifton Dalgard, Anthony J. Griswold, Goldie S. Byrd, Christiane Reitz, Jonathan Haines, Margaret A. Pericak-Vance, Jeffery M. Vance 4:06 p.m. S15.004 Belgian Carriers of Rare ABCA7 Mutations Present with Pronounced Cerebral Amyloid Angiopathy and Alzheimer’s Disease–Elisabeth Hendrickx Van de Craen, Liene Bossaerts, Anne Sieben, Sebastiaan Engelborghs, Caroline Maria Jozef Loos, Laetitia Yperzeele, Peter P. De Deyn, Patrick Cras, Christine Van Broeckhoven 4:18 p.m. S15.005 Prevalence and Location of White Matter Hyperintensities in Traumatic Brain Injury and Relationship to Outcome–Abbie Chan, Emily Ai, James J. Gugger, Alexa Walter, Emily Xu, Andrew Kim, Ramon R. Diaz-Arrastia 4:30 p.m. S15.006 Association of the Mediterranean Diet and Cognition Function among Hispanics/Latinos–Gabriela Trifan, Bayan Moustafa, Carmen Isasi, Richard B. Lipton, Daniela Sotres-Alvarez, Jianwen Cai, Wassim Tarraf, Hector M. Gonzalez, Ariana Stickel, Josiemer Mattei, Gregory Anthony Talavera, Martha Daviglus, Fernando Testai 4:42 p.m. S15.007 Evaluation of Intensive Versus Standard Blood Pressure Reduction and Association with Cognitive Decline and Dementia: A Systematic Review and Meta-Analysis–Caroline Dallaire-Théroux, Marie-Hélène Quesnel-Olivo, Karine Brochu, Frederic Bergeron, Sarah O’Connor, Alexis Turgeon, Robert Laforce, Steve Verreault, Marie-Christine Camden, Simon Duchesne 4:54 p.m. S15.008 Cardiorespiratory Fitness Is Protective Against Alzheimer’s and Related Disorders–Edward Y. Zamrini, Yan Cheng, Peter Kokkinos, Charles Faselis, Helen M. Sheriff, Yijun Shao, Ali Ahmed, Qing Zeng-Treitler 5:06 p.m. S15.009 A Retrospective Study of Androgen Targeting Therapies and Incidence of Neurodegenerative Outcomes in Male Prostate Cancer Patients: Implications for Clinic to Bench Translation–Greg Lawrence Branigan, Georgina Torrandell Haro, Kathleen Rodgers, Roberta Diaz Brinton 5:18 p.m. S15.010 Statin Responder Analysis for Precision Prevention of Neurological Diseases– Georgina Torrandell Haro, Greg Lawrence Branigan, Kathleen Rodgers, Roberta Diaz Brinton
8
2022 AAN Annual Meeting
S16 Movement Disorders: PD Biomarkers and Clinical Trials
CME
2
3:30 p.m. 2022 Jon Stolk Award in Movement Disorders for Young Investigators: This award recognizes young investigators who have made significant contributions to movement disorders research. Recipient: Bhooma Rajagopalan Aravamuthan, MD, PhD, St. Louis, MO 3:42 p.m. S16.002 Biomarkers for Parkinson’s Disease with Reflex Tears Stratified by Disease Duration–Mark F. Lew, Srikanth Janga, Yaping Ju, Danielle Feigenbaum, Amir Besharat, Dan Freire, Daniel Gerke, Maria Edman, Wendy Mack, Curtis Okamoto, Sarah Hamm-Alvarez 3:54 p.m. S16.003 Serial olfactory testing for the diagnosis of prodromal Parkinson disease in the Parkinson Associated Risk Syndrome (PARS) study–Pavan Vaswani, James F. Morley, Danna L. Jennings, Andrew D. Siderowf, Kenneth L. Marek 4:06 p.m. S16.004 Artificial intelligence identifies spectral biomarkers for use in adaptive deep brain stimulation in Parkinson’s disease–Lauren Hammer, Carina Renate Oehrn, Clay Smyth, Stephanie Cernera, Roee Gilron, Simon Little, Philip Starr 4:18 p.m. S16.005 Quantitative Electroencephalography as a Biomarker for Cognitive Dysfunction in Parkinson’s Disease–Katerina Markopoulou, Kevin Novak, Bruce A. Chase, Jaishree T. Narayanan, Premananda Indic 4:30 p.m. S16.006 Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson’s Disease Using a Multiple-Source, Constant-Current System: 5-year Follow-Up of a Prospective, Double-Blind RCT–Jerrold L. Vitek, INTREPID Study Group, Lilly Chen, Roshini Jain, Philip Starr 4:42 p.m. S16.007 Evaluating Outcomes in Parkinson’s Disease Patients Following COVID-19 Interventions–Ari Vandersluis, Shnehal Patel, John Elliott 4:54 p.m. S16.008 A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early Parkinson’s disease)–Gennaro Pagano, Stefano Zanigni, Annabelle Monnet, Kirsten I. Taylor, Andrea Hahn, Kenneth L. Marek, Ronald Postuma, Nicola Pavese, Fabrizio Stocchi, Tanya Simuni, Giulia D’Urso, Nathalie Pross, Michael Lindemann, Hanno Svoboda, Paulo Pacheco Fontoura, Rachelle Doody, Geoffrey A. Kerchner, Azad Bonni, Tania Nikolcheva 5:06 p.m. S16.009 Safety and Efficacy of 24-Hour/Day Subcutaneous Infusion of Foslevodopa/ Foscarbidopa in Advanced Parkinson’s Disease During a Phase 3 Study: 6-Month Interim Results–Jason Lamar Aldred, Bruno Bergmans, Camille Carroll, Eric Freire Alvarez, Jia Jia, Hideki Mochizuki, Weining Robieson, Amy Spiegel, David G. Standaert, Maurizio F. Facheris, Victor Fung 5:18 p.m. S16.010 A Phase 3 Trial of IPX203 vs CD-LD IR in Parkinson’s Disease Patients with Motor Fluctuations (RISE-PD)–Robert A. Hauser, Alberto J. Espay, Peter A. LeWitt, Aaron Ellenbogen, Stuart H. Isaacson, Rajesh Pahwa, Fabrizio Stocchi, Hester Visser, Richard DSouza
SCIENTIFIC SESSIONS Monday, April 4 3:30 p.m.–5:30 p.m. PT
S17 Cerebrovascular Disease: Clinical Trials and Outcomes Studies
CME
2
3:30 p.m. 2022 Michael S. Pessin Stroke Leadership Prize: This award recognizes emerging neurologists who have a strong interest in and have demonstrated a passion for learning and expanding the field of stroke research. Recipient: Amy Y. X. Yu, MD, Toronto, ON, Canada 3:42 p.m. S17.002 Home blood pressure telemonitoring-enhanced versus usual post-acute stroke care in an underserved setting: the Telehealth After Stroke Care pilot randomized clinical trial–Imama Ali Naqvi, Ken Cheung, Kevin Strobino, Kevin Schmitt, Hanlin Li, Yuliya Baratt, Kyra Lizardo, Marie Carmel Garcon, Carmen Elisabeth Castillo, Sarah Tom, Adriana Arcia, Olajide Abiodun Williams, Ian Kronish, Mitchell S. V. Elkind 3:54 p.m. S17.003 AHORA: An easy to use Spanish version of the BEFAST stroke scale–Trilok Stead, Anjali Banerjee, Latha Ganti, Maricela Gonzalez Wilson, Paul Banerjee 4:06 p.m. S17.004 The Effects of Hyperglycemia in Diabetic and Non-Diabetic Patients on Collateral Circulation with Large Vessel Occlusions Undergoing Mechanical Thrombectomy: A Single Center Experience–Omar Saeed, Brittany Marie Kasturiarachi, Leila Gachechiladze, Diana Leigh Alsbrook, Savdeep Singh, Ghaida Khalaf Zaid, Prasanna Venkatesan Eswaradass, Cheran Elangovan, Marc Malkoff, Adam Arthur, Balaji Krishnaiah, Andrei V. Alexandrov
4:18 p.m. S17.005 Early withdrawal of life-sustaining treatments after out-of-hospital cardiac arrest: a sub-analysis of a randomized trial of prehospital hypothermia–Sarah Wahlster, Kyle Danielson, Lindy Craft, Nassim Matin, James A. Town, Vasisht Srinivasan, David Carlbom, Francis Kim, Nicholas J. Johnson, David L. Tirschwell 4:30 p.m. S17.006 Variable Picture Naming Activation Patterns in Post-stroke Aphasia: A Functional Near-infrared Spectroscopy (fNIRS) Case Series Investigation.–Lisa Bunker, Hana Kim, Erin Meier, Argye E. Hillis 4:42 p.m. S17.007 Tenecteplase is Safe and Efficacious in Telestroke Patients with Confirmed Large Vessel Occlusions–Chris Hackett, Konark Malhotra, Russell Mitesh Cerejo, Christy A. Shurina, Kayla Marie Powell, Melanie Henderson, June Butterfield, Christine New, Patty Noah, Sandeep S. Rana, Robert Fishman, David G. Wright, Richard Williamson, Ashis H. Tayal 4:54 p.m. S17.008 Efficacy and Safety of Mechanical Thrombectomy in Elderly Patients–Aisha Maqsood Ali, Gabriela Trifan, Fernando Testai 5:06 p.m. S17.009 Cerebrovascular Injury During Left Ventricular Assist Device Support and Neurologic Outcomes After Cardiac Transplant–Aaron Shoskes, Catherine Hassett, Merry Huang, Randall Starling, Sung-Min Cho, Ken Uchino 5:18 p.m. S17.010 Non-invasive vagus nerve stimulation for the acute treatment of stroke–Ethem Murat Arsava, Mehmet Topcuoglu, Ilknur Ay, Eric J. Liebler, Hakan Ay
Industry Therapeutic Update From Sarepta Therapeutics: Exploring New Horizons in the Diagnosis and Care of Individuals With Duchenne Clinical Update on an Investigational rAAVrh74-based Gene Transfer Therapy Tuesday, April 5, 2022 7:00 pm PDT Grand Hyatt Seattle Princessa Ballroom 721 Pine Street, Seattle, WA
Hear expert insights into key considerations along the gene transfer therapy journey for neurologists and caregivers of individuals with Duchenne.
This is not a CME program nor will CME credits be given for attendance. This program is not part of the AAN Annual Meeting Education or Scientific programs and/or endorsed by the AAN. ©2022 SAREPTA THERAPEUTICS. Copying of this material by any means without Sarepta’s prior written consent is prohibited. C-NP-US-1355 02/22
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
9
SCIENTIFIC SESSIONS Tuesday, April 5 1:00 p.m.–3:00 p.m. PT
S18 COVID-19: From Bedside and Beyond
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. S18.001 Neurologic Manifestations of Patients Hospitalized with COVID-19 in the SCCM VIRUS Registry–Anna Marisa Cervantes-Arslanian, Chakradhar V K Venkata, Pria Anand, Joseph D. Burns, Charlene Jennifer Ong, Allison LeMahieu, Phillip Schulte, Tarun Deep Singh, Alejandro A. Rabinstein, Vishakha Kumar, Allan Walkey, Rahul Kashyap 1:12 p.m. S18.002 Association Between COVID-19 Vaccination and Cerebrovascular Accidents in Adults: A Vaccine Adverse Event Reporting System (VAERS) Study–Jeffrey M. Kornitzer, Kranthi Kiran Mandava, Mustafa Jaffry, Tarek Elshourbagy, Nizar Souayah 1:24 p.m. S18.003 Features of hospitalized pediatric patients with seizures and respiratory viruses: a comparison of SARS-CoV2, other coronaviruses, and influenza– Monique Rochlle Anderson, Yijin Xiang, Shasha Bai, Christina Rostad, Grace Gombolay 1:36 p.m. S18.004 Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients–Erica Normandin, Kathryn Holroyd, Sarah I. Collens, Bennett McClain Shaw, Katherine Joyce Siddle, Gordon Adams, Melissa Ann Rudy, Isaac H Solomon, Melis Anahtar, Jacob Lemieux, Bianca A. Trombetta, Pia Kivisakk Webb, Steven E. Arnold, Otto Rapalino, Anne Piantadosi, Pritha Sen, Eric S. Rosenberg, John A. Branda, Pardis Christine Sabeti, Shibani Sharon Mukerji 1:48 p.m. S18.005 The post-acute sequelae of COVID-19 (PASC) experience in an outpatient neurology setting–Sujata P. Thawani, Peyton Meyer, Lisena Hasanaj, Jennifer A. Frontera, Azizi Seixas, Steven Galetta, Laura J. Balcer 2:00 p.m. S18.006 Association Between COVID-19 Vaccination and Rhabdomyolysis in Adults: A Vaccine Adverse Event Reporting System (VAERS) Study–Kranthi Kiran Mandava, Mustafa Jaffry, Sanjana Rosario, Kamel Jedidi, Nizar Souayah 2:12 p.m. S18.007 Neuroradiological profile of Rhinoorbitocerebral mucormycosis in COVID-19 pandemic.–P.Haritha Kumari, Lakshmi N. Ranganathan, Thamilpavai Natarajan, Shrivarthan R 2:24 p.m. S18.008 Neurological impact of COVID-19: Sub-acute brain microstructural alterations in self-isolated individuals–Nick Teller, Jordan Chad, Eugenie Roudaia, Ali Hashemi, Haddas Grosbein, Asaf Gilboa, Maged Goubran, Ivy Cheng, Sandra E. Black, Rob Fowler, Chinthaka Heyn, Fuqiang Gao, Mario Masellis, Jennifer Rabin, Xiang Ji, Aravinthan Jegatheesan, Benjamin Lam, Allison Sekuler, Bradley MacIntosh, Simon James Graham, Jean Chen 2:36 p.m. S18.009 Phenotyping the Chronic Neurological Sequelae of Acute SARS-CoV-2 Infections–Matthew K. Schindler, Dennis L. Kolson, Danielle Sandsmark, Sara Manning 2:48 p.m. S18.010 Do Neurological Manifestations Following SARS-CoV-2 Infection Beget A Poor Prognosis?–Steve N. Gad, Kranthi Kiran Mandava, Mustafa Jaffry, Mohsen Ahmed, Kazim Jaffry, Nizar Souayah
10
2022 AAN Annual Meeting
S19 MS Biomarkers and Symptom Management 1:00 p.m.
CME
2
S19.001
Applicability of sNFL in Multiple Sclerosis as Additional Measure to Monitor Treatments in Clinical Practice and Implications in NEDA-3 Evaluation–Simona Malucchi, Paola Valentino, Fabiana Marnetto, Cecelia Irene Bava, Serena Martire, Antonio Bertolotto, Marco Alfonso Narduc Capobianco
1:12 p.m.
S19.002
Early Levels of Neurofilament Light Chain and Glial Fibrillary Acidic Protein Improve Prediction of MS Outcomes–Gauruv Bose, Brian Curran Healy, Shrishti Saxena, Fermisk Saleh, Anu Paul, Marinos G. Sotiropoulos, Hrishikesh A. Lokhande, Mariann Polgar-Turcsanyi, Bonnie Glanz, Charles R.G. Guttmann, Rohit Bakshi, Howard L. Weiner, Tanuja Chitnis
1:24 p.m.
S19.003
Kappa Free Light Chains Intrathecal Synthesis Biomarkers are Efficient Tools for the Diagnosis of Multiple Sclerosis: a Large Multicenter Cohort Study–Michael Levraut, Xavier Ayrignac, Kevin Bigaut, Sabine Chabalier, Manon Rival, Hanane Agherbi, Sanae Squalli, Helene Zephir, Tifanie Alberto, Jean David Pekar, Jonathan Ciron, Noellie Freitas, Damien Biotti, Jean-Phillippe Camdessanche, Yannick Tholance, Vincent Visneux, Olivier Casez, Audrey Le Gouellec, Jeanne Marion, Audrey Le Gouellec, Thibault Moreau, Daniela Lakomy, Thomasset Audrey, Elisabeth Maillart, Delphine Sterlin, Aude Maurousset, Auriane Rocher, Mikael Cohen, Adrien Delourme, Saskia Bresch, David Laplaud, Edith Bigot-Corbel, Jean Pelletier, José Boucraut, Pierre Labauge, Sophie Huby, Thierry Vincent, Jerome De Seze, Isabelle Jahn, Barbara SeitzPolski, Eric Thouvenot, Beverly Aagard-Kienitz
1:36 p.m.
S19.004
Utilizing P100 Wave Latency to Enhance The Accuracy of Diagnosing Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder–Mays Amir Garah, Lama Rayyis, Gulzar Karim, Manal A. Badawi, Ahmed Basndowah, Areej Bushnag, Edward J. Cupler, Ahmad Hassan, Fawzi Babtain
1:48 p.m.
S19.005
Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis–Ting-Yi Lin, Viktoriya Vitkova, Susanna Asseyer, Ivette Martorell Serra, Seyedamirhosein Motamedi, Claudia Chien, Marc Ditzhaus, Athina Papadopoulou, Pascal Benkert, Jens Kuhle, Judith Bellmann-Strobl, Klemens Ruprecht, Friedemann Paul, Alexander U. Brandt, Hanna Zimmermann
2:00 p.m.
S19.006
Lower Cerebral Arterial Blood Flow is Associated with Greater Serum Neurofilament Light Chain Levels in Multiple Sclerosis Patients–Dejan Jakimovski, Niels Bergsland, Michael G. Dwyer, Kunsang Choedun, Karen L. Marr, Bianca Weinstock-Guttman, Robert Zivadinov
2:12 p.m.
S19.007
Monoaminergic Networks Abnormalities Associated with Fatigue and Depression in Multiple Sclerosis–Maria Assunta Rocca, Antonio Carotenuto, Paola Valsasina, Paolo Preziosa, Laura Cacciaguerra, Raffaello Bonacchi, Massimo Filippi
2:24 p.m.
S19.008
Repetitive transcranial magnetic stimulation with the H-coil combined with intensive rehabilitation to improve gait in people with Multiple Sclerosis: a randomized controlled trial–Letizia Leocani, Simone Guerrieri, Marco Pisa, Gloria Dalla Costa, Marco Rovaris, Giancarlo Comi
2:36 p.m.
S19.009
Long-term efficacy of cognitive-behavioral approaches (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a randomized, parallel-group, multicenter, open-label, controlled trial versus standard care– Olivier Heinzlef, Fanny Hamelin, Frederic Barbot, Isabelle Vaugier, Marie Blanchere, Eric Manchon, Djamel Bensmail, Marie Claire Gay
2:48 p.m.
S19.010
Assessing cognitive impairment in Multiple Sclerosis using Smartphone-Based training Games: Results of a feasibility study–Silvan Pless, Tim Woelfle, Yvonne Naegelin, Johannes Lorscheider, Andrea Wiencierz, Óscar Gabriel Reyes Pupo, Jose Maria Santos, Pasquale Calabrese, Ludwig Kappos
SCIENTIFIC SESSIONS Tuesday, April 5 1:00 p.m.–3:00 p.m. PT
S20 Aging and Dementia 2
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. 2022 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases: This award recognizes major contributions to the understanding of the causes, prevention, treatment, and cure for Pick’s, Alzheimer’s, and related diseases. Recipient: Vladimir Hachinski, MD, DSc, FAAN, London, ON, Canada 1:24 p.m. S20.003 Head-to-head comparison of tau and amyloid PET visual reads for differential diagnosis: An international, multi-center study–David Nima SoleimaniMeigooni, Ruben Smith, Karine Provost, Orit Lesman-Segev, Hanna Cho, Lauren Edwards, Leonardo Iaccarino, Renaud La Joie, Rik Ossenkoppele, Olof Strandberg, Amelia Strom, Chul Hyoung Lyoo, Oskar Hansson, Gil Dan Rabinovici 1:36 p.m. S20.004 Plasma Neurofilament Trajectories are Markers of Disease Progression and Severity in Genetic Frontotemporal Dementia–Dario Saracino, Karim Dorgham, Agnes Camuzat, Daisy Rinaldi, Armelle Rametti Lacroux, Marion Houot, Florence Pasquier, Philippe Couratier, Claire Boutoleau-Bretonniere, Jeremie Pariente, Mira Didic, Olivier Colliot, Richard Levy, Isabelle Le Ber 1:48 p.m. S20.005 Speech and Language Correlates of Decreased and Increased Functional Connectivity in Semantic Variant Primary Progressive Aphasia–Maxime Montembeault, Zachary Miller, Amandine Geraudie, Peter Pressman, Antoine Slegers, Maria Luisa Mandelli, Nina Dronkers, Bruce L. Miller, Simona M. Brambati, Maria Gorno Tempini, Giovanni Battistella 2:00 p.m. S20.006 Frequent MAPT p.R406W Carriers with a Nonconforming FTD Phenotype in the Belgian Population–Helena Gossye, Sara Van Mossevelde, Julie Van Der Zee, Anne Sieben, Maria Bjerke, Sebastiaan Engelborghs, Peter P. De Deyn, Jan L. De Bleecker, Jan Versijpt, Jenneke Van Den Ende, Olivier Deryck, Paul M. Bourgeois, Jean-Christophe Bier, Maarten Goethals, Christine Van Broeckhoven 2:12 p.m. S20.007 Differences in rate and trajectory of TDP-43-associated neurodegeneration in brains with and without frontotemporal lobar degeneration–Marina Buciuc, Peter Martin, Nirubol Tosakulwong, Melissa Murray, Leonard Petrucelli, Matthew Senjem, Anthony Spychalla, David S. Knopman, Bradley F. Boeve, Ronald C. Petersen, Joseph E. Parisi, Ross Reichard, Dennis W. Dickson, Clifford R. Jack, Jennifer Louise Whitwell, Keith A. Josephs 2:24 p.m. S20.008 Education, Early Life Socioeconomic Status, and Later Life Alzheimer’s DiseaseRelated Neuropathological Lesions–Amol Mehul Mehta, Sarah Tom, Paul Crane, David A. Bennett, Stephanie Izard, Philip De Jager, Julie A. Schneider 2:36 p.m. S20.009 Dissecting the Neurodegenerative Causes of Rapidly Progressive Dementia: An Autopsy Study–Evelyn Lazar, Nikhil Bharat Ghayal, Shanu Roemer, Neill R. GraffRadford, Dennis W. Dickson, Gregory S. Day 2:48 p.m. S20.010 Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies–Fernando L. Pagan, Yasar Alejandro Torres-Yaghi, Michaeline Hebron, Barbara Wilmarth, Dalila Ferrante, Sara Matar, Raymond Turner, Jaeil Ahn, Charbel E H Moussa
S21 Neurocritical Care
CME
2
1:00 p.m. S21.001 Cerebral Autoregulatory Function Before, During, and After Therapeutic Interventions Following Severe Traumatic Brain Injury: A Secondary Analysis of the BOOST-II Study–Ayush Prasad, Jessica Kobsa, Alexandria Soto, David Bartolome, Yelyzaveta Begunova, Jennifer A. Kim, Emily Jean Gilmore, Kevin N. Sheth, Charles Matouk, Adam De Havenon, Ramon R. Diaz-Arrastia, Nils Petersen 1:12 p.m. S21.002 Poor Collaterals and Rapid Early Infarct Progression Are Associated With Increased Vulnerability to Blood Pressure Reductions–Yelyzaveta Begunova, David Bartolome, Jessica Kobsa, Alexandria Soto, Ayush Prasad, Milagros Galecio-Castillo, Juan A. Vivanco-Suarez, Darko Ernesto Quispe Orozco, Mudassir Farooqui, Lauren Hachmann Sansing, Joseph Schindler, Adam De Havenon, Charles Matouk, Kevin N. Sheth, Santiago Ortega Gutierrez, Nils Petersen 1:24 p.m. S21.003 Radiographic predictors of ventriculoperitoneal shunt requirement in aneurysmal subarachnoid hemorrhage–Aiden Meyer, Elyse Forman, Scott Moody, Christoph Stretz, Nicholas S. Potter, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Karen L. Furie, Ali Mahta 1:36 p.m. S21.004 Association Of Hemoglobin Over The First Week With Clinical Outcomes And Neuroimaging Characteristics In Patients With Spontaneous Intracerebral Hemorrhage–Camilo Diaz-Cruz, Kori Anahi Porosnicu Rodriguez, John Richard Gatti, David Zhao, Radhika Avadhani, Issam Awad, Daniel F. Hanley, Wendy C. Ziai 1:48 p.m. S21.005 Guillain-Barre Syndrome after HPV Vaccination: A Report from the Vaccine Adverse Event Reporting System (VAERS) (2006-2021)–Tarek Elshourbagy, Kranthi Kiran Mandava, Mustafa Jaffry, Nizar Souayah 2:00 p.m. S21.006 The Experiences And Needs Of Families Of Comatose Patients After Cardiac Arrest And Severe Neurotrauma: The Perspectives Of A National Key Stakeholders During An NIH-Funded Workshop–Susanne Muehlschlegel, Sarah Perman, Jonathan Elmer, Adrianne Haggins, Natalie Dyane Teixeira, Jennifer Huang, Liz Jansky, Jessica Kirchner, Renee Kasperek-Wynn, Paula Darby Lipman, Michael Fetters, Neal W. Dickert, Robert Silbergleit 2:12 p.m. S21.007 Survey of Practices and Physician Attitudes on Post-Cardiac Arrest Care– Melody Eckert, Nilan Bhakta, Fernanda Jacinto Pereira Teixeira, Carolina B. Maciel, Torben K. Becker, Casey Carr 2:24 p.m. S21.008 Quantitative Pupil Characteristics Following Analgo-Sedative Administration in Critically Ill Patients with Neurologic Emergencies–Wang Pong Chan, Brenton Prescott, Megan Barra, David Young Chung, Hanife Saglam, Emelia Benjamin, Stelios M. Smirnakis, Josee Dupuis, David M. Greer, Charlene Jennifer Ong 2:36 p.m. S21.009 Implementation of systematic safety checklists in a Neurointensive Care Unit: A quality and improvement study.–Gabriel Torrealba Acosta, Cesar Eduardo Escamilla-Ocanas, Pitchaiah Mandava, Eric Bershad, Mohammad I. Hirzallah, Chethan K. Venkatasubba Rao, Barbara Lorena Gutierrez-Flores, Rahul Damani 2:48 p.m. S21.010 Between Scylla and Charybdis: Risks of Early Therapeutic Anticoagulation for Venous Thromboembolism After Acute Intracranial Hemorrhage–Thuhien Nguyen, Monisha Sharma, Charles Patrick Crooks, Pratik Vishnu Patel, Robert Bonow, Claire Creutzfeldt, Sarah Wahlster
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
11
SCIENTIFIC SESSIONS Tuesday, April 5 3:30 p.m.–4:10 p.m. PT
S22 History of Neurology 3:30 p.m. 2022 Lawrence C. McHenry: An Award for the History of Neurology: This award recognizes excellence in research in the history of neurology. Recipient: David B. Burkholder, MD, Rochester, MN 3:54 p.m. S22.003 André Strohl: Why Was his Name Omitted from Guillain-Barré Syndrome’s Eponym?–Ahmed Abbas, Faisal Abdelaziz Ibrahim
12
2022 AAN Annual Meeting
3:30 p.m.–5:30 p.m. PT CME
0.5
S23 Therapeutics for Muscle Diseases
CME
2
3:30 p.m. S23.001 WITHDRAWN 3:42 p.m. S23.002 A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of SRP-9001 for Treating Patients with Duchenne Muscular Dystrophy–Jerry R. Mendell, Perry Shieh, Zarife Sahenk, Kelly Lehman, Linda Pax Lowes, Natalie F. Reash, Megan Iammarino, Lindsay N. Alfano, Brenna Powers, Jeremy Woods, Christy Skura, Howard Mao, Loretta Staudt, Rachael Potter, Danielle A. Griffin, Sarah Lewis, Tianle Hu, Sameer Upadhyay, Tejdip Singh, Louise R. Rodino-Klapac 3:54 p.m. S23.003 Antibody-Oligonucleotide Conjugates (AOCs) Demonstrate Potent and Durable Exon Skipping and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy–Usue Etxaniz, Matthew Diaz, Raghav Bhardwaj, Olecya Tyaglo, Kellie Lemoine, Maria Azzurra Missinato, Aaron George Anderson, Philip Kovach, Isaac Marks, Tyler Albin, Michael Cochran, Hae Won Kwon, Verna Zhao, Husam Younis, William M. Flanagan, Arthur A. Levin 4:06 p.m. S23.004 Phase 1/2a Trial of SRP-9001 in Patients with Duchenne Muscular Dystrophy: 3-Year Safety and Functional Outcomes–Jerry R. Mendell, Zarife Sahenk, Kelly Lehman, Carrie Nease, Linda Pax Lowes, Natalie F. Reash, Megan Iammarino, Lindsay N. Alfano, Jordan Vaiea, Sarah E. Lewis, Kathleen Church, Richard Shell, Rachael Potter, Danielle A. Griffin, Eric Pozsgai, Mark Hogan, Tianle Hu, Kathryn Anne Giblin, Louise R. Rodino-Klapac 4:18 p.m. S23.005 Safety, ß-Sarcoglycan Expression, and Functional Outcomes From Systemic Gene Transfer of rAAVrh74.MHCK7.hSGCB in LGMD2E/R4–Louise R. RodinoKlapac, Eric Pozsgai, Sarah Lewis, Danielle A. Griffin, Aaron Meadows, Kelly Lehman, Kathleen Church, Natalie F. Reash, Megan Iammarino, Brenna Powers, Lindsay N. Alfano, Linda Pax Lowes, Erica Koenig, Sarah Berten Neuhaus, Xiaoxi Li, Jerry R. Mendell 4:30 p.m. S23.006 Study Design of AOC 1001-CS1, a Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA)–Nicholas Elwood Johnson, John W. Day, Johanna Hamel, Katy Eichinger, S H. Subramony, William D. Arnold, Charles A. Thornton, Matthew P. Wicklund, Payam Soltanzadeh, Ben Knisely, Varun Goel, Kelly Ditrapani, Chao-Yin Chen, Kristi R. R, Alissa N. Peters, Carrie Heusner, Husam Younis, Mohita Kumar, Li-Jung Tai, Elizabeth Jane Ackermann 4:42 p.m. S23.007 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in Subjects with FSHD: ReDUX4–Alrabi Tawil, Katy Eichinger, Leo Hong-Li Wang, Angela L. Genge, Sabrina Sacconi, Hanns Lochmuller, David Reyes Leiva, Jordi Diaz Manera, Jorge Alonso-Perez, Nuria Muelas, Juan Jesus Vilchez Padilla, Alan Pestronk, Summer Gibson, Namita Goyal, Johanna Hamel, Lawrence J. Hayward, Nicholas Elwood Johnson, Samantha Jo LoRusso, Miriam L. Freimer, Perry Shieh, S H. Subramony, Doris G. Leung, Baziel G M van Engelen, Joost Kools, Olof Dahlqvist Leinhard, Per Wildholm, John Jiang, Adefowope Odueyungbo, William Tracewell, Alejandro Rojas, Anthony Accorsi, Lucienne Ronco, Diego Cadavid, Christopher Moxham, Christopher Morabito, Robert Gould, Michelle L. Mellion
SCIENTIFIC SESSIONS Tuesday, April 5 3:30 p.m.–5:30 p.m. PT
S23 Therapeutics for Muscle Diseases
CME
2
4:54 p.m. S23.008 An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1–Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel G M van Engelen 5:06 p.m. S23.009 Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4)–Michelle L. Mellion, Alrabi Tawil, Katy Eichinger, Leo Hong-Li Wang, Angela L. Genge, Sabrina Sacconi, Hanns Lochmuller, David Reyes Leiva, Jordi Diaz Manera, Jorge Alonso-Perez, Nuria Muelas, Juan Jesus Vilchez Padilla, Alan Pestronk, Summer Gibson, Namita Goyal, Johanna Hamel, Lawrence J. Hayward, Nicholas Elwood Johnson, Samantha Jo LoRusso, Miriam L. Freimer, Perry Shieh, S H. Subramony, Doris G. Leung, Baziel G M van Engelen, Joost Kools, Olof Dahlqvist Leinhard, Per Wildholm, John Jiang, Adefowope Odueyungbo, William Tracewell, Alejandro Rojas, Anthony Accorsi, Lucienne Ronco, Diego Cadavid, Christopher Moxham, Christopher Morabito, Robert Gould 5:18 p.m. S23.010 A Randomized, Double-Blind, Placebo-Controlled Study of Arimoclomol in Patients with Inclusion Body Myositis–Pedro Machado, Richard J. Barohn, Michael McDermott, Thomas Blaettler, Thomas E. Lloyd, Aziz I. Shaibani, Miriam L. Freimer, Anthony A. Amato, Emma Ciafaloni, Sarah M. Jones, Tahseen Mozaffar, Summer Gibson, Matthew P. Wicklund, Todd D. Levine, Claus Sundgreen, Thomas Carstensen, Karen Bonefeld, Anders Noerkaer Joergensen, Karina Phonekeo, Andrew Heim, Laura Herbelin, Michael George Hanna, Mazen M. Dimachkie
S24 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy
CME
2
3:30 p.m. S24.001 The New-Onset Refractory Status Epilepticus (NORSE/FIRES) Family Registry– Karnig Kazazian, Nicolas Gaspard, Lawrence J. Hirsch, Marissa Kellogg, Sara E. Hocker, Nora Wong, Raquel Farias-Moeller, Krista L. Eschbach, Teneille Gofton 3:42 p.m. S24.002 Limited resection preserved verbal memory outcome in drug-resistant dominant temporal lobe epilepsy due to temporal encephaloceles–Kelsey Marie Smith, Eva Alden, Kiran M. Kanth, Karl Krecke, Robert Witte, Jamie J. Van Gompel, Elson L. So, Jeffrey W. Britton, Gregory D. Cascino, Lily Wong-Kisiel 3:54 p.m. S24.003 Brain Temperature Elevations Parallel Unrestricted Water Movement And Increased Myelination In Temporal Lobe Epilepsy–Jerzy P. Szaflarski, Ayushe Alicia Sharma, Adam M. Goodman, Rodolphe Nenert 4:06 p.m. S24.004 Comparison of nationwide trends in 30-day readmission rates after laser interstitial thermal therapy (LITT) and open surgical procedures for refractory epilepsy (Nationwide Readmission database 2012-2018)–Varun Kumar, Mark Warman, Parisha Bhatia, Chirag Narshibhai Savani, Tejinder Singh 4:18 p.m. S24.005 Long-Term Cardiovascular Safety of Fenfluramine for Lennox-Gastaut Syndrome: Interim Analysis of Open-Label Safety Study–Anupam Agarwal, Gail M Farfel, Arnold Gammaitoni, Pierre Wong, Fausto J. Pinto, Bradley Galer 4:30 p.m. S24.006 Generic substitution of antiseizure medications: Is it time for narrow therapeutic index classification?–Sarah Elmer, Samba Reddy 4:42 p.m. S24.007 Use of Ceribell Rapid-Response EEG in 100 consecutive cases correlated with a reduction in anti-seizure medication usage–Deepika Kurup, Zach Davey, Phuong Thi Hoang, Katherine Michelle Clifford, Katherine Werbaneth, Varun Bipinchandra Shah, Prasanthi Govindarajan, Kimford J. Meador 4:54 p.m. S24.008 Clinical and EEG factors associated with antiseizure medication resistance in idiopathic generalized epilepsy–Brad Kenichi Kamitaki, Haiqun Lin, Gary Heiman, Hyunmi Choi 5:06 p.m. S24.009 Outcomes and Resource Utilization Associated with Readmissions after laser interstitial thermal therapy for refractory epilepsy: A Nationwide Readmission database study (2010-2018)–Varun Kumar, Mark Warman, Parisha Bhatia, Chirag Narshibhai Savani, Tejinder Singh 5:18 p.m. S24.010 Frequency of New Onset Seizures Amongst Adult Hospitalized Patients with COVID-19; A Systematic Review and Meta-Analysis–Daniah Shamim, Fatima Ashraf Ashraf, Gary S. Gronseth
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
13
SCIENTIFIC SESSIONS Tuesday, April 5 3:30 p.m.–5:30 p.m. PT
S25 Autoimmune Neurology 2: Clinical Trials and Treatment 3:30 p.m.
CME
2
S25.001
Anti-C1q Therapy ANX005 Inhibits CSF Antibody-Driven Complement Activity Elevated in Early Stage Guillain-Barré Syndrome– Poojan Suri, Sethu Sankaranarayanan, Ellen Cahir McFarland, Henk-Andre Kroon, Zhahirul Islam, Ted Yednock
3:42 p.m.
S25.002
Effect of Combined Intravenous Immunoglobulin and Classical Complement Inhibitor ANX005 in Guillain-Barré Syndrome–Thomas Harbo, Zhahirul Islam, Nowshin Papri, Shoma Hayat, Ananna Rahman, Israt Jahan, Gurudas Mondal, Sadekur Rahman Sarkar, Eric Humphriss, Ping Lin, Sanjay C. Keswani, Dean Richard Artis, Anita Grover, Henk-Andre Kroon, Quazi Deen Mohammad
3:54 p.m.
S25.003
WITHDRAWN
4:06 p.m.
S25.004
Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study–James F. Howard, Vera Bril, Tuan Hoang Vu, Chafic Y. Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Peter Ulrichts, Caroline T’ joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza
4:18 p.m.
S25.005
Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Open-label Extension–James F. Howard, Tuan Hoang Vu, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Nishi Rampal, Andreas Meisel
4:30 p.m.
S25.006
Real-world experience of eculizumab treatment for generalized myasthenia gravis: initial data from a registry of patients with generalized myasthenia gravis in the USA–Pushpa Narayanaswami, Gary Raymond Cutter, Richard J. Nowak, Ericka P. Greene, Srikanth Muppidi, Tahseen Mozaffar, Ema Rodrigues, Houari Korideck, James F. Howard
4:42 p.m.
S25.007
Serum IgG and Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Improvement in MG-ADL in Generalized Myasthenia Patients–Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven G. Meuth, Richard J. Nowak, Dianna Quan, Teresa Sevilla, Leona Ling, Yaowei Zhu, Keith Karcher, Sindhu Ramchandren, Hong Sun
4:54 p.m.
S25.008
Therapeutic Plasma Exchange in the Management of Stiff Person Syndrome Spectrum Disorders: A Case Series and Review of the Literature–Shuvro Roy, Nicolas Mercure-Corriveau, Yujie Wang, Danielle Obando, Xianming Zhu, Laetitia Daou, Aaron Tobian, Evan M. Bloch, Scott Douglas Newsome
5:06 p.m.
S25.009
Long-term Efficacy of Satralizumab in Aquaporin-4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Open-label Extension Periods of SAkuraSky and SAkuraStar–Ingo Kleiter, Anthony Traboulsee, Jacqueline Palace, Takashi Yamamura, Kazuo Fujihara, Albert Saiz, H. Christian Von Buedingen, Daniela Stokmaier, Gaelle Klingelschmitt, Jeffrey L. Bennett
5:18 p.m.
S25.010
Long-term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkuraSky and SAkuraStar Studies–Benjamin M. Greenberg, Jerome De Seze, Albert Saiz, Takashi Yamamura, Michael R. Yeaman, Carole Marcillat, Xiujing Kou, Kristina Weber, Kathleen Blondeau, Brian G. Weinshenker, Francesco Patti
14
2022 AAN Annual Meeting
ADVERTISEMENT
HELP YOUR ADULT PATIENTS WITH TARDIVE DYSKINESIA (TD)
Take.
Control.
Not actual size
Actor portrayal
INGREZZA is the simple, once-daily choice to reduce TD severity1
THE SIMPLE CHOICE
SYMPTOM REDUCTION
SAVINGS & SUPPORT
Once-daily INGREZZA is the simple choice to support patient adherence1,2,*
INGREZZA 80 mg reduced uncontrolled movements in 7 of 10 patients at 6 weeks (post hoc analysis)1,3,†
$10 or less out-of-pocket is what most patients pay for INGREZZA4
*Compared to once-daily regimens, timing adherence is 27% lower for twice-daily regimens, according to a meta-analysis of 51 studies in patients with chronic conditions. † Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score.
MOST PRESCRIBED TREATMENT FOR TARDIVE DYSKINESIA5
Click to View the Complete INGREZZA Story
Visit Booth 300
Important Information INDICATION & USAGE INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
WARNINGS & PRECAUTIONS (continued)
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.
Parkinsonism INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.
WARNINGS & PRECAUTIONS Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.
ADVERSE REACTIONS
QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.
Please see INGREZZA full Prescribing Information.
REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527-539. 3. Data on file. Neurocrine Biosciences, Inc. 4. Data on file as of Q1 2021. Neurocrine Biosciences, Inc. 5. Data on file as of Q3 2021. Neurocrine Biosciences, Inc. ©2022 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-1889 03/2022
SCIENTIFIC SESSIONS Wednesday, April 6 1:00 p.m.–3:00 p.m. PT
S26 MS Imaging
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. S26.001 Magnetic resonance imaging criteria at onset to differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study–Magnus Spangsberg Boesen, Morten Bjorn Blinkenberg, Lau Thygesen, Jurgita Ilginiene, Annika Langkilde 1:12 p.m. S26.002 Differences in age-related retinal and cortical atrophy rates in multiple sclerosis–Christian Cordano, Bardia Nourbakhsh, Hao H. Yiu, Nico Papinutto, Eduardo Caverzasi, Ahmed Mohamed Taha Abdelhak, Frederike Cosima Oertel, Alexandra Beaudry-richard, Adam Santaniello, Simone Sacco, Daniel Bennett, Apraham Gomez, Christina Sigurdson, Stephen L. Hauser, Bruce A. C. Cree, Roberta Magliozzi, Roland G. Henry, Ari Green 1:24 p.m. S26.003 Phenotyping Of Multiple Sclerosis Lesions According To Innate Immune Cell Activation Using TSPO-PET–Marjo Nylund, Marcus Sucksdorff, Markus Matilainen, Eero Polvinen, Jouni Tuisku, Laura Airas 1:36 p.m. S26.004 Machine Learning-Based Detection of Slowly Expanding Lesions using Radiomic Features from Cross-sectional Brain MRI–Bastien Caba, Arie Gafson, Aurélien Lombard, Dawei Liu, Alexandre Cafaro, Enzo Battistella, Rodrigo Perea, Elizabeth Fisher, Nathalie Franchimont, Douglas L. Arnold, Colm Elliott, Nikos Paragios, Shibeshih Belachew 1:48 p.m. S26.005 A Combined Lesion Distribution Parameter Predicts Disease Progression in Multiple Sclerosis–Eero Polvinen, Markus Matilainen, Marjo Nylund, Marcus Sucksdorff, Laura Airas 2:00 p.m. S26.006 Defining the spinal cord reserve concept in multiple sclerosis - measurement and association with disability of the spinal cord canal area–Jaume SastreGarriga, Alex Rovira, Aran Garcia-Vidal, Pere Carbonell, Manel Alberich, Cristina Auger, Mar Tinore, Xavier Montalban, Debora Pareto 2:12 p.m. S26.007 Slowly-Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression–Paolo Preziosa, Elisabetta Pagani, Alessandro Meani, Lucia Moiola, Mariaemma Rodegher, Massimo Filippi, Maria Assunta Rocca 2:24 p.m. S26.008 Paramagnetic Rims in Treatment Naïve Persons Around the Time of Multiple Sclerosis Diagnosis–Margareta A. Clarke, Rachael Elaine Cheek, Reece Clarke, Colin McKnight, Joy Derwenskus, James Everett Eaton, Run Fan, Fei Ye, Kristin O’Grady, Baxter Rogers, Seth A. Smith, Francesca Bagnato 2:36 p.m. S26.009 Machine Learning-Based Prediction of New Multiple Sclerosis Lesion Formation Using Radiomic Features from Pre-Lesion Normal Appearing White Matter–Bastien Caba, Arie Gafson, Aurélien Lombard, Dawei Liu, Alexandre Cafaro, Enzo Battistella, Rodrigo Perea, Elizabeth Fisher, Nathalie Franchimont, Douglas L. Arnold, Colm Elliott, Nikos Paragios, Shibeshih Belachew 2:48 p.m. S26.010 Serum Neurofilament Light Associates with Microglial Activation in the Multiple Sclerosis Brain–Maija Saraste, Markus Matilainen, Marcus Sucksdorff, David Leppert, Jens Kuhle, Laura Airas
16
2022 AAN Annual Meeting
S27 Innovations in Neuro-oncology
CME
2
1:00 p.m. 2022 Neuro-oncology Scientific Award: This award recognizes an individual from any discipline and of any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology. Recipient: Elizabeth R. Gerstner, MD, Boston, MA 1:12 p.m. S27.002 Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation–Scott R. Plotkin, Ludwine Messiaen, Pierre Wolkenstein, Patrice Susan Pancza, Susan Huson, Gareth Evans, Eric Legius 1:24 p.m. S27.003 Revised diagnostic criteria and nomenclature for neurofibromatosis 2 and schwannomatosis: an international consensus recommendation–Scott R. Plotkin, Ludwine Messiaen, Eric Legius, Patrice Susan Pancza, Susan Huson, Pierre Wolkenstein, Gareth Evans 1:36 p.m. S27.004 Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid–Wei Gu, Andreas Rauschecker, Elaine Hsu, Kelsey Zorn, Yasemin Sucu, Scot Federman, Shaun Arevalo, Hannah Sample, Eric Nguyen, Eric Talevich, Bardia Nourbakhsh, Carl Aaron Gold, Bruce A. C. Cree, Vanja C. Douglas, Megan Richie, Maulik Shah, S. Andrew Josephson, Jeffrey Marc Gelfand, Steve Miller, Linlin Wang, Tarik Tihan, Michael R. Wilson 1:48 p.m. S27.005 Leptomeningeal Disease in Patients with Histone-Mutant Gliomas–Maria Diaz Ordonez, Carlos Correia, Andrew L. Lin, Alexandra M. Miller, Elena Pentsova 2:00 p.m. S27.006 Caregiver Distress and Burden Over Time in Newly Diagnosed Gliomas–Lauryn Hemminger, Chinazom Uchenna Ibegbu, Jennifer N. Serventi, Joy Ellen Burke, Jessica Faith Occhiogrosso, Benzi Kluger, Nimish A. Mohile 2:12 p.m. S27.007 Clinical and Molecular Determinants of Survival Outcomes in Glioblastoma Patients Treated with Immune Checkpoint Inhibitors–Pushan Richard Dasgupta, Heather Lin, Zaid Arif Soomro, Charles Bornstein, Kristin Alfaro-Munoz, Ying Yuan, John F. De Groot, Nazanin Koohbanani Majd 2:24 p.m. S27.008 Long-term survival and cognitive function follow up of primary CNS lymphoma treated with R-MVP followed by high dose chemotherapy with autologous stem cell transplant consolidation–Kate Elizabeth Therkelsen, Christian Grommes 2:36 p.m. S27.009 CAR-T Cell Therapy in Recurrent Primary CNS Lymphoma (PCNSL): A Phase 2 Clinical Trial–Jorg Dietrich, Yi-Bin Chen, Kathleen Mary Ellen Gallagher, Justin T. Jordan, Deborah A. Forst, Scott R. Plotkin, Kevin Arthur Lindell, Daniella Cook, Gabriel DePinho, Michael Andrew Trailor, Tracy T. Batchelor, Marcela Maus, Matthew Frigault 2:48 p.m. S27.010 Clinical and Pathologic Determinants of Outcome for Non-Optic Pathway Gliomas in Adults with Neurofibromatosis Type 1–Anna Piotrowski, Jian Campion, Rebecca M. Brown, Jose Diarte, Fausto Rodriguez, Tejus Bale, Sonika Dahiya, Laura Prichett, Ingo K. Mellinghoff, Jaishri Blakeley, Carlos Ramos
SCIENTIFIC SESSIONS Wednesday, April 6 1:00 p.m.–3:00 p.m. PT
S28 Health Care Disparities
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. S28.001 Gender Authorship in Accepted AAN Abstracts During the COVID-19 Pandemic–Minseon Kim, Reniba Babu, Anjail Sharrief, Kristin Angelica Brown, Suur Biliciler, Thy Nguyen 1:12 p.m. S28.002 Racial Disparities in Long-Term Functional Outcome After Traumatic Brain Injury: An update–Alex Y. Chen, Leticia Simo, Shalini Tummala, Rachel Mahas, Sonia Veronica Eden 1:24 p.m. S28.003 Strong Heart Study: Cultural Factors and Risk of Cardiovascular Disease and Stroke in American Indians/Alaskan Natives–Tyria Heath, Ka-Ho Wong, Cameron Arkin, Adam De Havenon 1:36 p.m. S28.004 Racial Disparities in Dementia and Parkinson’s Disease Incidence, Healthcare Utilization, and Outcomes among Medicare Beneficiaries–Jay B. Lusk, Catherine Barasch Ford, Amy Clark, Melissa Greiner, Kim Graham Johnson, Margarethe Goetz, Brystana Kaufman, Sneha Mantri, Ying Xian, Richard J. O’Brien, Emily O’Brien 1:48 p.m. S28.005 Predictors of ED Presentation Times in Stroke Code Patients–Razaz Mageid, Richa Sharma, Dalton Neu, Rita Okumu, Ranisha Parker, Adam S. Jasne, Rachel Forman 2:00 p.m. S28.006 Cerebral small vessel disease and depressive symptoms in adults living in precarious housing or homelessness: A network approach–Andrea Amy Jones, Melissa Woodward, Lianne Cho, Lily Zhou, Jacob Stubbs, Alasdair Barr, Allen Thornton, Alexander Rauscher, Donna Lang, William Panenka, William Honer, Thalia S. Field 2:12 p.m. S28.007 Neighborhood income inequality associated with functional independence after ischemic stroke: a cohort study–Kathryn Cote, Megan Elizabeth Pudlo, Emma Jost-Price, Lester Y. Leung 2:24 p.m. S28.008 Geographic Distribution of Neurologists in Rural Areas–Micaela Rose Owens, Jasmine Owens, Christopher J. Whiting 2:36 p.m. S28.009 Increasing Mortality from Ischemic Stroke in the US, Racial and Etiological Analysis–Ali Abbas Fadhil, Sarah Delozier, Sophia Sundararajan 2:48 p.m. S28.010 Embedding general neurology and tertiary care headache services in community health centers (CHCs) in Boston, MA: establishment and early experiences–Angeliki Vgontzas, Cynthia So-Armah, Nadia Raymond, Pivel Morton, Juan Jaime de Zengotita
S29 Preclinical and Observational Studies of Neuromuscular Diseases 1:00 p.m.
CME
2
S29.001
PROMISE-MG: A Multicenter Prospective Observational Comparative Effectiveness Study of Myasthenia Gravis Treatments–Pushpa Narayanaswami, Donald B. Sanders, Jeff Guptill, Fan Li, Rishi Desai, Bo Liu, Jurgen Venitz, Andrew C. Krueger, Kathie Marie Bibeau, PROMISE-MG Study Group
1:12 p.m.
S29.002
Preclinical Pharmacology and Toxicology of intrathecally infused AAV9-hABCD1, a gene therapy candidate for AMN, in Non-Human Primates–Vidyullatha Vasireddy, Sean W. Clark, Mark Emory Cartwright, Karen Kozarsky, David William Anderson
1:24 p.m.
S29.003
INSPIRE-IBM: An NIH-funded, two-year, multicenter, observational study in inclusion body myositis (IBM)–Marie Wencel, Namita Goyal, Tahseen Mozaffar, The INSPIRE-IBM Study Group
1:36 p.m.
S29.004
Cell Culture Based Platform for High Throughput Screening of Biomolecules with Neuroprotective Effect Against Bortezomib-Induced Peripheral Neuropathy (BIPN) –Irina Utkina-Susunova, Hai Li, Charles Karan, Serge Przedborski
1:48 p.m.
S29.005
Repeat expansion size predicts age of onset in RFC1 CANVAS and disease spectrum–Andrea Cortese, Riccardo Curro, Natalia Dominik, Marios Hadjivassiliou, Annette Hartmann, Nazli Basak, Elisa Vegezzi, Marina Kennerson, Richard Roxburgh, Nigel G. Laing, Davide Pareyson, Franco Taroni, Fiore Manganelli, Paola Mandich, Gian Maria Fabrizi, Chiara Briani, Sinead Murphy, Manu Jokela, Jon Infante Ceberio, Filippo Santorelli, Alfredo Brusco, Gabriella Silvestri, Stephan Zuchner, Tanya Stojkovic, Charlotte J. Sumner, Matthis Synofzik, Mary Reilly, Henry Houlden, on Behalf of the RFC1 Study Group
2:00 p.m.
S29.006
Inflammasome inhibitors for the treatment of muscular dystrophies–Nicolas Dubuisson, Michel Abou Samra, Romain Versèle, Maria America Davis-López de Carrizosa, Camille Selvais, Laurence Noel, Peter Y.K. Van den Bergh, Sonia Brichard
2:12 p.m.
S29.007
Motor Outcomes to Validate Evaluations in Facioscapulohumeral muscular dystrophy (MOVE FSHD): Protocol for an observational study.–Michaela Walker, Russell Butterfield, John W. Day, Katy Eichinger, Bakri Elsheikh, Anna Faino, Seth Friedman, Kiley Higgs, Nicholas Elwood Johnson, Peter Lawrence Jones, Doris G. Leung, Leann Lewis, William Martens, Dennis W. Shaw, Perry Shieh, S H. Subramony, Jaya Raghav Trivedi, Leo Hong-Li Wang, Matthew P. Wicklund, Alrabi Tawil, Jeffrey Statland
2:24 p.m.
S29.008
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): Baseline characteristics–Jeffrey Statland, Katy Eichinger, Michael McDermott, Kiley Higgs, Michaela Walker, Doris G. Leung, Sabrina Sacconi, Karlien Mul, Valeria A. Sansone, Elena Carraro, Leo Hong-Li Wang, Perry Shieh, Bakri Elsheikh, Samantha Jo LoRusso, Russell Butterfield, Nicholas Elwood Johnson, Alrabi Tawil, Jeffrey Statland
2:36 p.m.
S29.009
Bioassay-confirmed Pathogenic De Novo ATP1A1 Variants Cause a Complex Neurodevelopmental Syndrome–Maike Dohrn, Adriana Rebelo, Siddharth Srivastava, Gerarda Cappuccio, Robert Smigiel, Alka Malhotra, Donald Basel, Ingrid M.B. Van de Laar, Rinze F Neuteboom, Nicola Brunetti Pierri, Stephan Zuchner
2:48 p.m.
S29.010
Ataxia And Cough Are Indicative For Biallelic RFC1 Repeat Expansions In Hereditary Sensory And Autonomic Neuropathy–Danique Beijer, Maike Dohrn, Jonathan De Winter, Sarah Fazal, Andrea Cortese, Tanya Stojkovic, Gorka Fernandez-Eulate, Mattia Gentile, Gauthier Remiche, Matthis Synofzik, Peter De Jonghe, Stephan Zuchner, Jonathan Baets
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
17
SCIENTIFIC SESSIONS Wednesday, April 6 3:30 p.m.–4:00 p.m. PT
S30 Autonomic Disorders
3:30 p.m.–5:30 p.m. PT CME
0.5
3:30 p.m. 2022 Irwin Schatz Award for Autonomic Disorders: This award recognizes young investigators who have advanced the field of autonomic disorders, or senior investigators who have made major contributions to the field. Recipient: Eduardo E. Benarroch, MD, FAAN, Rochester, MN 3:42 p.m. S30.002 Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure–Wolfgang Singer, Ann M. Schmeichel, Mohammad Shahnawaz, James Schmelzer, David Michael Sletten, Tonette Gehrking, Jade Gehrking, Mariana Suarez, Pinaki Pramathadhip Misra, Claudio Soto, Phillip A. Low
18
2022 AAN Annual Meeting
S31 Advances in Migraine Therapeutics
CME
2
3:30 p.m. 2022 Harold Wolff-John Graham Award: An Award for Headache/ Facial Pain Research: This award recognizes early investigators who have submitted research results in the field of headache and facial pain. Recipient: Caroline Ran, PhD, Stockholm, Sweden 3:42 p.m. S31.002 Patients With Chronic Migraine Improving to ≤4 Monthly Headache Days is an Effective Treatment Goal for CM–Robert G. Kaniecki, Deborah I. Friedman, Joe Hirman, Roger Cady 3:54 p.m. S31.003 Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by Cortical Spreading Depression (CSD)–Andrew Strassman, Agustin Melo Carrillo, Timothy Houle, Aubrey Manack Adams, Mitchell F. Brin, Rami Burstein 4:06 p.m. S31.004 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults–Richard Bertz, Mary Kathleen Donohue, Jennifer Madonia, Rajinder K. Bhardwaj, Joseph Stringfellow, Matt Anderson, David Stock, Beth Morris, Vladimir Coric, Robert Croop 4:18 p.m. S31.005 Efficacy and Safety of Erenumab 70 mg in Adult Patients with Chronic Migraine: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled DRAGON Study–Shuu-Jiun Wang, Byung-kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su, Shengyuan Yu 4:30 p.m. S31.006 Within-Person Analysis of Ubrogepant Treatment of Mild Versus ModerateSevere Headache Pain during a Phase 3 Long-Term Safety Extension Trial–Richard B. Lipton, David W. Dodick, Peter Goadsby, Sung Yun Yu, Brittany L. Jordan, Julia Ma, Janette Contreras-De Lama, Rami Burstein 4:42 p.m. S31.007 Six-month Safety and Efficacy of Fremanezumab in Migraine: Pooled Analysis from the Phase 3 FOCUS and HALO Studies–Larry Charleston, Verena Ramirez Campos, Xiaoping Ning, Lynda Krasenbaum, Lindsay Janka, Yoel Kessler, Stephanie J. Nahas 4:54 p.m. S31.008 Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis–David W. Dodick, Richard B. Lipton, Stephanie J. Nahas, Patricia Pozo-Rosich, Peter J. McAllister, Laszlo Mechtler, Julia Ma, Brett Dabruzzo, Matthew Beau Dufek, Lawrence Severt, Michelle Finnegan, Joel M. Trugman 5:06 p.m. S31.009 Utility of a Novel, Combined Biofeedback-Virtual Reality Tool as Add-on Treatment for Chronic Migraine–Ami Zarrillo Cuneo, Robin Yang, Ke Wang, Haoran Zhou, Sarah Goh, Yuntao Wang, John Raiti, Daniel Krashin, Natalia Murinova 5:18 p.m. S31.010 Reduction in Opioid Prescription Fills and Morphine Milligram Equivalent Dispensed Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study–Ali Mohajer, Jared Scripture, Gilbert J. L’Italien, Linda Harris, Vladimir Coric, Noah Rosen
SCIENTIFIC SESSIONS Wednesday, April 6 3:30 p.m.–5:30 p.m. PT
S32 Movement Disorders: Dystonia and Tremor Disorders
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. 2022 Movement Disorders Research Award: This award recognizes an individual for outstanding work in the field of Parkinson’s disease or other movement disorders for either a single outstanding contribution or for lifetime achievement. Recipient: Charles H. Adler, MD, PhD, FAAN, Scottsdale, AZ 3:54 p.m. S32.003 A Virtual Reality Platform to Facilitate Training on Treatment of Lower Limb Spasticity With OnabotulinumtoxinA–Erin McGonigle, Sherrya A. Downie, Alberto Esquenazi, Gerard E. Francisco, Monica Verduzco-Gutierrez, Kimberly Ifantides, Amin Boroujerdi, Adam Buser, Gaurang Patel, Nicholas Ketchum 4:06 p.m. S32.004 Effect of Unilateral & Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation on Vocal Tremor and Voice in Patients with Essential Tremor and Vocal Tremor. A Case Series.–Caroline Wilson, Kathryn Ruckart, Mary MoyaMendez, Lyndsay L. Madden, Carolyn Ann Nguyen, Jessica Tate, Mustafa S. Siddiqui 4:18 p.m. S32.005 Repetitive Transcranial Magnetic Stimulation to the Inferior Parietal Lobule in Task-Specific Focal Hand Dystonia: A Randomized, Sham control, Double Blind, Crossover Study–Seethalekshmi Bhadran, Roopa Rajan 4:30 p.m. S32.006 Role of supplementary motor area in cervical dystonia and sensory tricks–Hyun Joo Cho, Rebecca Waugh, Pattamon Panyakaew, Karin Mente, Demelio Alejandro Urbano, Mark Hallett, Silvina Horovitz 4:42 p.m. S32.007 Histopathology of the Cerebellar Cortex in Essential Tremor and Other Neurodegenerative Motor Disorders: Comparative Analysis of 311 Brains–Elan D. Louis, Regina Martuscello, Morgan C. McCreary, Sheng-Han Kuo, Jean Paul Vonsattel, Phyllis Faust 4:54 p.m. S32.008 Quantitative motion analysis and clinical characteristics of Holmes tremor as compared to other tremor types–Sally Rebecca Williams, Johnathan Lucas McKay, Douglas Bernhard, Mark Saad, Anh-Thu Ngo Vu, Richa Tripathi, Stewart A. Factor, Christine Doss Esper 5:06 p.m. S32.009 Translational Pharmacology of PRAX-944, a Novel T-type Calcium Channel Blocker for the Treatment of Essential Tremor–Corey Puryear, Liam Scott, Gabriel M. Belfort, Shane Raines, Zoe Hughes, Bernard M. Ravina, Marion Wittmann 5:18 p.m. S32.010 Prevalence of Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Normal Dopamine Transporter Imaging–Yajing Yan Yan Xiong, Kelly Nudelman, Lola Shukla, Jeanine Schulze, Marco Antonio Abreu, Tatiana Foroud, Lana Chahine
S33 Cerebrovascular Disease: Basic Sciences and Cohort Studies
CME
2
3:30 p.m. S33.001 Histone Deacetylase 3 Inhibition Decreases Cerebral Edema and Protects the Blood-Brain Barrier after Stroke–Hui Lu, Chin Lin, Victoria Clendaniel, Rudy Matheson, Marc Fisher, Eng Lo, Magdy H. Selim, Amjad Shehadah 3:42 p.m. S33.002 Role of ACE Polymorphism in Acute Ischemic Stroke–Alvee Saluja, Ankit Goyal, Kallur Nava Saraswathy, Priya Bansal, Kallur Saraswathy 3:54 p.m. S33.003 Skin Capillary Amylin Deposition Resembles Brain Amylin Vasculopathy–Saurav Das, Nirmal Verma, Gregory A. Jicha, Donna M. Wilcock, Larry B. Goldstein, Florin Despa 4:06 p.m. S33.004 Correlation between Optical Coherence Tomography Angiography ( OCT- A) changes at 3 to 6 weeks and functional outcome ( modified Rankin Scale – mRS) at 3 months of onset of acute ischemic stroke due to Extracranial Internal Carotid Artery Atherosclerotic Disease (ECAD)–Biswamohan Mishra, Awadh K. Pandit, Rohan Chawla, Swati Phuljhele, Padma Vasantha Hadakasira, Ajay Garg, Achal K. Srivastava, Venugopalan Y Vishnu, Rohit Bhatia, Shubham Misra 4:18 p.m. S33.005 Association of Plasma NfL Levels with Risk of Cardiovascular Disease in the Framingham Heart Study–Hugo Javier Aparicio, Jayandra J. Himali, Dibya Himali, Jose Rafael Romero, Vasileios-Arsenios Lioutas, Matthew Pase, Claudia L. Satizabal, Alexa Beiser, Ramachandran Vasan, Sudha Seshadri 4:30 p.m. S33.006 Sirtuin 1 Mediated Modulation of Inflammasome Signaling Confers Neuroprotection in Rodent Model of Ischemic Stroke Following Endovascular Mesenchymal Stem Cell Therapy–Deepaneeta Sarmah, Aishika Datta, Antra Chaudhary, Kiran Kalia, Anne-Marie Rodriguez, Dileep R. Yavagal, Pallab Bhattacharya 4:42 p.m. S33.007 Correlation Between Serum Low Density Lipoprotein (ldl) Levels And Hemorrhagic Stroke Severity: A Retrospective Review From Siren (preliminary findings)–Oladotun Victor Olalusi, Rufus O. Akinyemi, Mayowa Owolabi, Akintomiwa Makanjuola 4:54 p.m. S33.008 Vascular Territories In Spinal Cord Strokes: Topographic Analysis In 61 Cases–David Orlando Acero-Garces, Paula Barreras, Susana Carolina Dominguez Penuela, Carlos A. Pardo-Villamizar 5:06 p.m. S33.009 Temporal Evaluation of MicroRNA Expression profile in Acute Anterior Circulation Large Vessel Occlusion Stroke–Shraddha Mainali, Amy Hite, Paolo Fadda, Naduparambil K. Jacob, Elliott Crouser, Daniel Woo 5:18 p.m. S33.010 Genetic Analyses Support a Causal Role of Lung Cancer in Ischemic Stroke– Kevin Nhat Vanent, Julian Acosta, Cameron Both, Audrey Leasure, Victor Manuel Torres-Lopez, Natalia Szejko, Cyprien Rivier, Adam De Havenon, Richa Sharma, Michael Levitt, Kevin N. Sheth, Guido Jose Falcone
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
19
SCIENTIFIC SESSIONS Thursday, April 7 1:00 p.m.–3:00 p.m. PT
S34 Research Methodology and Education
1:00 p.m.–3:00 p.m. PT CME
2
1:00 p.m. S34.001 A Formal Mentored Peer Review Program Quantitatively Improves the Quality of Peer Review–Whitley Warfield Aamodt, Ariel Maia Lyons-Warren, Kathleen M. Pieper, Roy E. Strowd 1:12 p.m. S34.002 Gender Disparities in Neurology Research–Deborah Hall, Carolyn Cahill, AnaClaire L. Meyer, Amanda C. Peltier, Marisela E. Dy-Hollins, Myla D. Goldman 1:24 p.m. S34.003 The Neurology® Resident & Fellow Section (RFS): Performance, Internationalization, and Recent Challenges–Guillermo Ruben Delgado-Garcia, Whitley Warfield Aamodt, Jose G. Merino, Roy E. Strowd 1:36 p.m. S34.004 Enhancing Quality Improvement Education in a Neurology Residency Program– Sushma Kola, Monica Ann Krause, Rafid Mustafa, Andrea N. Leep Hunderfund, Lyell K. Jones 1:48 p.m. S34.005 The American Academy of Neurology Residents as Educators Workgroup Initiative: Nurturing future neurology educators–Miguel Chuquilin Arista, Joseph E. Safdieh, Marie C. Eugene, Dara V. Albert, Erica A. Schuyler, Igor Rybinnik, Doris Kung, Taylor Bartlett Harrison, Suur Biliciler, Adam Quick, Erin Furr-Stimming 2:00 p.m. S34.006 Enhancing medical student interest in careers in the clinical neurosciences through a hands-on procedure workshop–Collin James Sanderson, Khadijah Mazhar, Hina N. Dave 2:12 p.m. S34.007 A Longitudinal, Integrated Teleneurology Trainee Curriculum–Steve Choongheon Han, Rebecca Stainman, Neil A. Busis, Scott Grossman, Sujata P. Thawani, Arielle Marisa Kurzweil 2:24 p.m. S34.008 Scoping Review: Innovations in Clinical Neurology Education–William Denney Zimmerman, Melissa Betts Pergakis, Emily Gorman, Nicholas Allen Morris 2:36 p.m. S34.009 Adjusting to a new normal: A single center survey of neurology applicants participating in virtual interviews–Syed Daniyal Asad, Pireh Ansari, Erica A. Schuyler 2:48 p.m. S34.010 Experiential learning of communication and professionalism for neurology faculty through virtual objective structured clinical examinations (OSCEs): Methodology and preliminary survey results–Cen Zhang, Ariane Lewis, Perrin A. Pleninger, Aaron Lane Nelson, Lindsey Gurin, Sondra Zabar, Steven Galetta, Laura J. Balcer, Arielle Marisa Kurzweil
20
2022 AAN Annual Meeting
S35 Cerebrovascular Disease: Meta-analyses and Outcomes Research
CME
2
1:00 p.m. S35.001 Mortality and One-Year Readmission Rates Following Hospital Discharge in a Large Canadian Cerebral Venous Thrombosis Cohort–Lily Zhou, Long Ngo, Thalia S. Field 1:12 p.m. S35.002 Sickle Cell Disease and Stroke: Data from the Florida Stroke Registry–Nastajjia Krementz, Kefeng Wang, Carolina Gutierrez, Negar Asdaghi, Ralph L. Sacco, Jose Gabriel Romano, Tatjana Rundek, Iszet Campo-Bustillo 1:24 p.m. S35.003 Age-Related Macular Degeneration is Associated with Cerebral Amyloid Angiopathy–Bhrugun Anisetti, Hossam Youssef, Ahamed Mamoun Elkhair, Michelle P. Lin 1:36 p.m. S35.004 One-Year Survival and Related Prognostic Factors of Stroke Patients: The PROVE-Stroke Study–Mahshid Givi, Negin Badihian, Mazieh Taheri, Roya Rezvani Habibabadi, Mohammad Saadatnia, Nizal Sarrafzadegan 1:48 p.m. S35.005 Neurogenic Cardiac Outcome in Patients with Acute Ischemic Stroke: The Brain-Heart Connection–Jiangyong Min, Grant James Young, Abdullah Umar, Andrew Kampfschulte, Nabil Wees, Nadeem I. Khan, Malgorzata Miller, Muhib Khan 2:00 p.m. S35.006 The Efficacy of PFO Closure in Addition to Medical Management in Reducing the Recurrence of Cryptogenic Stroke - an Umbrella Meta-Analysis–Chetna Dengri, David Pielykh, Greshaben Patel, Muhammad Imtiaz Tar, Aakash Baskar, Yogesh Kothari, Satish Tadepalli, Appala Suman Peela, Syed Nazeer Mahmood, Amit Munshi Sharma, Urvish K Patel, Shamik Shah 2:12 p.m. S35.007 Mobile Stroke Units in Acute Ischemic Stroke: A Network Meta-analysis– Abdulrahman Ibrahim Hagrass, Mohammed Al-kafarna, Aya Mamdouh Fayoud, Aboalmagd Hamdallah, Bashar Khaled Almaghary, Mohammed Tarek Elgammal, Sarah Makram Makram, Khaled Mohamed Ragab, Mohamed Abdelhady Abdelsadik Mostafa, Mohamed Fahmy Doheim 2:24 p.m. S35.008 An Association of Antiplatelet Use and Outcomes In Aneurysmal Subarachnoid Hemorrhage–Bianca Haley Persaud, Kareem Joudi, Christoph Stretz, Nicholas S. Potter, Shawna M. Cutting, Linda C. Wendell, Bradford B. Thompson, Karen L. Furie, Jesse Menville, Ali Mahta 2:36 p.m. S35.009 Cholesterol-Lowering Medication Use Prior to Ischemic Strokes Secondary to Large Artery Atherosclerosis or Small Vessel Disease: A Single Center Study–Anisha Garg, Anna Baker, Kamil Faridi, Adam De Havenon, Kevin N. Sheth, Rachel Forman, Richa Sharma 2:48 p.m. S35.010 Contrast-Enhanced Transcranial Doppler Ultrasonography Versus Transesophageal Echocardiography as Screening Tool in Embolic Stroke–Farah Yolanda Fourcand, Nancy Gadallah, Arifa Ghori, Danisette Torres, Spozhmy Panezai, Laura Suhan, Siddhart Kumar Mehta, Jawad F. Kirmani
SCIENTIFIC SESSIONS Thursday, April 7 1:00 p.m.–3:00 p.m. PT
S36 Movement Disorders: Clinical and Pathologic Characterization of Neurodegenerative Movement Disorders
3:30 p.m.–4:00 p.m. PT CME
2
1:00 p.m. S36.001 Clinical spectrum of corticobasal degeneration: review of 238 autopsyconfirmed patients–Shunsuke Koga, Aya Murakami, Ece Bayram, Naomi Kouri, Irene Litvan, Dennis W. Dickson 1:12 p.m. S36.002 Later Onset Multiple System Atrophy: Poor Prognosis and Diagnostic Challenge–Hiroaki Sekiya, Shunsuke Koga, Yoshihisa Ohtsuka, Norio Chihara, Takehiro Ueda, Kenji Sekiguchi, Yukihiro Yoneda, Yasufumi Kageyama, Riki Matsumoto, Dennis W. Dickson 1:24 p.m. S36.003 Tau histopathological lesion type correlates of structural magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) biomarkers in 4-repeat tauopathies.–Arenn Faye Carlos, Nirubol Tosakulwong, Stephen Weigand, Marina Buciuc, Farwa Ali, Heather Clark, Hugo Botha, Joseph Duffy, Rene Utianski, Mary M. Machulda, Christopher Schwarz, Robert I. Reid, Matthew Senjem, Clifford R. Jack, J. Eric Ahlskog, Dennis W. Dickson, Keith A. Josephs, Jennifer Louise Whitwell 1:36 p.m. S36.004 Inhibition of C1q Reduces Nerve Damage as Measured by Neurofilament Light Chain in the HD R6/2 Mouse Model–Alessia Tassoni, Vidhu Mathur, Joseph Vereen, Ellen Cahir McFarland, Sethu Sankaranarayanan, Ted Yednock, Yaisa Andrews-zwilling 1:48 p.m. S36.005 Cutaneous Alpha-Synuclein Detection in Patients with Suspected Synucleinopathies–Christopher H. Gibbons, Bailey Bellaire, Roy L. Freeman, Todd D. Levine 2:00 p.m. S36.006 Glucocerebrosidase Deficiency Mediates Propagation of Protein Aggregation in Neurodegeneration via Modification of Extracellular Vesicles–Arnav Khera, Bernice Lin, Kathryn Jewett, Ruth Thomas, Chi Q. Phan, Selina Yu, Raja Elizabeth Estes, Leo Pallanck, Jessica Young, Marie Ynez Davis 2:12 p.m. S36.007 Preclinical In Vivo Characterization of UCB0599, an Orally Available, Small Molecule Inhibitor of a-Synuclein Misfolding in Development for Parkinson’s Disease–Diana Luz Price, Asma Khan, Rachel Angers, Alvaro Jesus Cardenas, Maria Key Prato, Martin Citron, Doug Bonhaus, Anja-Leona Biere 2:24 p.m. S36.008 Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations–Julian Paul Agin-Liebes, Richard Hickman, Jean Paul Vonsattel, Xena Flowers, Richard P. Mayeux, Matthew Surface, Karen S. Marder, Roy Alcalay 2:36 p.m. S36.009 Longitudinal Treatment Patterns for Chorea in Patients with Huntington Disease: Data from Enroll-HD–Erin Furr-Stimming, Daniel O. Claassen, Ginny Sen, Mallory Farrar, Ericha Franey, Chuck Yonan, Dietrich Haubenberger 2:48 p.m. S36.010 Mitochondrial Antigen Presentation In Correlation To Parkinson’s Disease-like Symptoms.–Moustafa Nouh Badr, Annie Laplante, Diana Matheoud
S37 Global Neurology
CME
0.5
3:30 p.m. S37.001 Age-, sex-, and risk-specific burden of neurological diseases in the Middle East and North Africa from 1990 to 2019: A systematic analysis of data from the Global Burden of Disease Study 2019–Abolfazl Avan, Derrick Bennett, Vladimir Hachinski, Saverio Stranges, Mayowa Owolabi, Valery L. Feigin 3:42 p.m. S37.002 Characteristics of Adults With First-Ever and Recurrent Strokes in Zambia– Aparna Nutakki, Lorraine Chishimba, Mashina Chomba, Stanley Zimba, Deanna Saylor
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
21
SCIENTIFIC SESSIONS Thursday, April 7 3:30 p.m.–5:30 p.m. PT
S38 All Things HIV and ID
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. 2022 AAN Neuro-infectious Disease Award: This award recognizes individuals who have made a contribution to neuro-infectious disease research. Recipient: Payal B. Patel, MD, Bellevue, WA 3:42 p.m. S38.002 Evolving Clinical and Epidemiological Patterns of CNS Infections in People with HIV Over 25 Years–Miranda Wan, Michael John Gill, Kevin Fonseca, Christopher Power, Raynell Lang 3:54 p.m. S38.003 Decreased Myelin Content and Associated Cognitive Performance in Adults Living with Perinatally-Acquired HIV–Payal B. Patel, Alyssa Vecchio, Peter Yi Ch’en, Jennifer Chiarella, Shannon Kolind, Michael N. Hoff, Serena Spudich, Christina Marra, Robert H. Paul, Swati Rane Levendovszky 4:06 p.m. S38.004 Unique Brain-Specific Antibody Signatures in Chronic HIV Infection–Marianna Spatola, Shibani Sharon Mukerji, Dana H. Gabuzda, Galit Alter 4:18 p.m. S38.005 Circadian trends in CSF Amyloid beta-42 levels in HIV–Visesha Kakarla, Ahmed Chenna, Christos John Petropoulos, Yolanda Lie, Dusica Curanovic, Melanie Crescini, John Winslow, Erin Sundermann, Scott L. Letendre, Ronald J. Ellis 4:30 p.m. S38.006 Time to Confirmed Neuro-infection Diagnoses: Characterization of Current Trends and Implications for Diagnostic Testing Approaches–Rachelle Dugue, Eileen Harrigan, Carla Kim, Abhilasha Pankaj Boruah, Kiran Thakur 4:42 p.m. S38.007 Infectious Causes of Chronic Meningitis in Neurosurgical Patients–Tyler Crissinger, Joseph Seemiller, John Herbst, J. David Avila, Kelly Baldwin 4:54 p.m. S38.008 Acute seizure risk in encephalitis; analysis and modelling of 436 patients from two independent multi-centre cohorts–Greta Wood, Mark Alexander Ellul, Rhys Huw Thomas, Ava Maria Easton, Girvan Burnside, Cordelia Dunai, Ali Alam, Sarah Aimee Boardman, Ceryce Collie, Hannah Castell, Bethany Facer, Sylviane Defres, Julia Granerod Whitehouse, David William Brown, Angela Vincent, Tom Solomon, Benedict Daniel Michael 5:06 p.m. S38.009 Utility and Feasibility of Portable Ultra-Low Field MRI in Patients with Progressive Multifocal Leukoencephalopathy–Karan Divyam Kawatra, Serhat Vahip Okar, Samantha By, Yair Mina, Anita M. Fletcher, Shila Azodi, Daniel Reich, Govind Nair, Irene CM Cortese 5:18 p.m. S38.010 Diagnostic Value of Clinical Phenotype and Clinical Tests in Early CreutzfeldtJakob Disease–Dror Shir, Evelyn Lazar, Jonathan Graff-Radford, Allen J. Aksamit, Jeremy K. Cutsforth-Gregory, David T. Jones, Hugo Botha, Vijay K. Ramanan, Christian Cameron Prusinski, Amanda Lynn Porter, Gregory S. Day
S39 Child Neurology and Developmental Neurology 3:30 p.m.
CME
2
S39.001
Development of Therapy for Canavan Disease Using Human Induced Pluripotent Stem Cells–Neal Prakash, Lizhao Feng, Jianfei Chao, Yanhong Shi
3:42 p.m.
S39.002
Effectiveness and Safety of Onasemnogene Abeparvovec in Older Patients with Spinal Muscular Atrophy (SMA): Real-World Outcomes from the RESTORE Registry–Laurent Servais, Darryl C. De Vivo, Janbernd Kirschner, Eugenio Mercuri, Francesco Muntoni, Eduardo Tizzano, Susana Quijano-Roy, Kyoko Saito, Melissa Menier, Nicole LaMarca, Fred Anderson, Omar Dabbous, Richard S. Finkel
3:54 p.m.
S39.003
SUNFISH: 3-year Efficacy and Safety of Risdiplam in Types 2 and 3 SMA–John W. Day, Nicholas Deconinck, Janbernd Kirschner, Elena Mazzone, Andrés Nascimento, Maryam Oskoui, Kyoko Saito, Carole Vuillerot, Giovanni Baranello, Odile BoespflugTanguy, Nathalie M. Goemans, Anna Kostera-Pruszczyk, Laurent Servais, Jessica Braid, Marianne Gerber, Ksenija Gorni, Carmen Martin, Renata Scalco, Wai Yin Yeung, Eugenio Mercuri
4:06 p.m.
S39.004
Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2–Kevin Strauss, Francesco Muntoni, Michelle A. Farrar, Kyoko Saito, Jerry R. Mendell, Laurent Servais, Hugh John McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Anne Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra Tauscher-Wisniewski, Bryan McGill, Thomas Macek
4:18 p.m.
S39.005
FIREFISH Parts 1 and 2: 24-month Safety and Efficacy of Risdiplam in Type 1 SMA–Basil T. Darras, Odile Boespflug-Tanguy, John W. Day, Nicholas Deconinck, Andrea Klein, Ricardo Masson, Maria Mazurkiewicz Beldzin, Eugenio Mercuri, Kristy Rose, Laurent Servais, Dmitry Vlodavets, Hui Xiong, Edmar Zanoteli, Angela Dodman, Muna El-Khairi, Eleni Gaki, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Giovanni Baranello
4:30 p.m. S39.006 Eladocagene Exuparvovec Gene Therapy Improves Motor Development in Patients With Aromatic L-Amino Acid Decarboxylase Deficiency–Paul Wuh-
Liang Hwu, Yin-Hsiu Chien, Ni-Chung Lee, Sheng-Hong Tseng, Antonia Wang, Traci B. Schilling, Chun-Hwei Tai
4:42 p.m.
S39.007
Phase 2/3 Clinical Trial Results: Safety & Efficacy Results of RT001, a site-specific (C11) di-deutero synthetic homologue of linoleic acid, in Infantile Neuroaxonal Dystrophy–Alexander James Fay, Darius Adams, Paldeep Atwal, Frederic Heerinckx, Mark Midei, Peter Milner
4:54 p.m. S39.008 Updated results of Transpher A, a multicenter, single-dose, Phase 1/2 clinical
trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)–Kevin M. Flanigan, Nicholas JC Smith, ML Couce, Maria Escolar, KV Truxal, KL McBride, MJ de Castro, M Fuller, Astrid Pañeda, J Ruiz, Ana Del Campo, Igor Grachev
5:06 p.m.
S39.009
Contributions of Purine Synthesis and Recycling During Brain Development: Relevance to Lesch Nyhan Disease–Fatemeh Seifar, Diane J. Sutcliffe, Piyush Joshi, H. A. Jinnah
5:18 p.m.
S39.010
Systematic Analysis of Brain MRI Findings in Adaptor Protein Complex 4 – associated Hereditary Spastic Paraplegia Reveals Patterns for Diagnosis and Disease Progression–Darius Ebrahimi-Fakhari, Julian Alecu, Marvin Ziegler, Afshin Saffari, Sanjay Prabhu, Mustafa Sahin, Edward Yang
22
2022 AAN Annual Meeting
SCIENTIFIC SESSIONS Thursday, April 7 3:30 p.m.–5:30 p.m. PT
S40 MS Diversity and Epidemiology
3:30 p.m.–5:30 p.m. PT CME
2
3:30 p.m. S40.001 Treatment Patterns Among Newly Diagnosed Patients With Multiple Sclerosis by Race and Ethnicity–Caroline K. Geiger, Daniel Sheinson, Tu My To, David E. Jones, Nicole Bonine 3:42 p.m. S40.002 Association of Socioeconomic Disadvantage and Neighborhood Disparities with Clinical Outcomes in Progressive Multiple Sclerosis–Justin Abbatemarco, Alise Carlson, Daniel Ontaneda, Marisa P. McGinley, Robert A. Bermel, Scott Husak, David Bruckman, Jesse Schold, Deborah M. Miller 3:54 p.m. S40.003 Racial Disparities in Hypertension Management Among Multiple Sclerosis Patients–Devon Conway, Farren Briggs, Ellen M. Mowry, Kathryn Fitzgerald, Carrie Michelle Hersh 4:06 p.m. S40.004 The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis–Devi Sai Sri Kavya Boorgu, Shruthi Venkatesh, Chirag M. Lakhani, Ines Aguerre, Claire Riley, Chirag Patel, Philip De Jager, Zongqi Xia 4:18 p.m. S40.005 Significant gender differences in clinical disease activity and severity of multiple sclerosis: a Danish nationwide cohort study–Melinda Magyari, Nils Koch-Henriksen 4:30 p.m. S40.006 A Prospective Study of Serum Levels of Polyunsaturated Fatty Acids and Effects on Multiple Sclerosis Disease Activity and Progression–Kassandra L. Munger, Kjetil Bjornevik, Marianna Cortese, Gilles Edan, Mark S. Freedman, Hans-Peter Hartung, Xavier Montalban, Rupert Sandbrink, Ernst-Wilhelm Radue, Frederik Barkhof, Eva-Maria Wicklein, Ludwig Kappos, Alberto Ascherio 4:42 p.m. S40.007 Ketogenic Diet as a Strategy for Improved Wellness and Reduced Disability in Relapsing Multiple Sclerosis–James Nick Brenton, Diana Lehner-Gulotta, Emma Woolbright, Rachael Coleman, Mark Conaway, Brenda Banwell, A. G. Christina Bergqvist, Myla D. Goldman 4:54 p.m. S40.008 The Burden of Opportunistic Infections in Hospitalized Multiple Sclerosis Patients: a United States population-based study of 25.8 million patients– Lindsay Petrenchik, Farren Briggs 5:06 p.m. S40.009 B cell subset dynamic during pregnancy and early post-partum in women with MS–Doriana Landi, Martina Severa, Alfonso Grimaldi, Gaia Cola, Giovanni Di Mauro, Giorgia Mataluni, Carolina Gabri Nicoletti, Fabiana Rizzo, Daniela Ricci, Eliana Marina Coccia, Gerolama Marfia 5:18 p.m. S40.010 Factors associated with Influenza vaccination rates among people with Multiple Sclerosis–Gaviria Mariana, Carolina Ferreira, Saul Reyes, Aristides Duque, Gavin Giovannoni
S41 Autoimmune Neurology 3: Autoimmune Encephalitis, Paraneoplastic Neurologic Disorders, Antibody-Mediated Diseases, Immunology
CME
2
3:30 p.m. S41.001 Applicability of Autoimmune Encephalitis Criteria in Clinical Practice–Emma Jilliana Orozco, Cristina Valencia Sanchez, Divyanshu Dubey, Eoin P. Flanagan, Nicholas L. Zalewski, Anastasia Zekeridou, Sean J. Pittock, Andrew McKeon 3:42 p.m. S41.002 Encephalitis with Autoantibodies against the Glutamate Kainate Receptor (GluK2)–Mar Guasp, Jon Landa, Federico Javier Miguez Cabello, Joana Almeida, Takayasu Mishima, Fumiko Oda, Frauke Zipp, Vladimir Krajinovic, Peter Fuhr, Jerome Honnorat, Maarten Jan Titulaer, Mateus Mistieri Simabukuro, Jesùs Planagumà, Eugenia Martinez-Hernandez, Thais Armangue, Albert Saiz, Xavier Gasull, David Soto Del Cerro, Francesc R. Graus, Lidia Sabater, Josep O. Dalmau 3:54 p.m. S41.003 Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD within a Real-world Large Institution Cohort–Giovanna Manzano, Rebecca Salky, Farrah J. Mateen, Eric Klawiter, Tanuja Chitnis, Michael Levy, Marcelo Matiello 4:06 p.m. S41.004 Interaction of Anti-Yo and anti-Hu Antibodies with Neurons in Living Mice Following Intracranial Injection or Infusion: Demonstration of Neuronal Antibody Uptake and Early Detection of Neuronal Death–Tammy L. Smith, Daniel R. Scoles, Noel Carlson, Stacey Clardy, John E. Greenlee 4:18 p.m. S41.005 Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis–Mar Guasp, Lorena Martín-Aguilar, Lidia Sabater, Miquel Bioque, Thais Armangue, Eugenia Martinez-Hernandez, Jon Landa, Estibaliz Maudes, Roger Borras, Amaia Muñoz-Lopetegi, Albert Saiz, Josefina CastroFornieles, Eduard Parellada, Francesc R. Graus, Luis Querol, Josep O. Dalmau 4:30 p.m. S41.006 Ovarian resection in anti-NMDAr encephalitis: A comparison of aggressive and conservative approaches–Yajur Iyengar, Julien Hebert, Seth Andrew Climans, Alexandra Muccilli, Gregory S. Day, Richard Wennberg, David F. Tang-Wai 4:42 p.m. S41.007 Paraneoplastic Cochleovestibulopathy: Clinical Presentations, Oncological and Serological Associations–M Bakri Hammami, Scott D. Eggers, Ajay Madhavan, Mayra Montalvo Perero, Sean J. Pittock, Divyanshu Dubey 4:54 p.m. S41.008 Pathogenic Th17 Cells in Autoimmune Myasthenia Gravis Exhibit a Proinflammatory Transcriptomic Signature that Promotes Disease Pathogenesis– Yingkai Li, John Yi, Changxin Wan, Zhicheng Ji, Tabitha Karatz, James F. Howard, Janice M. Massey, Vern C. Juel, Lisa Hobson-Webb, Karissa Gable, Manisha Chopra, Shruti M. Raja, Jeff Guptill 5:06 p.m. S41.009 Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data–Hiroyuki Murai, Shigeaki Suzuki, Yuji Fukamizu, Takehiko Osawa, Hidekazu Kikui, Kimiaki Utsugisawa 5:18 p.m. S41.010 Real-World Eculizumab Effectiveness on US Patient Outcomes in Myasthenia Gravis (ELEVATE): a Retrospective Chart Review–Ali A. Habib, Andrew Klink, Srikanth Muppidi, Anju Parthan, Chloe Sader, Alexandrina Balanean, AJeet Gajra, Richard J. Nowak, James F. Howard
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
23
Your Partner in Neurology In labs, clinics and hospitals around the world, we’re pursuing breakthroughs that will change neurology. For everyone struggling with Alzheimer’s, MS or any other disorder, we are leading the way for the future of neurology. Trust our comprehensive neurology portfolio to help you do more for your patients.
Visit us at Booth 440
©2022 Laboratory Corporation of America® Holdings All rights reserved. 40650-0222
To learn more, scan QR code or visit labcorp.com/neurology
Goes Here Time Poster # Date POSTERS SEATTLE The Poster Hall is going high tech with all digital displays. Visit the Poster Hall multiple times per day to catch all the latest abstract presentations with an interactive, touchscreen experience. Appropriate cleaning protocols will occur between each use. Posters on related topics are grouped together in “neighborhoods” for easy navigation. Standby times when authors will be available to present their research and answer questions will occur daily from 8:00 a.m.–9:00 a.m., 11:45 a.m.–12:45 p.m., and 5:30 p.m.–6:30 p.m.
Saturday, April 2 8:00 a.m.–9:00 a.m.
Poster Session 1
1
Autoimmune Neurology
Autoimmune Neurology: Autoimmune Encephalitis 1 P1.1-001 Anti-GABAA receptor encephalitis in patients with multiple myeloma after autologous stem cell transplant: A report of 3 cases – Yoji Hoshina, Jonathan Ross Galli, Ka-Ho Wong, Tibor Kovacsovics, Mary Steinbach, Eric Lancaster, M. Mateo Paz Soldan, Stacey Clardy P1.1-002 A Case of FIRES/NORSE Associated with a Pathogenic Heterozygous Variant in TNFRSF13B Implicated in Common Variable Immunodeficiency – Jennifer H. Yang, Jamie LaBuzetta, Cynthia Gonzalez, Daniel R. Cleary, Nicholas Scanlon, Anastasie M. Dunn-Pirio P1.1-003 Cyclophosphamide in Autoimmune GFAP Astrocytopathy – Mohona Reza, Bridget A. Bagert P1.1-004 Paraneoplastic Cerebellar Degeneration – Uncommon Presentations, Unclassified Autoantibodies – Susmit Tripathi, Harini Sarva, Rachna Malani P1.1-005 Seizure Control and Cognitive Outcomes in Patients with Encephalitis - A Retrospective Review – Omer Waqar Naveed, Rizamarie Empeno, John Furey, Edward J. Gettings, Mercedes P. Jacobson P1.1-006 Neuroimaging Findings In Case Series Of 8 Patients With Autoimmune Encephalitis In A Single Academic Center – Hongxuyang Yu, Hongyan Wu, Joe Joseph, Shitiz K. Sriwastava P1.1-007 A Pathway for Evaluation and Management of Anti-NMDA Receptor Encephalitis During Pregnancy – Diana Ontiveros, James Pham Ho, Dena Little
26
2022 AAN Annual Meeting
2
Headache
Headache: Advances in CGRP Inhibition for Precision Medicine 1 P1.2-001 Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial – Messoud Ashina, Stewart J. Tepper, Uwe Reuter, Andrew M. Blumenfeld, Susan Hutchinson, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman P1.2-002 Decrease in Body Weight With Once-Daily Atogepant for the Preventive Treatment of Migraine: A Post Hoc Analysis – David W. Dodick, Debbie L. Hay, Christopher Stuart Walker, Peter Goadsby, Jessica Ailani, Lawrence Severt, Michelle Finnegan, Julia Ma, Hua Guo, Joel M. Trugman P1.2-003 Evaluation of Headache Profiles in Pediatric Patients Pre and Post Participation in AntiCalcitonin Gene-Related Peptide Monoclonal Antibody (Anti-CGRP mAb) Studies – Megan Rooney, Jennifer McVige, Patrick Eugeni P1.2-004 Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients With Migraine: A Pooled Analysis of Phase 3 Studies – Larry Charleston, Joshua M. Cohen, Xiaoping Ning, Verena Ramirez Campos, Steve Barash, Tamar Lengil, Byung-kun Kim
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Risk Factors and Basic Science 1 P1.3-001 Association of Diastolic Dysfunction and Cognitive Impairment in the Framingham Heart Study – Alicia S. Parker, Jayandra J. Himali, Mini Jacob, Mitzi Gonzales, Alexa Beiser, Vinutha Ganapathy, Leila Saadatpour, Jonathan Donnelly, Ramachandran Vasan, Sudha Seshadri P1.3-002 Air Pollution and Dementia: A Systematic Review and Meta-Analysis – Elissa Wilker, Marwa Osman, Marc Weisskopf P1.3-003 Two novel brain iron networks explain agingrelated variation in deep gray matter – Jack Reeves, Niels Bergsland, Dejan Jakimovski, Fahad Salman, Juliane Damm, Nicklas Alexander Meineke, Michael G. Dwyer, Robert Zivadinov, Ferdinand Schweser P1.3-004 Offspring Sex and Parental Cognition in Mid-life and Older Adulthood – Katrin Wolfova, Di Wu, Jordan Weiss, Pavla Cermakova, Hans-Peter Kohler, Vegard Skirbekk, Yaakov Stern, Alison Gemmill, Sarah Tom
P1.2-005 A Case Report of 58-year-old Man with CADASIL Leading to Acute Ischemic Stroke and Intracerebral Hemorrhage Consecutively. – Dong Jin Shin, Tae Young Kim
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Date Goes Time AprilHere 2 8:00 a.m.–9:00 a.m. Poster Session 1 Poster #Saturday,
4
Pain and Palliative Care
Addressing Unmet Needs in Pain and Palliative Care P1.4-001 NYX-2925, a novel N-methyl-D-aspartate Receptor Positive Allosteric-Modulator, showed antinociceptive Activity in functional Neuroimaging evaluations correlated with improved Patient reported Pain and Fibromyalgia Symptoms – Harald Murck, Steven Harte, Tony E. Larkin, Andrew D. Schrepf, Chelsea Kaplan, Richard Harris P1.4-002 Clinical Milestones in PSP and MSA as Triggers for Palliative Care Intervention – Robin Bessemer, Alla Iansavitchene, Mary E. Jenkins, Elizabeth Finger, Teneille Gofton P1.4-003 Out of Sight and Out of Mind: The Nocebo Effect; An Unmet Educational Need in Academic Medical Centers – Derek J. Notch, Daniel Krashin, Natalia Murinova P1.4-004 Racial Differences In Palliative Care Utilization And Impact On Inpatient Mortality Length Stay And Costs Among Patients With Intracerebral Hemorrhage – Kahtan Fadah, Mohammad Rauf A. Chaudhry, Baljinder Singh, Danish Kherani, Mohammad Ghatali, Saqib A. Chaudhry, Anantha Ramana Vellipuram, Paisith Piriyawat, Alberto Maud, Gustavo J. Rodriguez, Isabel Victoria Narvaez- Correa P1.4-005 Implementing a Neuropalliative Care Curriculum for Neurology Residents – Sonya Taryn Gleicher, Caroline Hurd, Patricia Anne Weisner, Ali Marisa Mendelson, Claire Creutzfeldt, Breana Lynese Taylor P1.4-006 Implementing Team-Based Outpatient Palliative Care in Parkinson’s Foundation Centers of Excellence (COE): Study Design – Megan Dini, Sandhya Seshadri, Sally Norton, Jodi Summers Holtrop, Peggy Auinger, Nicole Lessard Yarab, Benzi Kluger P1.4-007 Fluoroscopy Guided Block in Nervus Intermedius Neuralgia – MerryJean Losso, Tigran Kesayan P1.4-008 Timing and Utilization of Inpatient Palliative Care Consultation in People with High-Grade Glioma – Rita Caroline Crooms, Nathalie Jette, Rachelle Hornick, Parul Agarwal, Nathan Goldstein, Barbara G. Vickrey
P1.4-009 Stressors Experienced by Primary Caregivers of Severe Acute Brain Injury Patients Recovering from Coma in Neurointensive Care Units: Preliminary Findings from a Multicenter Qualitative Study – Katherine Meurer, Rina Kubota, Nithyashri Baskaran, Qiang Zhang, Sarah M Bannon, Nathan Stone Fishbein, Mira Reichman, Paula Popok, Ethan Lester, Melissa Motta, Susanne Muehlschlegel, Jesse Menville, Matthew N. Jaffa, Claire Creutzfeldt, Corey R. Fehnel, Craig A. Williamson, Ana-Maria Vranceanu, David Y. Hwang, COMA-F Investigators P1.4-010 Ongoing Trial of Transcranial Magnetic Stimulation (TMS) for Chronic OroFacial Pain (COFP) – Mallory Blackwood, Mark Witcher P1.4-011 Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life: two preliminary case reports – Manon Auffret, Matthieu Béreau, Laurent Tatu, Marc Verin
5
Child Neurology and Developmental Neurology
Child Neurology: Demyelinating/ Leukodystrophy/Neuroimmunology 1 P1.5-001 Virtual Reality Testing to Assess Cerebral Visual Impairment in X-linked Adrenoleukodystrophy – Melissa Bambery, Camille Sierra Corre, Daniel Conor Kelly, Amanda Marie Nagy, Catherine Becker, Claire Manley, Christopher Richard Bennett, Lotfi Merabet, Florian Eichler P1.5-002 Refractory Acute Disseminated Encephalomyelitis-like Illness Found to be CNSisolated Hemophagocytic Lymphohistiocytosis due to a Novel PRF1 Mutation – Natalia Gonzalez Caldito, Cynthia X. Wang P1.5-003 Functional MRI Correlates of Intelligence Quotient and Visual-Motor Coordination in Pediatric Multiple Sclerosis – Laura Cacciaguerra, Chiara Curatoli, Carmen Vizzino, Paola Valsasina, Maria Assunta Rocca, Massimo Filippi P1.5-004 Cerebral Visual Impairment in Cerebral Adrenoleukodystrophy: Prevalence, Presentation, and Neuroimaging Correlates – Camille Sierra Corre, Melissa Bambery, Christopher Richard Bennett, Haley Andonian, Daniel Conor Kelly, Lotfi Merabet, Florian Eichler
Information is accurate as of February 8, 2022, and is subject to change.
P1.5-005 Comparing the natural history of pediatric multiple sclerosis with onset before or after pubertal age – Ermelinda De Meo, Massimo Filippi, Maria Trojano, Giancarlo Comi, Francesco Patti, Vincenzo Brescia Morra, Giuseppe Salemi, Marco Onofrj, Giacomo Lus, Eleonora Cocco, Mattia Fonderico, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Paola Valentino, Antonio Bertolotto, Alessandra Lugaresi, Roberto Bergamaschi, Marco Rovaris, Patrizia Sola, Gioacchino Tedeschi, Ilaria Pesci, Umberto Aguglia, Paola Cavalla, Davide Maimone, Franco Granella, Marika Vianello, Marta Simone, Emilio Portaccio, Maria Pia Amato
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Cognitive Aging, Dementia, and Memory 1 P1.6-001 The interplay between age at menopause, insomnia, and cognitive health: a populationbased study – Monica Shieu, Tiffany Braley, Afsara Zaheed, Julie Stein Perry, Jill B. Becker, Galit Levi Dunietz P1.6-002 Improving Early Recognition of Mimics of Creutzfeldt-Jakob Disease in Clinical Practice – Evelyn Lazar, Amanda Lynn Porter, Christian Cameron Prusinski, Steven Richard Dunham, Alfonso Sebastian Lopez, M Bakri Hammami, Divyanshu Dubey, Gregory S. Day P1.6-003 Transient global amnesia recurrence: prevalence and risk factor meta-analysis – Micaela Hernandez, Julieta E. Arena, Lucas Alessandro, Ricardo F. Allegri, Ismael Calandri P1.6-004 Companion Animals and Cognitive Health; A Population-Based Study – Monica Shieu, Jennifer W. Applebaum, Galit Levi Dunietz, Tiffany Braley P1.6-005 Open-ended, value-based decision making requires semantic memory: a computational, imaging, and clinical study – Andrew Kayser, Zhihao Zhang, Samira Maboudian, Ashley Jeanne Jackson, Sang Ngo, Winston Chiong, Ming Hsu P1.6-006 Clinical Profile of Frontotemporal Dementia: Case Series from a Neurological Care Center in Peru – Sheila Castro Suarez, Erik Alberto Guevara-Silva, Mario R. Cornejo Olivas
AAN.com/AM
27
Saturday, April 2 8:00 a.m.–9:00 a.m.
Poster Session 1
7
Sleep
Sleep: Focus on Hypersomnia and RBD 1 P1.7-001 Psychometric Evaluation of the Idiopathic Hypersomnia Severity Scale – Benjamin Banderas, Susan Morris, Luke Hickey, Caitlyn Lowe, Ethan Arenson, Junji Lin, Patricia Chandler, Yves Dauvilliers P1.7-002 Hybrid Interviews to Confirm the Content Validity of the Quantitatively Valid Idiopathic Hypersomnia Severity Scale – Bhavini Srivastava, Susan Morris, Benjamin Banderas, Caitlyn Lowe, Yves Dauvilliers P1.7-003 Long-Term Effects of Lower-Sodium Oxybate on Functioning and Work Productivity in Participants With Idiopathic Hypersomnia – Richard K. Bogan, Isabelle Arnulf, Michael J. Thorpy, Nancy R. Foldvary-Schaefer, Patricia Chandler, Luke Hickey, Jed Black, Yves Dauvilliers P1.7-004 Long-Term Efficacy and Safety of Lower-Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Idiopathic Hypersomnia – Nancy R. FoldvarySchaefer, Richard K. Bogan, Isabelle Arnulf, Michael J. Thorpy, Patricia Chandler, Luke Hickey, Jed Black, Yves Dauvilliers P1.7-005 Timing and Duration of Adverse Events in a Clinical Trial of Lower-Sodium Oxybate in Participants With Narcolepsy With Cataplexy – Richard K. Bogan, Nancy R. Foldvary-Schaefer, Roman Skowronski, Abby Chen, Michael J. Thorpy
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASMs General 1 P1.8-001 Cardiac Effects of Lamotrigine in a Veteran Population – Alexis Biehl, Maralena Taube, Barry E. Gidal, Robert Joseph Kotloski P1.8-002 Aggregated Safety and Tolerability Experience from the Ganaxolone Development Program – Maciej Gasior, Joseph Hulihan, Ian Miller P1.8-003 Non-Seizure Related Outcomes With Real-World Use of Cannabidiol (CBD) in Lennox-Gastaut Syndrome and Dravet Syndrome: BECOME, A Caregiver Survey – Anne T. Berg, M. Scott Perry, Tracy Dixon-Salazar, Mary Anne Meskis, Ngoc Minh Dang Le, Sherry Danese
28
2022 AAN Annual Meeting
P1.8-004 Cannabidiol decreases seizure severity and brain temperature in treatment-resistant epilepsy. – Ayushe Alicia Sharma, Jerzy P. Szaflarski P1.8-005 The Effects of Pregnancy on Levetiracetam Levels and Seizure Frequency – Kruthika Shanmugam, Chloe Electra Hill, Temenuzhka G. Mihaylova P1.8-006 Cenobamate for Uncontrolled Focal Seizures in Patients Living in a Group Home or With a Developmental Disability – Gregory S. Connor
9
Infectious Disease
Infectious Disease: Acute and Subacute Responses to COVID-19 1 P1.9-001 Are Elevated Interleukin-6 Serum Levels Associated with Increased Encephalopathy and In-hospital Mortality rates in SARS-CoV2 Patients – Pratibha Surathi, Sviatoslav Redko, Toluwalase Oluwakemi Tofade, Evan Huff, Mustafa Jaffry, Kranthi Kiran Mandava, Jeffrey M. Kornitzer, Nizar Souayah P1.9-002 Refractory Rhombencephalitis Secondary to SARS-CoV-2 Infection: A Case Report – Alexandra Mae Wood, Sam Hooshmand, Ahmed Z. Obeidat P1.9-003 A rare case of an acute ascending longitudinally extensive necrotizing transverse myelitis in a young woman: a severe post-COVID-19 infection neurological complication – Franklyn Rocha Cabrero, Nicole Baldwin, Luis Guada-Delgado, Ashok Verma P1.9-004 Diagnostic Characteristics and Outcomes of Chronic Meningitis – Joseph Seemiller, Tyler Crissinger, Jose Eduardo Eduardo Sarti, John Herbst, Eunice H. Bae, J. David Avila, Kelly Baldwin P1.9-005 Creutzfeldt-Jacob Disease: The Long and Short of It – Katherine Alexandra Stiles, Saima Chaudhry P1.9-006 A Case of Creutzfeldt-Jakob Disease Suspected to be Acquired from Gelatin Capsules – Gaurav Kathuria, Shimron Brown, Sean T. Kenniff P1.9-007 Infectious Causes of Chronic Meningitis – Tyler Crissinger, Joseph Seemiller, John Herbst, J. David Avila, Kelly Baldwin
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Interesting Cases 1 P1.10-001 Cryoglobulinemic Vasculitis as a Cause of Recurrent Small Vessel Strokes – Aaron Shoskes, Ghulam Abbas Kharal P1.10-002 A Challenging Case of Cerebral Amyloid Angiopathy-related Inflammation (CAAri): Implications for Secondary Stroke Prevention and Immunomodulation Therapies – Grant William Zeigler, Kerstin Bettermann, Cunfeng Pu P1.10-003 Tremor Associated with a Frontal and Parietal Cortical Infarct – Sayyeda Zahra, Cleo Zarina Alejo Reyes, Erafat Rehim, Tsneem Mbydeen, Hussam A. Yacoub P1.10-004 Carotis Stenosis Presenting as Hemichorea – Parisa Heidari, Daniela Zambrano P1.10-005 Cortical Hemiballismus Associated With An Isolated Insular And Temporal Infarct: A Case Report – Jaemyoung Sung, Cleo Zarina Alejo Reyes, Erafat Rehim, Ye Su, Atef Kokash, Yevgeniy Isayev P1.10-006 An unusual relapse of Amyloid-Beta related Angiitis – Lamya Ibrahim, Grant Meeks, Ashley Streseman, Muhammad Bilal Tariq, Meenakshi Bidwai Bhattacharjee, Sean I. Savitz P1.10-007 Cavernous Malformations: A Mini-Case-Series on Diagnosis and Management – Khadija Awais, Chetan Saini, Balaji Krishnaiah, Nitin Goyal P1.10-008 Ischemic Stroke as a Rare Manifestation from Graft Versus Host Renal Failure and Immunosuppressive Therapy – Mahrin Rahman, Ann Nguyen Ly, Lama M. Al-Khoury, Christian Adolfo Sam, Mark Girgis, Rony Dekermenjian P1.10-009 An Unusual Cause of Septic Emboli – Mariel Davila Martinez P1.10-010 Severe Allergic Reaction with Cerebral Edema Post Flow-Diverter Device Placement for Cerebral Aneurysm – Avi Landman, Jorge Luis Morales, Ankur Garg, Muhammad-Atif Zubairi
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 1
11
Movement Disorders
Movement Disorders: COVID, Telemedicine, and Community 1 P1.11-001 Telemedicine utilization and patient satisfaction in an ambulatory movement disorders clinic during COVID-19 – Shubhendu Mishra, Nikhil Dhuna, Nicola Lancki, Chen Yeh, Danielle Larson P1.11-002 TeleSCOPE: A Real-World Study of Telehealth for the Detection and Treatment of Drug-Induced Movement Disorders – Rimal Bera, Ericha Franey, Kendra Martello, Morgan Bron, Chuck Yonan P1.11-003 The Impact of Telemedicine on Serious Mental Illness and Movement Disorders: A Literature Review and Gap Analysis – Morgan Boname, Eric Jen, Kendra Martello P1.11-004 Impact of COVID-19 on Movement Disorders Patients in the Outpatient Setting – Shaila Ghanekar, Fnu Madhuri, Alina Shub, Luis Alejandro Lozano, Yangxin Huang, Yarema B Bezchlibnyk, Donald A. Smith, Robert A. Hauser, Arielle Mitchell, Theresa A. Zesiewicz P1.11-005 THRIVE-PD: Transforming Health and Resilience through Interdisciplinary Virtual Engagement in Parkinson Disease – Roshini Srinivasan, Sneha Mantri, Kyle T. Mitchell P1.11-006 The Impact of COVID-19 on People with Parkinson’s: Insights from Wearable Sensors – Meghan Elizabeth Pawlik, Stella Jensen-Roberts, Emma Waddell, Taylor Myers, Julia Marie Soto, Emily Hartman, Ekene Nnadika, Phillip T. Yang, Renee Wilson, Karlo J. Lizarraga, Christopher Tarolli, Ruth Schneider, E. Ray Dorsey, Jamie Lynn Adams P1.11-007 A novel tele-rehabilitation program aimed at reducing fall risk in Parkinson’s Disease patients – Noel Cabanas, Mitra Afshari, Andrea Hernandez, Glenn Thurston Stebbins, Christopher Goetz P1.11-008 Clinical Characteristics of COVID-19 in Patients with Parkinson’s Disease – Carlos Ivan Salazar Deras, Brad Tyson, Pinky Agarwal
12
Saturday, April 2 8:00 a.m.–9:00 a.m.
General Neurology
General Neurology: Cerebrovascular 1 P1.12-001 Factors associated with Idiopathic Intracranial Hypertension (IIH) in a population-based cohort. – Parashar Koirala, Sean Gratton P1.12-002 Posterior Reversible Encephalopathy Syndrome (PRES) from Immune Check Point Inhibitors (ICIs) – Sumayya Naz, Jonathan Doan, Prajwal Hegde, Sidra Saleem, Mehmood Rashid, Imran I. Ali P1.12-003 Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient with Isolated Bilateral Hippocampal Atrophy: A Case Report – Dushawn Harley, Adena Shahinian, Tapasya Dharmesh Surti, John Ko, Christopher Do, Chee Lim, Mark Mckenzie, Paul H. Janda P1.12-004 Case Report and Novel Theory for Transient Global Amnesia – William J. Kingston, Anne M. Moss P1.12-005 A case of pembrolizumab related PRES – Shreeja Kadakia, Catherine Rachel Craven, Seung Yun Kim, Brian James Hanrahan
13
P1.13-004 Inhibiting C1q Improves Compound Muscle Action Potential and Reduces Neuronal Damage in the SOD1G93A Mouse Model – Yaisa Andrewszwilling, Vidhu Mathur, Logan Kuhn, Sethu Sankaranarayanan, Ellen Cahir McFarland, Ted Yednock P1.13-005 Suppression of MicroRNA-9-5p Mitigates TDP-43 Neurotoxicity in ALS – Liang Lu, Yan Zhang, HanCheon Kim P1.13-006 Chlorovirus Exposure in ALS Patients Identified through Serum Antibodies also Accelerates Motor Deterioration in SOD1G93A Transgenic Mice – Gary L. Pattee, Tom Petro, Irina Agarkova, David Dunigan, James Van Etten P1.13-007 Filtration attenuates sporadic ALS CSF-induced motor neuron death in vitro – Ivy Gao, Rose Putnam Griffin, Nadia Merve Celestin, Jamie Wong, Saud A. Sadiq P1.13-008 Using In Vitro Experiments to Determine MFN2’s Function in ALS – Kristi Russell, Jon Downie, Summer Gibson, Karla Patricia Figueroa, Mark B. Bromberg, Charles Murtaugh, Lynn Jorde, Stefan M. Pulst
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1 P1.13-001 24-Week Results From Phase 3 Study MT1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis – Angela L. Genge, Gary L. Pattee, Gen Sobue, Philippe Couratier, Daniel Selness, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple P1.13-002 Lessons Learned From A Large-Scale Audio-Visual Remote Data Collection For Amyotrophic Lateral Sclerosis Research – Vikram Ramanarayananan, Michael Neumann, Aria Anvar, David Suendermann-Oeft, Oliver Roesler, Jackson Liscombe, Hardik Kothare, James D. Berry, Ernest Fraenkel, Raquel Norel, Alexander Sherman, Jochen Kumm, Indu Navar P1.13-003 Machine Learning Enables Smaller ALS Clinical Trials – Daniele Bertolini, Katelyn Arnemann, Diana Hall, Jonathan Walsh
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
29
Poster Session 2
1
Autoimmune Neurology
Autoimmune Neurology: Autoimmune Encephalitis 2 P2.1-001 Approach to patients with autoimmune encephalitis with no identifiable antibodies – Carolina Gil Tommee, Praveen Ramani, Erika Santos Horta, Sisira Yadala P2.1-002 Co-Occurrence of Sj/ITPR1 and NMDA Antibodies: A Case Report – William Daniel Chapman, Allison Macke, Joseph P. Broderick, Simona Ferioli P2.1-003 Isolated headache as the sole manifestation of autoimmune GFAP astrocytopathy – Eslam Hamdy Shosha, Colleen M. Connolly, Adrian Budhram P2.1-004 A Curious Case of LGI1 Autoimmune Encephalitis Presenting as Chronic Hyponatremia and Subacute Dementia Without Faciobrachial Dystonic Seizures – Joshua Luster, Ashley Barasa, William Hoffman P2.1-005 New Onset Seizures and Rapidly Progressive Cognitive Impairment in a Patient With Prion Negative 14-3-3 Tauopathy and GABA- B Receptor Antibody Encephalitis: Case Report and Literature Review – Schweta Parag Rane, Xiang Fang P2.1-006 Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Dementia with Lewy Bodies – Caroline Olvera, Thomas Jack Shoemaker, Jori Fleisher P2.1-007 A Case of Opsoclonus-Myoclonus Ataxia with Neuronal Intermediate Filament IgG Detected in CSF – Melody Merati, Janet C. Rucker, Sean J. Pittock, Andrew McKeon, Laura J. Balcer, Steven Galetta
2
Headache
Headache: Advances in CGRP Inhibition for Precision Medicine 2 P2.2-001 Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects – Richard Bertz, Matt Anderson, Julie Collins, Joseph Stringfellow, Jennifer Madonia, Rajinder K. Bhardwaj, Jeri-anne Finley, David W. Dodick, Vladimir Coric, Robert Croop
Saturday, April 2 11:45 a.m.–12:45 p.m.
P2.2-002 Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study – Christopher Jensen, Alexandra Thiry, Edward Kim, Meghan Lovegren, Robert Croop, Vladimir Coric, Gilbert J. L’Italien, Richard B. Lipton P2.2-003 Within-Person Consistency of Acute Treatment Success With Ubrogepant: Results From a Longterm Safety Study – Charles Iaconangelo, Daniel Serrano, Ella Engstrom, Janette Contreras-De Lama, Joel M. Trugman, Aubrey Manack Adams, Richard B. Lipton P2.2-004 Evaluation of the Pharmacokinetic Interaction and Safety of Coadministered Atogepant and Topiramate – Ramesh Boinpally, Danielle McGeeney, Lisa Borbridge, Matthew Butler, Lawrence Severt P2.2-005 Post-hoc Analysis of Safety in Phase 3 Atogepant ADVANCE Trial Participants with or without Cardiovascular Disease Risk Factors – Andrew M. Blumenfeld, Susan Hutchinson, Jelena M. Pavlovic, Patricia Jeanne Markovi Best, Teshamae Monteith, Julia Ma, Jonathan H. Smith, Lawrence Severt, Brett Dabruzzo, Stephanie J. Nahas P2.2-006 An Open-label, Intermediate-sized, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine – Robert Croop, Thomas Shiovitz, Arif Khan, Tamara Noonan, Stephen Kaplita, Mitch Mitchell Seymour, Christopher Jensen, Vladimir Coric
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Risk Factors and Basic Science 2 P2.3-001 Proteostasis Network Changes in Dermal Fibroblasts in Aging and Neurodegeneration – Ashlyn Johnson, James Webster, Eric Dammer, Duc Duong, Chad Hales P2.3-002 Chromatin accessibility differences between African and European Alzheimer Disease brains. – Katrina Celis, Anthony J. Griswold, Farid Rajabli, Kara Hamilton-Nelson, Sandra Weintraub, Marla Gearing, Changiz Geula, John Q. Trojanowski, Clifton Dalgard, David A. Bennett, Margaret A. Pericak-Vance, Juan Young, Jeffery M. Vance P2.3-003 Improving Precision For Early Detection of Stroke Risk: Biological Aging Physiology and DNA methylation Cross-Talk – Reem Waziry, Amelia Katharine Boehme, Daniel W. Belsky, Yian Gu
30
2022 AAN Annual Meeting
P2.3-004 AMPKa2 and Neuronal Structure: Implications for Metformin – Jonas Kruse, Kiran Chaudhari, Linshu Wang, Ali Winters, Ran Liu, Shaohua Yang P2.3-005 The Effects of Prolonged Water-Only Fasting on Senescence Associated Secretory Phenotype – Eugene L. Scharf, Marina Buciuc, Evelyn Zeiler, Breno Diniz, Toshia Myers
4
MS and CNS Inflammatory Disease
MS Biomarkers P2.4-001 Elevated Serum Glial Fibrillary Acidic Protein is a Biomarker of Disease Progression in Progressive Multiple Sclerosis Patients – Christian Barro, Brian Curran Healy, Yanqing Liu, Shrishti Saxena, Anu Paul, Mariann Polgar-Turcsanyi, Harald Kropshofer, Howard L. Weiner, Tanuja Chitnis P2.4-002 Association Between Serum Glial Fibrillary Acidic Protein and Retinal Structural Changes in Patients with AQP4-antibody Positive Neuromyelitis Optica Spectrum Disorder – Ting-Yi Lin, Patrick Schindler, Frederike Cosima Oertel, Angelo Lu, Seyedamirhosein Motamedi, Ankelien Duchow, Jens Kuhle, Pascal Benkert, Alexander U. Brandt, Friedemann Paul, Klemens Ruprecht, Hanna Zimmermann P2.4-003 Superiority of Serum NFL in Predicting Multiple Sclerosis STo develop and validate mathematical adjustment of serum neurofilament light chain (sNFL) for relevant confounders to strengthen its clinical utility everity – Peter Kosa, Ruturaj Masvekar, Mika Komori, Jonathan Phillips, Vighnesh Ramesh, Mihael Vito Varosanec, Mary Sandford, Bibiana Bielekova P2.4-004 miRNA as biomarkers of NEDA-3 in multiple sclerosis patients treated with fingolimod, glatiramer acetate and dimethyl-fumarate: Preliminary results – Alicia Gonzalez-Martinez, Brian Curran Healy, Hrishikesh A. Lokhande, Anu Paul, Shrishti Saxena, Mariann Polgar-Turcsanyi, Howard L. Weiner, Tanuja Chitnis P2.4-005 Functional analysis of validated miRNAs associated with MS disability – Alicia GonzalezMartinez, Hrishikesh A. Lokhande, Tanuja Chitnis P2.4-006 The role of serum neurofilament light chain in an adult cohort of patients with acquired demyelinating syndromes of the central nervous system – Luca Bollo, Pietro Iaffaldano, Maddalena Ruggieri, Claudia Palazzo, Mariangela Mastrapasqua, Francesca Caputo, Tommaso Guerra, Alessia Manni, Damiano Paolicelli, Marta Simone, Antonio Frigeri, Maria Trojano
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 2
P2.4-007 Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon ß-1a in the REFLEX Trial – Mali Cristina Coray, Andrea Seitzinger, Sanjeev Roy, Mark S. Freedman, Frederik Barkhof, Giancarlo Comi, Nicola De Stefano, Ludwig Kappos, Jens Kuhle, Matthias Mehling P2.4-008 Cortical remyelination failure predicts cortical atrophy and clinical progression in early multiple sclerosis – Andrea Lazzarotto, Mariem Hamzaoui, Matteo Tonietto, Vito Antonio Gerardo Ricigliano, Giacomo Boffa, Michael Khalil, Lukas Pirpamer, Stefan Ropele, Christian Enzinger, Marco Battaglini, Maria Laura Stromillo, Nicola De Stefano, Maria Assunta Rocca, Paolo Gallo, Claudio Gasperini, Bruno Stankoff, Benedetta Bodini P2.4-009 Association of Neuroaxonal and Glial Biomarkers with Clinical Phenotype in Underrepresented Minority Multiple Sclerosis Populations – Neda Sattarnezhad, Daniel B. Hier, Jason P. Mendoza, Linda A. Piccinini, Michael D. Carrithers
MS COVID 1 P2.4-010 COVID19 infections in patients with Multiple Sclerosis (MS) on Various treatments at Kaiser Permanent Mid-Atlantic States (KPMAS) – Ejaz Shamim, Kyle Tse, Crystal Xue, Daniel Tadeo, Edward Jiwon Yoon, Andrew J. Dutka, Melvin W. Kong, Ella Akkerman, Venkatesh Pusarla, Christopher Gordon-Cuno, Stephen Winn P2.4-011 The impact of COVID-19 on the disease activity of multiple sclerosis: A Retrospective cohort study – Abdulaziz Bajafar, Fawzi Babtain, Ohood Nazmi, Manal A. Badawi, Ahmed Basndowah, Areej Bushnag, Edward J. Cupler, Ahmad Hassan
5
Child Neurology and Developmental Neurology
Child Neurology: Demyelinating/ Leukodystrophy/Neuroimmunology 2 P2.5-001 NMDAR-Ab Encephalitis Presenting as a Rett Syndrome Mimic in a 2 year old – Young-Min Kim, Taryn Liu, Montserrat Montesinos, Sunitha Lena Nune, Gregory S. Aaen
Saturday, April 2 11:45 a.m.–12:45 p.m.
Child Neurology: Neurodevelopmental Disorders/CP/ASD 1 P2.5-003 Expanding the Phenotypic Spectrum of ECEL1Associated Distal Arthrogryposis – Akshata Huddar, Kiran Polavarapu, Preethish Kumar Veeramani, Mainak Bardhan, Gopikrishnan Unnikrishnan, Saraswati Nashi, Seena Vengalil, Karthik Kulanthaivelu, Gauthaman Arunachal, Atchayaram Nalini P2.5-004 The Mitochondrial Neurodegenerative Diseases MELAS and LHON-Plus: How Translational Research Converts Challenges into Therapeutic Opportunities and Clinical Trial Design – Andrea L. Gropman, Martine Uittenbogaard, Anne Chiaramello P2.5-005 FARSA Mutations Causing Cerebral Microcysts, Cystic Interstitial Lung Disease, Growth Restriction, and Developmental Delay – Charles J. Kidd, Cole Phillips Denkensohn
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Cognitive Aging, Dementia, and Memory 2 P2.6-001 The relation between thyroid dysregulation and impaired cognition/behaviour: An integrative review – Manizhe Eslami-Amirabadi, S. Ahmad Sajjadi P2.6-002 Factors Influencing Compliance in Independent In-Home Exercise Trial for Older Adults – Margaret Kelly Specht, Katherine Elaine Snyder, Justin Barber, Barbara J. Martin, Shani H. Bardach, Gregory A. Jicha P2.6-003 Delayed Leukoencephalopathy after an Opioidrelated Acute Amnestic Syndrome – Brady T. Mannett, Luis Guillermo Manrique, Elias Samaha
7
Sleep
Sleep: Focus on Hypersomnia and RBD 2 P2.7-001 Validation of a Clinical Scale for Defining RBD Severity in Participants of the North American Prodromal Synucleinopathy (NAPS) Consortium – Andrea Oana Busicescu, Parichita Choudhury, Joyce K. Lee-Iannotti, Pooja Rangan, David Shprecher, Maria Livia Fantini, Miranda M. Lim, John Elliott, Alon Y. Avidan, Daniel Huddleston, Donald Biwise, Michael J. Howell, Carlos H. Schenck, Susan Criswell, Emmanuel H. During, Emmanuel Mignot, Jennifer Svoboda McLeland, Amelie Pelletier, Jean-Francois Gagnon, Leah Kathleen Forsberg, Julie A. Fields, Erik Kent St. Louis, Aleksandar Videnovic, Yo-El Ju, Bradley F. Boeve, Ronald Postuma P2.7-002 Symptom Severity and Treatment Satisfaction in Patients With Idiopathic Hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE) – Logan D. Schneider, Joanne Stevens, Aatif M. Husain, Diane Ito, Wayne Macfadden, Douglas S. Fuller, Phyllis C. Zee P2.7-003 Where do patients get diagnosed with idiopathic Rapid Eye Movement Behavior Disorder? – Isabelle Havis, Vikas Kotagal P2.7-004 Development and Description of the International RBD Study Group RBD Symptom Severity Scale – Ronald Postuma, Maria Livia Fantini, Bruno Pereira, Parichita Choudhury, Joyce K. Lee-Iannotti P2.7-005 Factors Associated with Sleep Disturbance after Hemorrhagic Stroke – Sarah Ecker, Aaron S. Lord, Lindsey Gurin, Koto Ishida, Kara R. Melmed, Jose L. Torres, Barry M. Czeisler, Cen Zhang, Jennifer A. Frontera, Ariane Lewis
P2.6-004 Keep it in Sight: A Case of the Heidenhain Variant in Creutzfeldt-Jakob Disease – Claudia Vallin, Maria Gabriela Martucci, Damon Salzman P2.6-005 A case of apperceptive visual agnosia mistaken for Broca aphasia – Manizhe Eslami-Amirabadi, Oleg Yerokhin Yerstein
P2.5-002 Neurodegenerative Encephalomyelopathy Associated with ACOX-1 Gain-of-Function Mutation Partially Responsive to Immunotherapy – Saba Jafarpour, Mellad Khoshnood, Jonathan Santoro
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
31
Poster Session 2
8
Epilepsy/Clinical Neurophysiology (EEG)
Saturday, April 2 11:45 a.m.–12:45 p.m.
9
Infectious Disease
Epilepsy/Clinical Neurophysiology (EEG): COVID 19 and Others 1
Infectious Disease: Acute and Subacute Responses to COVID-19 2
P2.8-001 Position and Patient Safety Measures in the Epilepsy Monitoring Unit – Pamela O’Dea, Jeffrey Karduck, Juliana Leonardo, Andrew C. Schomer, Mark S. Quigg
P2.9-001 A Novel Case of Longitudinally Extensive Transverse Myelitis following COVID-19 Vaccination in a Pediatric Patient – Amna Imran, Susana Soto, Rupin Singh, Migvis Monduy
P2.8-002 NeuroMeasures™: Implementation of a WebBased Real-Time Quality Metric Tool to Improve Provider Practices in an Epilepsy Clinic – Maryam Jamil Syed, Rohit Ajay Marawar, Maysaa Merhi Basha, Deepti Zutshi
P2.9-002 Acute Transverse Myelitis: an upcoming complication of COVID-19 infection – Harshadayani Jagadish Kumar, Siddharth Bhattacharjee, Yash Bhattarai
P2.8-003 WITHDRAWN P2.8-004 Assessment of Adherence to Telehealth Versus Inperson Epilepsy Clinic Visits in the Pre- and During COVID-19 Era – Saniya Pervin, Ruta Nandan Yardi, Meriem K. Bensalem Owen, Sally Valentina Mathias P2.8-005 Seizure Control During COVID-19: A Study Using the Responsive Neurostimulation System (RNS) – Ryan Ward, Cemal Karakas, Henry Skrehot, Alexandra Vallera, Stephen Cleboski, Zulfi Haneef P2.8-006 COVID-19 Patient’s Background Frequency on EEG Predictive of Hospital Discharge Disposition – Wonhee Lee, Kaitlin Seibert, Amy Espinal, Alexandra Eid, Sumayyah Abumurad, Sara A. Klein, Shasha Wu, Sandra Rose, James X. Tao, Naoum P. Issa P2.8-007 Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic – Lilly Frohlich, Laura Whitmore, Stephanie Pfister, Rachel Gurrell, Ann Marie Dandurand, Pamela Perry, Matthew Leoni
P2.9-003 Transverse Myelitis associated with COVID-19 in adults – Allyson Heng, Nidhi Shankar Kikkeri, Vanessa Sui, William R. Meador, Shruti Prabodh Agnihotri Diagnostics and Other Considerations for Neuroinfectious Diseases 2 P2.9-004 Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Neuroinfectious Diseases – Abhilasha Pankaj Boruah, Adam Kroopnick, Carla Kim, Riddhi Thakkar, Rachelle Dugue, Eileen Harrigan, Walter Ian Lipkin, Nischay Mishra, Kiran Thakur P2.9-005 Inclusion Criteria for Sending Cerebrospinal Fluid pathogen Metagenomic Next-Generation Sequencing – Lei Liu, Jingxiao Zhang P2.9-006 Atypical Presentation of Neurosarcoidosis: A Case Report – Cleo Zarina Alejo Reyes, Negar Moheb, Ramiro Gabriel Castro Apolo, Christopher Melinosky P2.9-007 Delayed Toxic Encephalopathy Masquerading as Creutzfeldt-Jakob disease – Cory P. Hackmyer, Jenifer Nicole Moceri, Nora Ko, Brian James Hanrahan
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Interesting Cases 2 P2.10-001 Acute Embolic Stroke Presenting With Complete Hearing Loss – Ventaka Bendi, Connor Eggleston, Ram Mohan R. Sankaraneni P2.10-002 Reversible rapidly progressive dementia due to a high-grade, dural arteriovenous fistula: a case report – Juan José Mendez Gallardo, Mallyolo Eliezer Pelayo Salazar, Ivan Camilo Baracaldo, Santiago Ortega Gutierrez, Antonio Arauz, Alfredo Montenegro P2.10-003 Cerebral Venous Thrombosis: A Possible Complication of Clomiphene Therapy for in vitro Fertilization – Moises-Zacariah Garcia, Emily Liu, Arthur Andrada, Jebun Nahar P2.10-004 Iron Deficiency Anemia with Reactive Thrombocytosis Associated with Internal Carotid Artery Thrombus and Ischemic Infarction – Ashley Nelson, Cassie Lee Nankee, Chirantan Banerjee P2.10-005 Can she ever fly again? A curious case of a PICA infarct in a healthy woman at high altitude and a review of known cerebrovascular changes at high elevations – William Hoffman P2.10-006 Case Report of Takayasu Arteritis Presenting as Stroke – Sean W. Scarpiello, Hemal Patel, Hamidreza Abbasi, Nancy Gadallah, Jawad F. Kirmani P2.10-007 Isolated Abducens Nerve Palsy as a Presentation of Extracranial Internal Carotid Artery Dissection: A Case Report – Keyvan Heshmati, Jorge Luis Rodriguez Lee, Nora Montealegre, Volodymyr Vulkanov P2.10-008 Massive Cerebral Air Embolism in a Patient with Pulmonary Aspergillosis – Hyun-Wook Nah P2.10-009 Horizontal Gaze Palsy in Two Patients with Subcortical Stroke. Case Report – Leigham Breckenridge, Vaibhav Goswami P2.10-010 Retinal Claudication: A Rare Case of Light-Induced Amaurosis Fugax Secondary to Occlusive Carotid Artery Disease. – Ahmer Asif, Oleksandra Los, Juliane Chainakul, Ahmad Al-Awwad
32
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 2
11
Movement Disorders
Movement Disorders: Outcomes in DBS and PD 1 P2.11-001 Real-World Outcomes Using a Novel Directional DBS System for Parkinson’s disease – Guenther Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Steffen Paschen, Chong S. Lee, Andrea Kuehn, Jan Vesper P2.11-002 Social Support and Clinical Outcomes in Patients with Parkinson Disease After Deep Brain Stimulation – Sydney Morgan Spagna, Asra Askari, Parag Patil, Kelvin L. Chou P2.11-003 Real-World Deep Brain Stimulation Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Theresa A. Zesiewicz, Michael Barbe, Steffen Paschen, Corneliu C. Luca, Cong Zhi Zhao, Francisco Ponce, Jennifer Lyn Durphy, Jill L. Ostrem, Nestor Tomycz, Tino Prell, Mustafa S. Siddiqui, Lilly Chen, Roshini Jain P2.11-004 Outcomes After IPG Replacement Surgery Near End of Life in Parkinson’s Disease – Charlotte Wahle, Jacob Esper Yomtoob, Phillip Cem Cezayirli, Emad Eskandar, Todd Herrington P2.11-005 Effectiveness of Clinical Decision Support for the California Parkinson’s Disease Registry – Emily Laltoo, Lawrence Dardick, Keith Garb, Lauren Claire Byrne, April Michelle Taylor, Laxmi Kumar, Andrew M. Wilson, Allan Ding Wu P2.11-006 Impact of caregiver characteristics on patient outcomes in Parkinson’s disease – Rudmila Rashid, Nabila Dahodwala P2.11-007 Tandem gait step-width declines more rapidly in a stage-dependent manner with Parkinson’s disease progression – Jennie Burns, Lakshmi Pillai, Aliyah Jasmine Glover, Tuhin Virmani
12
Saturday, April 2 11:45 a.m.–12:45 p.m.
General Neurology
General Neurology: Cerebrovascular 2 P2.12-001 Assessment of Olfactory Function in Classical (Infratentorial) Superficial Siderosis – Natallia Kharytaniuk, Menelaos Pavlou, David Werring, Doris-Eva Bamiou P2.12-002 Delayed Post-hypoxic Leukoencephalopathy Presenting as Acute Psychosis without Focal Neurologic Deficits – Jeff Wang Jin, Samantha Hentosh, James Walker Wiggins, Vivek Nishad Mehta, Jordan Shull, Jay-Jiguang Zhu, Meenakshi Bidwai Bhattacharjee P2.12-003 Diffusion restriction in the splenium of the corpus callosum: Clinical presentation, neuro-imaging findings, and hospitalization outcomes – Brian Stamm, Christina Lineback, Mengxuan Tang, Dan Tong Jia, Farzaneh Aghdassi Sorond, Behnam Sabayan P2.12-004 Hypoxic-ischemic Injury as a Rare Complication of Sudden Severe Anemia – Alexandre Mason Sharma, Nikhil B. Bhana, James E. Siegler P2.12-005 Ascorbic Acid Deficiency As Culprit Of Cortical Spontaneous Subarachnoid Hemorrhage. Case Report And Literature Review. – Maria Shoaib, Ramsha Ali Bhutta, Nidhiben A. Anadani, Ahmad Al-Awwad
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Amyotrophic Lateral Sclerosis 2 P2.13-001 Retrospective Review of Outcomes After Intervention for Enteral Nutrition in ALS Patients Enrolled in Midwest Multi-disciplinary ALS Clinics – Timothy R. Fullam, Suzanne Hunt, Swathy Chandrashekhar, Omar Jawdat, Brian GhafariNaraghi, Ezequiel A. Piccione, J. Americo M. Fernandes, Richard J. Barohn, Katy Eichinger
P2.13-003 Use of Electrical Impedance Tomography to Assess Pulmonary Function in ALS Patients – Courtney E. McIlduff, Allaire Doussan, Irene Yator, Sarah Verga, Soleil Samaan, Hilda Victoria Gutierrez, Ethan K Murphy, Elijah Stommel, Sean Levy, Ryan J Halter, Seward B. Rutkove P2.13-004 Continued Intravenous Edaravone Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS) Increases Overall Survival Compared With No Intravenous Edaravone Treatment: Results from a US Administrative Claims Database – Benjamin R. Brooks, James D. Berry, Malgorzata Ciepielewska, Jeffrey Zhang, Ying Liu, Gustavo A. SuarezZambrano, Melissa Hagan P2.13-005 Treatment Outcomes Among Amyotrophic Lateral Sclerosis Patients Receiving Intravenous Edaravone (IV): 44 Months of Follow-up From US Specialty Infusion Centers – Melissa Hagan, Malgorzata Ciepielewska, Polina Da Silva, Ying Liu, Jeffrey Zhang, Barbara Prosser, Daniel Rosenberg, Anusha Patni, Marlena Anderson, Kayla Ortlip, Karen Martin, Stephen Apple P2.13-006 Clinical and Electrophysiological Findings in C9orf72 ALS – Sri Raghav Seshu Sista, Shahar Shelly, Carolina Parra-Cantu, Jennifer Marie Martinez-Thompson, Nathan P. Staff, Ruple S. Laughlin P2.13-007 Prognosis of Pathologically Confirmed Japanese Amyotrophic Lateral Sclerosis with Tracheostomy Invasive Ventilation, a Retrospective Institutebased Study – Kiyonobu Komai, Chiho Ishida, Kazuya Takahashi, Yuko Motozaki, Atsuro Tagami P2.13-008 Study Design for a Phase 3, Multicenter, OpenLabel, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-A03) – Daniel Selness, Manabu Hirai, Takeshi Sakata, Alejandro Salah, Stephen Apple
P2.13-002 Is There Any Association Between the Prevalence of ALS and Exposure to Hazardous Wastes? A Statewide Planning and Research Cooperative System (SPARCS) Study (2002-2014) – Yueqing Zhang, Sanjila Islam, Kranthi Kiran Mandava, Mustafa Jaffry, Nizar Souayah
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
33
Saturday, April 2 5:30 p.m.–6:30 p.m.
Poster Session 3
1
Autoimmune Neurology
Autoimmune Neurology: Peripheral Nervous System and Muscle 1 P3.1-001 Baseline Characteristics and Demographics of Patients Enrolled in an Expanded Access Program for Efgartigimod in Adult Patients with Generalized Myasthenia Gravis – Deborah Gelinas, Omar Rahman, Erin Powers Lambert, Benjamin Van Hoorick P3.1-002 Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study – Tuan Hoang Vu, Stephan Ortiz, Masahisa Katsuno, Djilalli Annane, Renato Mantegazza, Kathleen Beasley, James F. Howard P3.1-003 Safety of different IVIG doses for treatment of CIDP. The ProCID study – Elisabeth Clodi, David R. Cornblath, Pieter Van Doorn, Hans-Peter Hartung, Ingemar S.J. Merkies, Hans D. Katzberg, Doris Hinterberger, and the ProCID Investigators P3.1-004 The ProDERM study: Safety and Tolerability Results from randomized, double-blind, placebo-controlled Phase-III-Trial in Patients with Dermatomyositis. – Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, Zsuzsanna Bata-Csorgo, Mazen M. Dimachkie, Zoltan Griger, Sergey Moiseev, Chet Oddis, Elena Schiopu, Jiri Vencovsky, Irene Beckmann, Elisabeth Clodi, Todd D. Levine, and the ProDERM Investigators
2
Headache
Headache: Advances in CGRP Inhibition for Precision Medicine 3 P3.2-001 Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial – Brad C. Klein, Rosa Miceli, Lawrence Severt, Peter J. McAllister, Laszlo Mechtler, Jennifer McVige, Merle Diamond, Michael J. Marmura, Hua Guo, Michelle Finnegan, Joel M. Trugman P3.2-002 ALLEVIATE, a Clinical Trial-in-Progress of Eptinezumab in Patients With Episodic Cluster Headache – Stewart J. Tepper, Neli Boneva, Mette Josiassen, Elin Lof, Rigmor Jensen P3.2-003 Changes in Heart Rate and Blood Pressure in Participants Treated With Fremanezumab for Migraine: A Pooled Analysis of Phase 3 Studies – Steffen Naegel, Joshua M. Cohen, Yoel Kessler, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Stephanie J. Nahas P3.2-004 Efficacy and Disability Outcomes of Fremanezumab in Patients With Prior OnabotulinumtoxinA Treatment Failure: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies – Juliana VanderPluym, Xiaoping Ning, Verena Ramirez Campos, Steve Barash, Lynda Krasenbaum, Peter J. McAllister
P3.1-005 Missed Opportunities to Prevent N-methyl-Daspartate Receptor (NMDAR) Encephalitis in a DREAMer – Paul Daniel Crane, Matthew Jensen, Suzanne Liu, Justin Abbatemarco, Jana Wold, Holly Leydard, Umang Swami, Michelle Miranda, Stacey Clardy
P3.2-005 Long-term Safety and Tolerability of Erenumab In Episodic Migraine: A Pooled Analysis From Two Clinical Trials and Their Extension Phases – Messoud Ashina, Uwe Reuter, David W. Dodick, Feng Zhang, Shannon Ritter, Tracy E. Stites, Gabriel Paiva da Silva Lima, Michal Arkuszewski, Peter Goadsby
P3.1-006 A case of a 4-year-old female with Leucine Rich Glioma Inactivated protein (LGI1) encephalitis associated with a cystic nephroma, responsive to intravenous immunoglobulin (IVIG), corticosteroids, and rituximab – Brandon Chase Neeley, Alfred Balasa, Elizabeth McQuade, Sara A. McGuire
P3.2-006 Optimization of Acute Treatment and HeadacheRelated Impact Following Eptinezumab Initiated During a Migraine Attack: Post Hoc Analysis of the RELIEF Study – Dawn C. Buse, Richard B. Lipton, Anders Ettrup, Mette Josiassen, Annika Lindsten, Roger Cady
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Biomarkers and COVID-19 Impact 1 P3.3-001 Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study – DingDing Zhang, Yuan Cao, Jing-Yu Mu, Yi-Ming Liu, Feng Gao, Fei Han, Fei-Fei Zhai, Li-Xin Zhou, Jun Ni, Ming Yao, Mingli Li, Zheng-Yu Jin, Shu-Yang Zhang, Li-Ying Cui, Yong Shen, Yi-Cheng Zhu P3.3-002 COVID-19 case fatality and Alzheimer’s disease – Qiang Johnson Zhang, Jordan L. Schultz, Georgina M. Aldridge, Jacob E. Simmering, YoungCho Kim, Amy Ogilvie, Nandakumar Narayanan P3.3-003 Simple risk scores for the prediction of brain ß-amyloid and tau status in older adults with mild cognitive impairment – Ali Ezzati, Richard B. Lipton, Kellen Petersen P3.3-004 High Sensitivity Simoa Immunoassays to Evaluate Levels of Postsynaptic density protein 95 and Neuronal Pentraxin II as Predictors of Cognitive Function Loss in Alzheimer’s Diseases – Hana Na, Valerie Brachet P3.3-005 An Ultrasensitive Immunoassay for the Detection of p-tau231 in Plasma, Serum & CSF – Yao Chen, Valerie Brachet
4
MS and CNS Inflammatory Disease
MS Clinical Practice & Decision Making 1 P3.4-001 Sick leave and occupational burnout among nurse practitioners caring for patients with multiple sclerosis – Gustavo Saposnik, Guillermo Bueno, Beatriz del Río Muñoz, Alejandro Lendínez-Mesa, Cristina Azanza, Noelia Becerril Rios, Haydee Goicochea Briceño, Rosalia Horno Ocaña, Cesar Manuel Sanchez Franco, Nicolas Medrano, Jorge Maurino P3.4-002 Small Fiber Neuropathy in Multiple Sclerosis: A Case Series – Natalie Karina Erlich-Malona, Syed Rizvi, Todd Nguyen, Saima Chaudhry, Kara Stavros, Jonathan Cahill P3.4-003 Retrospective Evaluation of De-Escalation from Anti-CD20 Therapies to Fumarates as a Treatment Approach – Brandi L. Vollmer, Evan Riddle, Jason P. Mendoza, Enrique Alvarez
34
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 3
P3.4-004 Risk Perception in Multiple Sclerosis: Reasons for Switching Treatment Between High Efficacy and Non-high Efficacy Disease-modifying Therapies – Gustavo Seifer, Patricia Dominguez Castro, James Pike, Eddie Jones, Rainel Sanchez-De La Rosa P3.4-005 Dimethyl Fumarate Demonstrates Treatment Effectiveness in Patients One Year After Switching From Teriflunomide – Kathryn Giles, Richard A L Macdonell, Filipe Branco, Phoebe Jiang, Seth Nathatn Levin, Sai Shankar, Thomas Alois Berger
MS Immunology and Basic Science 1 P3.4-006 The Role of Human and Mouse BTK in Myeloid Cells – Claudia Bassani, Marta Molinari, Vittorio Martinelli, Roland Grenningloh, Ursula Boschert Shafaatian, Giancarlo Comi, Gianvito Martino, Luca Muzio, Cinthia Farina P3.4-007 Autoantibodies to an RNA binding protein exacerbate clinical disability and neurodegeneration in an in vivo model of multiple sclerosis – Cole Libner, Hannah Salapa, Michael C. Levin P3.4-008 Disruption of Stem Cell Proliferation and Differentiation Capacity in a Cerebral Organoid Model of Multiple Sclerosis – Mia DiCostanzo, Tara Edwards, Nicolas Daviaud P3.4-009 Long-term effects of oligodendrocyte-specific FGFR1 deletion on the signaling cascade and myelin protein expression in the CNS of adult C57BL/6J mice – Vinothkumar Rajendran, Ranjithkumar Rajendran, Franziska Kissel, Christine StadelmannNessler, Srikanth Karnati, Martin Berghoff P3.4-010 Quantitative Analysis of Wild Type (WT) and Shiverer (SHR) Mouse Spinal Cords using Ultrahigh-b DWI (UHb-DWI) – Kyle E. Jeong, Sophie Lee, Sukkeu Yeom, Noel Carlson, Lubdha Shah, John W. Rose, Eun-Kee Jeong P3.4-011 Thyromimetics improve disease endpoints and modulate potential target engagement biomarkers in rodent models of ALD and MS – Michaelanne Woerner, Jeffrey Vivian, Aryan Alavi, Amy Klova, Marc Hellerstein, Rohan Gandhi, Chan Beals, Brian Stearns, Deidre MacKenna
5
Saturday, April 2 5:30 p.m.–6:30 p.m.
Child Neurology and Developmental Neurology
Child Neurology: Demyelinating/ Leukodystrophy/Neuroimmunology 3
P3.6-003 Volumetric Brain MRI Quantification in Early Versus Late Onset Alzheimer’s Disease – Somayeh Meysami, Cyrus A. Raji, David Merrill, Verna R. Porter, Youssef I. Khattab
P3.5-001 Effects of sulfatide accumulation on peripheral nerves in metachromatic leukodystrophy – Christian Krarup, Christine I. Dali, Samuel Groeschel, Mihai Moldovan, David Whiteman, Ingeborg KragelohMann, Jing Li, Norman W. Barton, Mohamed Farah
P3.6-004 In Response to Social Acceptance, Nucleus Accumbens Mu Opioid Receptor Activation is Associated with Increased Self-Esteem and Positive Mood – Kathryn Hill, Stephan Taylor, Todd Ogden, Ramin Parsey, Christine DeLorenzo
P3.5-002 Increased Anxiety, Depression and Suicidal Ideation in Children with Neuromyelitis Optica – Margaret Codispoti, Alfred Balasa, Nikita Shukla, Timothy E. Lotze
P3.6-005 Clinical Features and Neuroimaging of Anomic Progressive Aphasia – Christine Cliatt Brown, Jonathan Graff-Radford, Joseph Duffy, Rene Utianski, Heather Clark, Mary M. Machulda, Wentao Li, Jennifer Louise Whitwell, Keith A. Josephs, Hugo Botha
Child Neurology: Neurodevelopmental Disorders/CP/ASD 2 P3.5-003 Tic Severity and Family Function in Children with Tourette Syndrome and Coprophenomena – Samantha Paige Myers, Jonathan W. Mink, Jennifer Anne Vermilion P3.5-004 Pediatric Functional Neurological Disorder: Investigating Demographic & Clinical Factors and Impacts on Management – Ria Pal, Emira Romero, Zihuai He, Terrell Stevenson, Cynthia Campen P3.5-005 Non Decussating Retinal-fugal Fiber Achiasmatic Syndrome, Expanding The Clinical and Radiological Features of an Exceedingly Rare Cause of Congenital Nystagmus, a Report of Additional Three Patients and a Review – Abdulhafeez Khair, Rahul Nikam, Stephen Falchek
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Cognitive and Behavioral Neuroimaging Topics 1 P3.6-001 Network Localization of Visual Anosognosia from 28 Cases of Anton Syndrome – Kyla Ann Gaudet, Michael D. Fox, Isaiah Kletenik P3.6-002 Discourse Comprehension in Healthy Adults and Individuals with Acute Aphasia: an fNIRS Study – Hana Kim, Lisa Bunker, Erin Meier, Argye E. Hillis
Information is accurate as of February 8, 2022, and is subject to change.
7
Practice, Policy, and Ethics
Practice, Pitfalls, and Innovation 1 P3.7-001 Real-World Resource Utilization and Productivity Loss among Patients with Myasthenia Gravis in Sweden: A Nationwide Population-based Study – Qiaoyi Zhang, Qian Cai, Nurgul Batyrbekova, Lilla Di Scala, Shane Kavanagh P3.7-002 Brain Dead or Alive: Pitfalls in Neurological Prognostication – Danielle Bazer, Matthew Orwitz, Nicholas Koroneos, Ryan Christopher Corn, Philip Yeung, Elizbieta Wirkowski P3.7-003 Defining and Understanding Barriers to Medication Reconciliation in the Outpatient Neurology Clinic – Alex Joseph Luke, Debolina Kanjilal, Binod Wagle P3.7-004 Seizure Alert: An Interdisciplinary Protocol for Timely Anti-Seizure Medication Administration in the Setting of Status Epilepticus – Kelly Lauren Block, Lauren Skalomenos, Joanna Jinghan Wu, Shaun O. Smart
7
Sleep
Sleep: Focus on Hypersomnia and RBD 3 P3.7-005 The Effect of Sleep Disordered Breathing on Cognitive Function in Patients with Normal Pressure Hydrocephalus – Raman Bhambra, Aruna S. Rao
AAN.com/AM
35
Saturday, April 2 5:30 p.m.–6:30 p.m.
Poster Session 3
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASMs General 2 P3.8-001 Safety Profiles of Second-Generation Antiseizure Medications: A Pharmacovigilance Study – Mokshal Porwal, Dhruvkumar Patel, Mit Patel, Hannah Carlson, Kushal Porwal P3.8-002 Everolimus for Treatment of Refractory Seizures in Tuberous Sclerosis – Nayana Prabhu, Hira Zafar, Praveen Ramani, Salman Zahoor, Sisira Yadala, Erika Santos Horta P3.8-003 Antiseizure drugs adherence in elderly patients with epilepsy – Carla Portinari, Tomas Ibañez, Adriana Sotelo, Gonzalo Lage, Federicoí Fabio Ramos, Marcos Sorbara, Gisela Zanga, Romina Diaz, Maria Martha Esnaola Y Rojas P3.8-004 Atypical Presentation of Lance Adams Syndrome in the setting of Clonazepam overdose and SARSCoV-2 pneumonia – Kaleb Logan Culpepper, Lauren A. Terpak, Luis Alberto Cruz-Saavedra, Suparna R. Krishnaiengar P3.8-005 WITHDRAWN P3.8-006 New-Onset Refractory Status Epilepticus After Pfizer-BioNTech COVID-19 Vaccination – Kristie Bauman, Jonathan Rosenthal, Jessica Lin
9
Infectious Disease
Infectious Disease: Long COVID and Vaccines 1 P3.9-001 Epochs Of Sternutation Induced By Coronavirus 19 – Sunjeet Brar, Alan R. Hirsch P3.9-002 Covid-19 Associated Extreme Fatigue Effects on Activities of Daily Living in Mild and Long-Haul Infections: Patient Perspectives from a Remote Patient Monitoring Program – Nicki Mohammadi, Emma Reford, Natalia Romano Spica, Jenna Tosto, Laura Rosenbaum Tabacof, David Putrino, Christopher Kellner P3.9-003 New Neurological Syndromes with COVID-19 Infection: Is Immune System Hyperactivity to Blame? – Mahjabin Islam, Maaz Nayyer, Daniel Madarshahian, Thomas M Jenkins
36
2022 AAN Annual Meeting
9
Neuro-oncology
Neuro-oncology: Neuroimaging and Informatics 1
P3.10-007 A Rare Case of Adult Onset Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes at Age 60 – Adriana Carola Mendez, Sruthi Devarinti, Azima Shaji
P3.9-004 Machine learning approaches for automated segmentation of gliomas – Avery Lum, Waverly Rose Brim, Harry Subramanian, Sam Payabvash, Ichiro Ikuta, MingDe Lin, Khaled Bousabarah, Michele Hackley Johnson, Ajay Malhotra, Mariam Aboian
P3.10-008 Subarachnoid Hemorrhage Secondary to An Exceedingly Rare Case of STELARA® (Ustekinumab) Induced Reversible Cerebral Vasoconstrictive Syndrome – Michael Hadler, Victoria Michelle Rice, Erika Webster, Tamra Ishan Jayendra Ranasinghe
P3.9-005 Quality Improvement Project: Number of Neurofibromatosis Type I Patients with Unidentified Bright Objects (UBOs) on MRI that Developed Subsequent Gliomas – Mekka Rae Garcia, Monica Eunseo Kim, Nora Jandhyala, Devorah Segal, Kaleb H. Yohay
P3.10-009 Pulmonary Arteriovenous Malformation (PAVM): An Uncommon Cause of Cryptogenic and Embolic Stroke of Undetermined Source (ESUS). – Teye Aniefiok Umanah, Farah Yolanda Fourcand, Siddhart Kumar Mehta, Gautam Karteek Visveswaran, Jawad F. Kirmani, Sara Strauss
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Interesting Cases 3 P3.10-001 Loeffler’s endocarditis: A rare cause of stroke resulting in person in the barrel syndrome – Maya Gabel, Faddi Ghassan M. Saleh Velez, Victor J. Del Brutto, Sebastian Koch P3.10-002 Recurrent Ischemic Strokes in Biliary tract malignancy: Role of Direct-Acting Oral Anticoagulants and Early Screening – Case Series – Noor Mahmoud, Sara Habib, Ahmad Al-Awwad P3.10-003 A Case of Hemichorea-Hemiballism Following a Cortical Stroke from Occlusion of an Anomalous Accessory Middle Cerebral Artery – Priyanka Moondra, Vishal Gupta, Ritesh Ramdhani, Jeffrey M. Katz, Rohan Arora, Richard Libman P3.10-004 Knot so Straight Forward: A Rare Case of Mixed Pial-Dural Arteriovenous Malformation combined with an Arteriovenous Fistula of the Posterior Circulation – Maria Gabriela Martucci, Claudia Vallin, Michal Obrzut P3.10-005 Cervico-Thoracic Spinal Dural Arteriovenous Fistula in a Patient with Lower Extremity Weakness Exacerbated by Steroids and Lumbar Puncture – Sukhraj Gill, Sandeep Gill, Matthew Hart, Mitchell Onken P3.10-006 Ocular lateral deviation as a clinical sign of medial PICA infarct – Nicole Platti, Rami Fakih, Joan Maley, Kaancan Deniz, Busranur Agac, Deema A. Fattal
P3.10-010 Short Term Acute Ischemic Stroke after Initiation of Gender-Affirming Hormone Therapy: A Case Report – Ricardo Murguia Fuentes, Abdullahi Musa Adamu, Prabandh Reddy Buchhanolla, Muhammed Ikbal Arvas
11
Movement Disorders
Movement Disorders: Huntington’s Disease P3.11-001 Young-Onset Huntington’s Disease: Defining an Emerging Clinical Cohort – Miguel Alonso Ruvalcaba, Christopher Jay Campos, Alexandra O’Neill Duffy P3.11-002 Differences in visual-cognitive performance between asymptomatic and symptomatic carriers of Huntington’s disease – Miriam Turuelo, Marian Acera, Maria Diez-Cirarda, Tamara Fernandez, Beatriz Tijero, Mar Carmona, Marta Ruiz Lopez, Johanne Hatteland Somme, Javier Ruiz-Martínez, Andrea Gabilondo, Ioana Croitoru, Lara Pardina Vilella, Naia Ayo, Ane Murueta-Goyena, Inigo Gabilondo Cuellar, Juan Carlos Gomez Esteban, Rocio Del Pino P3.11-003 Patient Experiences in early Huntington’s Disease - Qualitative Research to Inform Development of a Patient-Reported Instrument of Everyday Functioning – Jennifer Billet, Adele Levine, Jason K. Johannesen, Teya Lovell, Alissa Rams, Emily Gusse, Stefan Cano, Aaron Koenig
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 3
P3.11-004 The Association Between Lifestyle Factors and Huntington´s Disease Mortality – Esther Cubo Delgado, Laura Aguado García, Gonzalo Gamez Leyva Hernandez, Sara Calvo, Asuncion MartinezDescalls, Natividad Mariscal-Pérez, Maria Dolores Diaz Pineiro, Ignacio Muñoz-Siscart, Carla Collazo, Alvaro Garcia Bustillo, Lucía Simón Vicente, Irene Miguel, Carlos Fernandez Ramajo P3.11-005 Psychometric Validation of Huntington’s Disease Everyday Functioning (Hi-DEF) Scale –Study Design and Sample Characteristics – Jennifer Billet, Adele Levine, Jason K. Johannesen, Ruta Sawant, Teya Lovell, Alissa Rams, Emma Elliott, Aviva Gillman, Jee Bang, Danny Bega, Jennifer Klapper, Rajeev Kumar, Henry Paul Moore, Susan L. Perlman, Luis Alberto Sierra, Stefan Cano, Aaron Koenig P3.11-006 A Sentiment Analysis of Unstructured Electronic Medical Record Data of Patients Treated With Vesicular Monoamine Transporter 2 Inhibitors in Huntington’s Disease and Tardive Dyskinesia – Victor W. Sung, Christopher W. Yee, Rajeev Ayyagari, Jessica K. Alexander, Pooja Gandhi, Sam Leo P3.11-007 Clinical evidence that treatment with pepinemab, a novel regulator of neuroinflammation, provides cognitive benefit to patients with Huntington’s and potentially other neurodegenerative diseases – Elizabeth E. Evans, Terrence Fisher, Vikas Mishra, Megan Boise, Amber Lynn Foster, Ernest Smith, John Leonard, Andrew S. Feigin, Eric R. Siemers, Maurice Zauderer
12
General Neurology
General Neurology: Cerebrovascular 3 P3.12-001 Pontine Cavernous Hemangioma As a Possible Cause of New Onset Seizures and Millard-Gubler Syndrome in a Middle aged Female – Dylan Weaver, Schweta Parag Rane, Xiang Fang P3.12-002 No More Tissue: Elimination of Sneezing Due To Cerebellar Hemorrhage – Ashmeet Singh Sahni, Alan R. Hirsch P3.12-003 Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality versus Wishful Thinking? – Matthew SmithCohn, Nicholas Bond Burley, Stuart A. Grossman
13
Saturday, April 2 5:30 p.m.–6:30 p.m.
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Amyotrophic Lateral Sclerosis 3 P3.13-001 Clinical utility and feasibility of an ALS specific advance care directive: A retrospective chart review – Tyra Swanson, Kendall Nichols, Samuel J. Maiser P3.13-002 ALS and cerebellum: Study of Eyeblink conditioning in Subjects with ALS – Aiga Rakhesh, Amanda Haskell, Labeeby Servatius, Rick Servatius P3.13-003 Edaravone in The Disease Course of ALS Effect. Retrospective Trial – Federico Guido Man, Sara Palacios, Cecilia Quarracino Benchetrit, Mariana Bendersky, Natalia Bohorquez Morera, Raul Rey, Gabriel Rodriguez P3.13-004 Evaluation of Gastrointestinal Symptoms in an ALS Cohort – Rizamarie Empeno, Omer Waqar Naveed, John Furey, Terry D. Heiman-Patterson P3.13-005 An Open Label Study of Poly-MVA to Treat Fatigue in ALS – Amer Avdagic, Tejas R. Mehta, Krista Schoff, Raghav Govindarajan P3.13-006 Degeneration of upper and lower motor neurons in a novel CSF-mediated animal model of sporadic ALS – Rose Putnam Griffin, Ivy Gao, Nadia Merve Celestin, Jamie Wong, Saud Sadiq P3.13-007 COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry NCT04559009 – Urvi G. Desai, Benjamin R. Brooks P3.13-008 Adipose Tissue Distribution as a Predictor of Rate of Progression in Patients with Amyotrophic Lateral Sclerosis – Gracia Luoma-Overstreet, Rebecca Rhodes, Kelly G. Gwathmey P3.13-009 Barriers and facilitators to continuing non-invasive ventilation use in individuals with amyotrophic lateral sclerosis – Jennifer L. Marsella, Cynthia Gibson, Emma Ciafaloni P3.13-010 RACK1 Knockdown Alleviates TDP-43-Associated Global Translational Suppression in vitro, and Neurodegeneration in vivo – Beibei Zhao, Catherine M. Cowan, Ananya Saraph, Darren David Christy, Juliane Ashleigh Coutts, Johanne M. Kaplan, Neil R. Cashman
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
37
Poster Session 4
1
Autoimmune Neurology
Autoimmune Neurology: Peripheral Nervous System and Muscle 2 P4.1-001 Changes in Guillain-Barre Syndrome –Associated Ganglioside Antibody Test Results at a National Clinical Laboratory During the COVID-19 Pandemic – Michael K. Racke, Raymond Lorenz, Justin K. Niles, Harvey W. Kaufman P4.1-002 COVID-19 Cytokine Storm in Myasthenia Gravis Treated with Mesenchymal Stem Cells: A Case Report – Aldanica Olano, Mark Anthony Jalbuena Sta. Maria, Genica Lynne Maylem, Marc Joseph Oliver Buensalido, Karl Evans Rivera Henson, Alma Reyes Calavera P4.1-003 Autoimmune Acute Myelitis with Guillain-Barré Syndrome and Cerebellar Ataxia after COVID-19 Infection: a Case Report – Masashi Watanabe, Yukitoshi Takahashi, Keiko Tanaka, Ayumi Uchibori, Atsuro Chiba, Hitoshi Kubo, Itaru Kyoraku, Kensho Okamoto P4.1-004 New Diagnosis of Myasthenia Gravis in the Setting of COVID-19 Infection – Serena Wong, Osher Rechester, Anila Thomas P4.1-005 Myasthenia Gravis Syndrome Following COVID-19 Vaccination and Subsequent Tolerance of Booster Vaccine: A Case Report – Dana Most, Michelle Tiem, Dominic A. Ferrey, Anastasie M. Dunn-Pirio Autoimmune Neurology: Autoimmune Encephalitis and Antibody Associated Neurologic Disorders 3 P4.1-006 A case of Refractory Status Epilepticus in Autoimmune Encephalitis with autoantibodies against GABA-B receptors, and robust response to combination therapy. – Binod Wagle, Robert Evan Ungerer P4.1-007 Overlapping Autoimmune Neurologic Syndrome, A case report of triple-positive antibody – Kyle Edward Bonner, Hassan Osama Mostafa Aboul Nour, Anza Memon
38
2022 AAN Annual Meeting
2
Sunday, April 3 8:00 a.m.–9:00 a.m.
Headache
Headache: Clinically Oriented Headache Studies 1 P4.2-001 Nummular Headache in Children: A Case Series and Systematic Literature Review – Daniel Lax, Marielle Kabbouche, Joanne Kacperski, Andrew D. Hershey P4.2-002 A Rare Case of Chronic Refractory Short lasting Unilateral Neuralgiform Headache Attacks with Cranial Autonomic Symptoms [SUNA] responding well to Erenumab – Raja Hassan Imtiaz, Rosamma Joseph P4.2-003 Prevalence of Cognitive Dysfunction in Episodic and Chronic Migraine in an Academic Headache Clinic – Zachary Robateau, Daniel Krashin, Ami Zarrillo Cuneo, Sau Mui Chan-Goh, Marcel Budica, Natalia Murinova P4.2-004 Oculomotor, vestibular, reaction time, and cognitive assessment in vestibular migraine – Claire Ceriani, Alexandr Braverman, Alex Kiderman
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Biomarkers and COVID-19 Impact 2 P4.3-001 Association of plasma GFAP with neuroimaging measures of amyloid, tau, neurodegeneration and vascular pathology – Dror Shir, Jonathan Graff-Radford, Ekaterina Hofrenning, Timothy Lesnick, Scott Przybelski, Val John Lowe, David S. Knopman, Ronald C. Petersen, Clifford R. Jack, Prashanthi Vemuri, Michelle M. Mielke P4.3-002 Retinal Amyloid Count And Venular Tortuosity Correlate With Neurocognitive Status – Tania Torbati, Julia Sheyn, Dale Sherman, Mazyiar Khansari, Keith Black, Patrick D. Lyden, Yosef Koronyo, Maya Koronyo-Hamaoui, Oana Maria Dumitrascu P4.3-003 Association of Multiple Inflammatory Biomarkers with Cerebral Arterial Atherosclerosis and Dolichoectasia – Yuan Cao, Ding-Ding Zhang, JingYu Mu, Yi-Ming Liu, Feng Gao, Fei Han, Fei-Fei Zhai, Li-Xin Zhou, Jun Ni, Ming Yao, Mingli Li, Zheng-Yu Jin, Shu-Yang Zhang, Li-Ying Cui, Yong Shen, Yi-Cheng Zhu
P4.3-004 Clinical Prospective Research during COVID-19: Strategies to Mitigate the Impact of the Pandemic – Ryu Platinum Dorn, Erica S. Westphal, Maxwell Daniel Yargeau, Mandy Spaltman, Sarah Harlock, Bela Ajtai, Nandor K. Pinter P4.3-005 Plasma neurofilament light chain as a promising biomarker in preclinical and prodromal stages of Alzheimer’s Disease – Giulia Giacomucci, Valentina Bessi, Silvia Bagnoli, Deborah Leccese, Salvatore Mazzeo, Assunta Ingannato, Sonia Padiglioni, Sandro Sorbi, Benedetta Nacmias
4
MS and CNS Inflammatory Disease
MS Immunology and Basic Science 2 P4.4-001 NLPR3 Inflammasome Activation within Demyelinating Lesions in Cerebral Adrenoleukodystrophy – Isha Srivastava, Alejandro Aguirre, Romain Cayrol, Hannes Vogel, Troy Lund, Keith Van Haren P4.4-002 Neuroprotective effect of AZ257, a novel ureabased dopamine transporter inhibitor, in the experimental autoimmune encephalitis (EAE) mouse model – Mirla L. Avila, Jie Pan, Smathorn Thakolwiboon, Volker Neugebauer, Guangchen Ji, Nadezhda German P4.4-003 Function of miRNA profiled in Teriflunomide treated multiple sclerosis (MS) patients – Fermisk Saleh, Anu Paul, Tanuja Chitnis, Howard L. Weiner P4.4-004 Interleukin-6 as a Potential Prognostic Biomarker in Relapsing MOG Antibody Disease – Jamie C. McDonald, Neda Sattarnezhad, Anna Tomczak, Julia Sumera, Christopher Lock, May Han
MS Special Populations 1 P4.4-005 Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the CHIMES Trial – Lilyana M. Amezcua, Annette Okai, Anne H. Cross, Nancy Monson, Ben W. Thrower, Anthony Reder, Jeffrey B. English, Gregory F. Wu, Evanthia Bernitsas, Shereen Yap, Jugena Ndrio, Jinglan Pei, Ellen M. Mowry, Fabio Magrini, Mitzi Joi Williams P4.4-006 Academic Underachievement is Common in Pediatric-Onset Multiple Sclerosis – Wendy Sulina Vargas, Michael Glendinning, Hannah Zoe Street, Nicole A Ampatey, Gabriella Tosto, Robert Fee, Brenda Banwell, Philip De Jager
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 4
P4.4-007 Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab – Kerstin Hellwig, Bassem I. Yamout, Riley Bove, Pranava Reddy Katkuri, Ulf Schulze Topphoff, Dee Stoneman, Ronald Zielman, Ratnakar Pingili, Maria K. Houtchens P4.4-008 Cladribine and Pregnancy in Women with Multiple Sclerosis – a Case Series from Germany – Karen Dost-Kovalsky, Sandra Thiel, Andrea Ines Ciplea, Ralf Gold, Kerstin Hellwig P4.4-009 Comparison of Pharmacokinetic Profiles and Safety Outcomes with Peginterferon Beta-1a Administration in Black/African American and White Participants – Yuan Zhao, Jonathan Smith, Nancy Ramia, Maria Naylor, Cherie Butts P4.4-010 Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program (POP) Interim Analysis – Sibyl E. Wray, Marco Salvetti, Gereon Nelles, Arman Altincatal, Nydije Grimes, Achint Kumar, Maria Naylor P4.4-011 Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of MS DMTs: A Systematic Review – Helen Onuorah, Odelin Charron, Ethan Isaac Meltzer, Amanda Montague, Alexis Crispino, Avery Largent, Ashlea Lucas, Leorah Aude Emmanuelle Freeman
5
General Neurology
Neuroepidemiology 1 P4.5-001 Public-Private Collaboration in ALS Research by GUID Utilization Paves the Road to Patient-Centric Precision Research in Neurological Diseases – Alex Berger, Ervin Sinani, Igor Katsovskiy, Jaime Raymond, Derek D’Agostino, Natalia Tarasenko, Paul Mehta, Alexander Sherman P4.5-002 Spatial Clustering of Amyotrophic Lateral Sclerosis in Virginia – David Wheeler, Ryan Louis Naum, Paula Burke Brockenbrough, Michelle Gebhardt, LaVon Smith, Tremetris Harrell, Danielle Stewart, Kelly G. Gwathmey P4.5-003 Examination of Participant Demographics and ALS Symptom Characteristics from Pooled Resource Open-Access ALS Clinical Trials and National ALS Registry – Moon Han, Jaime Raymond, Theodore Larson, Paul Mehta, D Kevin Horton
Sunday, April 3 8:00 a.m.–9:00 a.m.
P4.5-004 Impact of Melatonin on Survival in ALS – Isaac Whitworth, Ervin Sinani, Derek D’Agostino, Kenneth Faulconer, Igor Katsovskiy, Natalia Tarasenko, Isaac Whitworth, Alexander Sherman P4.5-005 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Hazardous Waste Sites? A Statewide Planning and Research Cooperative System (SPARCS) Study 19982014 – Yueqing Zhang, Sanjila Islam, Mustafa Jaffry, Kranthi Kiran Mandava, Kazim Jaffry, Nizar Souayah
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Cognitive and Behavioral Neuroimaging Topics 2 P4.6-001 Exercise Changes White Matter and Neurite Morphology in Patients with Idiopathic Generalized Epilepsy – Malik Bolaji, Adam M. Goodman, Rodolphe Nenert, Jerzy P. Szaflarski, Jane B. Allendorfer P4.6-002 Thermodynamic Indices of Brain Activity to Identify People with Good Cognitive Capacity – Shivabalan K R, Anjali Byale, Karthik Ajith, Devvrat Yadav, Rahul Mishra, Misha Gautam P4.6-003 Machine learning methods to predict amyloid positivity using domain scores from cognitive tests – Guogen Shan, Jiong Shi, Charles Bernick P4.6-004 Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease – Aylin Cimenser, Holly Mrozak, Xiao Da, Taylor Travers, Evan R. Hempel, Chandran Seshagiri, Alyssa Boasso, Brent Vaughan, Jonathan Thomas Megerian, Zach Malchano, Mihaly Hajos
Genetics and Other Cognitive Topics 1 P4.6-005 Sharpening the Razor: Online Core Curriculum and Mastery (OCCAM) of Behavioral Neurology and Neuropsychiatry Program Strengths and Areas of Improvement – Lealani Mae Acosta, Maya Neeley, Charlene Dewey P4.6-006 Vitamin D is Associated with Visual Memory in Northern Adolescents – Katherine Rachel Fehr Bailey, Jacqueline Pettersen
Information is accurate as of February 8, 2022, and is subject to change.
7
Sleep
Sleep: Focus on Insomnia and TBI 1 P4.7-001 Assessment of the Effect of Lemborexant Versus Placebo and Zolpidem on the Duration of REM Sleep by Quarter-of-the-Night Intervals in Older Adults with Insomnia Disorder – Gary Zammit, Thomas Roth, Dinesh Kumar, Carlos Perdomo, Margaret Moline P4.7-002 An Assessment of Wake Bouts in Adults with Insomnia Treated With Lemborexant or Zolpidem – Thomas Roth, Gary Zammit, Dinesh Kumar, Margaret Moline P4.7-003 Patient-reported Experiences Associated with Falling Asleep/Sleep Onset in an Open-label Study of Lemborexant and Zolpidem – Charles Brendan Montano, Manoj Malhotra, Dinesh Kumar, Carlos Perdomo, Margaret Moline P4.7-004 Self-reported Perceptions of Medication Effectiveness in Subjects Receiving Lemborexant for up to 12 Months – Christopher Lawrence Drake, Jane Yardley, Kate Pinner, Carlos Perdomo, Margaret Moline
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Imaging 1 P4.8-001 The Utility of 18-FDG PET Neuroimaging in the Preoperative Workup for Epilepsy Surgery; Real World Experiences from an Irish Tertiary Referral Centre – Sarah Wrigley, Daniel Costello P4.8-002 Comparing CECT with NCCT in drug-responsive focal epilepsy- A prospective observational study – Jasmine Parihar, Mamta Bhushan Singh, Ajay Garg, Leve Joseph Devarajan Devarajan, Anuj Prabhakar, Maroof A. Khan, Padma Vasantha Hadakasira, Vinay Goyal Goyal, Vishnu VY, Shailesh Gaikwad, Garima Shukla P4.8-003 Handedness and Language Dominance as Revealed by Magnetoencephalography – Emma Balaan, Ajay Niranjan, Anto Bagic, Niravkumar Barot P4.8-004 Resting-State Voxel-Based Pathophysiologic Changes in Medial Temporal Lobe Epilepsy – Jonathan Michael Towne, Vahid Eslami, Jose E. Cavazos, Peter T. Fox
AAN.com/AM
39
Poster Session 4
P4.8-005 Functional Parcellation of the Cingulate Gyrus in Epilepsy Surgical Planning: Electrical stimulation, Electrocorticography, and fMRI study – Tritan Joseph Plute, Rafeed Alkawadri P4.8-006 Functional Parcellation of the Cingulate Gyrus in Epilepsy Surgical Planning: Electrical Stimulation, Electrocorticography, and fMRI. – Rawan Mahgoub, Ayse Bayram, Rafeed Alkawadri
9
Infectious Disease
Infectious Disease: Long COVID and Vaccines 2 P4.9-001 Investigating the relationship of Miller Fisher Syndrome and COVID-19 Vaccination: A Vaccine Adverse Event Reporting (VAERS) Study – Jorge Luis Rodriguez Lee, Mustafa Jaffry, Kranthi Kiran Mandava, Sanjana Rosario, Tarek Elshourbagy, Kazim Jaffry, Kamel Jedidi, Nizar Souayah P4.9-002 Post Covid-19 Neurological Impairment Effects on Activities of Daily Living: Patient Perspectives from a Remote Patient Monitoring Program – Emma Reford, Nicki Mohammadi, Natalia Romano Spica, Jenna Tosto, Laura Rosenbaum Tabacof, David Putrino, Christopher Kellner P4.9-003 Post-acute sequelae of SARS-CoV-2 infection (PASC): peripheral, autonomic, and central nervous system features in a child – David S. Younger
9
Neuro-oncology
Advancing Care in Neuro-oncology 1 P4.9-004 Comparing Methods Used to Identify People with Rare Tumor Predisposition Syndrome in the Electronic Health Record – Macy Early, John Richard Gatti, Bronwyn Slobogean, Bonnie J. Woods, Robert Bruce Ackerman, Anil Mathur, Joshua Roberts, Jaishri Blakeley P4.9-005 Breakthrough Seizures after COVID-19 Vaccines in Patients with Glioma – Trusha Shah, Karl Cristie Fines Figuracion, Bianca Schteiden, Jerome J. Graber P4.9-006 Functional Neurological Disorders in Primary Brain Tumor Patients – Katherine B. Peters, Margaret O. Johnson
40
2022 AAN Annual Meeting
10
Sunday, April 3 8:00 a.m.–9:00 a.m.
Cerebrovascular Disease and Interventional Neurology
Interventional Neurology and Thrombolytic Therapy 1 P4.10-001 Differences in Peripheral Leukocyte Subtypes Between Slow and Fast Progressors of Anterior Circulation Large Vessel Occlusion Stroke – Ji Yeon Son, Marcelo Rocha P4.10-002 Early Infarct Growth Rate is Correlated with IV Thrombolysis Outcomes in Telestroke Patients – Chris Hackett, Maulik Kantawala, Konark Malhotra, Sandeep S. Rana, David G. Wright, Richard Williamson, Timothy Quezada, Ashis H. Tayal, Russell Mitesh Cerejo P4.10-003 Emergent Intracranial Rescue Stenting for Acute Ischemic Stroke patients undergoing Thrombectomy with Incomplete Recanalization – Maria A. Parekh, Juan Carlos Martinez-Gutierrez, Juan Carlos Rodriguez, Sergio Salazar Marioni, Rania Abdelkhaleq, Arash Niktabe, Youngran Kim, Peng R. Chen, Spiros Blackburn, Gary Richard Spiegel, Sunil Sheth P4.10-004 Associations of Admission and Follow-up Neutrophil-lymphocyte Ratios with Clinical Outcomes in Patients with Ischemic Stroke Undergoing Endovascular Therapy – Russell E. Bartt, Erica Sercy, Yasaman Pirahanchi, Donald Frei, David Bar-Or P4.10-005 In-Hospital Glucose Measurements are Associated with Mortality after Thrombectomy for Acute Ischemic Stroke – Penina Krieger, Amanda Jin Zhao, Leah Croll, Hannah Irvine, Jose L. Torres, Kara R. Melmed, Aaron S. Lord, Koto Ishida, Jennifer A. Frontera, Ariane Lewis P4.10-006 A Comparison Of Primary Angioplasty versus Angioplasty with Stent Placement for Treatment of Internal Carotid Artery Occlusion in Acute Ischemic Stroke Settings – Sachin M. Bhagavan, Nitish Kumar, Attiya Jaura, Muhammad Fawad Ishfaq, Brandi R. French, Camilo Ramiro Gomez, Farhan Siddiq, Adnan I. Qureshi P4.10-007 Failure of Tenecteplase in Maintaining Collateral Circulation in Large Vessel Occlusion Strokes – Farah Yolanda Fourcand, Nancy Gadallah, Arifa Ghori, Danisette Torres, Abdallah Omar Amireh, Haralabos Zacharatos, Siddhart Kumar Mehta, Jawad F. Kirmani P4.10-008 Predicting Risk of Malignant Stroke Post Thrombectomy in Anterior Circulation Stroke using ASPECT-PASS Score (A-P Score), a Retrospective Cohort Study – Avirag Goswami, Juan Solano, Jonathan Dissin, Aparna M. Prabhu
P4.10-009 Real-World Bridging with Intra-arterial therapy is safe after Tenectplase in patients with Acute Ischemic Stroke – Sindhu Sahito, Hemal Patel, Nasar Ali, Teye Aniefiok Umanah, Siddhart Kumar Mehta, Haralabos Zacharatos, Spozhmy Panezai, Farah Yolanda Fourcand, Jawad F. Kirmani, Yenna Le P4.10-010 Initial Experience with Tenecteplase as the Intravenous Thrombolytic of Choice Before Mechanical Thrombectomy for Large Vessel Occlusion Acute Ischemic Stroke – Steven Frederick Platko, Fatima Zahra Bensabeur, Umran Ugur, Ronald Markert, David Mark Peters, John Brooks Terry, Esteban Cheng-Ching
11
Movement Disorders
Movement Disorders: PD Non-Motor Symptoms or Parkinsonism and NMS 1 P4.11-001 Predictive value of UPSIT subsets in prodromal Parkinson disease – Pavan Vaswani, James F. Morley, Danna L. Jennings, Andrew D. Siderowf, Kenneth L. Marek P4.11-002 Dysautonomia as a Prognostic Marker for Phenoconversion and Functional Dependence in Prodromal Parkinson’s Disease – Cameron MillerPatterson, Jesse Yenchih Hsu, Lana Chahine, James F. Morley, Allison Wright Willis P4.11-003 Influence of Co-Morbid PTSD in Parkinson’s Disease on Motor and Non-Motor Symptoms – Gulrana Syed, Eric Cheung, Yaseen Saleh, Dilip Pandey, Brandon Barton P4.11-004 Prevalence, Consequences and Correlates of Aggression Towards Caregivers in Parkinson’s Disease and Related Disorders: A Mixed Methods Approach – Zachary Macchi, Roman Ayele, Meredith Bock, Janis Miyasaki, Steven Z. Pantilat, Elizabeth Santos, Hillary Lum, Stefan Sillau, Benzi Kluger P4.11-005 Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease: An update – Shemonti Hasan, Charles H. Adler, Cynthia M. Stonnington, Geidy Serrano, Lucia Sue, Holly A. Shill, Shyamal Mehta, Thomas Beach, Erika DriverDunckley P4.11-006 Clinical characteristics to predict the onset of visual hallucinations in Parkinson’s disease – Sayaka Akazawa, Hiroaki Sekiya, Yoshihisa Otsuka, Yukihiro Yoneda, Yasufumi Kageyama
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 4
P4.11-007 Survival Differences Among Patients with Parkinson’s Disease and Parkinson’s Disease Psychosis: a Population-based Study (2006-2015). – Cole Daniel Stang, Emanuele Camerucci, Aidan Mullan, Gretchen Ahrens, Pierpaolo Turcano, James H. Bower, Bradley F. Boeve, Rodolfo Savica P4.11-008 Apathetic Parkinson’s Disease Patients Have Slower Gait Initiation Following a Verbal Cue – Ségolène De Waele, Emke Maréchal, Patrick Cras, Ann Hallemans, David Crosiers
12
General Neurology
General Neurology: Clinical Practice and Telemedicine 1 P4.12-001 Teleneurology Outpatient Consultations: Patient and Referring Provider Perceptions – Linda S. Williams, Holly Martin, Ziyi Yang, Joanne Daggy, Steven S. Schreiber, Aditi Narechania, Jayne R. Wilkinson P4.12-002 The National TeleNeurology Program (NTNP): Targeting rural Veterans to provide equitable access to specialty care – Aditi Narechania, Steven S. Schreiber, Heidi Watson, Linda S. Williams, Holly Martin, Jayne R. Wilkinson P4.12-003 A Longitudinal Comparison of Ambulatory Neurology Patient Experiences with Telehealth during the COVID-19 Pandemic: How have telehealth interest and satisfaction changed over time? – Kevin Alexander Soltany, Carly Jo Olszewski, Sharon Thomson, Kelly Ann Pring, Rebecca Siobhan-Ivy Cox, Rebecca Merrill, Emily Fishman, Alexander Paul Ambrosini, Gabriella Marie Bognet, Lauren Doyle Strauss, Rachel Graham, Amy K. Guzik, Roy E. Strowd P4.12-004 Differences in Ambulatory Neurology Patient Experiences According to Distance Traveled: How do telephone and video visits compare to in-person? – Alexander Paul Ambrosini, Carly Jo Olszewski, Sharon Thomson, Kelly Ann Pring, Rebecca Siobhan-Ivy Cox, Rebecca Merrill, Emily Fishman, Kevin Alexander Soltany, Gabriella Marie Bognet, Lauren Doyle Strauss, Rachel Graham, Amy K. Guzik, Roy E. Strowd P4.12-005 Telehealth in Outpatient Neurology: Physician and Patient Perspectives – Shreya Shah, Babar Khokhar, Jeremy Moeller
13
Sunday, April 3 8:00 a.m.–9:00 a.m.
Neuromuscular and Clinical Neurophysiology (EMG)
Diagnostic Techniques, Biomarkers and Therapies in Neuromuscular Disease 1 P4.13-001 Benefit of nerve ultrasound in patients with combined central and peripheral demyelination (CCPD) – Amandine Kassab P4.13-002 Ultrasound-enhanced Electrical Impedance Tomography as a New Tool to Assess Primary Muscle Disease – Irene Yator, Ethan K Murphy, Hilda Victoria Gutierrez, Soleil Samaan, Sarah Verga, Courtney E. McIlduff, Seward B. Rutkove, Ryan J Halter P4.13-003 Predictive Value of Single Fiber Electromyography in a Low Prevalence Cohort – Yorjannys Gomez, Araya Puwanant, James B. Caress P4.13-004 Clinical, Electrodiagnostic, and Radiographic Features of Patients with Brachial Plexopathy following Axillary Artery Cannulation – Andres De Leon Benedetti, Rocio Carolina Garcia Santibanez, Adam Singer, Philip Wong, Nicholas Boulis, Vita Kesner
Neuromuscular Disease: Spinal Muscular Atrophy and Other Motor Neuron Disorders 1 P4.13-009 Novel Use of Nusinersen in a Premature Neonate as a Therapeutic Bridge to Onasemnogene Abeparvovec-xioi – Wilfreda Johnice Lindsey, Leah Ferrante, Alexandria Melendez-Zaidi, Timothy E. Lotze P4.13-010 Single Center Experience of Nusinersen Treatment in Spinal Muscular Atrophy Type 2 And Type 3 in Turkey – Arman Cakar, Sezan Mergen Kilic, Hacer Durmus, Fatma Yesim Parman P4.13-011 Change in Body Mass Index is a Significant Predictor of Change in Patient-reported Function in Adults with Spinal Muscular Atrophy Monitored Over a 10-year Period – Kristina Marie Kelly, Wendy Marie King, Matt Linsenmayer, Jerold E. Reynolds, Amy M. Bartlett, Marco Tellez, John T. Kissel, Stephen J. Kolb, William D. Arnold, Bakri Elsheikh
P4.13-005 Comparing Acute Skeletal Muscle Repair in Aged and Young Mice – Katerine Alvarez P4.13-006 Caregiver burden and soluble urokinase-type plasminogen activator receptor (SuPAR) levels in healthy volunteers – Jessica Joyce, Noel Cabanas, Rohan Pisharody, Roshni A. Patel, Bichum Ouyang, Jochen Reiser, Deborah Hall, Natalie P. Witek P4.13-007 Intravenous Immune Globulins vs Plasma Exchange Usage in Patients with Neuromuscular and Neuro-immunological Conditions – Melissa Jeannie Rethana, Adeel Zubair, Anthony K. Ma, Lindsay Sarah McAlpine, Ahmad Abulaban, Richard J. Nowak, Bhaskar Roy P4.13-008 Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies – Michelle L. Mellion, Jay Han, Jennifer Shoskes, Alrabi Tawil, Katy Eichinger, Leo Hong-Li Wang, Angela L. Genge, Sabrina Sacconi, Hanns Lochmuller, David Reyes Leiva, Jordi Diaz Manera, Jorge Alonso-Perez, Nuria Muelas, Juan Jesus Vilchez Padilla, Alan Pestronk, Summer Gibson, Namita Goyal, Johanna Hamel, Lawrence J. Hayward, Nicholas Elwood Johnson, Samantha Jo LoRusso, Miriam L. Freimer, Perry Shieh, S H. Subramony, Doris G. Leung, Baziel G M van Engelen, Joost Kools, Christopher Morabito, John Jiang, William Tracewell, Alejandro Rojas, Anthony Accorsi
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
41
Sunday, April 3 11:45 a.m.–12:45 p.m.
Poster Session 5
1
Autoimmune Neurology
Autoimmune Neurology: Autoimmune Encephalitis 3 P5.1-001 Serial Longitudinal EEG as a Biomarker in Autoimmune Encephalitis: A Retrospective Cohort Analysis – Cameron Mohammadi, Tian Wang, Amy Li Safadi, Robert K. Shin, Tricia Y. Ting P5.1-002 Residual Symptoms and Long-term Outcomes after All-Cause Autoimmune Encephalitis – Hesham Ahmed Abboud, Farren Briggs, Robin A. Buerki, Mohamed Elkasaby, Guadalupe FernandezBaca Vaca, Neel Fotedar, Christopher D. Geiger, Cynthia Griggins, Catherine Lee, Alexander Lewis, Alessandro Serra, Rajeet Shrestha, Jill Winegardner, Aasef Shaikh P5.1-003 Validation of Clinical, Radiographic, and Laboratory Screening Criteria for Autoimmune Encephalitis – Daniela Raffaela Galluzzo, Sidra Zaheer, Kristina Maselli, Sydney Moseley, Yarden Bornovski, Jin Li P5.1-004 The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis – Gregory S. Day, Maarten Jan Titulaer, Ka-Ho Wong, James C. Torner, Merit E. Cudkowicz, Christopher Coffey, Codrin I. Lungu, Eric Klawiter, J. Robinson Singleton, Dana Katherine Mitchell, Janel Fedler, Dixie Jean Ecklund, David Klements, Michele Costigan, Stacey Clardy P5.1-005 Brazilian autoimmune encephalitis network (BrAIN): results from a nationwide multicentric study – Fabio Fieni Toso, Bruna Dias, Maria Eduarda Slhessarenko, Rene De Araújo Gleizer, Alessandra Dellavance, Luiz Eduardo Andrade, Romana Hoeftberger, Livia Almeida Dutra Antonio P5.1-006 Autoimmune encephalitis in a tertiary hospital in the Philippines – Nikolai Gil Diwa Reyes, Adrian Isidoro Espiritu, Jerson Flores Agabao, Joshual Emmanuel Abejero, Rhea Angela M. Salonga, Leonor Cabral-Lim, Roland Dominic Jamora, Jose Leonard R Pascual, Marc Laurence Fernandez, Katerina Tanya Perez Gosiengfiao P5.1-007 Balint Syndrome as an Atypical Presentation of Paraneoplastic Anti-NMDA Receptor Encephalitis: A Case Report and Review of the Literature – Neda Sattarnezhad, Jamie C. McDonald, Evan Madill, May Han
42
2022 AAN Annual Meeting
2
Headache
Headache: Clinically Oriented Headache Studies 2 P5.2-001 Arachnoiditis After Epidural Blood Patch to Treat Low Pressure Headache : A Case Study – Shawna Huckell, Shawna Huckell, Andrew R. Sas P5.2-002 Migraine-Associated Gene Expression in Vascular Cell Types – Luke Skyler Vest, Mengyi Xu, Angeliki Vgontzas, William R. Renthal P5.2-003 Perfusion Imaging in Acute Hemiplegic Migraine – Kyle R. Marden, James E. Siegler
Headache and Population Health 1 P5.2-004 Patient Satisfaction Is Associated With Positive Communications With Health Care Professionals: Interim Results From a Survey of an Online Migraine Community – Heather Lapidus Glassner, Jaclyn Klepper, Jessica Cirillo, Edward Kim, Richard B. Lipton
P5.3-003 A First-in-Human Study of the Anti-Sortilin Antibody AL101 – Michael Ward, Robert Paul, Felix Leejia Yeh, Hua Long, Michael Kurnellas, Amber Silva, Emmanuel Ang, Jane Green, Daniel Maslyar P5.3-004 A Phase 1 Study of AL002 in Healthy Volunteers – Michael Ward, Robert Paul, Hua Long, Herve Rhinn, Anna Rychkova, Guang Tu, Cheryl Barner, Santiago Viveros Salazar, Felix Leejia Yeh, Tina Schwabe, Sam Jackson P5.3-005 A Phase 2 Study of AL001 in Frontotemporal Dementia Patients Carrying a Granulin Mutation – Julie Huang, Robert Paul, Felix Leejia Yeh, Michael Ward, Herve Rhinn, Jenna Pappalardo, Yijie Liao, Hua Long, Sam Jackson
4
MS and CNS Inflammatory Disease
MS Clinical Trials and Therapeutics 1
P5.2-005 Alcohol as a risk factor for migraine attacks. Results from a large prospective cohort study in English-speaking countries. – Marina VivesMestres, Xavier Puig, Josep Ginebra, Amparo Casanova, Noah Rosen
P5.4-001 Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor in Relapsing Multiple Sclerosis Over 2.5 Years of The Open-Label Extension to a Phase II Trial – Xavier Montalban, Jerry S. Wolinsky, Douglas L. Arnold, Martin Weber, Ivan Staikov, Karolina PiaseckaStryczynska, Davorka Tomic, Emily C. Martin, Kristina Holmberg, Hans Guehring
P5.2-006 Migraine and Adverse Pregnancy Outcomes: the nuMoM2b Study – Gular Mammadli, Eliza Miller, Sarah Vollbracht, Whitney Booker, Leslie Moroz, Cynthia Gyamfi-Bannerman, Marianna Yugrakh, David Haas, Mary D’Alton, Ronald Wapner, Natalie Bello, Kristi Chau, William Grobman, Lisa Levine
P5.4-002 Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND Study – Le Hua, Amit Bar-Or, Fred D. Lublin, Xiangyi Meng, Gina Cox, Bruce A. C. Cree, Robert J. Fox
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Trials 1 P5.3-001 Cerezen (Renew™ NCP-5) for the Treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type in Subjects With Type 2 Diabetes – Patrick M. Moriarty, Lauryn K. Gorby, David H. Salat, Jeffrey M. Burns, Thomas Moreno, Jonathan Helfgott P5.3-002 A Phase 1 Study of AL003 in Healthy Volunteers and Participants with Alzheimer’s disease – Daniel Maslyar, Robert Paul, Hua Long, Herve Rhinn, Ilaria Tassi, Glenn Morrison, Felix Leejia Yeh, Tina Schwabe, Michael Ward
P5.4-003 Efficacy and Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior Disease-Modifying Therapies: 3-Year Data From CASTING and LIBERTO (LIBERTO 1-Year Interim Results) – Patrick Vermersch, Celia Oreja Guevara, Bart Van Wijmeersch, Heinz Wiendl, Jens Wuerfel, Regine Buffels, Petra Dirks, Thomas Kuenzel, Karen Kadner, Giancarlo Comi P5.4-004 Long-term Efficacy of Ofatumumab in Patients With Relapsing Multiple Sclerosis – Stephen L. Hauser, Edward J. Fox, Angela Aungst, Wendy Su, Ronald Zielman, Ayan Das Gupta, Xixi Hu, Dee Stoneman, Derrick Robertson, Jeffrey Alan Cohen, Ludwig Kappos
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 5
P5.4-005 Impact of ozanimod treatment on cortical grey matter volume: up to 5 years’ experience in phase 3 and extension trials – Chahin Pachai, James K. Sheffield, Xavier Montalban, Bruce A. C. Cree, Ludwig Kappos, Giancarlo Comi, Hans-Peter Hartung, Chun-Yen Cheng, Diego Silva, Jeffrey Alan Cohen, Douglas L. Arnold P5.4-006 Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis: Post Hoc Analysis from the EXPAND Study – Iris Katharina Penner, Gavin Giovannoni, Tanuja Chitnis, Patrick Vermersch, Sophie Arnould, Jeff Maca, Virginia De Las Heras Revilla, Goeril Karlsson, Daniela Piani Meier, Ludwig Kappos, Ralph H. B. Benedict P5.4-007 Vaginal Estriol as a potential adjunctive therapy for MS remyelination – Mirla L. Avila, Jie Pan, Roberto Hernandez Quintana, Dargelis Chi, Smathorn Thakolwiboon, Alan Peiris, Kenn Alan Freedman, Charles D. Thompson, John Matthew Garza P5.4-008 Effect of Ponesimod Compared With Teriflunomide on Treatment With Concomitant Corticosteroids for Relapse in Patients with Relapsing Forms of Multiple Sclerosis – Camilo Obando, Ibrahim Turkoz, James Simples, Monica Doring, Maria Ait Tihyaty P5.4-009 Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies – Bruce A. C. Cree, Edward J. Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl E. Wray, Derrick Robertson, Deren Huang, Krzysztof W. Selmaj, Daniel R. Wynn, Michael S. Weiss, Jenna Bosco, Sean Power, Koby Mok, Lily Lee, Lawrence Steinman P5.4-010 Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot – Shlomo Flechter, Ariel L. Miller, Laura Popper, Nadav Bleich Kimelman, Shai Rubnov, Uri Danon, Ehud Marom, Ron E. Milo, Joab Chapman, Alla Shifrin, Ronit Gilad, Chen Hoffmann, Tamir Ben Hur, Dimitrios Karussis, Arnon Karni
Sunday, April 3 11:45 a.m.–12:45 p.m.
P5.4-011 Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. – Christine Lebrun Frenay, Cassandre Landes-Chateau, Aksel Siva, Maria Pia Sormani, Lydiane Mondot, Patrick Vermersch, Anne Caroline Papeix, Eric Thouvenot, Pierre Labauge, Francoise Durand Dubief, Husnu Efendi, Emmanuelle Le Page, Murat Terzi, Nathalie Derache, Bertrand Bourre, Robert Hoepner, Rana Karabudak, Jerome De Seze, Jonathan Ciron, Pierre Clavelou, Sandrine Wiertlewski, Omer Faruk Turan, Nur Yuceyar, Mikael Cohen, Orhun H. Kantarci, Daniel Pelletier, Darin T. Okuda
5
General Neurology
Neuroepidemiology 2 P5.5-001 Physical Activity Moderates the Association Between White Matter Hyperintensity Burden and Cognitive Change – Suhang Song, Yunglin Gazes, Seonjoo Lee, Christian Habeck, Yaakov Stern, Yian Gu P5.5-002 Survival analysis of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): data from a systematic literature review of published case studies – Spyridon Papapetropoulos, Angela Pontius, Matthew Brennan, Ryan O’Mara P5.5-003 COVID-19 Outcomes of 10,881 patients: Retrospective study Of Neurological symptoms and Associated manifestations (Philippine CORONA Study) – Adrian Isidoro Espiritu, Marie Charmaine Cootauco Sy, Michelle Anlacan, Roland Dominic Jamora P5-5.004 WITHDRAWN P5.5-005 Head Injury and All-Cause Mortality in Community-Dwelling Adults – Holly Elser, Rebecca F. Gottesman, Alexa Walter, Josef Coresh, Ramon R. Diaz-Arrastia, Tom Mosley, Andrea Lauren Christman Schneider
Information is accurate as of February 8, 2022, and is subject to change.
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Genetics and Other Cognitive Topics 2 P5.6-001 Efficacy of Everolimus for Tuberous Sclerosis Complex: A Systematic Review and Metaanalysis. – Fatma Mohamed Sayed, Mohamed Sayed Zaazouee, Elfatih A. Hasabo, Sara Mohamed Hasan, Anas Zakarya Nourelden, Alaa Ahmed Elshinbary, Manar Mohammed Hosny, Amal Abdelfattah Mahmoud, Amira Benmelouka, Mariam Abdelwhaab Asela, Ghada Said Hammad, Mostafa Mahmoud Meshref, Sherouk Shawkat Moham Elkady, Khaled Mohamed Ragab, Mohamed Fahmy Doheim P5.6-002 A Rare MED13 Variant as the Potential Cause of Early Onset Cognitive Decline and Brain Iron Accumulation: A Case Report – Kaancan Deniz, Tiffany K. Grider, Chad Eric Grueter, Joel C. Geerling P5.6-003 Multifaceted presentation of a rare mitochondrial syndrome- HAREL-YOON SYNDROME - Story of 3 siblings – Muralikrishna Konda P5.6-004 C9Orf72 Repeat Expansion and MyoclonusEpilepsy: a case report and literature review – Nivedita Jha, Subin Mathew, Christopher M. McGraw P5.6-005 Gene Expression Analysis of CCL2, MOBP and OPALIN in Major Depressive Disorder and Suicidality – Rui Tang, Javier Vargas Medrano, Enrique Ivan Ramos, Peter Thompson, Bharathi Gadad P5.6-006 A New Adult Neurodevelopmental Disabilities Clinic: Description of Population and Yield of Genetic Testing in the First Year – Moriah Mabry, Sharon Scarbro, Jessica Sanders
7 Medical Student Essay Awards P5.7-001 A Comparison of Telehealth and In-Person Visits in Ambulatory Neurology: What are the factors that patients consider when selecting future visit type? – Carly Jo Olszewski, Sharon Thomson, Kelly Ann Pring, Rebecca Siobhan-Ivy Cox, Rebecca Merrill, Emily Fishman, Alexander Paul Ambrosini, Kevin Alexander Soltany, Gabriella Marie Bognet, Lauren Doyle Strauss, Rachel Graham, Amy K. Guzik, Roy E. Strowd
AAN.com/AM
43
Sunday, April 3 11:45 a.m.–12:45 p.m.
Poster Session 5
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy and Clinical Neurophysiology (EEG): Epilepsy Imaging 2
9
Infectious Disease
Infectious Disease: Tricky Viruses 1
P5.8-001 Hyperintense acute reperfusion marker (HARM) due to status epilepticus- A potential imaging pitfall’ – Mustafa Al-Chalabi, Sidra Saleem, Ajaz Sheikh
P5.9-001 Varicella Zoster Meningitis Presenting as Unilateral Vocal Cord Paralysis – Omar Muhsin Ali Al-Janabi, Supreeth Gowda Narayana Gowda, Padmaja Sudhakar
P5.8-002 Focal Seizures with Ictal Bradycardia from Right Insular Lesion in Tuberous Sclerosis: A Rare Case – Alok Dabi, Kamakshi A. Patel, Vijaya Lakshmi Valaparla, Brian Walter
P5.9-002 West Nile Myelitis Disguised as Severe Compressive Myelopathy – Elizabeth Anderson, Tejas Ranade, Connor David Welsh, Huiam Mubarak
P5.8-003 A novel customized representation of source space in epilepsy pre-surgical evaluation – Darion Toutant, Graham Alexander McLeod, Parandoush Abbasian, Amirhossein Ghassemi, Maziar Fazel Darbandi, Marcus Ng
P5.9-003 Clinical Characteristics of 11 Cases with Visual Impairment After Herpes Virus Infection – Jingxiao Zhang, Lei Liu
Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Genetics and Surgery 1 P5.8-004 Long-term seizure and functional outcome following occipital or ”occipital-plus” resection for refractory epilepsy in children – Elham Abushanab, Ahsan Moosa Naduvil Valappil, William Bingaman, Deepak K. Lachhwani, Elia Margarita Pestana Knight P5.8-005 Infantile Spasms in Cardiofaciocutaneous Syndrome: Associations with Genotype, Phenotype and Treatment Response – Dante James Rogers, Samuel Kroening, Ashley Whitmarsh, Abigail Zatkalik, Martin Zenker, Amy Roberts, Rene Pierpont, Daniel L. Kenney-Jung P5.8-006 Genetic Testing Informs Epilepsy Treatment Management: Results from An International Study of Clinical Practice and Patient Outcomes – Dianalee McKnight, Ana Morales, Kathryn Hatchell, Sara Bristow, Edward D. Esplin, Chad Moretz, Felippe Borlot, Kaitlin Angione, M. Scott Perry, Joshua Bonkowsky, Loreto Rios-Pohl, Anne T. Berg, Swaroop Aradhya P5.8-007 Cognitive Outcomes Following Pediatric Epilepsy Surgery – Navkiranjot Kaur, Amy Nowacki, Jennifer Haut, Patricia Klaas, Lisa Ferguson, Deepak K. Lachhwani, William Bingaman, Tara T. Lineweaver, Robyn Busch
44
2022 AAN Annual Meeting
P5.9-004 Perpetuating PML- Alcohol Induced Lymphopenia causing JC virus Reactivation – Mikul Minesh Bhikha, Chandra Sekhar Mannyam, Camille Barbour
9
Neuro-oncology
Neuro-oncology: Therapies and Toxicities 1 P5.9-005 Concurrent Olaparib and Temozolomide for Recurrent Glioma – Marina Kushnirsky, Andrew L. Lin, Alexandra M. Miller, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Ingo K. Mellinghoff, Thomas J. Kaley, Lauren Rhea Schaff P5.9-006 A multicenter observational study of Cs-131 seeds embedded in a collagen carrier tile in intracranial brain neoplasms – trial in progress – Erin M. Dunbar, David Jason McCracken, Adam Wayne Nowlan, Clark Chen, Kathryn Dusenbery, Rupesh Kotecha, Michael William McDermott, John Wanebo, Kenneth Stuart Lee, Toral R. Patel, Zabi Wardak, John Robert Floyd, David Monyak, John E. Trusheim, Mitesh Shah, David Brachman P5.9-007 BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib – Elizabeth Coffee, Thomas J. Kaley, Eli Diamond, Alexandra M. Miller, Lauren Rhea Schaff
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Basic and Translational Science 1 P5.10-001 Microglial IL-1RA ameliorates brain damage after ischemic stroke via inhibiting astrocyte-derived CXCL1 – Xiaoyan Huang, Mingyan Guo P5.10-002 Immunoreactivity and A New Staining Method of MCT-1 Located in Endothelial Cells of Cerebral Vessels of Human Brain in Distinguishing Cerebral Venules from Arterioles – Yuan Cao, Dong-Hui Ao, Chao Ma, Wen-Ying Qiu, Yi-Cheng Zhu P5.10-003 Analysis of Protein Networks Associated with Hemorrhagic Conversion In Emergent Large Vessel Occlusion Patients Undergoing Mechanical Thrombectomy – Madison Sands, Chintan K. Rupareliya, Jacqueline A. Frank, Christopher McLouth, Benton Maglinger, Amanda L. Trout, Jadwiga Turchan, David Dornbos, Shivani Pahwa, Lila Emily Sheikhi, Ann Stowe, Keith Pennypacker, Justin Fraser Interventional Neurology and Thrombolytic Therapy 2 P5.10-004 Validating Existing Stroke Scales for Acute Identification of Cerebrovascular Events in an Inpatient Setting – Adriana Naomi Sari, Faddi Ghassan M. Saleh Velez, Shyam Prabhakaran P5.10-005 Identifying Delays Associated with Door-toDevice Time for Potential Large Vessel Occlucion Thrombectomy Patients in the Emergency Department – Anirudh Sreekrishnan, Nirali Vora P5.10-006 Acute stroke reperfusion therapies in patients with Posterior Reversible Encephalopathy Syndrome – Monica Sarkar, Vivien H. Lee P5.10-007 Stent Retrievers Utilization in Endovascular treatment of Cerebral Venous Sinus Thrombosis – Abdallah Omar Amireh, Hassan M. Ali, Muhammad Nagy, Siddhart Kumar Mehta, Haralabos Zacharatos, Farah Yolanda Fourcand, Jawad F. Kirmani P5.10-008 Risk of Distal Embolization in Large Vessel Occlusion Strokes Treated with Tenecteplase – Siddhart Kumar Mehta, Nasar Ali, Teye Aniefiok Umanah, Arifa Ghori, Rafia Jawed, Spozhmy Panezai, Ilya Dubinsky, Haralabos Zacharatos, Farah Yolanda Fourcand, Jawad F. Kirmani
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 5
11
Movement Disorders
Movement Disorders: Deep Brain Stimulation in Parkinson’s Disease 1 P5.11-001 Patient Preferences for Deep Brain Stimulation Products in Parkinson’s Disease: What Really Matters to Them? – Teresa Lee, Michelle Fullard, Tammy Rogers, Steven Ojemann, Drew S. Kern P5.11-002 Impact of pre-existing small vessel disease on Motor Outcomes after Deep Brain Stimulation in Parkinson’s Disease – Heather Martin, Rushna Ali, Morgan Maley, Muhib Khan P5.11-003 Subthalamic Peak Beta RatioPower is Asymmetric in Glucocerebrosidase Mutation Carriers with Parkinson’s Disease: A Pilot Study – Fabian David, Miranda Munoz, Jay Shils, Michael Pauciulo, Philip Hale, William C. Nichols, Mitra Afshari, Sepehr Sani, Leonard Verhagen Metman, Daniel Corcos, Gian D. Pal P5.11-004 Subthalamic tremor related oscillatory neuron plays a role in the generation of Parkinson’s tremor – Ping Zhuang, Mark Hallett, Yuqing Zhang, Jianyu LI, Jiping Li P5.11-005 Algorithm-Guided Deep Brain Stimulation Programming Using Automated Motion SensorBased Functional Mapping Improves Programming Efficiency – Aaron Hadley, Vibhor Krishna, Aristide Merola, Rozena Davis, Danielle Englert, Nicholas James Fleming, Benjamin L. Walter, Erica Hennigs, Dustin A. Heldman P5.11-006 Programming Time and the Use of a Visualization Tool for DBS Programming of a Multiple-Source, Constant-Current System – Jason Lamar Aldred, Theresa A. Zesiewicz, Juan Ramirez Castaneda, Michael S. Okun, Corneliu C. Luca, Ritesh Ramdhani, Leonard Verhagen Metman, Jennifer Lyn Durphy, Mustafa S. Siddiqui, Yarema B Bezchlibnyk, Jonathan Carlson, Kelly D. Foote, Sepehr Sani, Alexander M. Papanastassiou, David Weintraub, Jonathan Jagid, Julie Pilitsis, Lilly Chen, Roshini Jain Movement Disorders: PD Non-Motor Symptoms or Parkinsonism and NMS 2 P5.11-007 Severity of Depressive and Motor Symptoms Impacts Quality of Life in Parkinson’s Disease Patients of High Socioeconomic Status – Brianne Lacy, Hien Piotrowski, Mustafa Husain P5.11-008 Real-world digital driving profiles in PD index motor and non-motor clinical symptom severity – Jun Ha Chang, Danish Bhatti, Matthew Rizzo, Jennifer Merickel
12
Sunday, April 3 11:45 a.m.–12:45 p.m.
General Neurology
General Neurology: Clinical Practice and Telemedicine 2 P5.12-001 Neurological findings in sickle cell disease patients without a history of neurological insult: prevalence, risk factors and practice implications – Ahmed Moh’d Yassin, Mohammed Bassam Nawaiseh, Mohammed Qussay Ali Al-Sabbagh, Ahmad Al Nawaiseh, Mohammad Abu-Rub P5.12-002 Clover-Leaf Curling Recovery in Functional Tongue Weakness – Michael Patrick Harlan Stanley P5.12-003 A Clinical Decision Rule Predicting Outcomes of Emergency Department Patients with Altered Mental Status – Tyrell Jonathan Simkins, David P. Bissig, Gabriel M. Moreno, Nimar Kahlon, Fredric A. Gorin, Alexandra O’Neill Duffy P5.12-004 Psychotherapeutic approach for the treatment of generalized anxiety disorder (GAD) improves outcome when delivered under specific (narrow band) green light condition. – Raul J. Rodriguez, Paul Hart, Brittany Lipinski, Lacey Burkett, Skyler Rosen, Erica Sanes, Cara Harbaugh, Agustin Melo Carrillo, Rami Burstein P5.12-005 Gender and decistion making in Neurology, an Argentinian study. – Maria Gaitan, Celica Ysrraelit, Laura Negrotto, Veronica A. Bruno, Maria Cecilia Fernandez, María Del Carmen García, Carolina Laura Azcona, Maria Justich, Mariela Cabrera, Maria Soledad Rodriguez Perez, Maia Gomez Schneider, Marina Romano, Viviana Andrea Ibarra, Jimena Miguez, Lucia Derosa, Guadalupe Bruera, Lucia Jimena Zavala
13
Neuromuscular and Clinical Neurophysiology (EMG)
Diagnostic Techniques, Biomarkers and Therapies in Neuromuscular Disease 2
P5.13-004 Does High Resolution Ultrasound Guided Femoral Nerve Conduction Study Makes a Difference When Compared To Conventional Technique? – Abhinay Kumar Gattu, Yerasu Muralidhar Reddy, Shyam Krishnakumar Jaiswal, Pidaparthi Lalitha, kiran Erranki, Ravi Nulaka, P Anusha, Jagarlapudi Murali Krishna Murthy P5.13-005 Value of Diaphragm Electromyography and Phrenic Nerve Conduction Studies in Suspected Diaphragm Paresis – Divya Rahul Shah, Steven Vernino, Shaida Khan P5.13-006 Electrodiagnostic Findings in Covid patients: A single center experience – Sajid Hameed Shaikh, Sara Khan P5.13-007 A pilot study of neuromuscular ultrasound as a biomarker for spinal-bulbar muscular atrophy – Abdullah Zahi Alqahtani, Katharine Alter, Joseph Shrader, Galen Joe, Angela Kokkinis, Christopher Grunseich, Kenneth H. Fischbeck Neuromuscular Disease: Spinal Muscular Atrophy and Other Motor Neuron Disorders 2 P5.13-008 Quantitative muscle strength changes in adults with Spinal Muscular Atrophy receiving Nusinersen – Dana McDonnell, Sally Dunaway, Whitney Tang, Connie Wolford, Zihuai He, John W. Day, Tina Duong P5.13-009 Real-World Data of Nusinersen in Adults with Spinal Muscular Atrophy: A Single Center Experience – Doruk Arslan, Berin Inan, Muhammed Kilinc, Can Ebru Kurt, Sevim Ozdamar, Ersin Tan P5.13-010 LOTS in the Needle Examination – Zara Abigail Togher, Sue Zann Gan, John C. McHugh, Sean O’Dowd, Sinead Murphy
P5.13-001 Genetic Testing Analysis in Patients with Neuromuscular Disorders: A Single Health System Experience – Madelyn Kay Smiley, J. David Avila, Scott M. Friedenberg, Madeline Williamson P5.13-002 Dermal Nerve Bundles Offer a Comprehensive, Accessible, Cutaneous Nerve Analysis – Kendall Nichols, Brian McAdams, Adam Loavenbruck P5.13-003 Refining Compound Muscle Action Potential as a Translational Biomarker of Neuromuscular Integrity – Sindhuja Ayyagari, Hallie Harris, William D. Arnold
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
45
Sunday, April 3 5:30 p.m.–6:30 p.m.
Poster Session 6
1
Autoimmune Neurology
Autoimmune Neurology: Neurosarcoidosis and Vasculitis P6.1-001 Characterization of Neurosarcoid Myelitis and Assessment of Treatment Response in a SingleHospital System. – Giovanna Manzano, Denis Tan Kerim Balaban, Ahya Sajawal Ali, Brian Curran Healy, Bart Chwalisz, Michael Levy, Shamik Bhattacharyya P6.1-002 Identification of Brain and Spinal Cord Abscesses in a Patient with Recently Diagnosed Neurosarcoidosis – Karishma Anjuli Popli, Ryan Tyler Lamb, Yasir Al-Khalili, Neel Dixit P6.1-003 Stroke in Patients with Sarcoidosis: A Comprehensive Review of 42 Reported Cases – Danielle Kei Pua, Pria Anand, Shamik Bhattacharyya P6.1-004 “String of pearls” in the spinal cord: a novel magnetic resonance imaging sign in necrotizing sarcoid granulomatosis myelitis – Xiaoyang Li, Leonardo Morantes Gomez, Mahmoud Al Masry, Irena Dujmovic Basuroski P6.1-005 Neurosarcoidosis after infection with COVID-19, a case report and review of the literature – Daniel Esteban Mafla Delgado, Sharon G. Lynch, Maryam Matloub P6.1-006 Primary angitis of the central nervous system (PANCS) mimicking Glioblastoma in a pediatric patient – Alfred Balasa, Elizabeth McQuade P6.1-007 Susac Syndrome with a Unique Involvement of the Thoracic Spinal Cord – Robert Evan Ungerer, Rola Mahmoud, Michael J. Schwartzman
2
Headache
Headache and Population Health 2 P6.2-001 Migraine and the Risk of Venous Thromboembolism among Women – Pamela M. Rist, Flora Chang, Julie E. Buring, Daniel Chasman, Robert J. Glynn, Tobias Kurth P6.2-002 Factors Associated With Seeking Care For Migraine: Results Of The OVERCOME (US) Study – Sait Ashina, Eva Jolanda Muenzel, Robert A. Nicholson, Anthony J Zagar, Dawn C. Buse, Michael L. Reed, Susan Hutchinson, Robert E. Shapiro, Eric M. Pearlman, Richard B. Lipton
46
2022 AAN Annual Meeting
Headache Validation and Education Research 1 P6.2-003 Validation of Measures of Treatment Expectancy in Children & Adolescents with Headache – Christina Lynch Szperka, Danielle Joy Kellier, Nichelle Raj, Blanca Marquez de Prado, Steven L. Kugler, Jocelyn Kalkbrenner, Naomi Hughes, Kevin Pettijohn, Dana Haagen, Gerardo Velasquez, Jesse Yenchih Hsu, Andrew D. Hershey, John T. Farrar P6.2-004 Translation and validation to Spanish of the diagnostic test ID-Migraine ® – Roberto Rodriguez, Carlos Alberto Moreno Martinez P6.2-005 Pediatric Pain Neuroscience Education: Pilot Trial in Primary Headache Patients – Isidora Rose Beach, Rachel Munik Madhur, Peter M. Bingham P6.2-006 The Migraine Disability Assessment (MIDAS) as an Indicator of Resilience in Patients with Headaches – Deborah I. Friedman, Avneet Hans, Cynthia M. Stonnington
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Trials 2
P6.3-005 Design and methods of a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimer’s disease with vascular pathology – Chad E Glasser, Jennifer Chickering, Phebe Wilson, Emily Florine, Christopher Wright, Christopher Winrow
4
MS and CNS Inflammatory Disease
MS Clinical Trials and Therapeutics 2 P6.4-001 Effect of Siponimod on Disability Progression as Measured by the Ambulation Score, a Subscore of the Neurostatus-EDSS: Post hoc Analysis of the EXPAND Trial in SPMS – Marcus D`Souza, Gavin Giovannoni, Patrick Vermersch, Jeff Maca, Soudeh Ansari, Goeril Karlsson, Daniela Piani Meier, Ludwig Kappos P6.4-002 Long-Term Suppression of MRI Disease Activity and Reduction of Global/Regional Volume Loss: Results from OPERA I/II and ORATORIO OpenLabel Extension – Douglas L. Arnold, Anthony Traboulsee, Jerry S. Wolinsky, Stephen L. Hauser, Ludwig Kappos, Xavier Montalban, Frederik Barkhof, Ulrike Bonati, Wei Wei, Laura Gaetano
P6.3-001 Allopregnanolone as a Regenerative Therapeutic for Early Alzheimer’s Disease: Phase 1b/2a Clinical Trial Outcomes – Gerson David Hernandez Rivera, Claudia Lopez, Wendy Mack, Sonia Pawluczyk, Dawn Matthews, Yonggang Shi, Meng Law, Michael A. Rogawski, Lon Schneider, Roberta Diaz Brinton
P6.4-003 Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study – Bernhard Hemmer, Heinz Wiendl, Karsten Roth, Hendrik Wessels, Josef Hoefler, Cyrill Hornuss, Bernd Liedert, Krzysztof W. Selmaj
P6.3-002 PostGraduate Open-label Rollover Study: Evaluation of Subcutaneous Gantenerumab Long-term Safety, Tolerability, and Efficacy in Participants with Alzheimer’s Disease – Christopher Lane, Angeliki Thanasopoulou, Paul Delmar, Alison Searle, Francesca Mazzo, Patricia Ehrhard, Paulo Pacheco Fontoura, Monika Baudler, Geoffrey A. Kerchner, Rachelle Doody
P6.4-004 Estimating long-term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model: EXPAND data up to 7 years – Bruce A. C. Cree, Nicolas Rouyrre, Robert J. Fox, Patrick Vermersch, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Jeff Maca, Daniela Piani Meier, Goeril Karlsson, Ludwig Kappos
P6.3-003 Development of the Monoclonal Antibody AL101 to block the Sortilin/Progranulin Interaction as a Potential Therapy for Neurodegenerative Diseases – Ananya Mitra, Robert Paul, Hua Long, Guang Tu, Cheryl Barner, Michael Ward, Stella McCaughey, Nadine Anne Tatton, Michael Kurnellas P6.3-004 Integrated Alzheimer’s Disease Rating Scale (iADRS): Clinically Meaningful Change Estimates – Ellen Dennehy, Dorene M. Rentz, Alette Wessels, Michael G. Case, John R. Sims
P6.4-005 Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) – Enrique Alvarez, Lawrence Steinman, Edward J. Fox, Hans-Peter Hartung, Peiqing Qian, Sibyl E. Wray, Derrick Robertson, Deren Huang, Krzysztof W. Selmaj, Daniel R. Wynn, Michael S. Weiss, Jenna Bosco, Sean Power, Koby Mok, Lily Lee, Bruce A. C. Cree
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 6
MS Therapeutics MOA and Safety 1 P6.4-006 Effectiveness of Natalizumab Treatment Inpatients With Early Relapsing-Remitting Multiple Sclerosis (RRMS) who were TreatmentNaive Versus Those Who Had Prior DiseaseModifying Therapy (DMT) Use – Jai Perumal, Roumen D. Balabanov, Roger Chang, Laura J. Balcer, Steven Galetta, Robin L. Avila, Danette J. Rutledge, Robert J. Fox P6.4-007 Innovative Comparative Study Assessing the Effect of Siponimod on Reactive Microglia/ Astrocytes in Patients With Secondary Progressive Multiple Sclerosis: Study Design – Robert Zivadinov, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Michael G. Dwyer, Ferdinand Schweser, Dejan Jakimovski, Niels Bergsland, Daniela Piani Meier, Harald Kropshofer P6.4-008 Humoral immunological memory is retained in patients with multiple sclerosis receiving cladribine therapy – Tobias Moser, Georg Pilz, Peter Wipfler P6.4-009 Autologous HSCT Outside of Clinical Trials in Patients with Multiple Sclerosis – Jennifer Lord, John W. Rose, M. Mateo Paz Soldan P6.4-010 Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies – Edward J. Fox, Lawrence Steinman, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl E. Wray, Derrick Robertson, Deren Huang, Krzysztof W. Selmaj, Daniel R. Wynn, Michael S. Weiss, Jenna Bosco, Sean Power, Koby Mok, Lily Lee, Bruce A. C. Cree P6.4-011 Guillain-Barré Syndrome After Alemtuzumab Treatment in a Patient with Multiple Sclerosis: a Case Report – Hasim Gezegen, Ozgu Kizek, Tuncay Gunduz, Mefkure Eraksoy, Murat Kurtuncu
5
Child Neurology and Developmental Neurology
Child Neurology: Seizures/Genetic Syndromes 1 P6.5-001 Use of Lacosamide in Neonatal Seizures – Abdullah Bin Shoaib, Alison M. Dolce, Michelle Machie, Jennifer Lauren Thomas
Sunday, April 3 5:30 p.m.–6:30 p.m.
P6.5-002 Variants in PNPLA8 are Associated with Developmental Epileptic Encephalopathy and Cerebellar Atrophy. – Cheryl Fields, Elissa Yozawitz, Margo Sheck Breilyn, Indirapriya Avulakunta, Supriya Bisht, Nagma Dalvi, Leslie D. Delfiner, Donya Eizadkhah, Solomon L. Moshe, Sarah Alexandra Nitka, Kimberly O’Neill, Aparna Polavarapu Ramarao, Orna Rosen, Apirada Thongsing, Solomon L. Moshe
5
General Neurology
Neuroepidemiology 3 P6.5-003 Trends in Diagnosis of Post-Stroke Depression in the U.S. (2003 – 2019) – Holly Elser, Michelle Rae Caunca, David Rehkopf, Rebecca F. Gottesman, Kristine Yaffe, Andrea Lauren Christman Schneider P6.5-004 Sex Differences in Inpatient Outcomes following Hospitalization for Myasthenic Crisis – Maryam Jamil Syed, Ayaz M. Khawaja P6.5-005 Neurocysticercosis in Mexico. A persistent health problem or on-track to eradication? – Roberto Rodriguez, Agnès Fleury
6
P6.6-004 Wernicke-Korsakoff syndrome and catatonia: a case report – Alexandra Seide Cardoso, Viviane Tavares Carvalho, Matheus Castro, Caroline Bittar Braune, Isadora Versiani de Lemos, Gabriel R. Freitas, Marcia Cristina Antu Ribas P6.6-005 Psychogenic Non-Epileptic Seizures in the Elderly – Maheen Islam, Shanti S. Thirumalai, Reid D. Taylor, Coleman Cabe, Tasha Denise Frye P6.6-006 Psychological Outcome after Hemorrhagic Stroke is related to Functional Status – Sarah Ecker, Aaron S. Lord, Lindsey Gurin, Koto Ishida, Kara R. Melmed, Jose L. Torres, Barry M. Czeisler, Cen Zhang, Jennifer A. Frontera, Ariane Lewis P6.6-007 Piperlongumine and Piperlonguminine Mitigate Rotenone Induced Neurotoxicity: Implications for a Novel Parkinson’s Disease Treatment– Jessica Guo P6.6-008 A Novel Strategy for the Reversal of Glioblastoma Tumor Cell Immortality – Samuel Wu P6.6-009 An Integrated Genome and Phenome-Wide Association Study Approach to Understand Alzheimer’s Disease Predisposition – Archita Khaire
Aging, Dementia, Cognitive, and Behavioral Neurology
Behavioral and Cognitive Neurology: Neuropsychiatry 1 P6.6-001 Outcomes of tailored psychotherapy for dissociative seizures in a developing functional neurology service – James William Mitchell, Katie Robb, Mariana Decheva, Jayne Martlew, Christine Emma Burness P6.6-002 Emotional and Behavioral Dyscontrol Is More Likely After Intracerebral Hemorrhage than Subarachnoid Hemorrhage – Daniel Talmasov, Sarah Ecker, Anlys Olivera, Aaron S. Lord, Lindsey Gurin, Koto Ishida, Kara R. Melmed, Jose L. Torres, Barry M. Czeisler, Cen Zhang, Jennifer A. Frontera, Ariane Lewis P6.6-003 Professional Exhaustion Syndrome and Depression in Two Cohorts of Medical Residents Before and After the Covid-19 Pandemic – Carla Florencia Bolano Diaz, jesica Pszenyckyj, Franco Emanuel Appiani, Daiana Micucci, Guido David Vazquez, Carlos Santiago Claverie, Santiago O’Neill, Alfredo Thomson
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
47
Sunday, April 3 5:30 p.m.–6:30 p.m.
Poster Session 6
7
Neuro Trauma and Critical Care
Neurocritical Care: ICH, SAH, Ischemic Stroke and Other Topics 1 P6.7-001 Cerebral hypoperfusion after nimodipine administration is associated with worse functional outcomes in subarachnoid hemorrhage patients – David Bartolome, Yelyzaveta Begunova, Ayush Prasad, Alexandria Soto, Jessica Kobsa, Ilayda Top, Darko Ernesto Quispe Orozco, Mudassir Farooqui, Cynthia Zevallos, Jennifer A. Kim, Emily Jean Gilmore, Rachel Beekman, Adam De Havenon, Charles Matouk, Kevin N. Sheth, Santiago Ortega Gutierrez, Nils Petersen P6.7-002 Exploring the Role of Perihematomal Edema in Delirium after Intracerebral Hemorrhage – Jesse Menville, Nathaniel Rex, Mikaela Springsteen, Scott Collins, Elizabeth Chen, Olga Boukrina, Lori Daiello, Karen L. Furie, Richard Jones, Jesse Menville P6.7-003 National Trends In Utilization And Outcomes Of Acute Ischemic Stroke And Intracerebral Hemorrhage Patients Undergoing Gastrostomy Tube Placement – Mohammad Rauf A. Chaudhry, Kahtan Fadah, Danish Kherani, Baljinder Singh, Mohammad Ghatali, Saqib A. Chaudhry, Faheem Gulamabbas Sheriff, Anantha Ramana Vellipuram, Alberto Maud, Paisith Piriyawat, Gustavo J. Rodriguez, Isabel Victoria Narvaez- Correa, Adnan I. Qureshi P6.7-004 A Quality Improvement Project to improve the Standardization of Hospital-wide Initiation of chemical VTE Prophylaxis in ICH Patients – Sang Han, Vi Tran, Zachary Thomas Lazzari, Peter Soh, William A. Kilgo, Rebecca L. Sugg
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy and Clinical Neurophysiology (EEG): Epilepsy Others 1 P6.8-001 Serotonin and Focal Epilepsy: A Therapeutic Role? – William H. Theodore, Irene Dustin, Edythe Wiggs P6.8-002 Predictors of 30-day Readmission Post Index Hospitalization With Epilepsy: 5 Years National Estimate – Parisha Bhatia, Varun Singh, Neena Viswanathan, Tejinder Singh, Tanushri Bhushan P6.8-003 Improved Access to Rapid Electroencephalography at a Community Hospital Reduces Inter-Hospital Transfers for Suspected Non-Convulsive Seizures – Kapil Gururangan, Evan Madill, Prashanth Krishnamohan
48
2022 AAN Annual Meeting
Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Genetics and Surgery 2 P6.8-004 Quality of Life in Elderly Epilepsy Patients implanted with Vagus Nerve Stimulator – Ana Suller Marti, Keith MacDougall, Jonathan C. Lau, Jorge G. Burneo P6.8-005 Insular Involvement in Cases of Epilepsy Surgery Failure – Jimmy Li, Sandra Reiter-Campeau, Dina Namiranian, Denahin Hinnoutondji Toffa, Alain Bouthillier, Francois Dubeau, Dang Khoa Nguyen
P6.9-006 Piedmont Brain Tumor Center’s Experience with GammaTile Intracranial Brachytherapy for Malignant Intracranial Tumors – Erin M. Dunbar, Adam Wayne Nowlan, Tyler Kenning, Courtney Pollard III, David Jason McCracken
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Basic and Translational Science 2
P6.8-006 Suspected SCN1A gain of function mutation causing refractory neonatal seizures responsive to sodium channel blocking antiepileptics – Kelly Landry Angelle, Jeremy Toler, Rachel Evans, Julie Gallois, Anne Tufton
P6.10-001 Leukocyte Count and Neutrophil-to-Lymphocyte Ratio as Simple Hematologic Predictors of Stroke Severity and Functional Outcome in Acute Ischemic Stroke Patients – Vanessa Veronica, Rizaldy Taslim Pinzon
P6.8-007 The Language of Seizure Identification: A Qualitative Investigation – Jacob Pellinen, Ellen Snyder, Kelly G. Knupp
P6.10-002 Endoplasmic Reticulum Stress exacerbate Stroke outcome in Chronic Kidney Disease – Pallab Bhattacharya, Aishika Datta, Deepaneeta Sarmah, Antra Chaudhary, Priya Jagtap, Priti Madhavrao Patale, Debarati Ghosh, Dileep R. Yavagal
9
Neuro-oncology
Neuro-oncology: Therapies and Toxicities 2 P6.9-001 Assessing the Impact of Adjuvant Temozolomide Duration on Survival in Patients with IDH-Mutant Low-Grade Gliomas – Isabella Densmore, Tresa McGranahan P6.9-002 Sarcopenia Measured by Temporalis Muscle Thickness Independently Predicts Early Relapse and Short Survival in Primary CNS Lymphoma – Anthony Michael Menghini, Alipi Bonm, Jerome J. Graber P6.9-003 Single Center Experience of Dopamine Antagonist ONC-201 for Recurrent H3K27M-mutant Glioblastoma in Adults – Chukwuyem Ekhator, Ramin Rak, Jai Grewal P6.9-004 Treatment Outcomes In Patients With H3K27 M Variant Glioma – Tejas Ranade, Sami Kaldawi, Zain Ashary, Huiam Mubarak, Ekokobe Fonkem P6.9-005 Cognitive Sequelae of Radiotherapy in Primary Brain Tumors – Sofia Ramirez Guerrero, María Paula Vargas-Cuellar, Jesus David Charry Sanchez, Claudia Talero-Gutierrez
P6.10-003 Correlation Between Plasma Glutamate Levels and Post Stroke Depression – Lea Colantonio, Jessica Frey, Nicholas Koenig, Amelia Karen Adcock Cerebrovascular Disease: Clinical Science 1 P6.10-004 Intracerebral Hemorrhage as a Marker for Mycotic Aneurysm in Patients with Infective Endocarditis – Thomas James Williams, Zach Porterfield, Sami El-Dalati P6.10-005 Safety and Efficacy of Sphenopalatine Ganglion Block in Post-Stroke Headache Cohort: A Single Center Experience – Cecilia Peterson, Ka-Ho Wong, Marissa Marie Castillo, Varsha Muddasani, Nazanin Sheibani, Lourdes Peralta, Kayla Navarro, Gauri Garg, Seniha N. Ozudogru, Adam De Havenon P6.10-006 Predictors of cortical surface subarachnoid hemorrhage in reversible cerebral vasoconstriction syndrome – Oscar Emanuel Garat, Julieta Rosales, Ismael Calandri, Mario Emiliano Ricciardi, Virginia Andrea Pujol Lereis, Sebastian F. Ameriso P6.10-007 Cannabis Use and Outcomes in Spontaneous Aneurysmal Subarachnoid Hemorrhage: A Descriptive Study – Julianne Hall, Asad Rehman, Caitlin Radnis, Anjali Asthana, Ivan Da Silva
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 6
P6.10-008 Characteristics of Strokes in Down Syndrome Patients, A single center decade experience – Anam Syed, Jasmine Singh, Michael Joel Schneck, Jose Biller P6.10-009 Hypertension Associated with Functional Status Early After Hospitalization for Ischemic Stroke: a Cohort Study – Megan Elizabeth Pudlo, Kathryn Cote, Emma Jost-Price, Lester Y. Leung
11
Movement Disorders
Movement Disorders: Tardive Dyskinesia and PD Imaging 1 P6.11-001 Long-Term Efficacy and Safety of Deutetrabenazine in Patients With Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use – Hadas Barkay, Robert A. Hauser, Hubert H. Fernandez, Stewart A. Factor, Joohi Jimenez Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Mark Forrest Gordon, Juha M. Savola, Karen E. Anderson P6.11-002 Genotype-specific white matter microstructural alterations in prodromal Parkinson’s disease – Amgad Droby, Avital Yoffe Vasiliev, Moran Artzi, Nir Giladi, Anat Mirelman, Avner Thaler P6.11-003 Association between Parkinson’s disease and Acute or Subacute Subdural Hemorrhage, a Retrospective Study – Amna Imran, Saif Ullah, Alexis Lea Finer P6.11-004 Once-Daily Valbenazine Is Effective for Tardive Dyskinesia in Elderly Patients (=65 Years) – Martha Sajatovic, Khody Farahmand, Chirag Shah, Leslie Lundt P6.11-005 Impact of Tardive Dyskinesia on Physical, Psychological, and Social Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States – Rakesh Jain, Rajeev Ayyagari, Sarah King, Georgia Grace Keller Edwards, Amanda Wilhelm, Sam Leo P6.11-006 Using PSMD, a novel DTI measure, to assess the role of white matter disease on structural connectivity in Parkinson’s disease. – Isaac Goldszer, Leonardo F. G. Bonilha, Christine Cooper
Sunday, April 3 5:30 p.m.–6:30 p.m.
Movement Disorders: PD Non-Motor Symptoms or Parkinsonism and NMS 3 P6.11-007 Palliative Care for Parkinson’s Disease: Literature Review – Wendy Gaztanaga, Jason H. Margolesky, Danielle Spengler Shpiner, Melissa Ann Fellman
12
General Neurology
General Neurology: Neuropathy and Myopathy 1 P6.12-001 Peripheral Neuropathy May Be the Major Cause of Imbalance in Older Patients – Akhand Pratap Singh, Karen Stephenson, Ahmed Osameh Alwahaidy, Jennifer L. Cox, Lixin Zhang P6.12-002 Isolated Hypoglossal Nerve Palsy: Two Case Reports – Iftekhar Ahmed, Robert Evan Ungerer P6.12-003 Multiple Cranial Neuropathies; A Diagnostic Challenge – Mohammad Ali Shahab, Grace Marie Nicole Biso, Muthu Kuzhali Ganapathy, Carolina Cuello-Oderiz P6.12-004 A Rare Case of Giant Cell Arteritis Presenting With Transient Polycranial Neuropathies – Harinoor Mann, Troy Desai P6.12-005 Hypokalemic periodic palsy masquerading as Guillaine Barrè syndrome – Sahil Naik, Vivek Varun, Nivedita Jha
13
Neuromuscular and Clinical Neurophysiology (EMG)
P6.13-004 Myasthenic crisis patient characteristics, readmissions, treatments, and outcomes: A single center analysis – Jeffrey Mullen, Ali A. Habib P6.13-005 A prospective natural history study and biorepository for patients with myasthenia gravis (EXPLORE-MG2) – Jeff Guptill, Richard J. Nowak, Amanda C. Guidon, James F. Howard, Betty C. Soliven, Alex Hammett, Bailey Munro Sheldon, Yingkai Li, Taylor Meece, Immaculada Aban, Gary Raymond Cutter, Henry J. Kaminski, Jeff Guptill P6.13-006 Emergent Comorbid Events in First Year of Immunomodulatory Treatment in Adults With Generalized Myasthenia Gravis treated in a Neurology Clinic: A Retrospective Review – Nakul Katyal, Naureen Narula, Raghav Govindarajan P6.13-007 Clinical and Laboratory Remission with Rituximab Treatment in anti-MuSK-positive Myasthenia Gravis Patients – Berin Inan, Can Ebru Kurt, Sevim Ozdamar, Ersin Tan P6.13-008 Treatment Burden According to Patients with Generalized Myasthenia Gravis – Katherine Ruzhansky, Neelam Goyal, Suraj Muley, Tuan Hoang Vu P6.13-009 A Case of Lambert Eaton Myasthenic Syndrome with Cerebellar Ataxia Complicated by Encephalopathy and Confounded by Generalized Pain – Marissa Urbano, Sandeep Singh, Antonio Moya, Margaret Adler P6.13-010 Pembrolizumab Associated Myasthenia Gravis and Myocarditis Associated with Anti-striational Antibody – Swaroopa Pulivarthi, Warda Faridi, Jordan Lee Preston, Jared Scott Hollinger
Neuromuscular Disease: Myasthenia Gravis 1 P6.13-001 Efficacy of Apraclonidine in Treating Ptosis Secondary to Myasthenia Gravis – Mohamad Khodr Agha, Helen Ismail, Raja Sawaya, Johnny Salameh P6.13-002 Measuring Adverse Event Burden in Myasthenia Gravis: Single Center Prospective Evaluation of the Adverse Event Unit (AEU) – Michael K. Hehir, Mark Conaway, Avery Berit St Sauveur, Noah A. Kolb, Waqar Waheed, Brendan Lee McNeish, Nicole Lucie Tweedy, Donald B. Sanders, Pushpa Narayanaswami, Ted M. Burns P6.13-003 Comparison of clinical and electrophysiological characteristics in Myasthenia Gravis patients with favorable and unfavorable outcomes – Gabriel Pina Paiva, Joao Aris Kouyoumdjian
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
49
Monday, April 4 8:00 a.m.–9:00 a.m.
Poster Session 7
1
Autoimmune Neurology
Autoimmune Neurology: Treatmentassociated Neuroinflammatory Syndromes 1 P7.1-001 Paraneoplastic Sensorimotor Neuropathy and Ventral Cauda Equina Nerve Root Enhancement as Initial Presentation of Small Cell Lung Carcinoma: a Case Study – Meshari Alsaeed, Ah Ryung Lim, Alyson Rylie Plecash, Tychicus Chen P7.1-002 New-Onset GFAP Astrocytopathy And DRESS Syndrome – Mattia Rosso, Muayad Abdulaziz Alzuabi, Charles Francis Palmer, Mini Singh P7.1-003 Severe Discoid Lupus Erythematosus Associated with Eculizumab: A Case Report and Review – Rishi Sharma, Moises Adrian Romo Sanchez, Flavia Nelson P7.1-004 CNS and PNS Manifestation in Immune Checkpoint Inhibitors: A Systematic Review – Erum Khan, Ashish Kumar Shrestha, Hannah Elizabeth Wilson, Shitiz K. Sriwastava Autoimmune Neurology: NMOSD and MOGAD 1 P7.1-005 Neuromyelitis Optica Spectrum Disorder With Comorbid Complex 1 Mitochondrial Disease, Leukopenia And Neutropenia, A Challenging Case With Difficult Management – Gina Susana PerezGiraldo, Edith Graham, Stephen A. VanHaerents, Roumen D. Balabanov P7.1-006 Severe Presentation of Neuromyelitis Optica with Positive Antibody Following COVID-19 Vaccination – Afra Janarious, Saif Ullah P7.1-007 Seronegative Neuromyelitis Optica Spectrum Disorder (NMOSD) Or Neuro-Behcet’s? Do Complement Inhibitors Effectively Control NeuroBehcet’s Disease? – Negar Molazadeh, Michael Levy
2
Headache
Headache: Innovation and Technology 1 P7.2-001 Acute Treatment of Migraine in Adolescents: Post Hoc Analysis of Remote Electrical Neuromodulation (REN) vs. Standard-care Medications Efficacy – Andrew D. Hershey, Samantha Lee Irwin, Liron Rabany, Yaron Gruper, Alon Ironi, Dagan Harris, Roni Sharon, Jennifer McVige
50
2022 AAN Annual Meeting
P7.2-002 Efficacy of Relivion® MG in the Acute and Preventive Treatment of Migraine. Findings from Two Recent Studies. – Roni Sharon, Oved Daniel, Stewart J. Tepper P7.2-003 Exposure to narrow band green light (nbGL) reduces migraineous headache and photophobia: Large open-label study conducted online using daily headache diary – Richard B. Lipton, Mark Severs, Agustin Melo Carrillo, Michael L. Reed, Rami Burstein P7.2-004 The Effects of a Digital Mental Health Intervention in Migraine Patients: A Pilot Study – Lauren S. Weiner, Eliane Boucher, Murray Zucker, Acacia C. Parks P7.2-005 The Impact of Telehealth During the COVID-19 Pandemic on the Clinical Evaluation and Outcome of Headache in Children and Adolescents – Michaela Reuter, Tate Reuter, Paul Horn, Andrew D. Hershey, Marielle Kabbouche
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Frontotemporal Dementia and Primary Progressive Aphasia 1 P7.3-001 Automated Analysis of Functional Written Communication in the Three Variants of Primary Progressive Aphasia – Sylvia Josephy, Neguine Rezaii, Amelia Belle Jones, Daisy Hochberg, Megan Quimby, Bonnie Wong, Bradford Dickerson P7.3-002 Development of a novel digital speech composite measure for Frontotemporal Dementia – Jessica Robin, Mengdan Xu, Liam D. Kaufman, Bill Simpson, Stella McCaughey, Charles Wolfus, Sam Jackson, Michael Ward P7.3-003 Loss of speech and functional impairment in Alzheimer’s disease-related primary progressive aphasia: predictive factors of decline – Salvatore Mazzeo, Cristina Polito, Silvia Bagnoli, Marta Mattei, Sonia Padiglioni, Valentina Berti, Gemma Lombardi, Giulia Giacomucci, Maria Teresa De Cristofaro, Camilla Ferrari, Benedetta Nacmias, Sandro Sorbi, Valentina Bessi P7.3-004 Unraveling globular glial tauopathy: a clinical and neuroimaging study – Marina Buciuc, Nha Trang Thu Pham, Joseph Duffy, Farwa Ali, David S. Knopman, Bradley F. Boeve, Jonathan GraffRadford, Val John Lowe, Dennis W. Dickson, Jennifer Louise Whitwell, Keith A. Josephs
P7.3-005 Novel Chinese Linguistic Markers for Semantic variant Primary Progressive Aphasia – Boon Lead Tee, Lorinda Li Ying Kwan-Chen, Ta-fu Chen, Joshua Tsoh, Andrew Lung Tat Chan, Raymond Y. Lo, Chien Long Lu, Pei-Ning Wang, Yu Sun, Maria Gorno Tempini
4
MS and CNS Inflammatory Disease
MS Clinical Trials & Therapeutics 3 P7.4-001 Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot – Shlomo Flechter, Laura Popper, Nadav Bleich Kimelman, Shai Rubnov, Uri Danon, Ehud Marom, Ron E. Milo, Ronit Gilad, Boaz Weller, Adi Vaknin-Dembinsky, Mark Hellman, Alla Shifrin, Arnon Karni P7.4-002 Repeated Confirmed Disability Progressions Analyses of the OPERA and ORATORIO Studies and Their Open-Label Extensions – Ludwig Kappos, Hans-Peter Hartung, Stephen L. Hauser, Robert T. Naismith, Hans-Martin Schneble, Ben Townsend, Qing Wang, Jerry S. Wolinsky P7.4-003 Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis – Heinz Wiendl, Laura Airas, Tanuja Chitnis, Mitzi Joi Williams, Jin Nakahara, Robert A. Bermel, Allison Mann, Marina Ollervides Ziehn, Alit Bhatt, Brian Hunter, Ying Zhang, Rajesh Karan, Bernd C. Kieseier, Xavier Montalban P7.4-004 High-dose biotin for Multiple Sclerosis: A Systematic Review and Meta-Analyses of Randomized Controlled Trials – Adrian Isidoro Espiritu, Patricia Remalante-Rayco P7.4-005 Comparative Effectiveness of Cladribine versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN (MavEnclad Real worLd comparative efficacY non-iNterventional) Study – Wallace Brownlee, Aiden Haghikia, Brooke Hayward, Nathalie Waser, Sheena Kayaniyil, Zaeem Khan, Julie Duncan, Stefanie Millar, Gerard Harty
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 7
MS Therapeutics MOA and Safety 2 P7.4-006 Duration of B-cell depletion in patients receiving ocrelizumab or rituximab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders – Mahmoud A. AbdelRazek, Marcel Casasola, Roohallah Mollashahi, Alexander Brodski, Scott James Morin, Aleksandra Augustynowicz, Sarmad Jassim, Marcelo Matiello, Jacob Alexander Sloane P7.4-007 Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of Relapsing Multiple Sclerosis: Interim Results of the Phase 3b EXCHANGE Study – Amit Bar-Or, Bianca Weinstock-Guttman, Yang Mao-Draayer, Linda-Ali Cruz, Xiangyi Meng, Gina Cox, Stanley L. Cohan P7.4-008 Diroximel Fumarate in Patients with RelapsingRemitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study – Sibyl E. Wray, Barry A. Singer, Jelena Drulovic, Hailu Chen, Jennifer Lyons, Florian Then Bergh, Donald Negroski, Shivani Kapadia P7.4-009 Long-Term Safety and Effectiveness of Delayedrelease Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice – Krupa Pandey, Kathryn Giles, Konstantin E. Balashov, Richard A L Macdonell, Jorg Windsheimer, Mikel Ander Martinez Oyarzabal, Ivan Bozin, Nydije Grimes, Phoebe Jiang, Shivani Kapadia, Jennifer Lyons, Oksana Mokliatchouk, Annette Okai P7.4-010 Comparative Effectiveness, Discontinuation, and Safety of Ocrelizumab and Rituximab in Two Years of Treatment in Multiple Sclerosis – Brandi L. Vollmer, Michlene Passeri, Nassim Ijadi, Anthony Declusin, Stefan Sillau, Kavita Nair, John Corboy, Timothy L. Vollmer, Enrique Alvarez P7.4-011 Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Data from Clinical Studies and Post Marketing Experience – John F. Kramer, Ratnakar Pingili, Ronald Zielman, Ayan Das Gupta, Pranava Reddy Katkuri, Wendy Su, Elisabeth Braun Lucassen, Dee Stoneman, Olaf Hoffmann
Monday, April 4 8:00 a.m.–9:00 a.m.
P7.4-012 Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod – Ludwig Kappos, Giancarlo Comi, Krzysztof W. Selmaj, Lawrence Steinman, Amit Bar-Or, Douglas L. Arnold, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, Chahin Pachai, James K. Sheffield, Chun-Yen Cheng, Diego Silva, John Vaile, JeanPierre Morello, Jeffrey Alan Cohen, Bruce A. C. Cree
5
Child Neurology and Developmental Neurology
Child Neurology: Infectious Disease/ COVID-19 2 P7.5-001 A rare pediatric case of hemichoreahemiballismus secondary to vein of Galen thrombosis – Hemani Ticku, Gaurav Chenji, Ankita Prasad, Neel Fotedar P7.5-002 Assessing the Impact of COVID-19 in Healthcare Providers Treating Spinal Muscular Atrophy (SMA) – Mary Curry, Ilse Peterson, Lisa Belter, Mary K. Schroth, Jill Jarecki Child Neurology: Neurovascular/Critical Care/Quality 2 P7.5-003 Characterization of Neuropsychological Outcomes in a Cohort of Pediatric Patients with Moyamoya Arteriopathy – John Richard Gatti, Alicia Cannon, Rachel Peterson, Laura Malone, Lisa Sun P7.5-004 Fetal Neurology Consultation and Institutional Review of Neonatal Outcomes – Rae Leonor Ferrer Gumayan, Brett Klamer, Margie A. Ream P7.5-005 Evidence of Locked-in-Syndrome in Pediatric Nonfatal Drowning: Results of a Family Caregiver Survey. – Muslima Sonia Razaqyar, Jonathan Michael Towne, Mariam Ishaque, Florence Chiang, Peter T. Fox
Information is accurate as of February 8, 2022, and is subject to change.
6
Aging, Dementia, Cognitive, and Behavioral Neurology
Behavioral and Cognitive Neurology: Neuropsychiatry 2 P7.6-001 Calming Effect of Clinically Designed Improvisatory Music for Patients Admitted to Epilepsy Monitoring Unit during COVID-19 Pandemic – Borna Bonakdarpour, Guangyu Zhou, Daniel Huang, Christina Zelano, Clara Takarabe P7.6-002 Cognitive disorder and depression screening in acute stroke. – A. M. Barrett, Janice ConvoyHellmann, David W. Loring, Jessica Saurman, Karima Benameur, Felicia Goldstein, Shilpa Krishnan, Fadi B. Nahab P7.6-003 Examining Levels of Catecholamine Neurotransmitter Regulatory Proteins Within the Prefrontal Cortex of Rodents Following Traumatic Brain Injury – Eleni Papadopoulos, Christopher Knapp, Claire M. Corbett, Jessica A. Loweth, Rachel L. Navarra P7.6-004 The Clock Drawing Test as a Predictor of Postoperative Delirium After Urgent Hip Fracture Surgery – Benjamin Chapin, Katie Rodriguez, Erin Formanski, Nila Radhakrishnan, Patrick James Tighe, Catherine Price
6
Research Methodology and Education
Medical Education to Improve Clinical Experience 1 P7.6-005 Prevention and acute treatment of migraine: Evaluating the impacts of education in empowering clinicians and their patients into shared decision making – Carole Drexel, Angelique Vinther, Nim Lalvani, Stewart J. Tepper P7.6-006 Preparing for a New Era in SMA Care with Disease Modifying Therapies: The Role of Tethered, Aligned, Patient/Caregiver and Clinician Education – Carole Drexel, Mary K. Schroth, Katie Kowalski, Julie Anne Parsons
AAN.com/AM
51
Monday, April 4 8:00 a.m.–9:00 a.m.
Poster Session 7
7
Neuro Trauma and Critical Care
Neurocritical Care: ICH, SAH, Ischemic Stroke and Other Topics 2 P7.7-001 A Single Center Retrospective Review of Long Term Outcomes in Spontaneous Intracranial Hemorrhage Patients Who Received Hyperosmolar Therapy – Anna Whitham, Sonora Andromeda Windermere, Asim Zia Mian, Courtney Takahashi P7.7-002 Intracranial Dermoid/Epidermoid Cyst Mimicking acute cerebellar hemorrhage – Maryum Shoukat, Hammad Naeem, Maria Shoaib, Ahmad AlAwwad P7.7-003 Computational Analysis of Subarachnoid Hemorrhage Pattern Can Indicate the Presence of Aneurysm – Daniel Mandel, Kelly Pan, Scott Moody, Bradford B. Thompson, Linda C. Wendell, Jesse Menville, Karen L. Furie, Ali Mahta P7.7-004 Hypereosinophilic Syndrome Presenting as an Acute Stroke – Kenneth Riley Dalton, Todd Looney, Nawaz Hack P7.7-005 Assessment of Cerebral Autoregulation during Head of Bed Maneuvers in Acute Large Vessel Occlusions – Catherine Hassett, Moein Amin, Madihah Amima Hepburn, Joao Antonio Gomes
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): Neuromodulation and Electrocorticography 1 P7.8-001 Neurostimulation in People with Drug-Resistant Epilepsy: Systematic Review and Meta-Analysis from the ILAE Surgical Therapies Commission – Benedicte Dansereau, Lahoud Touma, Alvin Chan, Nathalie Jette, Churl-Su Kwon, Kees Braun, Daniel Friedman, Lara Jehi, John D. Rolston, Sumeet Vadera, Lily Wong-Kisiel, Dario Englot, Mark Robert Keezer P7.8-002 Propagation of Epileptiform Discharge along the Papez Circuit Demonstrated with Stereotactic EEG in a Patient with Temporal Lobe Epilepsy – Brian Joseph Coffey, Giridhar P. Kalamangalam, Maria J. Bruzzone
P7.8-004 Responsive Neurostimulation vs. Vagus Nerve Stimulation in Epilepsy – Henry Skrehot, Dario Englot, Zulfi Haneef P7.8-005 The Potential of Invasive and Non-invasive Vagus Nerve Stimulation to Improve Verbal Memory Performance in Epilepsy Patients – Ann Mertens, Stefanie Gadeyne, Emma Lescrauwaet, Evelien Carrette, Alfred Meurs, Veerle De Herdt, Frank Dewaele, Robrecht Raedt, Marijke Miatton, Paul A.J.M. Boon, Kristl Vonck P7.8-006 Investigation of Neuroplasticity with the Responsive Neurostimulation (RNS) System during Battery Failure – Alexandra Vallera, Ryan Ward, Cemal Karakas, Henry Skrehot, Stephen Cleboski, Zulfi Haneef P7.8-007 Dual Device Neurostimulation in Drug Resistant Epilepsy – Brin Freund, Diogo Garcia, Anteneh Mekonnen Feyissa, Anthony L. Ritaccio, Joseph I. Sirven, Erik Middlebrooks, Sanjeet S. Grewal, William O. Tatum
9
Infectious Disease
Infectious Disease: Acute and Subacute Responses to COVID-19 3 P7.9-001 Retrospective Multihospital Prevalence Study of COVID-19 Acute Neurological Manifestations – Wan Yee Kong, Mihir Kakara, Mahsa Sadeghi, Hossein Salimnia, Anthony R. Seely, Robert Mitchell, Jerry L. Chen, Kumar Rajamani, Ayaz M. Khawaja P7.9-002 A Single Center, Retrospective Analysis of Inpatient Neurologic Consultations of Patients Infected with SARS-CoV-2 – Brian Edward Emmert, Stephanie Gandelman, David Do, Matthew K. Schindler
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Science 2 P7.10-001 Downstream Impact of an Inpatient Telemedicinebased Stroke Care Delivery Model – Solmaz Ramezani Hashtjin, Shayan Khan, Adam R. Lipschultz, Savannah Gabrielle Novy, Cynthia Zheng, Monica Ngo, Kathryn Bard, Sarah A. Engkjer, Christopher Streib P7.10-002 Predictive Factors for Depressive Symptoms in the Stroke Recovery Follow-Up Period – Julie Sunjoo Yi, Justin Lu, Annie Yang, Elisabeth B. Marsh P7.10-003 Prevalence and Overlap of Potential Embolic Sources in Embolic Stroke of Undetermined Source in Tunisia – Mouna Naguez, Mouna Aissi, Mariem Mhiri, Mahouba Frih P7.10-004 Walk Your Dizzy Patients! Gait Assessment in the Initial Evaluation of Posterior Circulation Stroke – Isaac Smith, Eduard Humberto Valdes, Kara R. Melmed P7.10-005 Depression after the first stroke not only in the affected patients but also in their caregivers – Majdi Al Qawasmeh, Mays Khweileh, Belal Adel Aldabbour, Ahmed Moh’d Yassin, Khalid I. El-Salem P7.10-006 Characteristics and short-term outcomes of delirium after acute ischemic stroke – Mohammad Jamil Ahmad, Sahar Anjum, Aditya Kumar, Jacob Sebaugh, Michele Joseph, Bethany Williams, Alicia Zha P7.10-007 Prevalence and Risk Factors of Polyvascular Disease in Patients with Cerebrovascular or Ischemic Heart Diseases Undergoing Diagnostic Angiography – Yi Shen, Jian Wu, Xiaofeng Zhang
P7.9-003 Pediatric COVID Encephalitis: A Case Report – Nelson Donovan Gonzalez, Dustin Jacob Paul, Ana Hernandez Almeda, Samuel Serna, Linette C. Linsangan
P7.10-008 Embolic Stroke in Setting of Iliac Vein Stenosis in an Avid Cyclist – Nikita Chhabra, Benzion Blech, F David Fortuin, Susan Wilansky, Bart M. Demaerschalk, Oana Maria Dumitrascu
P7.9-004 COVID-19 Related Hashimoto’s and VGKC Encephalitis – Mohammad Ali Shahab, Kehan Zhao, Sutanaya Pal
P7.10-009 Characteristics of Cerebral Cavernous Malformations in a Large Multiethnic Cohort – N. Abimbola Sunmonu, Chad Aldridge, Bradford B. Worrall
P7.8-003 An Acquisition Infrastructure for High-Resolution Intracranial Electroencephalography – Lisa Yamada, Tomiko Oskotsky, Paul Nuyujukian
52
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 7
P7.10-010 Identification of Thrombophilia in Cerebral Infarction, and Potential Effect of Antithrombotic Therapy on Outcome of Cerebral Infarction in Association with Hypercoagulability in the Nationwide Inpatient Sample, 2016-2018 – Prabandh Reddy Buchhanolla, Shyamal Chandra Bir, Annie Lewis, Alexis Angelette, Sandeep Kandregula, Bharat Guthikonda, Vijayakumar Javalkar, Oleg Y. Chernyshev, Roger E. Kelley
11
Movement Disorders
Movement Disorders: PD Therapeutics 1 P7.11-001 Influence of Istradefylline Treatment on Levodopa Dose Escalation in PD Patients from over 10 Years of Experience – Nobutaka Hattori, Daijiro Kabata, Shinji Asada, Tomoyuki Kanda, Takanobu Nomura, Ayumi Shintani, Shelby M King, Ross Goldstein, Akihisa Mori P7.11-002 Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation – Ahmad M. Al-Sabbagh, Samuel Testino, Darshana Shah, Minako Koga, Kathleen E. Clarence-Smith, Thomas N. Chase P7.11-003 Novel class of compounds for the treatment of levodopa-induced dyskinesia – Thomas T. Oh, Elyas Daadi, Jeffrey Kim, Etienne Daadi, PengJen Chen, Gourav Roy-Choudhury, Jonathan A. Bohmann, Benjamin E. Blass, Marcel Daadi P7.11-004 Levodopa and Dopamine Agonist Medication Utilization among Patients with Parkinson’s Disease Enrolled in Commercial and Medicare Advantage Part D Health Plans – Monica Frazer, Lisa Le, Steve Arcona, Rahul Sasane P7.11-005 The clinical and humanistic value of “good ontime” among patients with advanced Parkinson’s disease: A real-world study from 7 countries – Joohi Jimenez Shahed, Aristide Merola, Irene Malaty, Jean Philippe Azulay, Connie H. Yan, Aditi Kharat, Ali Alobaidi, Prasanna Lakshmi Kandukuri, Pavnit Kukreja, Jorge Zamudio, Alexander James Gillespie, Angelo Antonini P7.11-006 Transcutaneous Afferent Patterned Stimulation Provides Upper Limb Motor Symptom Relief in Patients with Parkinson’s Disease – Salima Brillman, Pravin Khemani, Stuart H. Isaacson, Rajesh Pahwa, Ruta Deshpande, Vivien Zraick, Apoorva Rajagopal, Kathryn Rosenbluth, Dhira Khosla
12
Monday, April 4 8:00 a.m.–9:00 a.m.
General Neurology
General Neurology: Neurotoxicity P7.12-001 Cefepime-induced Neurotoxicity in the Critically Ill: A Modifiable Risk Factor – Mohona Reza, Bridget A. Bagert, Gregory Reese, Mary Ann Reeves P7.12-002 Nitrous Oxide/’Whippets’ Induced Thoracic Spinal Cord Myelopathy and Cognitive Decline with Normal Serum Vitamin B12 – Bahadar Singh Srichawla, Kavneet Kaur P7.12-003 Delayed Neurologic Deterioration after Opioid Overdose - an Uncommon Result of a Common Problem – Kathryn Zuchowski, Aaron Stephen Bower, Nicholas Blondin P7.12-004 Nitrous Oxide Induced Subacute Combined Degeneration (SCD) of Spinal Cord. – Shaweta Khosa, Gurveer Singh Khosa, Shrikant Mishra, Gyanesh Mani Tripathi P7.12-005 Effects of Alcohol Use on Mental Health and EQ – Francisco Eduardo Ramirez, Jonathan Jensen, Jordan Tarusenga Jojo, Kylie Northrop
13
Neuromuscular and Clinical Neurophysiology (EMG)
P7.13-004 Coexisting Myasthenia Gravis and Sjogren’s Syndrome Patients at Virginia Commonwealth University – Kelly G. Gwathmey, Christina Renee Graley P7.13-005 Concentric Needle Jitter Abnormalities in Patients with Ocular and Generalized MG – Gabriel Pina Paiva, Joao Aris Kouyoumdjian P7.13-006 Poor response to Eculizumab in Caucasian Patients with Treatment Refractory Generalized Myasthenia Gravis – Nakul Katyal, Raghav Govindarajan P7.13-007 Immune Checkpoint Inhibitor Associated LRP4 Positive MG – Sarah Mauney, Joseph Nguyen, James Grogan P7.13-008 Atypical presentation of asymmetric limb dystonia in a patient with CHAT gene mutation – Wan Yee Kong, Fatema Jahan Serajee, Ahm Mahbubul Huq P7.13-009 Refractory Myasthenia Gravis Exacerbation associated with Marginal Zone Lymphoma – Karan Philip, Christina Xia, Ruham Alshiekh Nasany, Jenny Meyer P7.13-010 Novel congenital myasthenic syndrome caused by homozygous mutation in 3’-UTR of low-density lipoprotein receptor-related protein 6 (LRP6) gene – Xin Ming Shen, Duygu Selcen, Andrew G. Engel
Neuromuscular Disease: Myasthenia Gravis 2 P7.13-001 12-year trend in utilization of IVIG and plasmapheresis following acute myasthenia exacerbation and myasthenic crisis in the United States and their association with outcome. – Bhavya Narapureddy, Ahmed Ibrahim, Julius Latorre, Fadar Oliver Otite P7.13-002 Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit (AEU) – Michael K. Hehir, Mark Conaway, Avery Berit St Sauveur, Donald B. Sanders, Pushpa Narayanaswami, Noah A. Kolb, Waqar Waheed, Brendan Lee McNeish, Nicole Lucie Tweedy, Ted M. Burns P7.13-003 Spatial Association between Myasthenia Gravis and Hazardous Waste Sites: A Statewide Planning and Research Cooperative System (SPARCS) Study (2002-2014) – Sanjila Islam, Yueqing Zhang, Mustafa Jaffry, Kranthi Kiran Mandava, Nizar Souayah
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
53
Monday, April 4 11:45 a.m.–12:45 p.m.
Poster Session 8
1
Autoimmune Neurology
Autoimmune Neurology: Treatmentassociated Neuroinflammatory Syndromes 2 P8.1-001 AMPA-receptor encephalitis in a patient with metastatic breast cancer receiving palbociclib – Elizabeth Matthews, Jordan Gallegos, Barrie Schmitt, Dana Coutts, Karen Dianne Orjuela, Amanda Lee Piquet P8.1-002 Immune Checkpoint Inhibitor Rechallenge Following Neurologic Immune-Related Adverse Events in Cancer Patients: A Systematic Review – Mahsa Eskian, Balwant-Amrit V. Singh, Leyre Zubiri, Leeann Brigham Burton, Lisa Philpotts, Kerry Reynolds, Amanda C. Guidon P8.1-003 Nivolumab-Induced Limbic Encephalitis Associated with Glutamic Acid Decarboxylase 65 Antibodies – Al-alya Alsabah, Robert Altman P8.1-004 Acute Onset, Rapidly Progressive Anti-Yo Positive Paraneoplastic Cerebellar Degeneration, Associated with Ovarian Cancer, in the Setting of Immune Checkpoint Inhibitor Pembrolizumab Use: a Case Report – Yoon Jae Choi, Jerica Lomax, Xiao-Tang Kong P8.1-005 Rapidly Progressive Dementia from treatment with a novel IGF-1R inhibitor – Zoe Olga Marinides, Casey Christopher Gower, Charles J. Kidd, John Kent Werner Autoimmune Neurology: NMOSD and MOGAD 2 P8.1-006 Immune Reconstitution Therapy in NMOSD – Staley A. Brod P8.1-007 Very-late Onset Neuromyelitis Optica Spectrum Disorder – Alexander Besser, Brandi Baker, Sean T. Kenniff
2
Headache
Headache Validation and Education Research 2 P8.2-001 Non-Neurologist Perspectives on Migraine: Results of a cross-sectional advisory board survey – Edward Kim, Gilbert J. L’Italien, Ali Mohajer P8.2-002 Choosing Multiple Headache Preventive Medications Wisely: A Comprehensive Analysis Of Reported Versus Theoretical Drug-Drug Interactions – Ian Hakkinen, Jay Dave, Pengfei Zhang P8.2-003 Expert Consensus on the Benefits and Limitations of the Diagnostic Criteria for Post-Traumatic Headache as Defined by the International Classification of Headache Disorders-3rd Edition: A Qualitative Study – Emily Lane L. Schlitz Fortenberry, Jason J. Sico P8.2-004 Trivializing Migraines – Karthik Meda
Secondary Headache 1 P8.2-005 Gorham-Stout Disease of the Skull and the Delicate Balance Between Intracranial Hyper- and Hypotension – Mark Cohen, Gian Carlo Rossi P8.2-006 Treatment of Thoracic Outlet Syndrome in Outcome of Chronic Headaches – Lindsey Randall, Yoon-Hee Cha
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Frontotemporal Dementia and Primary Progressive Aphasia 2 P8.3-001 Understanding the lived experience of persons affected by frontotemporal degeneration (FTD): perceptions from persons diagnosed, their families and caregivers via the FTD Disorders Registry (FTDDR) Disease Impact Survey – Diana Wheaton, Sherry Harlass, Sweatha Reddy, Lakecia Vincent, Nadine Anne Tatton
P8.3-003 Anomalous Language Lateralization in Semantic Dementia: a Neurodevelopmental Hypothesis – Zachary Miller, Leighton Hinkley, Rian Bogley, Valentina Borghesani, Danielle Mizuiri, Maxime Montembeault, Isabel Allen, David C. Perry, Bill Seeley, Bruce L. Miller, Srikatan Nagarajan, Maria Gorno Tempini P8.3-004 Insights on FTD: An Externally-Led PatientFocused Drug Development Meeting – Debra Niehoff, Shana Dodge, Elizabeth Graham, Megan Barker, Stephanie Cosentino, Diana Wheaton, Sharon Denny, Penny Dacks, Susan Dickinson P8.3-005 Expanding the clinical presentations of primary progressive aphasia: evidence of progressive dynamic aphasia – Petronilla Battista, Valentina Borghesani, Michael G. Erkkinen, Maxime Montembeault, Boon Lead Tee, Eduardo Europa, Ariane E. Welch, Suzee Lee, Bruce L. Miller, Maria Luisa Mandelli, Maria Gorno Tempini, Zachary Miller
4
MS and CNS Inflammatory Disease
MS Clinical Practice & Decision Making 2 P8.4-001 Quantifying Subclinical Square Wave Jerks (SWJs) in Multiple Sclerosis (MS). – Luigi Pesce Ibarra, Christy Stefano Sheehy, Calen Walshe, Ari Green, Shivany Condor Montes, Daniel Bennett P8.4-002 Screening for differential diagnoses in MS: Evaluation of inclusion criteria for extensive diagnostic workup – Richard Schmidt, Sarah Haars, Astrid Unterlauft, Rami Jamra, Florian Then Bergh P8.4-003 B-cell CNS Lymphoma Disguised as Tumefactive Multiple Sclerosis Relapse in Patient on Ocrelizumab – Kelsey H. Carr, Mary Alissa Willis, Sameer Sharma P8.4-004 Differences in quality of care between neurology clinics - do they correlate to patient outcomes? A nationwide observational study. – Anna He, Ali Manouchehrinia, Jan A. Hillert, Kyla A. McKay
P8.3-002 Social cognition and behavioral assessments improve the diagnosis of behavioral variant of frontotemporal dementia in older Peruvians with low educational levels – Nilton Custodio Capunay, Rosa Montesinos, Lizardo Cruzado, Eder HerreraPerez, Virgilio E. Failoc-Rojas, Maritza PintadoCaipa, Wendy Seminario, José Cuenca, Carlos Alberto Gamboa Acasiete, Monica M. Diaz
54
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 8
MS Therapeutics MOA and Safety 3 P8.4-005 Post-approval Safety of Subcutaneous Interferon ß-1a in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections – Mark S. Freedman, Milorad Todorovic, Zuzana Murgasova, Dominic Jack P8.4-006 Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data – Amit Bar-Or, Bianca Weinstock-Guttman, Yang MaoDraayer, Angel R. Chinea, Gina Cox, Linda-Ali Cruz, Xiangyi Meng, Stanley L. Cohan P8.4-007 Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the Phase 3 EXPAND Study – Stanley L. Cohan, Le Hua, Amit Bar-Or, Fred D. Lublin, Xiangyi Meng, Gina Cox, Patricia K. Coyle, Robert J. Fox P8.4-008 Real-world data on cladribine effectiveness and safety: a two-year follow-up study – Maria Petracca, Elisabetta Signoriello, Elena Barbuti, Antonio Ianniello, Rosanna Missione, Simona Bonavita, Giovanna Borriello, Giacomo Lus, Carlo Pozzilli, Serena Ruggieri
MS Special Populations 2 P8.4-009 INFORM – Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden – Meritxell Sabidó Espin, Kiliana Suzart-Woischnik, Nydije Grimes, Lisa Prach, Liwei Zhao, Katja Hakkarainen P8.4-010 Case of Leber Hereditary Optic Neuropathy Mimicking Neuromyelitis Optica Spectrum Disorder – Keli Tahara, Nina Maithi Long, Diana Yang, Niki Maki, Kimberly L. Pargeon P8.4-011 Clinical Features and Course of Cerebral Amyloid Angiopathy-Related Inflammation – Moein Amin, Albert Aboseif, Ken Uchino, Ghulam Abbas Kharal
5
Monday, April 4 11:45 a.m.–12:45 p.m.
Child Neurology and Developmental Neurology
Child Neurology: Infectious Disease/ COVID-19 1 P8.5-001 Impact of the COVID-19 Pandemic on Behavioral Health of People with Intellectual and/or Developmental Disabilities – Jessica Sanders, Rachel Sturley, Rajapillai Pillai, Miya Asato, Stefan Sillau, Bhooma Rajagopalan Aravamuthan, Mackenzie Cervenka, Nancy Hammond, Karen Bonuck, joanne siegel, Vincent Siasoco, Benjamin Alexander Margolis P8.5-002 Assessing the Fatality Rate of Congenital Zika Syndrome Since the 2015 Zika Outbreak – Nilson Nogueira Mendes Neto, Jessika Thais da Silva Maia, Marcelo Rodrigues Zacarkim P8.5-003 A Pediatric Case of Severe, Treatment-Resistant, COVID-19 Associated Acute Longitudinally Extensive Transverse Myelitis with Masquerading Confounding Variables – Tasneem Fatema Hasan, Rachel E. Triay, Maroun J. Mhanna, Sheila Joyce Asghar, Rosario Maria S. Riel-Romero P8.5-004 Anosmia and Ageusia after COVID-19 vaccination in Pediatrics Population: A Vaccine Adverse Event Reporting System (VAERS) Study – Jeffrey M. Kornitzer, Mustafa Jaffry, Kranthi Kiran Mandava, Tarek Elshourbagy, Nizar Souayah P8.5-005 A Pediatric Case of Sensory Predominant GuillainBarré Syndrome Following COVID-19 Vaccination – Yunsung Kim, Zahra Zhu, Ashutosh Kumar
6
Research Methodology and Education
Medical Education to Improve Clinical Experience 2 P8.6-001 Continuity Clinic Experience in Neurology Residency – Aman Dabir, Vincent Arnone, Umer Najib, Gauri V. Pawar P8.6-002 Caring for Women with Neurologic Disease: A Single Center Survey Exploring Neurology Residents Knowledge, Perception, and Practices – Areeba Siddiqui, Ayra Siddiqui, Mona Sazgar
P8.6-004 Creating and Implementing a Virtual Simulation for Neurology Trainees – Rebecca Stainman, Steve Choongheon Han, Scott Grossman, Neil A. Busis, Arielle Marisa Kurzweil P8.6-005 High Fidelity Simulation of Acute Neurology Enhances Confidence and Knowledge of Rising Residents – Zahari Tchopev, Alexis E. Nelson, Morgan Christina Jordan P8.6-006 Driving Shared Decision-Making and Best Practices for Insomnia: The Impact of Tethered, Aligned Education on Clinicians, Patients, and Caregivers – Carole Drexel, Angelique Vinther, William Christopher Winter, Russell Rosenberg
7
Neuro Trauma and Critical Care
Neurocritical Care: ICH, SAH, Ischemic Stroke and Other Topics 3 P8.7-001 A rare mechanism of Acute Ischemic Stroke following Intrathecal Methotrexate – Navreet Kaur, Christina Xia, Karan Philip, Hesham Masoud, Fadar Oliver Otite P8.7-002 Sinking Skin Flap Syndrome Presenting as Paradoxical Herniation Syndrome – Leonid Groysman, Daniel Ilchoong Ro P8.7-003 Acute Ischemic Leukoencephalopathy Secondary to Circulatory Shock and Metabolic Acidosis – Sharanya Ramakrishnan, Neha Sharma, Moin Ud Din, Muhammad Faisal Khan P8.7-004 Neuropsychiatric Manifestations of Shiga Toxin Producing E Coli Induced Hemolytic Uremic Syndrome in an Adult: A Case Report – Nefize Turan, Valeria Ariza Hutchinson, Steve Bibu, Deborah M. Green-LaRoche, Joshua A. Kornbluth P8.7-005 Ciliospinal Reflex – A Clinical Clue to Avoid Unnecessary Procedures in a Barbiturate Coma Patient – Negar Moheb, Ramiro Gabriel Castro Apolo, Cleo Zarina Alejo Reyes, Jaspreet Johal, Preet M. Varade
P8.6-003 Harnessing Continuing Education to Address Advances in the Management of Patients with NMOSD While Elucidating Persisting Educational Needs for Future Programs – Katie Robinson, Simon Cooper, Nick Nowotarski, Jennifer Frederick, Jenna Gentile, Robert Esgro
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
55
Poster Session 8
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy and Clinical Neurophysiology (EEG): Neuromodulation and Electrocorticography 2 P8.8-001 Stereo-EEG Seizure Localization in Epilepsy Patients with History of Viral Brain Infection – Irina Podkorytova, Kan Ding, Ryan Hays, Ghazala Perven P8.8-002 Decreasing VNS Settings Improves Seizure Control in a Patient with VNS-induced OSA – Rebecca Stainman, Mackenzie Cervenka, Grace Pien, Christopher Carosella Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus and Autoimmune Epilepsy 1 P8.8-003 Status Epilepticus: Analysis of the Time to Follow Up; A Retrospective cohort study – Jasmine Policherla, Muhammad Irshad Khan, Rohit Ajay Marawar, Maysaa Merhi Basha P8.8-004 An Autoimmune Epilepsy Case Series: Atypical Presentations with Atypical Autoimmune Antibodies. – Samir Sadik Al-Ghazawi, Saleem Mohamad Al Mawed, Gaurav Kathuria, Adnan Subei, Tarek Zakaria P8.8-005 Withdrawal of Antiepileptic Drugs After MRI– Guided Laser Interstitial Thermal Therapy in ExtraTemporal Lobe Epilepsy – Arjun Athreya, Rebecca E. Fasano, Daniel L. Drane, Jon T. Willie, Robert E. Gross, Ioannis Karakis P8.8-006 De novo KCND3 Causing Encephalopathy and Cardiac Arrhythmias: A Case Report – Eiman Ali, Imane Abdelmoumen, Melanie Ortiz, Stephen Falchek
9
Infectious Disease
Infectious Disease: Bacteria, Fungi, and Parasites on the Mind and Body 1 P8.9-001 Nonconvulsive Status Epilepticus - A Potentially Underrecognized Consequence of Infant Botulism – Rachel Pauley, Levi Dygert, Aaron Lane Nelson, Heather Lau P8.9-002 Case Report of Central Nervous System Cryptococcosis Mimicking Stroke – Mangayarkarasi Thandampallayam Ajjeya, Kara Jo Swafford
56
2022 AAN Annual Meeting
Monday, April 4 11:45 a.m.–12:45 p.m.
P8.9-003 Pseudomonas Meningoencephalitis Stemming From Occult Chronic Sacral Abscess – Connor David Welsh, Tejas Ranade, Elizabeth Anderson P8.9-004 Acute Ischemic Stroke In Patients With Tuberculous Meningitis – Akshay Deepak, Shankar Venkatasubramanian P8.9-005 Cryptococcal Meningitis and Suspected Small Vessel Vasculitis in an Immunocompetent Patient: A Case Report – Richa Mehta Thakkar, Kyle R. Marden, Cyrus Mowdawalla, Alvin Mercado, James E. Siegler P8.9-006 Case Report: Hemorrhagic Septic Emboli Secondary to disseminated Listeria monocytogenes in a Patient with a St. Jude aortic Prosthetic Valve – Vi Tran, Sang Han, William A. Kilgo, Rebecca L. Sugg, Juan G. Ochoa P8.9-007 A rare case of Meningitis due to Streptococcus suis in an immunocompetent patient – Roseliny Martins Batista, Carlos Correia
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Science 3 P8.10-001 Acute Hypotension and Bradycardia Due to Unilateral Carotid Artery Dissection: A Case Report – Cleo Zarina Alejo Reyes, Ramiro Gabriel Castro Apolo, Tsneem Mbydeen, Preet M. Varade P8.10-002 Necessity of Universal Echocardiograms in First-Time Stroke: A Retrospective Chart Review – Anthony Michael Harrington, Stefan Sillau, Sharon Poisson P8.10-003 Characterization and Comparison of Hospitalization Outcomes Between Symptomatic and Asymptomatic Urinary Tract Infection in Acute Ischemic Stroke Patients. – Wenyang Li, Elif Pinar Coskun, Jessica Doyle Lee P8.10-004 Post Stroke Delirium Does Not Predict Poor Cognitive Outcome at Discharge in Patients with Acute Ischemic Stroke – Sahar Anjum, Jacob Sebaugh, Bethany Williams, Alicia Zha P8.10-005 Intracerebral Hemorrhage Severity Predicts LongTerm Functional Outcomes After Anticoagulation Reversal with Andexanet alfa – Nikita Chhabra, Johnny Cebak, Molly Catherine Klanderman, Kara A. Sands, Harn Shiue
P8.10-006 Admission rates, time-trends, risk factors and outcomes of ischaemic and haemorrhagic stroke in German nationwide data – Dearbhla Kelly, Jeanette Koeppe, Peter Rothwell, Holger Reinecke P8.10-007 Comparison of Probable Cerebral Amyloid Angiopathy Diagnosed by Clinical Versus Imaging Features of Previous Hemorrhage – Varun Jain, Yoram Roman Casul, Nandakumar Nagaraja P8.10-008 NIHSS-SAAD (Skew deviation, truncal Ataxia, nystAgmus, abnormal saccaDes) score a better predictor of posterior circulation stroke – Saad Hasan, John M Hourihane P8.10-009 Initiation of Anti-Seizure Medications in Atrial Fibrillation-Related Stroke – Colby Allen Richardson, David Z. Rose, Wei Deng, Nhi Tran, Swetha Renati P8.10-010 Functional Neurological Disorders in Telestroke – Attitudes and Practice Patterns – Johanna L. Morton, Jaime Hatcher-Martin, Eric Anderson, Robert Jason Hallock
11
Movement Disorders
Movement Disorders: Deep Brain Stimulation in Parkinson’s Disease 2 P8.11-001 Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial – Tamara Stiep, Adolfo Ramirez Zamora, Alexander I. Troster, Roshini Jain, Lilly Chen, Mahsa Malekmohammadi, Michael S. Okun P8.11-002 Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial – Tamara Stiep, Alexander I. Troster, Adolfo Ramirez Zamora, Roshini Jain, Lilly Chen, Michael S. Okun P8.11-003 Deep Brain Stimulation Parameter Prediction using GuideXT and Traditional Monopolar Survey in Parkinson’s Disease Patients – Alina Shub, Donald A. Smith, Theresa A. Zesiewicz, Teresita Malapira, Chase Michael Kingsbury, Roshini Jain, Yarema B Bezchlibnyk
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 8
Movement Disorders: Genetics 1 P8.11-004 Heterogenous neuropathology in a pedigree with RAB39B-related Parkinson’s disease – Kimmy Su, Caitlin Shannon Latimer, Marika Bogdani, Dirk Keene, Cyrus P. Zabetian P8.11-005 Attitudes Regarding Genetic and Risk Factor Screening for Parkinson’s Disease (PD) among Research Study Participants in the Parkinson’s Progression Markers Initiative (PPMI) – Adrienne Lange Clark, Cheryl Meng, Brenda Valerie Luan, Ethan G. Brown, Jill L. Ostrem, Lana Chahine, Nijee Sharma Luthra, Marta San Luciano, Kenneth L. Marek, Caroline M. Tanner P8.11-006 Homozygous CADPS2 mutations cause neurodegenerative disease with Lewy bodies in amazon parrots – Oswaldo Lorenzo Betancor, Livio Galosi, Laura Bonfili, Anna Maria Maria Eleuteri, Valentina Cecarini, Ranieri Verin, Fabrizio Dini, Anna Rita Attili, Patrizia Robino, Maria Cristina Stella, Dora Yearout, Michael Dorschner, Cyrus P. Zabetian, Giacomo Rossi, Debby W. Tsuang P8.11-007 Eye movement abnormalities in patients with Parkinson’s disease (PD) and heterozygous GBA variants versus non-carrier PD – Hannah Marie Conn, Giulietta Riboldi, Todd Hudson, John Ross Rizzo, John Martone, Kelly Astudillo, Janet C. Rucker P8.11-008 Investigating a Neuroprotective Role for GBA in Astrocytes – Raja Elizabeth Estes, Bernice Lin, Jessica Young, Marie Ynez Davis
12
General Neurology
General Neurology: Clinical Practice and Telemedicine 3 P8.12-001 Effect of Neuro-hospitalist Program on Health Care Outcomes: An Observational Cohort Study & Narrative Review – Justin Mikhail Tiongson, Krystal Hunter, James E. Siegler P8.12-002 Effects of Flexible Scheduling and Virtual Visits on Burnout for Clinicians – Amy B. Sullivan, Sara Davin, Brittany Lapin, Andrew Schuster, Raed Dweik, Karen F. Murray, Susan Rehm, Andre Machado P8.12-003 Assessing Medical Student Competency in the Teleneurology Examination – Stephen Esguerra, Alyssa J. Espinoza, Robert S. Allen, Tarun Girotra, Sharon Czech-Siewert, Sarah Grant, Daniel Devitt Barnett, Asad Ikram, Deirdre Hill
Monday, April 4 11:45 a.m.–12:45 p.m.
General Neurology: Neuropathy and Myopathy 2 P8.12-004 Red Ear Syndrome – James Christian Hiana, Adrian Marchidann, Simona Treidler P8.12-005 A Case of Multiple Diagnoses Contributing to a Clinical Presentation Consistent with Myopathy – Rebecca Pratt, Shilpa Haldal, Rohan Sharma, Rucha Bahekar, Sumera Ali
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Peripheral Neuropathy 1 P8.13-001 Central Nervous System Involvement in HINT1 Neuropathy: An Overlooked Phenotypical Feature? – Arman Cakar, Ayse Nur Ozdag Acarli, Ayse Candayan, Serdar Ceylaner, Esra Battaloglu, Hacer Durmus, Fatma Yesim Parman P8.13-002 A double-blind, placebo controlled trial of Gamunex-C in Patient with Small Fiber Neuropathy Associated with Autoantibodies to TS-HDS and FGFR3 – Christopher H. Gibbons, Sharika Rajan, Katherine Senechal, Erin Auriel Hendry, Brady McCallister, Todd D. Levine
P8.13-006 Treatment Response in Patients with Clinical and Supportive Laboratory Features of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Without Demyelinative Findings on Nerve Conduction Studies – Patrick Curry, David N. Herrmann, Michael Stanton, Phillip C. Mongiovi, Eric L. Logigian P8.13-007 Long-term Outcome in Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review and Meta-analysis – Ali Al-Zuhairy, Johannes Jakobsen P8.13-008 Pre-treatment Axonal Loss as Biomarker for Longterm Disability in CIDP – Ali Al-Zuhairy, Johannes Jakobsen, Christian Krarup P8.13-009 The Motor Axon Threshold Variability Is Increased in Chronic Inflammatory Demyelinating Polyneuropathy – Christian Krarup, Ali Al-Zuhairy, Johannes Jakobsen, Mihai Moldovan P8.13-010 Poly-nutritional Deficiency in Acute to Subacute Polyneuropathy in Patients with Weight Loss – Ian Bakk, Mamatha Pasnoor, Mazen M. Dimachkie, Constantine Farmakidis
P8.13-003 Autonomic Dysfunction in Patients with GuillainBarré Syndrome and Related Prognosis: From the Clinic to the Electrophysiology. – Anna Lisette Bazan, Jesus Alberto Ruiz Avalos, Eunice Martínez Jiménez, Adib Jorge De Sarachaga, Juan Carlos Lopez, Elizabeth Leon, Edwin S. Vargas P8.13-004 Hereditary Transthretin Amyloidosis (hATTR) V142I Polyneuropathy Characteristics: A MultiCenter Perspective – Urvi G. Desai, Hristelina S. Ilieva, James Eyer, Amanda C. Peltier P8.13-005 Guillain-Barré Syndrome after the ZIKV Epidemic in Colombia: A Multicenter, Prospective, Casecontrol Study – Susana Carolina Dominguez Penuela, Martha Moyano, Jose Enrique Vargas Manotas, Jorge Andres Jimenez-Arango, Guillermo Gonzalez-Manrique, Jairo Francisco Lizarazo Nino, Jorge Angarita, Andres Felipe Zea-Vera, Reydmar Lopez, Daniela Zuluaga Lotero, David Orlando Acero-Garces, Maria Alejandra Garcia-Dominguez, Jose Miguel Enciso, Maria Fernanda Ramos Sanchez, Julie Benavides, Katherine V Claros, Jaime Quintero, Jonathan Urrego, Christian Rojas, Juan Pablo Rojas, Fernando Rosso, Gustavo Eduardo Ramos, Luis Carlos Quintero, Mario Llanos, Angela Catalina Vallejo Cajigas, Viviana Martinez, Carlos A. PardoVillamizar, Beatriz Parra, Lyda Osorio
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
57
Monday, April 4 5:30 p.m.–6:30 p.m.
Poster Session 9
1
Autoimmune Neurology
Autoimmune Neurology: MOGAD 1 P9.1-001 A case of a 14 year old male with MOGAD (Myelin Oligocyte Glycoprotein Antibody Disease) post-COVID-19 infection responsive to high dose corticosteroids and intravenous immunoglobulin (IVIG) therapy – Alfred Balasa, Brandon Neely, Sara A. McGuire P9.1-002 MOG Antibody Myelitis Following HIV Seroconversion – Tejas Ranade, Zain Ashary, Sami Kaldawi P9.1-003 Initial Presentation of MOGAD Masquerading as Acute Para-infectious Flaccid Myelitis – Raissa Aoun, Doris Xia, Elina Zakin P9.1-004 Should we test anti-MOG in probable autoimmune encephalitis? Results from a large Brazilian cohort – Bruna Dias, Fabio Fieni Toso, Rene De Araújo Gleizer, Maria Eduarda Slhessarenko, Orlando Povoas Barsottini, Mariana Braatz Krueger, Valéria Granja, Alessandra Dellavance, Andressa Maldonado, Luiz Eduardo Andrade, Romana Hoeftberger, Livia Almeida Dutra Antonio P9.1-005 MOG-IgG associated disease is uncommon during treatment with TNF inhibitors – Vyanka Redenbaugh, Eoin P. Flanagan, Valentina Floris, Pietro Zara, M. Tariq Bhatti, Francisco Roberto Sanchez Moreno, Matthew Koster, Sara Mariotto, Sean J. Pittock, John Chen, Alberto Cauli, Paolo Solla, Elia Sechi P9.1-006 A Case of MOG-associated Encephalomyelitis in the Setting of Post-COVID-19 Infection – Ali-Musa R. Jaffer, Muhammad Hasanayn Jaffer, Sheyar Amin, Ushtar Amin P9.1-007 The Role of Socioeconomic, Demographic, and Serologic Factors in Determining the Differential Pathogenesis of Myelin Oligodendrocyte Glycoprotein Antibody Disorder versus Multiple Sclerosis in Pediatric Patients – Brian Christopher Florenzo, James Nick Brenton
2
Headache
Secondary Headache 2 P9.2-001 Fear of Brain Tumor in Patients with Migraine in an Academic Headache Clinic – Derek J. Notch, Daniel Krashin, Ami Zarrillo Cuneo, Sau Mui Chan-Goh, Marcel Budica, Natalia Murinova P9.2-002 Cerebral Venous Sinus Thrombosis (CVST) As A Complication Of COVID-19 Infection Presenting As Post COVID-19 Headache – Mohammad Dibs, Ram Mohan R. Sankaraneni P9.2-003 Headache Frequency and Quality of Life in Patients with Post-Acute Sequelae of COVID-19 – Sujata P. Thawani, Peyton Meyer, Lisena Hasanaj, Jennifer A. Frontera, Steven Galetta, Laura J. Balcer
P9.3-005 Computational modeling of tau pathology spread reveals genetic correlates of regional vulnerability and the impact of a LRRK2 mutation – Eli Cornblath, Howard Liu Li, Lakshmi Changolkar, Bin Zhang, Hannah Jean Brown, Ronald James Gathagan, Modupe Folaranmi Olufemi, John Q. Trojanowski, Danielle Smith Bassett, Virginia Lee, Michael Henderson
4
MS and CNS Inflammatory Disease
MS Clinical Practice & Decision Making 3 P9.4-001 Diagnosis of myotonia congenita and multiple sclerosis in a patient with a familial history – Alexander Abud, Kara Stavros, Syed Rizvi
P9.2-004 Occipital Neuralgia Secondary to an Occipital Bone Lesion Revealing Multiple Myeloma – Anvita Suneja, Maryann Mays, Aarushi Suneja
P9.4-002 Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? – Kimberley Allen-Philbey, Monica Marta, Sharmilee Gnanapavan, David Baker, Klaus Schmierer
P9.2-005 A case of cerebral vasculitis mimicking RCVS – Valentina Poretto, Valeria Bignamini, Bruno Giometto, Sabrina Marangoni
P9.4-003 Clinical-pathological correlation of progressive solitary sclerosis: a case report – Nathan Chu, Sumit Das, Penelope Sybol Smyth
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Neuroimaging: Aging and Alzheimer’s Disease 1 P9.3-001 Exploratory Imaging Outcomes of a Phase 1b/2a Clinical Trial of Allopreganolone as a Regenerative Therapeutic for Alzheimer’s Disease: Structural and Functional Connectivity Outcomes – Roberta Diaz Brinton, Adam Raikes, Gerson David Hernandez Rivera, Dawn Matthews, Ana Lukic, Yonggang Shi, Meng Law, Lon Schneider
P9.4-004 Rapidly Progressive Demyelinating Disease Secondary to the Marburg Variant of Multiple Sclerosis: A Case Report – David M. Anson, Natalie Bartnik, Daniah Shamim, Yunxia Wang P9.4-005 Small Fiber Neuropathy in People with MS with Neuropathic Pain and Dysautonomia: A Case Series – Mary Kelley, Leorah Aude Emmanuelle Freeman, Ethan Isaac Meltzer, Ashlea Lucas, Helen Onuorah
P9.3-002 WITHDRAWN P9.3-003 Cross-sectional and longitudinal effects of APOE genotype on atrophy and tau burden in atypical Alzheimer’s disease – Neha Atulkumar Singh, Nirubol Tosakulwong, Jonathan Graff-Radford, Mary M. Machulda, Stephen Weigand, Nilufer Taner, Christopher Schwarz, Matthew Senjem, Clifford R. Jack, Val John Lowe, Keith A. Josephs, Jennifer Louise Whitwell P9.3-004 Longitudinal hypothalamic atrophy and its association with amyloid-ß and tau pathology in Alzheimer’s disease – Alice Tao, Zachary Myslinski, Yushan Pan, Costantino Iadecola, Jonathan Dyke, Gloria Chiang, Makoto Ishii
58
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 9
MS Therapeutics MOA and Safety 4 P9.4-006 Two-Year Interim Analysis of the TREAT-MS Alemtuzumab Study in Germany Differentiated by Direct Pretreatment – Tjalf Ziemssen, Stephan Richter, Frank Hoffmann, Angeliki Konstantinidou, Laura Quint P9.4-007 Updated Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis – Brittney Lager, Jacob Liseno, Catherine Miller, Sai Shankar, Jason P. Mendoza, James B. Lewin P9.4-008 Diroximel Fumarate (DRF) Has High Rates of Real-World Adherence and Persistence in Patients with Multiple Sclerosis (MS): Retrospective Claims Analysis – Nicholas PharmD Belviso, Carl DeMoor, Sai Shankar, Changyu Shen, Catherine Miller
MS Special Populations 3 P9.4-009 Patients with Multiple Sclerosis Attempting Conception: Interim Analysis from PREG-MS and CANPREG-MS Prospective Pregnancy Registries. – Maria K. Houtchens, Preksha Kukreja, Irene Yee, Jeta Pol-Patil, Adele Sadovnick P9.4-010 Association of Epigenetic Biomarkers of Neoplasia with Multiple Sclerosis in an Underrepresented Minority Population – Jeremy Michael Bingen, Lindsay Virginia Clark, Mark Band, Rajeev Ranjan, Michael D. Carrithers P9.4-011 Impact of symptomatic MS therapy on pregnancy course and outcome – Laura Witt, Sandra Thiel, Andrea Ines Ciplea, Ralf Gold, Kerstin Hellwig
5
Monday, April 4 5:30 p.m.–6:30 p.m.
Child Neurology and Developmental Neurology
Child Neurology: Neurovascular/Critical Care/Quality 1 P9.5-001 Rett-like phenotypes in HNRNPH2-Related Neurodevelopmental Disorder – Joseph Gonzalez, Olivia Thornburg, Sylvie Goldman, Melissa T. Carter, Jennifer M. Bain P9.5-002 Psychophysiological Markers Predict the Effect of Propranolol on Conversational Reciprocity in Autism Spectrum Disorder – David Q. Beversdorf, Bradley Ferguson, Carrina Appling, Nanan Nuraini, Samantha Hunter, Kathy Hirst, Bridget Lolli, Julie Muckerman, Ryan Holem, Nicole Takahashi P9.5-003 Utility of General Movement Assessment (GMA) in predicting the neurodevelopmental outcomes of term and late preterm infants exposed to severe hyperbilirubinemia in the neonatal period – Chandana Bhagwat, Lokesh Saini, Arushi Gahlot Saini, Naveen Sankhyan, Praveen Kumar, Rajni Sharma, Christa Einspieler P9.5-004 PFO Closure Following Childhood Stroke – Laurel Rose Persa, Catherine M. Amlie-Lefond P9.5-005 Shunting Prevalence in Patients with Moyamoya – Lori Xu, Wilmot Bonnet, Michael M. Dowling
6
Research Methodology and Education
Curriculum Development in Neurology Medical Education 1 P9.6-001 Longitudinally Integrated Clerkships and Interwoven Learning Experiences: Adapting Neuroscience Education to Evolving Medical School Curricula – Aaron M. Carlson, Trevor Hawkins, Pearce Korb, C. Alan Anderson, Hannah R. Daniels, Chad Stickrath, Shanta Mary Zimmer, Maureen Estevez Stabio P9.6-002 The Journey with Our Evolving Neurology Residency Curriculum in Molding Humanistic Neurology Graduates – Aileen Antonio, Christopher Morgan, Emily C. Johnson, Taylor R. Anderson
P9.6-004 A Novel Approach to Orientation for Incoming Neurology Residency through Simulation-Based Education – Madeline Louise Singer, Huiam Mubarak, Tejas Ranade, Sami Kaldawi, Tejas Ranade, Kelly Breaux, Valerie Sharf, Justin Hoskin P9.6-005 Retrospective Study of an Adult Neurology Residency’s Implementation of an Academic Half Day Curriculum – Sonali Sharma, Mohamed Ridha, Mohammed Al-Dulaimi, Cristie S. Draconi, Joshua A. Kornbluth P9.6-006 Resident Driven Quality Improvement: A SelfSustaining Model for New Milestones – Micaela Rose Owens, Alyssa Marie Smith, Cynthia Correll, Anthony Noto, Megan E. Esch, Joseph C. Alario
7
Neuro Trauma and Critical Care
Neurocritical Care: COVID-19, TBI and Other Topics 1 P9.7-001 Underutilization of Neuro Critical Care during the COVID-19 Pandemic – Shubham Biyani, Naren Raj Arulprakash, Abhilash Thatikala, Krishna Nalleballe, Sanjeeva Reddy Onteddu, Vishank Arun Shah P9.7-002 Delivery of Neurocritical Care Services to Critically Ill Patients with Altered Mental Status Before and During the COVID-19 Pandemic: A Single Center Study – Jonathan Reid Crowe, Rajesh Amerineni, Lidia Maria Veras Rocha Moura, Michael Brandon Westover, Sahar Fatima Zafar P9.7-003 COVID-19 Associated Aortic Thrombosis Mimicking Transverse Myelitis – Anand Kumar, Deepika Joshi, Varun Kumar Singh P9.7-004 Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes – Tia Chakraborty, Christopher Lawrence Kramer, Eelco F. M. Wijdicks, Alejandro A. Rabinstein P9.7-005 Comparison of Invasive and Non-Invasive Brain Tissue Oximetry after Pediatric Traumatic Brain Injury – Ann Oh, M’hamed Temkit, Michael Kuwabara, P. David Adelson, Brian L. Appavu
P9.6-003 The impact of an X+Y schedule model on Neurology residency training – Shuvro Roy, Katherine Fu, Timothy Edward Ryan, Yvette Bordelon, Charles C. Flippen, Adrienne M. Keener
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
59
Monday, April 4 5:30 p.m.–6:30 p.m.
Poster Session 9
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus and Autoimmune Epilepsy 2
9
Infectious Disease
Infectious Disease: Peripheral Manifestations Take Center Stage in COVID-19 1
P9.8-001 Faciobrachial seizures in LGI1 encephalitis are not always dystonic. – Noushin Chini Foroush, Subramanian Muthusamy, Udaya K. Seneviratne
P9.9-001 Peripheral Nervous System Complications of SARS-CoV-2 – Chelsea Schmoll, Stefanie Jordan Rodenbeck
P9.8-002 Incidence and Predictors of in-hospital mortality associated with Status Epilepticus using Nationwide inpatient population cohort database (2011-2014) – Tejinder Singh, Parisha Bhatia, Neena Viswanathan, Varun Kumar, Tanushri Bhushan, Ashmeet Kaur, Chirag Narshibhai Savani
P9.9-002 Case Series: Post-COVID Small Fiber Neuropathy – Lindsay Sarah McAlpine, Adeel Zubair, Serena Spudich
P9.8-003 Epileptic spasms and neurodevelopmental regression: a rare presentation of Anti-NMDAreceptor encephalitis – Valentina Stephen Joseph, Paul E. Youssef, Jan-Mendelt Tillema, Anthony L. Fine, Katherine C. Nickels, Lily Wong-Kisiel P9.8-004 National estimate of incidence and predictors of generalized convulsive status epilepticus following traumatic brain injury (TBI) using Nationwide inpatient sample database.(20112014) – Tejinder Singh, Neena Viswanathan, Parisha Bhatia, Varun Kumar, Tanushri Bhushan, Ashmeet Kaur, Chirag Narshibhai Savani P9.8-005 Continuous Renal Replacement Therapy versus Peritoneal Dialysis in reversing Cefepime-Induced Non-Convulsive Status Epilepticus: A Case Report – Noor Mahmoud, Veronica Astrid Moreno Gomez, Maria Shoaib, Sameera Siddiqui, Sarah R. Durica P9.8-006 Use of Ketogenic Diet in New-Onset SuperRefractory Status Epilepticus (NOSRSE): A Case Report with Literature Review – Daniel Li, Daniel Mandel, Jason B. Richards P9.8-007 Hashimoto Encephalopathy Presenting with Seizures and Uncommon EEG pattern - Case Report – Hasmik Amirjanyan, Shivanee Sodani, Musab Zorlu, Jose Antonio Montes-Rivera, Marie C. Eugene
P9.9-003 Vestibular Dysfunctions Related to COVID-19 Infection: A Clinical Case Report – Rebecca Potts, Hongyan Li P9.9-004 Dysautonomia in Long Haul Covid-19 Infection Impairs Activities of Daily Living and Mental Health: The Patient Perspective – Emma Reford, Nicki Mohammadi, Natalia Romano Spica, Jenna Tosto, Laura Rosenbaum Tabacof, David Putrino, Christopher Kellner P9.9-005 Sensory Neuronopathy Following COVID-19 Infection: a Case Series – Venkatraman Thulasi, Shaul Shaulov, Rijul Asri, Machteld E. Hillen P9.9-006 COVID-19?associated myositis with severe proximal and bulbar weakness – Hui Zhang, Zeinab Charmchi, Roberta J. Seidman, Yaacov Anziska, Vinodkumar Velayudhan, Jonathan Perk P9.9-007 Guillain-Barre and Miller Fisher Overlap Syndrome: A Masked Neurological Consequence of COVID-19 – Reha Rabbani, Stephen Vetter, Bradley Moore
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Science 4 P9.10-001 Increased Prevalence of Autoimmune Disease in Individuals with Down Syndrome and Moyamoya Disease – Jonathan Santoro, Sarah Lee, Anthony C. Wang, Eugenia Ho, Deepti Nagesh, Runi Tanna, Mellad Khoshnood, Ramon A Angel Durazo Arvizu, Melanie Manning, Brian Gary Skotko, Gary Steinberg, Michael S. Rafii P9.10-002 A Case of Atrioesophageal Fistula as a Rare Complication of Atrial Fibrillation Ablation Leading to Multifocal Embolic Ischemic Strokes – Merry Huang, Eric Dunn, Ghulam Abbas Kharal
60
2022 AAN Annual Meeting
P9.10-003 Early Onset Cerebral Amyloid Angiopathy in the Context of Perinatal Hydrocephalus and VP Shunt Instrumentation – Joshua Augustin Modeste, Isabelle Snider, Alexis N. Simpkins P9.10-004 Sex-specific lesion pattern of long-term functional outcome after stroke – Anna Katharina Bonkhoff, Martin Bretzner, Sungmin Hong, Markus D. Schirmer, Christina Jern, Arne Lindgren, Jane Maguire, Danilo Bzdok, Ona Wu, Natalia Sana Rost P9.10-005 P2RX7 stimulates Mac-1/ICAM-1-dependent leukocyte-endothelial Adhesion through promotion of Neurovascular Insult during Septic Encephalopathy – Muhammad Masood Ahmed, Huan Wang, Shumaila Andleeb, Rong-Rong Tao, Syed Nisar Hussain Shah P9.10-006 Thrombotic Thrombocytopenic Purpura Atypically Presenting as Acute Ischemic Stroke – Kelsey H. Carr, Ryan Pinosky, Sameer Sharma P9.10-007 Do Retinal Microvascular Changes Improve TIA Risk Stratification Scores? ABCD2 vs. ABCDEye in the FOTO-TIA Study – Beau Benjamin Bruce, Fadi B. Nahab, Jeffery Siegelman, Nicolas Antonio Bianchi, Mung Yan Lin, Benjamin Meyer, Michael Ross, David W. Wright, Nancy J. Newman, Valerie Biousse P9.10-008 “Early Mobilization Protocol” Can Be Initiated in the Intensive Care Unit in Acute Ischemic Stroke Patients After Receiving Intravenous Alteplase – Muhammad Fawad Ishfaq, Shruthi HR Pulimamidi, Megan Sweeney, Anudeep yelam, Eric T. Lybeck-Brown, Wei Huang, Attiya Jaura, Swathi Beladakere Ramaswamy, Nakul Katyal, Kunal Bhatia, Brandi R. French, Camilo Ramiro Gomez, Adnan I. Qureshi P9.10-009 Application of Machine Learning Model to Prognosticate Functional Outcome in Patients with Acute Ischemic Stroke Secondary to Proximal Large Vessel Occlusion – Sankar Prasad Gorthi, Srinivasa Rao Kundeti, Krithishree S. P9.10-010 Incidence of Access Site Complications in Patients Receiving Tenecteplase as Bridging Therapy to Endovascular Treatment – Brigitte Percival, Nasar Ali, Sindhu Sahito, Abdallah Omar Amireh, Laura Suhan, Spozhmy Panezai, Haralabos Zacharatos, Siddhart Kumar Mehta, Farah Yolanda Fourcand, Jawad F. Kirmani
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 9
11
Movement Disorders
Movement Disorders: Tardive Dyskinesia and PD Imaging 2 P9.11-001 Dose Patterns for Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia by Baseline Abnormal Involuntary Movement Scale Item 8 Score – Hadas Barkay, Stacy Finkbeiner, Amanda Wilhelm, Jessica K. Alexander, Nayla Chaijale, Mark Forrest Gordon P9.11-002 Effects of Long-Term Deutetrabenazine Treatment in Patients With Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders – Mark Forrest Gordon, Robert A. Hauser, Hadas Barkay, Hubert H. Fernandez, Stewart A. Factor, Joohi Jimenez Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Juha M. Savola, Karen E. Anderson P9.11-003 Evaluation of brain SPECT with 99mTc - TRODAT-1 in the differential diagnosis of Parkinsonism – Giorgio Fabiani, Carlos Henrique Ferreira Camargo, Rui Kleber Martins-Filho, Gabriel Sampaio Froehner, Helio Afonso Ghizoni Teive P9.11-004 Role of Nuclear Imaging (18-Fluro-FDG PET Brain and 99m-TC-TRODAT-1-SPECT Brain) in Supporting the Clinical Diagnosis in Patients with Idiopathic Parkinson’s Disease, Progressive Supranuclear Palsy and Vascular Parkinsonism , along with their Characteristic Imaging Findings – Shankar Balakrishnan, Amruthavarshini Srinivasan
Movement Disorders: Trials 1 P9.11-005 Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial – Camille Malatt, Tina Wu, Catherine Bresee, Elliot James Hogg, Jeffrey C. Wertheimer, Echo Tan, Hayley Pomeroy, Gloria Obialisi, Michele Tagliati P9.11-006 Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD) – Ethan G. Brown, Dave Alonso, Lana Chahine, Christopher Coffey, Roseanne D. Dobkin, Monica Korell, Ana Lorenzo, Connie C. Marras, Werner Poewe, Todd Sherer, Andrew D. Siderowf, Tanya Simuni, Eduardo S. Tolosa, Daniel Weintraub, Sohini Chowdhury, Kenneth L. Marek, Caroline M. Tanner
Monday, April 4 5:30 p.m.–6:30 p.m.
P9.11-007 Real-world Effect of Age on Long-term Effectiveness and Safety of Levodopa-Carbidopa Intestinal Gel: A Post Hoc Analysis From the Prospective, Multinational, Observational DUOGLOBE Study – Mihaela A. Simu, Ray Chaudhuri, Norbert Kovacs, Francesco Pontieri, Jason Lamar Aldred, Paul M. Bourgeois, Thomas L. Davis, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Lars Bergmann, Omar Ladhani, Tianming Gao, David G. Standaert, Esther Cubo Delgado
12
General Neurology
General Neurology: COVID-related Conditions and Outcomes 1 P9.12-001 A systemic review of neurological manifestations of COVID-19 infection – Sahil Naik, Nivedita Jha, Varsha Muddasani, Shivani Naik P9.12-002 Cerebral Venous Sinus Thrombosis (CSVT) and Bilateral Thalamic Infarcts Following PfizerBioNTech mRNA Vaccine in a Patient with Ulcerative Colitis – Akshaya Prabhakaran Sudha, Natalie Bartnik, Arpan Patel P9.12-003 Acute Inflammatory Demyelinating Polyneuropathy as the first presenting feature of COVID 19 infection – Praveen Ramani, Jose Ricardo Lopez-Castellanos, Joshua K. Walls, Lucas H. Nalley, Nidhi Kapoor General Neurology: Neuropathy and Myopathy 3 P9.12-004 69-Year-Old with Flaccid Paraplegia Immediately Post Epidural Steroid Injection – Hayden Wisely, Spencer Nam, Zoe Olga Marinides, Charles J. Kidd, Kenneth Riley Dalton P9.12-005 Single Neuron Recruitment during Direct Electrical Stimulation in the Human Cortex – Oludamilola Ademoyero, Angelique Christine Paulk, Sydney Cash
13
Neuromuscular and Clinical Neurophysiology (EMG)
P9.13-002 Chronic Inflammatory Demyelinating Polyneuropathy at a reference center in a low income country: Eleven year’s experience – Marco Antonio Alvarado, Mitzi Gabriela Marquez Vargas, Jesus Millan-Padilla, Anna Lisette Bazan P9.13-003 Idiopathic Brachial Plexopathy Presenting with Unilateral Vocal Cord Paresis – Marjorie Anne Dela Cruz Bagnas P9.13-004 Carpal and Cubital Tunnel Surgical Release in HNPP and CMT1A: Success Predictors and Outcomes – Pitcha Chompoopong, Zhiyv Niu, Kamal Shouman, Nicolas N. Madigan, Paola Sandroni, Sarah E. Berini, Alexander Y. Shin, Jeffrey Brault, Andrea Boon, Ruple S. Laughlin, Thorland Erik, Jayawant Narayan Mandrekar, Christopher J. Klein P9.13-005 Conus Medullaris Damage by West Nile Virus Infection – Ghadeer Fatani, Wan Yee Kong, James F. Selwa, Maher Fakhouri, Neha Venkatesh, Jun Li P9.13-006 Chronic Inflammatory Demyelinating Polyradiculoneuropathy associated with Enfortumab Vedotin – Ali Ebrahim, Kevin Elmore, Susan Shin P9.13-007 A Unique Presentation of Amyloid-like IgM Deposition Neuropathy with Microvasculitis. – Pannathat Soontrapa, Christopher J. Klein, P. James B. Dyck, Sarah E. Berini, Pitcha Chompoopong, JaNean Engelstad, Kamal Shouman P9.13-008 Acute and Chronic Demyelinating Neuropathies following COVID-19 Vaccination: A Report of Four Cases – Erin Dennis, Elizabeth A. Hartman, Nicolas W. Cortes-Penfield, Ezequiel A. Piccione, Pariwat Thaisetthawatkul P9.13-009 A rare case of bilateral Bell’s Palsy in the setting of SARS-CoV-2 – Ameen Fahad, Manali Desai, Yulia Salamatova, Shannon M. LaBoy P9.13-010 Association between Sarcopenia and Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis. – Thapat Wannarong, Persen Sukpornchairak, Christopher D. Geiger, Patompong Ungprasert
Neuromuscular Disease: Peripheral Neuropathy 2 P9.13-001 Amyloidosis Presenting as Mononeuropathy Multiplex – Michael D. Weiss, Priyank Patel, George Banks, P. James B. Dyck
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
61
Poster Session 10
1
Autoimmune Neurology
Autoimmune Neurology: Clinical Observations 1 P10.1-001 Adult-onset MELAS Syndrome Mimicking Autoimmune Encephalitis – Rumyar Vojdanian Ardakani, Lauren Tardo, Benjamin M. Greenberg, Jaya Raghav Trivedi, Paula Hardeman, Elisabeth Golden P10.1-002 DiGeorge Syndrome Associated with Longitudinally Extensive Transverse Myelitis – Jenelle Raynowska, Jennifer H. Yang, Anastasie M. Dunn-Pirio P10.1-003 Transverse Myelitis Secondary to Insect Bite: A Case Series and Proposed Pathophysiologic Mechanism – Evan Madill, Shawn J. Lee, Julia Sumera, Neda Sattarnezhad, May Han P10.1-004 Title: Faciobrachial Dystonic Seizures in a patient with NMDAR (N Methyl D aspartate receptor) Encephalitis – Naga Krishnakanth Madireddy, Shivani Naik, Zarmina Mufti, Vishwanath Sagi P10.1-005 Cerebral Calcifications in Systemic Lupus Erythematosus – Rishika Singh, Andrew N. Wilner, Jessica Lynn Bertram, Hunter Leigh Mitchell, Syed Raza P10.1-006 A Subacute Neurologic Presentation of Fibrosing Inflammatory Pseudotumor – Mattia Rosso, Cori Afton Cummings, Mini Singh
2
Headache
Headache: Migraine in the Real World 1 P10.2-001 Treatment Satisfaction and Optimization With Real-World Use of Ubrogepant for the Acute Treatment of Migraine in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study – Janette Contreras-De Lama, Aubrey Manack Adams, Daniel Serrano, Ella Engstrom, Weijie Poh, Francois Cadiou, Richard B. Lipton P10.2-002 A Real-World, Observational Study of Erenumab for Migraine Prevention in Canadian Patients With Prior Prophylactic Treatment Failure – Werner J. Becker, Sian D. Spacey, Elizabeth Leroux, Rose A. M. Giammarco, Christine L. Lay, Jonathan P. Gladstone, Suzanne N. Christie, Sarah Power, Jagdeep Kaur Minhas, Johanna Mancini, Driss Rochdi, Ayca Filiz, Natacha Bastien
62
2022 AAN Annual Meeting
Tuesday, April 5 8:00 a.m.–9:00 a.m.
P10.2-003 Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine When Used in Combination With an Anti-Calcitonin Gene– Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study – Aubrey Manack Adams, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Weijie Poh, Francois Cadiou, Richard B. Lipton P10.2-004 Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study – Todd J. Schwedt, Jae Hyun Lee, Kerry Louise Knievel, Jennifer McVige, Weiying Wang, Zheng Wu, Patrick J. Gillard, Darshini Shah, Andrew M. Blumenfeld
Secondary Headache 3 P10.2-005 Bridging the Gap With Gift Bags: A MulltiDepartmental, Multidisciplinary Approach to Headache in the EmergencyDepartment – Ellen Michelle Gibson, Courtney Sarah White, Brittany Lynn Heckel P10.2-006 Use of Anti-CGRP Monoclonal Antibodies to Treat Headache in Patients with Idiopathic Intracranial Hypertension: A Retrospective Study – Lindsay Frerichs, Karabi Nandy, Deborah I. Friedman
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Neuroimaging: Aging and Alzheimer’s Disease 2 P10.3-001 Cognitive Screening Subscores and Cortical Thickness in Amnestic and Non-Amnestic Mild Cognitive Impairment – Carolyn Parsey, Daniel Jon Peterson, Roy Seo, Annika Noreen, Thomas J. Grabowski P10.3-002 Disrupted white matter microstructural integrity and network connectivity are related to poor cognition functions: data from a large communitybased aging population – Zi-Yue Liu, Feifei Zhai, Fei Han, Ming-Li Li, Li-Xin Zhou, Jun Ni, Ming Yao, Shu-Yang Zhang, Li-Ying Cui, Zheng-Yu Jin, Yi-Cheng Zhu P10.3-003 MRI Investigation of Caudate Networks in the Normal Aging – Federica Agosta, Silvia Basaia, Giacomo Sferruzza, Matteo Zavarella, Camilla Cividini, Maria Antonietta Magno, Laura Cacciaguerra, Marco Bacigaluppi, Gianvito Martino, Massimo Filippi
P10.3-004 Greater Functional Connectivity in Right Temporal Cortex was Associated with SuperAging – SooHyun Kim, Hyung Ho Kim, Bori R. Kim, Geon Ha Kim P10.3-005 Longitudinal changes of subcortical volumes in SuperAgers – Hyung Ho Kim, Soo-Hyun Kim, Bori R. Kim, Geon Ha Kim
4
MS and CNS Inflammatory Disease
MS Symptom Assessment & Management 1 P10.4-001 Impact of Vaginal estriol on urogenital symptoms in Relapsing Remitting Multiple Sclerosis – Mirla L. Avila, Roberto Hernandez Quintana, Jie Pan, Smathorn Thakolwiboon, Dargelis Chi, Alan Peiris, Charles D. Thompson, John Matthew Garza P10.4-002 Reduced Reward Responsiveness: A Unique Phenotypic Presentation of Depressive Symptoms in Multiple Sclerosis – Tali R. Sorets, Jordyn Anderson, James F. Sumowski P10.4-003 Sources of Cannabis Information and Medical Guidance Among People With Multiple Sclerosis: NARCOMS Survey Results – Robert J. Fox, Amber Salter, Gary Raymond Cutter, Joshua R. Steinerman, Kathryn Nichol, Karry Smith P10.4-004 Discordance between Neurologists and People With Multiple Sclerosis on the Perception of the Presence and Burden of Cognitive Impairment – Iris Katharina Penner, Virginia De Las Heras Revilla, Eddie Jones, Suzannah Ryan, Patricia Dominguez Castro, Emma Houchen, Shruti Narasimham, Himanshu Karu, Rahul Chetlangia, Sourav Debsarma Biswas, Vladimir Bezlyak, Daniela Piani Meier, Carol Lines P10.4-005 Validation of Novel Semantic Word-Retrieval Tasks as Sensitive to Word-Finding Difficulty in Multiple Sclerosis – Emily Dvorak, James F. Sumowski P10.4-006 Treating Mild, Moderate, or Severe Spasticity Matters to People with Multiple Sclerosis - SEENMSS Survey – Ben W. Thrower, Scott Douglas Newsome, Barry A. Hendin, Robert Chinnapongse, Sherry R. Danese, Jenifer Patterson P10.4-007 Heart Rate Variability (HRV) Corresponds to Multiple Sclerosis Symptom Burden – Giuseppina Pilloni, Pamela Best, Lauren B. Krupp, Ilya Kister, Leigh Elkins Charvet
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 10
P10.4-008 Sexual dysfunction in multiple sclerosis as a function of concomitant risk factors: an intersectional approach – Maria Petracca, Antonio Carotenuto, Cristiano Scandurra, Marcello Moccia, Laura Rosa, Sebastiano Arena, Antonio Ianniello, Agostino Nozzolillo, Mariavittoria Turrini, Lidia Mislin Streito, Gianmarco Abbadessa, Maria Cellerino, Sebastiano Bucello, Elisabetta Ferraro, Manuela Mattioli, Alessandro Chiodi, Matilde Inglese, Simona Bonavita, Marinella Clerico, Cinzia Cordioli, Lucia Moiola, Francesco Patti, Luigi Lavorgna, Giovanna Borriello, Emanuele D’Amico, Vincenzo Brescia Morra, Roberta Lanzillo P10.4-009 Subcortical brain volumes are sexually dimorphic and related to neurofunctional outcomes in MS – Victoria Leavitt, Claire Riley, James F. Sumowski, Korhan Buyukturkoglu P10.4-010 Impact of Social Distancing during the COVID-19 Pandemic on Longitudinal Severity of Depression in Patients with Multiple Sclerosis – A Single Site Analysis – Magdalena Lana, Alexis Ahmad, Myra Lewontin, Carlo S. Tornatore P10.4-011 Beyond the Physical Symptoms of Spasticity for People With MS Spasticity: Results From SEEN-MSS, a Large-scale, Self-reported Survey – Scott Douglas Newsome, Ben W. Thrower, Barry A. Hendin, Joanne M. Wagner, Sherry Danese, Jenifer Patterson
5
Child Neurology and Developmental Neurology
Child Neurology: Seizures/Genetic Syndromes 2 P10.5-001 Eladocagene Exuparvovec Improves Body Weight and Reduces Respiratory Infections in Patients With Aromatic L-Amino Acid Decarboxylase Deficiency – Paul Wuh-Liang Hwu, Yin-Hsiu Chien, Sheng-Hong Tseng, Antonia Wang, Traci B. Schilling, Chun-Hwei Tai P10.5-002 Early Psychotherapy in Post-Concussion Syndrome. A Study in the Pediatric Population and Young Adults. – Alcy Torres, Relfa Proano, Joyce Antonella Jimenez-Zambrano, Jose F. OrtegaTola P10.5-003 Design and Rationale of SMART, a Phase IIIb Study Evaluating Intravenous Onasemnogene Abeparvovec in Spinal Muscular Atrophy – Arseniy Lavrov, Richelle Randazzo, Florencia Segal
Tuesday, April 5 8:00 a.m.–9:00 a.m.
P10.5-005 Decision Support for AAN Quality Measures – Stephen Downs, Katie Hentges, Nicky Young, Ann Clark, Anup D. Patel
6
Research Methodology and Education
Curriculum Development in Neurology Medical Education 2 P10.6-001 Standardized Site Description Template Meeting LCME Elements – Celia Linton Walker, Stephen A. Berman P10.6-002 Leadership and Professional Development Innovation in a Military Adult Neurology Residency Program to Enhance Medical Readiness – Zahari Tchopev, Alexis E. Nelson P10.6-003 Implementing Collaborative, Innovative TraineeCentered Strategies to Enhance the Mayo Clinic Arizona Neurology Residency Educational Experience – Sara Dawit, Benzion Blech, Marlene Girardo, Erika Driver-Dunckley P10.6-004 A Single-Center Study Surveying Neurology Trainees and Faculty’s Perceptions of the Impact of the COVID-19 Pandemic on Residents’ Medical Education – Hisham Alhajala, Ahmad Riad Ramadan, Aarushi Suneja, Lonni Schultz, Iram Zaman
7
History of Neurology
History of Neurology 1 P10.7-001 Were the Incas Skilled Surgeons? A Comparison of Survival Rates Between Incan and Contemporary Cranial Procedures – Jorge Arturo Cespedes, John Vargas, Matthew Grady, David Fonseca P10.7-002 The Neurology in Shakespeare – Lance Fogan P10.7-003 “Stranger than fiction”: the nineteenth-century media coverage of the case of Phineas Gage – Manon Auffret
8
Neuro Trauma and Critical Care
Neuro Trauma 1 P10.8-001 Does Tranexamic Acid (TXA) post Traumatic Brain Injury (TBI) return Service Members to the Battlefield? – Matthew Donald Holtkamp P10.8-002 Influence of Ethnoracial and Sociodemographic Variables on Incidence and Management of Traumatic Brain Injury Patients in Hawaii – Kayti Luu, Michelle Pang, Rachel Gorenflo, Frances Tiffany Morden, Ariel Ma, Nicholas Lee Sims, Lauren Keiko Fujii, Kent Yamamoto, Enrique Carrazana, Jason Viereck, Kore K. Liow P10.8-003 Clinical Profiles of Concussed U.S. Soldiers Injured During the January 8th, 2020 Iranian Theatre Ballistic Missile Attack on Al Asad Air Base, Iraq: A Real World, Chaotic, Blast-related TBI Mass Causality Event – Jeffrey Brian Hainsworth, Alan Paul Johnson, Shana Godfred-Cato, George Smolinski, Kendra Wagers
8
Sports Neurology
Sports Neurology 1 P10.8-004 Standardized Neurologic Exam Findings Following Sports Related Concussion – Nicholas Samuel Streicher, Andrea Almeida, Bara Alsalaheen, Michael Popovich, James T. Eckner, Matthew T. Lorincz P10.8-005 Traumatic Encephalopathy Syndrome in a cohort of Professional Fighters – Charles Bernick, Guogen Shan, Aaron Ritter P10.8-006 Menstrual Cycle Function Following Concussion in Adolescent Patients. – Patricia Rhys Roby, Adda Grimberg, Christina Master, Kristy Arbogast P10.8-007 Stratifying Risk for Failure to Receive Concussion Care – Jonathan Davidow, Andrew John Carlson, Paige Buddenhagen, Kate M. Essad
P10.7-004 Babinski and His Sign – Sanem Pinar Uysal
P10.5-004 Therapeutic Hypothermia in Neonatal Encephalopathy: Creating a Post-Pandemic Playbook – Justin Rosati, Jennifer ToTran Nguyen
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
63
Poster Session 10
9
Infectious Disease
Infectious Disease: Tricky Viruses 2 P10.9-001 New Onset Refractory Status Epilepticus secondary to HIV CNS Syndrome – Mustafa Al-Chalabi, Jennifer Amsdell, Mehmood Rashid, Ajaz Sheikh P10.9-002 WITHDRAWN P10.9-003 A Rare Case of Postherpetic Wallerian Degeneration of the Trigeminal nerve – Ademilola Tejuoso, Erik Seroogy, Mehyar Mehrizi, Ranjit Bagga P10.9-004 West Nile Virus Encephalitis with Flaccid Myelitis and Atypical T1 Hyperintensities on Brain Magnetic Resonance Images after Transplant – Ada Breitenbucher, Rebecca Anne Silverstein, Meredith Wicklund, Ruchira M. Jha P10.9-005 Progressive Multifocal Leukoencephalopathy as the Initial Presenting Sign of Underlying Immune Abnormalities: A Series of 3 Cases. – Busranur Agac, Mouaz Alsawas, Kyle Conway, Marco Hefti, Tracey Cho
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Science 5 P10.10-001 The Bulbar Imposter: A Case Presentation of Foix-Chavany-Marie Syndrome – Christina Xia, Raja Rama Godasi, Ahmed Ibrahim, Navreet Kaur, Rashid Ali Ahmed, Neil Suryadevara, Cornelia Mihai P10.10-002 Association of Cerebral Microbleeds in ARDS and Acute Vascular Pathology on MRI – Aron Gedansky, Merry Huang, Catherine Hassett, Aaron Shoskes, Abhijit Duggal, Pravin George, Andrew Blake Buletko, Sung Min Cho, Ken Uchino P10.10-003 When to suspect depression among patients who suffered from stroke – Mays Khweileh, Majdi Al Qawasmeh, Belal Adel Aldabbour, Khalid I. ElSalem, Haneen Faisal Al Refa’i, Raid M. Kofahi P10.10-004 Consider Holding DAPT Acutely for Patients with Large Strokes Who May Need Procedures – Elisabeth B. Marsh, Elma Chowdhury
64
2022 AAN Annual Meeting
Tuesday, April 5 8:00 a.m.–9:00 a.m.
P10.10-005 Effect of non-invasive vagus nerve stimulation in hemorrhagic brain injury and permanent ischemic stroke in rats – Ilknur Ay, Eric J. Liebler, Hakan Ay P10.10-006 Postpartum Risk of Cerebral Venous Thrombosis – Tehniyat Baig, Hamza Chaudhry, Santosh Bhaskar Murthy, Neal S. Parikh, Ava L. Liberman, Hooman Kamel, Cenai Zhang, Alexander Merkler P10.10-007 Venous Thromboembolism Development in Stroke Patients: A Retrospective Analysis of Predictors – Youssra Hany Saqr, Hera Ashraf Kamdar, Juan Peng, Archana Hinduja P10.10-008 Management and Outcomes of Stroke in Patients with Parkinson’s Disease – Lynda Nwabuobi, Chenel Morrison, Aryeh Zolin, Cenai Zhang, Babak Navi, Hooman Kamel P10.10-009 Clinical and Demographic Characteristics Associated With Poor Posterior Circulation Stroke Outcomes: Greater Cincinnati/Northern Kentucky Stroke Study – Lina Chervak, Stacie Leigh Demel, Heidi Sucharew, Adam S. Jasne, Daniel Woo, Sharyl R. Martini, Tracy E Madsen, Eva Akshitkumar Mistry, Dawn O. Kleindorfer, Brett M. Kissela P10.10-010 Reversible Ischaemia Without Infarction Presenting as Progressive Hemichorea – Sarah Wrigley, Ronan Killeen, Sean O’Riordan P10.10-011 Early-onset delirium after spontaneous intracerebral hemorrhage – Federico Marrama, Maéva Kyheng, Marco Pasi, Mathieu Rutgers, Solene Moulin, Didier Leys, Charlotte Cordonnier, Hilde Henon, Barbara Casolla
11
Movement Disorders
Movement Disorders: Trials 2 P10.11-001 Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Phase 1 Clinical Studies – Gina Pastino, Josh Yuan, Sridhar Duvvuri, Matthew Leoni, Kimberly Largay, Ih Chang, Amy Giugliano, Stacey Versavel, David Gray, Raymond Sanchez, John Renger P10.11-002 Duration of Benefit Per Dose: Post Hoc Analysis of ”Good On” Time Per Dose for IPX203 vs CD-LD IR in the RISE-PD Phase 3 Trial – Robert A. Hauser, Hubert H. Fernandez, Kevin J. Klos, Susan Criswell, Neepa J. Patel, Ghazal Banisadr, Stanley Fisher
P10.11-003 Long-Term Motor Function and Quality of Life Outcomes from a Prospective, International DBS Registry – Guenther Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Steffen Paschen, Chong S. Lee, Andrea Kuehn, Jan Vesper P10.11-004 SAGE-718 in Parkinson’s Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) – Aaron Koenig, Jason K. Johannesen, Emily Freitag, Sigui Li, Jennifer Billet, Jeffrey Wald, Steve Kanes, Michael Quirk, James Doherty P10.11-005 SPAN-PD: Subgroup Analyses by Baseline Characteristics of Patients Treated With Levodopa Inhalation Powder 84mg or Placebo to Treat OFF Symptoms in Patients With Parkinson’s Disease (PD) as Measured by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) Score and Patient Global Impression of Change (PGIC) – Stuart H. Isaacson, Ping Zhao, Burkhard Blank P10.11-006 Long-term safety of continuous levodopa/ carbidopa infusion with ND0612: Results from the ongoing BeyoND study – Stuart H. Isaacson, Tanya Simuni, Laurence Salin, Ryan J. Case, Liat Adar, Nissim Sasson, Tamar Yardeni, Werner Poewe P10.11-007 Monoclonal Antibodies Targeting Alpha Synuclein- a revolutionary treatment for Parkinson’s Disease – Harshadayani Jagadish Kumar, Bina Patel, Ivonne De la Hoz, Lordstrong Akano
12
General Neurology
General Neurology: COVID-related Conditions and Outcomes 2 P10.12-001 Hospital-based Observational Study of Neurological Disorders in Patients Recently Vaccinated with COVID-19 mRNA Vaccines – Jasmine Koh, Rebecca Hui Min Hoe, Ming Hui Yong, Hui Jin Chiew, Yihui Goh, Kok Pin Yong, Tian Ming Tu, Derrick WS Chan, Benjamin Yong Qiang Tan, Leonard Leonard Yeo, Amy May Lin Quek, Isabel Siow, Monica Saini, Jasmyn De Leon, Sharmini Rathakrishnan, Geraldine Chen, Andrew C-F Hui, Aftab Ahmad, Moe Pearl Shwe, Kevin Tan, Chee Seong Seet, Mingshi Cai, Simin Kuo, Ling Li Foo, Umapathi Thirunagnam P10.12-002 Machine Learning Analysis of Anosmia and Ageusia after COVID-19 Vaccination: A Vaccine Adverse Event Reporting System (VAERS) Study – Kranthi Kiran Mandava, Mustafa Jaffry, GM Fahad Bin Mostafa, Kazim Jaffry, Hafiz Khan, Nizar Souayah
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 10
P10.12-003 Dizziness After COVID-19 Infections or Vaccinations – Maxwell Graham Kahn, Karen Stephenson, Jennifer L. Cox, Lixin Zhang P10.12-004 Assessing the Impact of COVID-19 on Clinical Trials within Neurology – Annabella R. Strathman, Julie Cannon, Joy Lin, Veronica E. Santini P10.12-005 A Case of Chronic Inflammatory Demyelinating Polyneuropathy after Pfizer COVID-19 Vaccination. – Irma Nora Duncan, Alexander Steve Renpenning, Roberto Alejandro Cruz
13
Neuromuscular and Clinical Neurophysiology (EMG)
COVID-19 Related Neuromuscular Complications and Care 1 P10.13-001 No Significant Increase of Guillain-Barré Syndrome after COVID-19 Vaccination in Adults: A Vaccine Adverse Event Reporting System (VAERS) Study – Mustafa Jaffry, Tarek Elshourbagy, Kranthi Kiran Mandava, Samar Eldahtoury, Mawj Al-Ani, Ayatalla Ahmed, Jeffrey M. Kornitzer, Nizar Souayah P10.13-002 Retrospective Cohort Study Evaluating Outcomes in Myasthenia Gravis Patients with COVID-19 – Minseon Kim, Youngran Kim, Xiaojin Li, Guo-Qiang Zhang, Aziz I. Shaibani, Thy Nguyen
Tuesday, April 5 8:00 a.m.–9:00 a.m.
Neuromuscular Disease: Peripheral Neuropathy 3 P10.13-003 Herpes Zoster may be a trigger for Lumbosacral Radiculoplexus Neuropathy – Catarina Aragon Pinto, Marcus Vinicius Rocha Pinto, P. James B. Dyck P10.13-004 Electrodiagnostic characteristics of hereditary (hATTR) and wild-type amyloid (wt-TTR) neuropathy – Akhil Shivaprasad, Melody Badii, Sheetal Shroff P10.13-005 Small Fiber Neuropathy Incidence, Prevalence, Longitudinal Impairments, and Disability – Stephen A. Johnson, Kamal Shouman, Shahar Shelly, Paola Sandroni, Sarah E. Berini, P. James B. Dyck, E. Matthew Hoffman, Jayawant Narayan Mandrekar, Zhiyv Niu, Christopher Lamb, Phillip A. Low, Wolfgang Singer, Michelle L. Mauermann, John R. Mills, Divyanshu Dubey, Nathan P. Staff, Christopher J. Klein
P10.13-007 Compound Mutations in IGHMBP2 are Associated with a Demyelinating Polyneuropathy – Xue Yang, Sadaf Saba, Karen Krajewski, Ryan Castoro, Yongsheng Chen, Bo Hu, Jun Li P10.13-008 Hereditary TTR amyloid neuropathy unmasked by bortezomib chemotherapy for multiple myeloma – Xiaoyang Li, Rebecca Traub P10.13-009 Use of Botulinum Toxin in the Treatment of Neuropathic Pain: A Case Series – XinLi Du, Deep Patel P10.13-010 Adult-Onset Krabbe Disease Presenting as Demyelinating Neuropathy in a Much Older Adult: A Case Report – Aparna Nutakki, Ryan David Jacobson
P10.13-006 Demyelinating Features More Common in Recurrent Guillain-Barré Syndrome: is Monophasic GBS a Different Disease? – Adib Jorge De Sarachaga, Juan Carlos Lopez, Eunice Martínez Jiménez, Anna Lisette Bazan, Elizabeth Leon, Edwin S. Vargas
Experience the Takeda Neuroscience Medical Affairs Booth in Augmented Reality! Visit the Takeda Neuroscience Medical Affairs booth #234
Copyright © 2022 Takeda Pharmaceutical Company Limited. All Rights Reserved. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. VV-MEDMAT-60076 . 02/2022.
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
65
Tuesday, April 5 11:45 a.m.–12:45 p.m.
Poster Session 11
1
Autoimmune Neurology
Autoimmune Neurology: Clinical Observations 2 P11.1-001 A Case of Paraneoplastic Cerebellar Degeneration and Autonomic Neuropathy in a Patient with P/Q Type Calcium Channel and CRMP-5 Antibodies and Prostate Adenocarcinoma – Jennifer Amsdell, Mehmood Rashid P11.1-002 A Devastating Neurologic Disorder: AntiDipeptidyl Peptidase like Protein-6 Encephalitis Mimicking Creutzfeldt-Jakob Disease – Neeharika Thottempudi, Aimalohi Esechie, Chilvana V. Patel, Elena Shanina, Xiangping Li P11.1-003 Unusual Presentation of Paraneoplastic LimbicEncephalitis (PLE) with Acute Retrograde-Amnesia as Presenting Symptom. – Madiha Tariq, Barbara O’Brien P11.1-004 New-onset Headache in Neurosarcoidosis: An Early Sign of Leptomeningeal Involvement. – Danwei Wu, Anna Tomczak, Neda Sattarnezhad, Jamie C. McDonald, Julia Sumera, Lucas Kipp, Christopher Lock, Jeffrey E. Dunn, May Han P11.1-005 The First Ever Report of Morvan’s Syndrome associated with a Pseudopapillary Pancreatic Tumor. – Rajinder Kumar Dhamija, Alvee Saluja
2
Headache
Headache: Innovation and Technology 2 P11.2-001 Direct-To-Consumer Asynchronous Telemedicine as a Solution to Improve Health Access for Underrepresented Minorities in Migraine Care – Sara C. Crystal, Alexander Mauskop, Alan M. Rapoport, Robert Cowan, Philip Arthur Bain, Elizabeth Faust Murdoch, Alexander Grigorenko, Kristen Miranda, Adam B. Cohen, Neil Parikh P11.2-002 A Cognitive Behavioral Therapy Pilot Program Delivered via Telemedicine Is Associated with Reduced Headache Disability in Patients with Migraine – Sara C. Crystal, Alexander Mauskop, Alan M. Rapoport, Robert Cowan, Philip Arthur Bain, Kristen Miranda, Adam B. Cohen, Neil Parikh, Chelsea Orcutt, Laura Berk, Jeffrey Janata
66
2022 AAN Annual Meeting
Headache: Migraine Therapeutics 1 P11.2-003 Long-Term Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the MOVEMENT Phase 3 Trial – Amanda Jones, Herriot Tabuteau P11.2-004 The Effect of Pharmacogenomic Data on Adequate Dosages of Verapamil for The Prevention of Primary Headache Disorders- a pilot exploratory study – Yi-Chieh Chen, Han Wang, Jayawant Narayan Mandrekar, Carrie E. Robertson, Amaal J. Starling, F. Michael Cutrer, Chia-Chun Chiang P11.2-005 A Phase 3 randomized, double-blind, shamcontrolled Trial of e-TNS for the Acute treatment of Migraine (TEAM) – Deena Kuruvilla, Amaal J. Starling, Stewart J. Tepper, Joseph I. Mann, Gregory Panza, Michael Johnson
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Non-Alzheimer’s Dementia: Genetics and Neuroimaging 1 P11.3-001 Prevalence and Phenotype of TBK1 Mutations: an In-Depth Description – Helena Gossye, Sara Van Mossevelde, Jan L. De Bleecker, Patrick Cras, Sebastiaan Engelborghs, Peter P. De Deyn, Tim Van Langenhove, Christine Van Broeckhoven P11.3-002 Genotype–phenotype correlations in adultonset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) – Spyridon Papapetropoulos, Angela Pontius, Matthew Brennan, Ryan O’Mara P11.3-003 Diagnostic whole-exome sequencing and C9orf72 repeat expansion testing in an Austrian cohort with early onset dementia – Sara Silvaieh, Theresa Koenig, Tandis Parvizi, Raphael Wurm, Evelyn Berger-Sieczkowski, Alexander Zimprich, Elisabeth Stogmann P11.3-004 CAG repeats within the non-pathological range in the HTT gene influence personality traits in patients with Subjective Cognitive Decline – Valentina Moschini, Filippo Emiliani, Assunta Ingannato, Camilla Ferrari, Valentina Bessi, Sandro Sorbi, Benedetta Nacmias, Silvia Bagnoli, Salvatore Mazzeo, Sonia Padiglioni P11.3-005 Multimodal Imaging and Perceptual Features in Two Patient with Anterior Versus Posterior Primary Progressive Prosopagnosia – Kathleen Bradbury, Madison N. Shyer, Johanna Evans Appleton, Quentin Funk, Victoria Arbones, Joseph C. Masdeu, Belen Pascual
4
MS and CNS Inflammatory Disease
MS COVID 2 P11.4-001 Post-vaccination Central Nervous System Inflammation at a Tertiary Neuroimmunology Clinic: Impact of Influenza, SARS-CoV-2, and Other Vaccines – Hannah Marie Kelly, Collin Jakubecz, Alessandro Serra, Hesham Ahmed Abboud P11.4-002 Survey of Immune Response to SARS-CoV-2 mRNA Vaccines in Patients on anti-CD20 Therapy for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. – Toluwalase Oluwakemi Tofade, Pratibha Surathi, Jorge Luis Rodriguez Lee, Machteld E. Hillen P11.4-003 Neutralizing Antibody Response to SARS-CoV-2 Vaccination in Multiple Sclerosis – Tirisham Gyang, John Evans, Joseph Scott Miller, Kariss Michelle Alcorn, Juan Peng, Erica Bell, Cong Zeng, Richard Gumina, Shan-Lu Liu, Benjamin M. Segal P11.4-004 Longitudinal Myelitis as a COVID-19 Neurological Manifestation – Lindsay Celentano, Alexander Besser, Amaris Alayon, Adnan Subei P11.4-005 Clinical Outcomes in Patients With COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update – Victoria Yavorskaya, Radmila Karan, Laszlo Borsi, Nektaria Alexandri P11.4-006 Case Series of New-Onset CNS Immunological Disorders Temporally Associated with mRNAbased COVID-19 Vaccines – Ahmad A. Ballout, Anna Babaie, Michael Dmitriy Kolesnik, Natasha Hameed, Glenn E. Waldman, Frasat Chaudhry, Sami Saba, Asaff Harel, Souhel Najjar P11.4-007 SARS-CoV-2 specific T cell immunity in Spike Protein Antibody negative MS patients after vaccination – Clemens Goedel, Anna Bartalis, Andreas Boldt, Ulrich Sack, Florian Then Bergh P11.4-008 Corpus Callosum in COVID-19 Cytokinopathy. – Vilakshan Alambyan, Yan Zhang, Brooke Devenney, Aparna M. Prabhu, George C. Newman P11.4-009 COVID-19 mRNA vaccines associated with MOGAb disease and transverse myelitis: Two case reports – Jonathan Morena, Tirisham Gyang
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 11
P11.4-010 Anti-SARS-Cov-2 neutralizing antibodies in subjects with multiple sclerosis: an Italian monocentric study – Marinella Clerico, Alessandro Maglione, Marta Morra, Rachele Francese, Andrea Civra, David Lembo, Simona Rolla P11.4-011 Covid19 in Multiple Sclerosis Patients in Dubai : Observational Study – Mona Chetan Thakre, Jihad Said Inshasi
5
Child Neurology and Developmental Neurology
Child Neurology: Neurodevelopmental Disorders/CP/ASD 4 P11.5-001 Patient Journey and Clinical Burden of Rett Syndrome in the United States – Damian Michael May, Kalé Kponee-Shovein, Malena Mahendran, Nathaniel Downes, Kristy Sheng, Patrick Lefebvre, Wendy Cheng P11.5-002 Longitudinal Case Series of Development and Behavior among Children with Dup15q Syndrome – Maya Christina Ayoub, Carly Hyde, Shafali Jeste, Charlotte Distefano P11.5-003 Impact of Insurance Status, Hospital Ownership Type, and Children’s Hospital Designation on Outcomes for Pediatric Neurosurgery Patients Following Spasticity Procedures in the United States – Amaris Alayon, Vivian Hagerty, James Botros, Tamar Leah Levene, Shenae Samuels, Heather S. Spader Child Neurology: Seizures/Genetic Syndromes 3 P11.5-004 Safety & Feasibility of Responsive Neurostimulation in Children with Refractory Epilepsy – Maria El-Hallal, Shefali Karkare, Shaun Rodgers, Sanjeev V. Kothare P11.5-005 Patient-focused Remote Study Design in a Natural History Study for KCNT1-related Epilepsy – Viet Nguyen, Sarah Hubbard, Marco A. Rizzo, Heather Adams, Laurie Eileen Seltzer, Carolyn Dickinson, Courtney Aponte, Jonathan J. Cherry, David Bearden
6
Tuesday, April 5 11:45 a.m.–12:45 p.m.
Research Methodology and Education
Social Media and Technology in Medical Education 1 P11.6-001 Neurology Virtual Morning Report: An online Campaign to #EndNeurophobia – Maria Jimena Aleman, Gabriela Figueiredo Pucci, Valeria Roldan, Aaron L. Berkowitz P11.6-002 Podcasting for Exam Preparation: Tuning into Alternative Study Strategies for Residents – Safa Abdelhakim, Aaron Stephen Bower, Jeremy Moeller P11.6-003 Piloting Teleneurology Simulations for Adult Neurology Residents – Alicia Zha, Rohini D. Samudralwar, Shivika Chandra, Amanda L. Jagolino-Cole P11.6-004 Online Modules Support a Neurology Resident Teleneurology Curriculum - Pilot Data – Shivika Chandra, Alicia Zha, Rohini D. Samudralwar, Amanda L. Jagolino-Cole P11.6-005 Reported levels of comfort and experience with interprofessional and telehealth skills in a cohort of neurology faculty – Cen Zhang, Arielle Marisa Kurzweil, Perrin A. Pleninger, Aaron Lane Nelson, Lindsey Gurin, Sondra Zabar, Steven Galetta, Laura J. Balcer, Ariane Lewis P11.6-006 Group Text Messaging as a Residency Teaching Tool in Outpatient Neurology – Anjeli Song, Joseph E. Safdieh, Matthew S. Robbins
7
7
Sleep
Sleep: Focus on Insomnia and TBI 2 P11.7-003 PTSD Effects on Sleep in Active Duty Service Members – Brent Jacobus P11.7-004 REM-Sleep: Remote Monitoring for Sleep Promotion – Hannah Beaman, Vanja C. Douglas, Sara LaHue
8
Neuro Trauma and Critical Care
Neuro Trauma 2 P11.8-001 Associations Between Inpatient mTBI Patient Cognitive Profile and Outpatient Functional Status at 6 Months Post-Injury, a University of California Davis Cognitive Screener (UCD-Cog) Study. – Wentao Li, Matthew Nedjat-Haiem, Erin D. Bigler, Dana Farias, Rejane A. Wittmann, Ryan M. Martin P11.8-002 Determining the molecular drivers of neurodegeneration using a novel in vitro model of secondary brain injury – Gabriel Reynaldo Arismendi, Josh Karp, Julian Klein, Bruce A. Citron, Vedad Delic P11.8-003 Systematic Comparison of Diffusion MRI-Derived Conventional Single-Tensor and Advanced VoxelWise Metrics Towards Understanding White Matter Tract Disorganization Due to Repeated Head Impacts – Virendra R. Mishra, Aaron Ritter, Charles Bernick
History of Neurology
History of Neurology 2 P11.7-001 Ketogenic Diet and Pediatric Epilepsy – A Historical Review (1920 – 1964) – Joseph Mark Maes, Ram Mohan R. Sankaraneni, Sanjay P. Singh P11.7-002 Contemporary Representation of African American Female Physicians in Vascular Neurology Clinical Leadership Positions – Melanie Marcille, Tiyannah Everett, Devin Pranay Patel, Rishubh Hitesh Shah, Sherita Chapman, Alison L. Christy, Richard T. Benson, Alexis N. Simpkins
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
67
Poster Session 11
8
Sports Neurology
Sports Neurology 2 P11.8-004 Tolerance of Supervised Exercise Among Concussed Adolescents with Potential Risk Factors for Prolonged Recovery – Cory Kathleen Dodson, Jennifer Andrea Fokas, Matthew T. Lorincz, Andrea Almeida, James T. Eckner, Jeremiah Freeman, Brooke Ernst, Michael Popovich P11.8-005 Resting-State Connectivity Between the Insula and Prefrontal Cortex Is Sensitive to Acute Injury and Symptom Persistence After Sport-Related Concussion – Christopher Andrew Sheridan, Kevin Bickart, Corey M. Thibeault, Christopher Giza, Christopher Thomas Whitlow, Robert Hamilton, Meeryo Choe P11.8-006 Pediatric Femoral Nerve Palsy Due to Traumatic Iliacus Muscle Hematoma – Robert Samuel Sacks, Sabrina Bulancea, Kathryn Zapata, Simona Treidler, Jason Wong P11.8-007 Second Impact Syndrome in Adults: a case report and review of the literature – Bryce Sarcar, Jiping Zhou, Philip Mark Ross, Murali Guthikonda, Wazim Mohamed
9
Infectious Disease
Infectious Disease: Tricky Viruses 3 P11.9-001 Neuroinvasive West Nile Virus Presenting with Anton Syndrome – Bahadar Singh Srichawla, Jonathan Min P11.9-002 Adult-onset Neurodegeneration in XMEN – Anusha Ebrahim, Daniel Benavides, Michael Leonardo, William Gahl, Lynne Wolfe, Juan Carlos Ravell Aumaitre, Camilo Toro P11.9-003 Mycophenolate Mofetil for the Treatment of HTLV-1 Associated Myelopathy: A Case Report – Alexandra Aria Mandel, Sofia Chernet, Pritha Ghosh, Henry J. Kaminski
Tuesday, April 5 11:45 a.m.–12:45 p.m.
P11.9-004 Clinical Characteristics and Outcomes of Neuroinvasive West Nile virus infection in Immunosuppressed and Immunocompetent individuals treated at the Mayo Clinic Hospitals – David Gritsch, Ehab Yaser Khaled Harahsheh, Sabirah Kasule, Shemonti Hasan, Angela Parsons, Cynthia M. Stonnington, Richard Butterfield, Harn Shiue, Kathryn Norville, Jenna Reynolds, Brian Chong, Marie Francisca Grill P11.9-005 A Wolf in Sheep’s Clothing: West Nile Virus presenting as Guillain Barre Variant – Subhan Tabba, Asif Amin Kabani
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: COVID-19 1 P11.10-001 Delays in thrombolysis during COVID-19 are associated with worse neurological outcomes: the Society of Vascular and Interventional Neurology Multicenter Collaboration – Sitara Koneru, Dinesh V. Jillella, Fadi B. Nahab, Thanh Ngoc Nguyen, Mohamad Abdalkader, David S. Liebeskind, Nirav Vora, Vivek Rai, Diogo Casarin Haussen, Raul G. Nogueira, Shashvat Desai, Ashutosh P. Jadhav, Alexandra L. Czap, Alicia Zha, Italo Linfante, Ameer Hassan, Darko Ernesto Quispe Orozco, Santiago Ortega Gutierrez, Priyank Khandelwal, Pratit Dhirajlal Patel, Osama O. Zaidat, Tudor G. Jovin, Scott Kamen, James E. Siegler
P11.10-007 Characteristics and Outcomes of Stroke Patients with Concurrent SARS-CoV-2 Infection from March 1, 2020 to February 28, 2021: An Analysis from the N3C Database – Jackson Narrett, Ethan D. Assefa, Arti Patel, Indika Mallawaarachchi, Johanna Loomba, Sarah Ratcliffe, Ofer Sadan, Teshamae Monteith, Bradford B. Worrall, Donald Brown, Karen C. Johnston, Andrew Mebane Southerland Interventional Neurology and Thrombolytic Therapy 3 P11.10-008 Differences in Time to Presentation, Initial Imaging and Revascularization Between Right and Left Hemisphere Acute Ischemic Stroke – John Henry Erdman, Parul Agarwal, Naomi Mayman, Danielle Wheelwright, Connor Mensching, Nathalie Jette, Mandip Singh Dhamoon, Laura Stein P11.10-009 OR-Converted Angiography Suite in Mechanical Thrombectomy Case with Difficult Access – Adam T. Mierzwa, Sumayya Naz, Mustafa Al-Chalabi, Mouhammad A. Jumaa P11.10-010 Is Neutrophilia a Risk Factor for Fast Stroke Progression in Large Vessel Occlusion? – Jawad F. Kirmani, Farah Yolanda Fourcand, Nancy Gadallah, Arifa Ghori, Danisette Torres, Abdallah Omar Amireh, Haralabos Zacharatos, Siddhart Kumar Mehta
P11.10-002 Predicting Risk of Stroke in Hospitalized Patients with COVID-19: A Machine Learning Approach – Vikraant Kohli, Danny Truong, Ethan Isaac Meltzer P11.10-003 Telestroke Care for Acute Ischemic Stroke Patients Admitted to a Comprehensive Stroke Center During the COVID-19 Pandemic: TELECASTCSC – Solmaz Ramezani Hashtjin, Adam R. Lipschultz, Monica Ngo, Jodi Mueller-Hussein, Apameh Salari, Collin Daniel Gradin, Kathryn Bard, Amelia Solei, Nasima Omar, Sarah A. Engkjer, Oladi Sedjio Bentho, Christine Elizabeth Yeager, Benjamin Robert Miller, Christopher Streib P11.10-004 COVID-19 and Seasonal Temperature’s Influence on Cerebral Venous Thrombosis – Natalie ANN Ivey, Lauren A. Fowler, Joseph P. Hanna P11.10-005 Evidence of Ischemic Stroke in Pediatric Patient with Post-COVID-19 Syndrome – Chandler Harrison Lichtefeld, Michael K. Sowell P11.10-006 Investigating Cerebral Sinus Venous Thrombosis after COVID-19 Vaccination in Adults – Kazim Jaffry, Kranthi Kiran Mandava, Mustafa Jaffry, Sanjana Rosario, Kamel Jedidi, Nizar Souayah
68
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 11
11
Movement Disorders
Movement Disorders: Outcomes in DBS and PD 2 P11.11-001 Dry Cleaning & Parkinson’s Disease: Evaluation of a Potential Cluster – Meghan Elizabeth Pawlik, Maryam Zafar, Samantha Lettenberger, Madeleine Coffey, Aayush Sarkar, Caroline M. Tanner, Samuel Goldman, Briana De Miranda, Karl D. Kieburtz, Daniel R. Kinel, E. Ray Dorsey P11.11-002 Prescribing Patterns for Patients With Parkinson’s Disease in Long-Term Care Facilities – Andrew Thach, Andrew J. Epstein, Dom Nunag, Jennifer Wilbanks, Darshan Mehta
Movement Disorders: PD Therapeutics 2 P11.11-003 Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease – Caroline M. Tanner, Judy Lytle, Andrea Formella P11.11-004 Amantadine DR/ER Improved OFF-State Dystonia Motor Complications in PD – Caroline M. Tanner, Jill L. Ostrem, Judy Lytle, Andrea Formella, Alberto J. Espay P11.11-005 Potential Utility of Amantadine DR/ER for Persons with Parkinson’s Disease Under Consideration for Device-Aided Therapy – Andrea Formella, Santosh Mahadevana Goud, Robert A. Hauser
12
Tuesday, April 5 11:45 a.m.–12:45 p.m.
General Neurology
General Neurology: Neurogenetics P11.12-001 Impact of neurofibromatosis type 1 in an adult community population – Timothy Gregory, Gregory Douglas Phillips, John W. Henson P11.12-002 Vitamin D defiency as Neurological manifestation of Neurofibromatosis Type1 – Hans H. Shuhaiber P11.12-003 Management and Progression of Arginase 1 Deficiency Over 2 Decades of Follow-up – Deborah Marsden, Alexandra Eaton P11.12-004 Arginine: The Key Driver of Pathophysiology and Progression in Arginase 1 Deficiency – George A. Diaz, Mark Bechter, Stephen David Cederbaum
General Neurology: Neurodegeneration P11.12-005 Two Probable Creutzfeldt-Jakob Disease Cases Within One Month in a Single Hospital in Grand Rapids, Michigan – Lingling Rong, Philip Michael McCarthy, Jessica Feistel, Dania Mallick
13
Neuromuscular and Clinical Neurophysiology (EMG)
COVID-19 Related Neuromuscular Complications and Care 2
P11.11-006 Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612 – Tal Birnberg, Ryan J. Case, Liat Adar, Werner Poewe, Marcus Björnsson, Mats Karlsson
P11.13-001 Guillain-Barré Syndrome During the COVID-19 Pandemic – Yigit Karasozen, Andrew A. Collins, Xiaojin Li, Youngran Kim, Guo-Qiang Zhang, Kazim Ali Sheikh, Thy Nguyen
P11.11-007 Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment – Michael Serbin, Carol Mansfield, Colton Leach, Chuck Yonan, Olga Klepitskaya, Margaret Sheehan, Anne Donnelly
P11.13-002 Is COVID-19 Vaccination Associated with an Increased Reporting Rate of Myasthenia Gravis? A Vaccine Adverse Event Reporting System (VAERS) Study – Jorge Luis Rodriguez Lee, Mustafa Jaffry, Kranthi Kiran Mandava, Sanjana Rosario, Kazim Jaffry, Kamel Jedidi, Nizar Souayah
P11.11-008 Adverse drug reactions to apomorphine: a worldwide pharmacovigilance database analysis – Manon Auffret, Claire Le Corre, Marc Verin, Elisabeth Polard
P11.13-004 Understanding the Resiliency of the Muscular Dystrophy Community One-Year into the COVID-19 Pandemic – Leann Lewis, Katy Eichinger, Nuran Dilek, Kiley Higgs, Michaela Walker, David Palmer, John Cooley, Nicholas Elwood Johnson, Alrabi Tawil, Jeffrey Statland P11.13-005 COVID Spike antibodies in neuromuscular condition: KU experience – Ameen Khalid Tajuddin, Mazen M. Dimachkie, Omar Jawdat, Duaa Jabari, Erik R. Ensrud, Swathy Chandrashekhar, Constantine Farmakidis, Mamatha Pasnoor P11.13-006 Is Rhabdomyolysis after SARS-CoV-2 infection a Factor of Poor Prognosis? – Steve N. Gad, Mohsen Ahmed, Mustafa Jaffry, Kranthi Kiran Mandava, Kazim Jaffry, Nizar Souayah P11.13-007 Small Fiber Neuropathy Associated with SAR-CoV-2 Infection – Rory Abrams, Saritha Kosarussavadi, David M. Simpson, Allison P. Navis, Nathalie Jette, Lan Zhou, Susan Shin P11.13-008 COVID-19 Associated Guillain-Barre Syndrome: Comparing Six Cases of This Rare Presentation – Shaily Patel, Rachana Gandhi P11.13-009 Factors associated with utilization of telemedicine during the COVID-19 pandemic among patients with myasthenia gravis: A retrospective regional cohort study – Amanda C. Guidon, Jeff Guptill, Michael K. Hehir, David Bates, Julie Fiskio, Ximin Jessica Sun, Mahsa Eskian, William S. David, James F. Howard P11.13-010 Immune Mediated Bulbar Myasthenia Gravis Incited by SARS-CoV2 mRNA Vaccination. – Jarrett Leech, Monica Petluru, Thomas E. Ragole, Brian M. Sauer
P11.13-003 Safety and Tolerability of SARS-Cov-2 Vaccination in Patients with Neuromuscular Disorders: A Single Center Experience – David Stevens, Melanie Meton, Jeffrey Mullen, Shadi Milani, Manisha Kak Korb, Namita Goyal, Tahseen Mozaffar, Ali A. Habib
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
69
Tuesday, April 5 5:30 p.m.–6:30 p.m.
Poster Session 12
1
Autoimmune Neurology
Autoimmune Neurology: Clinical Observations 3 P12.1-001 Acute Hemorrhagic Leukoencephalitis as a Primary Presentation in an Immunocompromised Patient With Cerebral Toxoplasmosis – Lindsey Ladd, Max Keeling, Maryam Zulfiqar, Anand Mamdani P12.1-002 A case report of Granulomatous angiitis associated with Cogan syndrome. – Praveen Ramani, Hira Zafar, Nayana Prabhu, Salman Zahoor, Sisira Yadala P12.1-003 HSV-2 Encephalitis Presenting with ImmuneResponsive Chorea – Michael Dmitriy Kolesnik, Ahmad A. Ballout, Natasha Hameed, Souhel Najjar P12.1-004 NMDAR-Antibody Encephalitis Presenting with Faciobrachial Dystonic Seizues in a Gravid Nigerian Woman – Fatima Ilemona Abdulai, Gerald Awele Onwuegbuzie, Peter Alabi, Nkechi Obianozie P12.1-005 Primary Brain Tumours Masquerading as Autoimmune Neurological Disorders- A Possible Paraneoplastic Association? A Retrospective Case Series – Harini Pavuluri, KP Divya, Bejoy Thomas, George C. Vilanilam, Rajalakshmi Poyuran, Ajith Cherian P12.1-006 Spectrum of Combined Central and Peripheral Demyelination: A Case Report – Reya Marie Hayek, Maryam Zulfiqar, Clara Adele Thiel P12.1-007 Pediatric AMPA Receptor Encephalitis (AMPARE): A Case Report and Literature Review – Ezgi Saylam, Alexandra Estelle Sankovic, Brenda Shen, Lauren Hurst, Setty Magana
2
Headache
Headache: Migraine in the Real World 2 P12.2-001 Real-World Effectiveness of Ubrogepant Among Participants With Prior Treatment Failure: Subgroup Analysis From the UNIVERSE Study – Anand R. Shewale, Weijie Poh, Michael L. Reed, Jinjie Liu, Francois Cadiou, Kate Burslem, Richard B. Lipton
70
2022 AAN Annual Meeting
P12.2-002 Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis – Maurice Driessen, Lynda Krasenbaum, Verena Ramirez Campos, Robert DiEgidio, Marc Tian, Michael Seminerio
P12.3-003 Active elite rugby participation predicts alterations in right precentral cortical thickness – Thomas David Parker, Karl Zimmerman, Niall Bourke, Etienne Laverse, Neil Samuel Nyholm Graham, Amanda Heslegrave, Henrik Zetterberg, Simon Kemp, Huw R. Morris, Sharp James David
P12.2-003 Reduction in Period Prevalence of Medication Overuse Headache Following Initiation of Nurtec ODT Treatment – A Real World Administrative Claims Study – Gilbert J. L’Italien, Linda Harris, Ali Mohajer, Jared Scripture, Vladimir Coric, Noah Rosen
P12.3-004 White Matter Hyperintensity on Cholinergic Pathways is Associated with Dementia Severity in e4 Carriers, not in Non-carriers – Tracy Ming-Chun Yu, Shu Ching Wu, Chia-Ju Chou, Yi-Chien Liu
Headache: Migraine Therapeutics 2 P12.2-004 Early Prediction of Response to INP104 for the Acute Treatment of Migraine – Sara E. Sacco, Robert Vann, Sutapa Ray, Stephen Bevan Shrewsbury, Sheena K. Aurora P12.2-005 Efficacy and Safety of Subcutaneous Sumatriptan for Acute Migraine Attacks Compared with other treatments: A Systematic Review and Network Meta-analysis. – Mohamed Sayed Zaazouee, Walid Abdel-Aziz, Gena M. ELassall, Yasmine Adel Mohammed, Mohamed Ibrahim Gbreel, Abdelrahman M. Attia, Alaa Elshanbary, Hagar Rohim, Mariam Alsayd Alsayd, Asmaa Khaled Alsiouty, Anas Zakarya Nourelden, Khaled Mohamed Ragab, Ahmed Sayed, Mohamed Fahmy Doheim
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Non-Alzheimer’s Dementia: Genetics and Neuroimaging 2 P12.3-001 Functional Connectivity Rearrangements Propagating from Disease Epicenters in Frontotemporal Lobar Degeneration Variants – Edoardo G. Spinelli, Francesco Falbo, Silvia Basaia, Camilla Cividini, Nilo Riva, Elisa Canu, Veronica Castelnovo, Giuseppe Magnani, Francesca Caso, Paola Caroppo, Sara Prioni, Giacomina Rossi, Lucio Tremolizzo, Ildebrando H. Appollonio, Vincenzo Silani, Massimo Filippi, Federica Agosta P12.3-002 Neuroinflammation biomarker in non-fluent/ agrammatic variant of primary progressive aphasia and/or apraxia of speech – Belen Pascual, Quentin Funk, Kathleen Bradbury, Johanna Evans Appleton, Paolo Zanotti Fregonara, Mohammad Obadah Nakawah, David Robert Beers, Alirexa Faridar, Stanley H. Appel, Masahiro Fujita, Joseph C. Masdeu
P12.3-005 Neuronal intranuclear inclusion disease (NIID) showing positive results on Pittsburgh Compound-B PET imaging – Pu-Tien Chiang, HsinHsi Tsai
4
MS and CNS Inflammatory Disease
MS Clinical Practice & Decision Making 4 P12.4-001 Neurological Disease Burden in Females with X-linked Adrenoleukodystrophy – Natalie Grant, Yedda Li, Claudia Maria Brito Pires, Reza Sadjadi, Florian Eichler P12.4-002 Imaging Features of Adult-Onset Genetic Leukodystrophies Misdiagnosed as Multiple Sclerosis in Clinical Practice – Alise Carlson, Emmanuel Obusez, Natalia Shor, Yann Nadjar, Jeffrey Alan Cohen, Gabrielle Macaron P12.4-003 Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry – Helmut Butzkueven, Timothy Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne J. Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem I. Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez Menoyo, Yolanda Blanco Morgado, Daniele Litterio A. Spitaleri, Vincent Van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard A L Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon Wong, MSBase Study Group P12.4-004 A retrospective evaluation of people with Multiple Sclerosis, to determine factors predicting who declines Disease Modifying Therapies – Thomas Jackson, Gagana Mallawaarachchi, Jack Grimshaw, Joyutpal Das, David Rog P12.4-005 Outcomes and prognostic factors in myelopathies – Maria Alejandra Garcia-Dominguez, Paula Barreras, Carlos A. Pardo-Villamizar
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 12
P12.4-006 Knowledge, skills, and confidence of healthcare professionals participating in the ECHO MS program – Kevin Alschuler, Darren Ball, Annette Wundes, Salim Chahin, Mark B. Skeen, Gloria Von Geldern
MS Neuroimaging 1 P12.4-007 Regional Atrophy of the Thalamus as a Biomarker for Progressive Multiple Sclerosis – Showly Nicholson, Andrew Russo, Kristina Brewer, Heidi Bien, Ani Eloyan, Eric Klawiter, Sean Tobyne P12.4-008 Choroid plexus enlargement in multiple sclerosis is associated with decreased brain volume – Niels Bergsland, Michael G. Dwyer, Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov P12.4-009 DeepGRAI (Deep Gray Rating via Artificial Intelligence) Provides Feasible and Clinically Meaningful Thalamic Volume Measurement on Multi-Center Clinical-Quality T2-FLAIR Images – Robert Zivadinov, Niels Bergsland, Dejan Jakimovski, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Jon V. Riolo, Diego Silva, Michael G. Dwyer P12.4-010 White Matter Binding in PET: Pittsburgh Compound-B and Flutemetamol – Burcu Zeydan, Christopher Schwarz, Scott Przybelski, Timothy Lesnick, Walter Kremers, Matthew Senjem, HoonKi Min, Brad Kemp, Clifford R. Jack, Orhun H. Kantarci, Kejal Kantarci, Val John Lowe P12.4-011 Brain Network Centrality Abnormalities Underpin Multiple Sclerosis Disease Course – Antonio Carotenuto, Paola Valsasina, Menno M Schoonheim, Jeroen JG Geurts, Frederik Barkhof, Antonio Gallo, Gioacchino Tedeschi, Nikolaos Petsas, Patrizia Pantano, Massimo Filippi, Maria Assunta Rocca
5
Child Neurology and Developmental Neurology
Child Neurology: Seizures/Genetic Syndromes 4
Tuesday, April 5 5:30 p.m.–6:30 p.m.
P12.5-003 Successful remission with ACTH after early therapeutic pyridoxine fails to prevent the development of infantile spasms in ALDH7A1-related epilepsy – Darrah Haffner, Jorge A. Vidaurre, John R. Mytinger P12.5-004 Diurnal Periodicity in Spontaneously Occurring High-Frequency Oscillations in Intracranial EEG – Gabrielle Taylor Petito, Jeremy Housekeeper, Jason Buroker, Craig William Scholle, Brian Ervin, Ravindra Arya P12.5-005 Epilepsy Characteristics in Children With Neurofibromatosis type 1, What We Have Learnt From a Tertiary Center Five Years’ Experience – Abdulhafeez Khair, Gurcharanjeet Kaur, Stephen Falchek
6
Research Methodology and Education
Social Media and Technology in Medical Education 2 P12.6-001 Online CME-Certified Expert Panel Discussion Improved Knowledge of Clinically-Relevant Information Regarding Cannabinoids Among Neurologists – Thomas Finnegan, Kathy Merlo, Michael Targowski, Barry E. Gidal P12.6-002 A SIGN Group’s Diverse Virtual Neurology Education Programs: Successes, Barriers, and Future Directions – Sophia Gillian Musacchio, Ahmed Z. Obeidat P12.6-003 A Simulated Hospital in a COVID-19 Pandemic Environment for Undergraduate Neurology Students. – Jaime Toro, Juan Sebastian Rivera Perez, Daniela Sofia Rodriguez, Laura Andrea Serna, Jairo Alejandro Gaitan Alfonso, Thomas Felipe Medina Ramirez, Fabián Cortés, Manuel S. Yepes P12.6-004 Online CME-certified Case Challenges in Migraine Increase Knowledge and Competence Among Neurologists and PCPs – John Maeglin, Thomas Finnegan, Kathy Merlo, Deborah I. Friedman
7
Neuro Trauma and Critical Care
Neurocritical Care: COVID-19, TBI and Other Topics 2 P12.7-001 Advanced Practice Providers in Neurocritical Care: Model for Orientation and Onboarding to Ensure Quality of Patient Care, APP Autonomy, Retention and Job Satisfaction – Tyler John Schaefer, Blair Cotton, Benjamin Carroll Grant, Danielle Diekevers, Elizabeth Michel, Kyla Beckman, Chelsea Borta, Bridget Russell, Sarah Nava, Kaitlin Schoder, Trisha Raelynn Dickey, Hildalicia Guerra, Tia Chakraborty, Joseph Zachariah, Muhib Khan P12.7-002 RLS-0071-101 a study in healthy human volunteers demonstrates safety, complement and inflammatory effector target engagement activity of this novel peptide – Kenji Mason Cunnion, Parvathi Kumar, Neel Krishna, Ulrich Thienel, L Matthew Frank P12.7-003 Diabetic Striatopathy, a rare complication of uncontrolled diabetes: A review of distinct clinical presentations of three different cases – Navreet Kaur, Kehan Zhao, Rashid Ali Ahmed, Julius Latorre, Elena Schmidt P12.7-004 Feasibility and safety of the Metaneb® System in neurocritical care patients – Evien Albazi, Azam Tolla, Aaron Abramovitz, Tracy J. Koehler, Meredith A. Kriger, Rajit Pahwa, Brandon Francis P12.7-005 A Rare Case of Acute Toxic Leukoencephalopathy: Is Sevoflurane the Culprit? – Saleem Mohamad Al Mawed, Samir Sadik Al-Ghazawi, Niral K. Patel P12.7-006 Guillain-Barre Syndrome after Influenza Vaccination in Adults – Tarek Elshourbagy, Mustafa Jaffry, Kranthi Kiran Mandava, Kazim Jaffry, Jorge Luis Rodriguez Lee, Mawj Al-Ani, Mustafa Turkmani, Samar Eldahtoury, Ayatalla Ahmed, Ahmed Ezzeldein Omran, Youssef Ahmed Ragab Ali, Hagar Adel Abuelazm, Nizar Souayah
P12.5-001 Intractable Epilepsy and Ischemic Strokes in Two Children, both with CACNA1A Gene Mutations – Kristen Bolte, Melissa Assaf, Tamara Zach, Shubhangi Shahaji Peche P12.5-002 Hemiconvulsion-Hemiplegia-Epilepsy Syndrome in the Setting of COVID-19 Infection and Multisystem Inflammatory Syndrome in Children – Paul Gong, Bethanie N. Morgan, Cemal Karakas
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
71
Tuesday, April 5 5:30 p.m.–6:30 p.m.
Poster Session 12
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 1 P12.8-001 Sustainability of Seizure Control With Adjunctive Cenobamate in the Phase 3 C021 Study – David G. Vossler, William E. Rosenfeld, Sean Stern, Robert T. Wechsler P12.8-002 Phase 2 Open-label Clinical Study Evaluating Oral Ganaxolone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex – Mary Kay Koenig, Rajeshwari Mahalingam, Jurriaan Peters, Brenda E. Porter, Rajsekar R. Rajaraman, Muhammad Shahzad Zafar, Alex Aimetti, Ian Miller, Joseph Hulihan, Darcy Krueger P12.8-003 An Open-Label Pilot Trial Assessing the Safety and Efficacy of SPN-817 (Huperzine A ExtendedRelease) in Adults with Treatment-Resistant Focal Impaired Awareness Seizures – Jeanelle Portelli, Lovingly Q. Park, Brendan Lujan, Gregory Busse, Jonathan Rubin, Azmi Nasser P12.8-004 Fenfluramine Improves Everyday Executive Functioning in Patients With Lennox-Gastaut Syndrome: Analysis of Phase 3 Data – Kim I. Bishop, Peter Isquith, Gerard A. Gioia, Kelly G. Knupp, Joseph Sullivan, Rima Nabbout, Gail M Farfel, Bradley Galer, Arnold Gammaitoni P12.8-005 Effect of Add-on Cannabidiol (CBD) on Seizure Frequency and Seizure-Free Intervals in Patients With Seizures Associated With Tuberous Sclerosis Complex (TSC): Phase 3 Trial GWPCARE6 Post Hoc Analysis – Elizabeth Thiele, E Martina Bebin, Finbar O’Callaghan, Steven Paul Sparagana, Floor Jansen, Ashley Schreiber, Farhad Sahebkar-Moghaddam P12.8-006 Phase 2b Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults with Focal Epilepsy (X-TOLE) – Jacqueline French, Roger J. Porter, Emilio Perucca, Martin Brodie, Michael A. Rogawski, Simon Pimstone, Ernesto Aycardi, Cynthia L. Harden, Yi Xu, Constanza Luzon, Christopher J. Kenney, Gregory N. Beatch P12.8-007 Efficacy and Safety of Cannabidiol (CBD) Dose Adjustment in Patients With Lennox-Gastaut Syndrome (LGS): Post Hoc Analysis of Phase 3 Randomized Controlled Trial (RCT) GWPCARE3 and Open-Label Extension (OLE) Trial GWPCARE5 – Elaine C. Wirrell, Ashley Schreiber, Timothy B. Saurer, Robert T. Wechsler
72
2022 AAN Annual Meeting
9
Neuro-oncology
Advancing Care in Neuro-oncology 2 P12.9-001 Modified Frailty Index (mFI) in Elderly Patients with Glioblastoma Correlates with Survival – Amy Khine Chang, Alissa Ashley Thomas P12.9-002 Feasibility of an Electronic Patient Reported Steroid Toxicity Monitoring Program in Patients with Malignant Gliomas – Jared Macher, Andrea C. Wasilewski P12.9-003 Disparities in Pediatric Medulloblastoma: A Large Center’s Outcomes and Review of the Literature – Karthik Jagannath P12.9-004 Summary of virtual tumor board platforms and implementation in Neuro-Oncology – Chukwuyem Ekhator, Santosh Kesari, Jai Grewal P12.9-005 Disparities in Enrollment of Primary CNS Lymphoma Trials in the US – Camille Stevenson, Nimish A. Mohile P12.9-006 Validation of the Chimeric Antigen Receptor (CAR) T-cell Therapy Neurotoxicity: A Single Center Study – Carlen Amy Yuen, Kourosh Rezania, Thomas J. Kelly, Michael Bishop P12.9-007 The Impact of COVID-19 on Neuro-Oncology Clinical Trials During Wave 1 and Wave 2 at a Frontline Detroit Healthcare System – Carmen Griffin, Joshua Alton, James Snyder, James Snyder, Tobias Walbert
10
Cerebrovascular Disease and Interventional Neurology
Interventional Neurology 1 P12.10-001 Acute Ischemic Stroke Patients Receiving Reperfusion Therapy Do Not Have Worse 90-day Outcomes After Delirium – Mohammad Jamil Ahmad, Sahar Anjum, Aditya Kumar, Jacob Sebaugh, Michele Joseph, Bethany Williams, Alicia Zha P12.10-002 Predicting Aneurysmal Etiology Using Admission Head CT in Patients with Aneurysmal Pattern Subarachnoid Hemorrhage – Karl Viktor Baumgartner, Aiden Meyer, Daniel Mandel, Scott Moody, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Karen L. Furie, Ali Mahta
P12.10-003 Association of External Ventricular Drain Duration and Outcomes in Aneurysmal Subarachnoid Hemorrhage: a Single Center Study – Wendy Elizabeth Gonzalez, Elyse Forman, Nicholas S. Potter, Christoph Stretz, Linda C. Wendell, Jesse Menville, Karen L. Furie, Bradford B. Thompson, Ali Mahta P12.10-004 Association Between Asymptomatic Cerebral Vasospasm and Outcomes in Aneurysmal Subarachnoid Hemorrhage – Alizeh Shamshad, Ali Mahta, Elijah Malik Persad-Paisley, Christoph Stretz, Linda C. Wendell, Nicholas S. Potter P12.10-005 Assessing Thrombectomy Capacity and Characteristics of Thrombectomy Capable Centers World-wide Using the MT2020+ Global Thrombectomy Tracking Smartphone App ? – Syed F. Zaidi, Alicia Castonguay, Kaiz Shabbar Asif, Santiago Ortega Gutierrez, Violiza A. Inoa, Nabeel Herial, Fawaz Al-Mufti, Viktor Szeder, Dileep R. Yavagal P12.10-006 Induction of Vasodilation to Prevent Ophthalmic Complications Before Middle Meningeal Artery Embolization – Kiana Moussavi, Mohammad Moussavi P12.10-007 Identification of large vessel occlusion on CTA head using artificial intelligence – James Michael Hillis, Bernardo Canedo Bizzo, Charles J. Lu, Christopher Philip Bridge, John Kent Chin, Stuart Robert Pomerantz, Keith Dreyer, Katherine Patricia Andriole, Michael H. Lev, Ramon Gilberto Gonzalez P12.10-008 Early Neurological Improvement Can Reduce Intensive Care Unit Length of Stay in Aneurysmal Subarachnoid Hemorrhage – Ryan Snow, Alizeh Shamshad, Alexandra Helliwell, Nicholas S. Potter, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Christoph Stretz, Karen L. Furie, Ali Mahta P12.10-009 Post-Thrombectomy Outcome is Not Associated with Administration of Intravenous Thrombolysis – Amanda Jin Zhao, Penina Krieger, Leah Croll, Hannah Irvine, Jose L. Torres, Kara R. Melmed, Aaron S. Lord, Koto Ishida, Jennifer A. Frontera, Ariane Lewis
Cerebrovascular Disease: Neuroimaging 1 P12.10-010 Blood Pressure Changes Impact Corticospinal Connectivity and Downstream Gait and Balance Control – Elizabeth A. Coon, Anna Castillo, Timothy Lesnick, Michelle M. Mielke, Robert I. Reid, B. Gwen Windham, Ronald C. Petersen, Jonathan Graff-Radford, Prashanthi Vemuri
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 12
11
Movement Disorders
Movement Disorders: Dystonia and Botulinum Toxin 1
12
Tuesday, April 5 5:30 p.m.–6:30 p.m.
General Neurology
General Neurology: Neuro-Immunology and Neuro-Infectious diseases
P12.11-001 Treatment of Camptocormia in Parkinsonism: A Comparison of Different Interventions in a Single Center – Carly Jo Olszewski, Jessica Tate, Mark A. Hirsch, Erwin Van Wegen, Mustafa S. Siddiqui
P12.12-001 Neurological Outcomes of Organ Transplantation: A Systematic Review – Jenny Paola Garzon, Ana Garcia, Maria Paula Silva Sanchez, Lizeth Rodriguez, Marcela Cardona, Federico Silva
P12.11-002 A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia – Jaroslaw Slawek, Peter J. McAllister, Sebastian Paus, Daniel D. Truong, Todd Gross, Roman Rubio, James P. Kesslak, Domenico Vitarella
P12.12-002 Progressive Multifocal Leukoencephalopathy in immunocompetent a case report and review of literature – Syed Hassan Khalid, Erum Khan, Durgesh Chaudhary, Shitiz K. Sriwastava
Movement Disorders: Genetics 2 P12.11-003 Rare Variants In ARSA Are Associated With Parkinson’s Disease – Konstantin Senkevich, Aliza Dworkind, Eric Yu, Jamil Ahmad, Jennifer Ruskey, Farnaz Asayesh, Dan Spiegelman, Stanley Fahn, Cheryl H. Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupre, Lior Greenbaum, Sharon Hassin, Roy Alcalay, Ziv Gan-Or P12.11-004 VCP Mutations and Parkinsonism: An Emerging Link – Ashley Mary Paul, Jumana Tariq A Alshaikh, Emile Sami Moukheiber, Sonja Waltraud Scholz, Alexander Pantelyat P12.11-005 DNA Methylation-based Surrogates of Plasma Proteins are associated with Parkinson’s Disease Risk – Katherine Fu, Kimberly C. Paul, Ake TzuHui Lu, Steve Horvath, Adrienne M. Keener, Yvette Bordelon, Jeff M. Bronstein, Beate Ritz P12.11-006 Transcriptome patterns and their regulation by alternative splicing in Parkinson’s disease. – Krithi Irmady, Caryn R. Hale, Rizwana Qadri, John Fak, Serge Przedborski, Thomas Samuel Carroll, Robert B. Darnell P12.11-007 Remote follow up of prodromal Parkinson’s disease in a LRRK2 G2019S cohort – Ruth Schneider, Taylor Myers, Stella Jensen-Roberts, Meghan Elizabeth Pawlik, Emily Hartman, Samantha Lettenberger, Alexandra N. Kaplan, Renee Wilson, Peggy Auinger, E. Ray Dorsey, Blanca Yvette Valdovinos, Katherine D. Amodeo, Saloni Sharma, Robert G. Holloway, Caroline M. Tanner, Roy Alcalay, Julia Marie Soto
P12.12-003 Treatment Challenges of Active Multiple Sclerosis in the Setting of Cryptococcal Meningitis: A Case Report and Review of the Literature – Crystal A. Honold, Brandi Anderson, Andrea Loggini, Jonatan Hornik, Alejandro Hornik, Hope Merkley, Tiffany Ward, Abdelhameed Nawwar P12.12-004 Bannwarth Syndrome Mimicking Neurolymphomatosis – Sanem Pinar Uysal, John A. Morren
General Neurology: Neuro-oncology P12.12-005 Brainstem Gliomatosis Cerebri Presenting as a Cerebellopontine Angle Tumor – Anthony Thompson, Kayla Schusterman, Julianne Lee, Charles Maitland, Isabella Canut
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Inherited Muscle Disorders 1 P12.13-001 Quantitative muscle analysis in FSHD using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis – Per Wildholm, Markus Karlsson, Olof Dahlqvist Leinhard, Alrabi Tawil, Katy Eichinger, Leo Hong-Li Wang, Perry Shieh, Baziel G M van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion
P12.13-004 Pharmacokinetics, Biodistribution, and Exploration of the Mechanism of Central Nervous System Penetration of a PATrOL™-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1 after a Single Subcutaneous or Intravenous Administration in the BALB/c Murine Model – Renta Hutabarat, Barry A. Badeau, Dani Stoltzfus, William Mann, Dietrich A. Stephan, Sandra Rojas-Caro Neuromuscular Disease: Peripheral Neuropathy 4 P12.13-005 Creatine kinase A Novel Prognostic Marker in GBS – Kaushik S, Lakshmi N. Ranganathan, Balasubramanian Samivel, Uma Maheswari E P12.13-006 Sciatic Nerve Mononeuropathy After An Uncomplicated Vaginal Delivery – Nader Gamil Boutros, Milad Sabouri, Mark Girgis, Bhavesh Trikamji P12.13-007 Super Slow Conduction Velocities in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Jeremy Zung, Kunal V. Desai P12.13-008 Optimization of intrathecal delivery of an infused AAV9 vector for delivery of a gene therapy candidate for Adrenomyeloneuropathy (AMN) in Non-Human Primates (NHP) – Vidyullatha Vasireddy, Sean W. Clark, Karen Kozarsky, David William Anderson P12.13-009 Understanding the Adrenomyeloneuropathy (AMN) Patient Journey – Rohan Gandhi, Emma Drysdale, Gregory Brooks, Jessica Lee, Chan Beals, Florian Eichler P12.13-010 Gender Differences in the Development of Cardiomyopathy in Friedreich’s Ataxia Patients: A Retrospective Study. – Yoona Lee, Jaya Raghav Trivedi, Pradeep Mammen
P12.13-002 Regional Body Composition in Myotonic Dystrophy Type 2: Associations of Lower Extremity Lean Mass Index and Clinical Endpoints – Carolyn Foster Aldendail, Diana Alejandra Madrid, Rebecca Knapp, Delanie Lynch, Ashley A. Weaver, Paula R. Clemens, Araya Puwanant P12.13-003 ADSSL1 Myopathy: A Case Report – David Atherton, Megan Leitch
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
73
Poster Session 13
1
Autoimmune Neurology
Autoimmune Neurology: COVID-19 and Autoimmune Neurologic Disorders 1 P13.1-001 Immunosuppression in Chronic Autoimmune Neurological Disorders during the COVID-19 Pandemic – Shubham Biyani, Abhilash Thatikala, Rohan Sharma, Sukanthi Kovvuru, Krishna Nalleballe, Sanjeeva Reddy Onteddu, Nidhi Kapoor, Karthika Durga Veerapaneni, Sisira Yadala, Robert L. Archer P13.1-002 The Impact of COVID-19 in Patients With Stiff Person Syndrome – Alexandra Christina Simpson, Sarah Snoops, Scott Douglas Newsome P13.1-003 A case of Optic neuropathy post COVID-19 vaccination – Badria Munir, Shitiz K. Sriwastava P13.1-004 Acute disseminated encephalomyelitis after COVID-19 vaccination: A case report – Monica He, Christopher Joseph Bondoc, Robert Fekete P13.1-005 Neurologic Sequela of COVID-19. Guillain Barré Syndrome Following Johnson and Johnson COVID-19 Vaccination; A Case report – Octavio Carranza-Renteria, Sadia Waheed, Denis Babici, Fawad Yousuf Autoimmune Neurology: Clinical Observations 4 P13.1-006 Systemic Lupus Erythematous Flare Up Presenting as Myelitis – Deema Sawass Najjar, Kush Sharma, Adrian Marchidann, Elizabeth Chernyak, Simona Treidler P13.1-007 Uncovering the putative pathogenesis of Stiff Person Syndrome (SPS): is there a neuroinflammatory mechanism? – Maria Isabel Reyes, Samantha Hao, Susana Carolina Dominguez Penuela, David Orlando Acero-Garces, Carlos A. Pardo-Villamizar, Scott Douglas Newsome
Wednesday, April 6 8:00 a.m.–9:00 a.m.
2
Headache
Headache: Migraine Therapeutics 3 P13.2-001 Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment – Tanya Rochelle Bilchik, Robert Vann, Sutapa Ray, Stephen Bevan Shrewsbury, Sheena K. Aurora P13.2-002 Long-Term Safety and Tolerability of STS101, A Novel Investigational Dihydroergotamine Nasal Powder: Initial Data from the ASCEND Study – Stewart J. Tepper, Shannon Strom, Detlef Albrecht P13.2-003 Pharmacokinetics and Safety of STS101, A Novel Investigational Dihydroergotamine Powder DrugDevice Combination in Healthy Subjects – Detlef Albrecht, Richard B. Lipton, Shannon Strom P13.2-004 Pharmacokinetic Comparison of STS101 (A Novel Investigational DHE Nasal Powder) with Liquid Nasal, Injectable and Oral Inhaled DHE Formulations – Shannon Strom, Detlef Albrecht P13.2-005 Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3, Randomized, Double-blind, Active- and Placebocontrolled Trial – Amanda Jones, Stewart J. Tepper, Richard B. Lipton, Herriot Tabuteau
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Neuropsychology and Remote Assessments 1 P13.3-001 Clusters of Cognitive Performance among Aging People Living with HIV: the Application of Unsupervised Machine Learning – Akarin Hiransuthikul, Thanapoom Rattananupong, Waragon Phusuwan, Chaipat Chunharas, Tanakorn Apornpong, Vitool Lohsoonthorn, Anchalee Avihingsanon P13.3-002 Next Generation Tablet-based Digital Clock Drawing Task for Characterizing Change to Cognitive Status – Timothy Helbig, William A. Souillard-Mandar, Connor Patrick Higgins, Anthony Le, Sadhvi Saxena, Joyce Rios Gomes-Osman, Alvaro Pascual-Leone, David James Bates, John Langton, Sean Tobyne
P13.3-003 Empathy deficit along Alzheimer’s Disease continuum: from Subjective Cognitive Decline to dementia. – Giulia Giacomucci, Giulia Galdo, Cristina Polito, Valentina Berti, Sonia Padiglioni, Salvatore Mazzeo, Maria Teresa De Cristofaro, Benedetta Nacmias, Sandro Sorbi, Valentina Bessi P13.3-004 The Brain Health Champion Study: A Health Coaching Intervention with Mobile Technology in Older Adults with Mild Cognitive Impairment or Risk Factors for Dementia – Sergio RamirezSalazar, Taylor Krivanek, Brittany McFeeley, Casey Nicastri, Demsina Babazadeh, Kirk R. Daffner, Seth Gale P13.3-005 Initial Validity Evidence for the Mobile Toolbox (MTB): A Completely Remote Platform for Cognitive Research – Zahra Hosseinian, Aaron Kaat, Sarah Pila, Cindy Nowinski, Jerry Slotkin, Yusuke Shono, Miriam Novack, Maria Varela Diaz, Saki Amagai, Hubert Adam, Lara Mangravite, Sonia Carlson, Larsson Omberg, Michael Kellen, Jonathan King, Richard Gershon
4
MS and CNS Inflammatory Disease
MS Special Populations 4 P13.4-001 Pregnancy in women with Multiple Sclerosis: Recommendations from the French Multiple Sclerosis Society – Sandra Vukusic, Jonathan Ciron, Clarisse Carra-Dalliere, Elisabeth Maillart, Laure Michel, Emmanuelle Leray, Anne Marie Guennoc, Bertrand Bourre, David Laplaud, Geraldine Androdias-Condemine, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Mikael Cohen, Elodie Daval Imbert, Romain Deschamps, Cécile Donzé, Anne-Laure Dubessy, Cécile Dulau-Metras, Francoise Durand Dubief, Maxime Guillaume, Benjamin Hebant, Laurent D. Kremer, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Julie Pique, Thomas Roux, Romain Marignier, Beverly Aagard-Kienitz P13.4-002 MOGAD Atypical Presentations in Pediatric Patients – Victoria A. Adeseye, Grace Reynolds, Nikita Shukla P13.4-003 Incidence and Prevalence of MS in Indigenous Populations of the Americas: A systematic review – Michael Vincent Robers, Brigitte Furth Hurtubise, Melissa H. Roberts, Hollie K. Schmidt, Lilyana M. Amezcua, Brigitte Furth Hurtubise P13.4-004 Eculizumab Induces Remission of Highly Active Aquaporin-4 Neuromyelitis Optica Spectrum Disorder (AQP-4 NMOSD) in a Pediatric Patient – Cynthia X. Wang
74
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 13
P13.4-005 Anti-Neurofascin Antibodies, White Matter Abnormalities and Cancer: Caught in the Act or Innocent By-Stander? – Rana K. Zabad, Navnika Gupta, Afsaneh Shirani P13.4-006 Pregnancy in women with Neuromyelitis Optica Spectrum Disorders: Recommendations from the French Multiple Sclerosis Society – Sandra Vukusic, Jonathan Ciron, Clarisse Carra-Dalliere, Elisabeth Maillart, Laure Michel, Emmanuelle Leray, Anne Marie Guennoc, Bertrand Bourre, David Laplaud, Geraldine Androdias-Condemine, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Mikael Cohen, Elodie Daval Imbert, Romain Deschamps, Cécile Donzé, AnneLaure Dubessy, Cécile Dulau-Metras, Francoise Durand Dubief, Maxime Guillaume, Benjamin Hebant, Laurent D. Kremer, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Julie Pique, Thomas Roux, Romain Marignier, Beverly Aagard-Kienitz P13.4-007 Validation of MRI radiological reports in pediatric MS according to the McDonald 2017 criteria: A Danish nationwide multicenter cohort study – Magnus Spangsberg Boesen, Annika Langkilde, Jurgita Ilginiene, Melinda Magyari, Morten Bjorn Blinkenberg MS Symptom Assessment & Management 2 P13.4-008 SARS-CoV-2 vaccine response in RMS patients treated with ozanimod and other DMTs – Daniel Kantor P13.4-009 Distinct immune repertoire characteristics are associated with secondary autoimmunity following LEMTRADA® therapy – Sumanta Barman, Tobias Ruck, Christoph Lehrich, HansPeter Hartung, Nico Melzer, Heinz Wiendl, Sven G. Meuth, Norbert Goebels P13.4-010 Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared With Every-4-Week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database – Lana Zhovtis Ryerson, John F. Foley, Ilya Kister, Gary Raymond Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Karen Smirnakis, Liesel DSilva, Wai Chin, Evan Riddle P13.4-011 Risks of Minor and Severe Infections in Multiple Sclerosis Patients Treated with Long-term B-cell Depletion – John Peters, Erin Longbrake
5
Wednesday, April 6 8:00 a.m.–9:00 a.m.
Child Neurology and Developmental Neurology
Child Neurology: Neurodevelopmental Disorders/CP/ASD 3 P13.5-001 Evaluation of an Artificial Intelligence-Based Medical Device Designed to Aid in the Diagnosis of Autism Spectrum Disorder in the Primary Care Setting – Jonathan Thomas Megerian, Sangeeta Dey, Ruan Melmed, Daniel Coury, Marc Alan Lerner, Christopher John Nicholls, Kristin Sohl, Rambod Rouhbakhsh, Anandhi Narasimhan, Jonathan Romain, Sailaja Golla, Safiullah Shareef, Andrey Ostrovsky, Jennifer Shannon, Colleen Kraft, Stuart Liu-Mayo, Halim Abbas, Diana Elena GalSzabo, Dennis Wall, Sharief Taraman P13.5-002 A Phase IV, Prospective, Observational, Multicenter Study Evaluating the Effectiveness and Safety of AbobotulinumtoxinA in Pediatric Lower Limb Spasticity (PLLS) – Mark Gormley, Edward R. Dabrowski, Mauricio R. Delgado, Ann H. Tilton, Asare Christian, Sarah Helen Evans, Francoise Calvi-Gries, Jumaah Goldberg P13.5-003 Predictors of Resident Physician Comfort with Individuals with Intellectual and Developmental Disabilities – Jessica Sanders, Hannah Johnson P13.5-004 Top Ten Research Themes for Dystonia in Cerebral Palsy: A community-driven research agenda – Laura Gilbert, Darcy L. Fehlings, Paul Gross, Michael C. Kruer, Wendy Kwan, Jonathan W. Mink, Michele Shusterman, Bhooma Rajagopalan Aravamuthan P13.5-005 Altered Gut Bacteriome and Mycobiome in Neurodevelopmental Disorders – Ibrahim Laswi, Ameena Shafiq, Dana Al-Ali, Zain Ali Burney, Krishnadev Vijaykumar Pillai, Mohammad Salameh, Nada Mhaimeed, Dalia Zakaria, Ali Chaari, Noha Yousri, Ghizlane Bendriss
6
Research Methodology and Education
Teaching Across the Spectrum of Medical Education in Neurology 1 P13.6-001 Diversity of Grand Rounds Presentations at Large Academic Medical Centers – Trusha Shah, Alec Gibson, Jerome J. Graber
P13.6-003 Evaluation of a Novel Clinical Training Program for Medical Students on their Neurology Clerkship – Caitlin Mulligan, Chris Cannavino, Shannon O’Donnell, Jamie LaBuzetta P13.6-004 Review of Neuroscience and Neurology Education in Physician Assistant Programs – Daniel Steven Harrison, Margaret Naclerio, Kathryn Swider, Andrew Busler, Lena Liu, Andrew Tien-Wai Yu, Christopher T. Doughty P13.6-005 Neurology Residents as Teachers of Undergraduate Neuroscience - an Untapped Resource! – Alyssa Marie Smith, Sandeep Gill, Micaela Rose Owens, Scott M. Friedenberg, Robert Waldeck, Madelyn Kay Smiley P13.6-006 Online Medical Education Improves Knowledge of Recent Data in Epilepsy and Related Clinical Applicability Among General Neurologists and Epileptologists – Thomas Finnegan, Kathy Merlo, Jovana Lubarda, Louis Ferrari, Gregory L. Krauss, Michael R. Sperling
7
Neuro Trauma and Critical Care
Neurocritical Care: Status Epilepticus, Brain Death and Cardiac Arrest 1 P13.7-001 Super Refractory Status Epilepticus in Seronegative Autoimmune Encephalitis – Steven Yang, Kelsey Curd Ladt, Venkataditya Dugyala P13.7-002 Assessment of Adherence to Status Epilepticus Treatment Guidelines at a Single Institution – Steven Yang, Michelle Lan, Victoria Lily Wu, William Cang, Navaz Karanjia P13.7-003 Massive Cerebral Edema and Super-Refractory Status Epilepticus: A Rare Postsurgical Complication of Cranioplasty – Ramiro Gabriel Castro Apolo, Erafat Rehim, Jaspreet Johal, Christopher Melinosky, Preet M. Varade P13.7-004 Hyperammonemia and Status Epilepticus after Lung Transplant – Jonathan Rosenthal, Alexa Dessy, Samantha Smalley, Cherisse Berry, Serena Arnouk, Luis Angel, Kara R. Melmed
P13.6-002 NeuroLytes: Developing Clinical Reasoning for Medical Students on the Neurology Clerkship – Muhammad Suhaib Qasim, Michael Zachary Moore, Catherine R Garcia, Alexander Sellers, Ramneek Manchanda, Ibrahim Noorbhai, Rebecca Eleanor Fenelon, Fabio Nascimento, Doris Kung
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
75
Poster Session 13
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 2 P13.8-001 Results for the Quality of Life in Epilepsy Scale From a Long-Term Safety Study of Diazepam Nasal Spray for Seizure Clusters – Sunita N. Misra, R Edward Faught, Enrique Carrazana, Adrian Rabinowicz P13.8-002 12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study – Vicente Villanueva, Wendyl J. D’Souza, R Edward Faught, Pavel Klein, Markus Reuber, Felix Rosenow, Javier Salas-Puig, Adam Strzelczyk, Jerzy P. Szaflarski, Kristen Ricchetti-Masterson, Cedric Laloyaux, Veronica Sendersky, Sophia Zhou, Florin Floricel, Tony Daniels, Bernhard Steinhoff P13.8-003 Cenobamate for Uncontrolled Focal Seizures in Patients With Previous Epilepsy-Related Surgery: A Post-hoc Analysis – Bassel W. Abou-Khalil, Sami M. Aboumatar, Pavel Klein, Gregory L. Krauss, Michael R. Sperling, William E. Rosenfeld P13.8-004 Cognitive and Behavioral Effects and Tolerability of Adjunctive Brivaracetam in Children and Adolescents with Focal Seizures: Pooled Interim Analysis – Jan-Peer Elshoff, Sofia Grigory Fleyshman, Christine M De la Loge, Xavier Nondonfaz, Christoph Reichel, Florin Floricel, Patricia Maria Smeyers P13.8-005 Cognitive and Psychiatric Adverse Events During Adjunctive Cenobamate Treatment in Phase 2 and Phase 3 Clinical Studies – Gregory L. Krauss, Steve S. Chung, Louis Ferrari, William E. Rosenfeld P13.8-006 Seizure-Related Outcomes With Real-World Use of Cannabidiol (CBD) in Lennox-Gastaut Syndrome and Dravet Syndrome: BECOME, A Caregiver Survey – Tracy Dixon-Salazar, Anne T. Berg, Sherry Danese, M. Scott Perry, Mary Anne Meskis, Ngoc Minh Dang Le P13.8-007 Early Intervention with Midazolam Nasal Spray and Efficacy in Patients with Seizure Clusters: Post-hoc Analysis of an Open-label Extension Trial – James W. Wheless, Marcus Brunnert, Florin Floricel, Svetlana Dimova, Brandi Fannon
Wednesday, April 6 8:00 a.m.–9:00 a.m.
9
Neuro-oncology
Molecular Determinants of Neurooncology 1 P13.9-001 An IDH Wildtype, EGFR Amplified and TERT Promoter Mutated Astrocytoma that is Clinically and Molecularly Incompatible with the Diagnosis of Glioblastoma, IDH Wildtype. – Marina Kushnirsky, Richard Hickman, Lauren Rhea Schaff, Brandon Stuart Imber, Jamal Benhamida, Andrew L. Lin P13.9-002 Alpha-Synucleinopathy is a Potential Modifier of Neuro-Oncologic Outcome – Eric Tai-Lee Wong, Huan Yang, Lan Luo, Roy L. Freeman, Christopher H. Gibbons P13.9-003 Cloning and overexpression of multi-domain enhancer protein p300, to study its involvement in childhood-diffuse intrinsic pontine glioma (DIPG) cell proliferation. – Steven Summers, Pinki Chowdhury P13.9-004 STING is silenced by DNA methylation in primary brain tumors and is rescued by methyltransferase inhibition – Justin Thomas Low, Vidyalakshmi Chandramohan, Michelle Bowie, Michael Brown, Matthew Waitkus, Aaron Briley, Kevin Stevenson, Rebecca Fuller, Zachary J. Reitman, Andrea M. Muscat, Seethalakshmi Hariharan, Janell Hostettler, Nick Wong, Matthias Gromeier, David Ashley P13.9-005 BRAT1 Associated Leukodystrophy exacerbated by Lymphoma directed Chemotherapy – Sara J Hooshmand, Karan Chohan, Michael Wren Ruff P13.9-006 Using Cerebrospinal Fluid (CSF) tumor cells to track disease burden and treatment response in patients with Leptomeningeal Disease (LMD) from solid cancers – Akanksha Sharma, Nathan Sweed, Barbara Blouw, Lan Huynh, Deanna Fisher, Kaitlyn S. Armijo, Smitha Boorgula, Steven Hsiao, Tony Pircher, Julie Mayer, Naveed Wagle, Jose A. Carrillo, Minhdan Nguyen, Judy Dang Truong, Eve J. Landa, Michael J. Dugan, Santosh Kesari
10
Cerebrovascular Disease and Interventional Neurology
Interventional Neurology 2 P13.10-001 Markers of Inflammation Predict PostThrombectomy Mortality in Acute Stroke – Hannah Irvine, Leah Croll, Penina Krieger, Amanda Jin Zhao, Jose L. Torres, Kara R. Melmed, Koto Ishida, Aaron S. Lord, Jennifer A. Frontera, Ariane Lewis
76
2022 AAN Annual Meeting
P13.10-002 Impaired Cerebral Autoregulation Related Blood Pressure Reductions After Nimodipine Are Associated with Ischemic Changes on EEG After Subarachnoid Hemorrhage – Ilayda Top, Yilun Chen, David Bartolome, Amedeo Rapuano, Emily Jean Gilmore, Kevin N. Sheth, Charles Matouk, Nils Petersen, Jennifer A. Kim P13.10-003 Double-Stent Retrieval Thrombectomy Technique For MCA Bifurcation Thrombus: A Case Report – Milagros Galecio-Castillo, Cynthia Zevallos, Juan A. Vivanco-Suarez, Mudassir Farooqui, Santiago Ortega Gutierrez P13.10-004 Endovascular Therapy Delay for Acute Large Vessel Occlusion (LVO) is Associated with Worse Functional Outcome and Increased Mortality - Quantified – Julian David Carrion-Penagos, Sonam Thind, Elisheva Ruth Coleman, James R. Brorson, Cedric McKoy, Scott J Mendelson, Shyam Prabhakaran, Ali Mansour, Tareq Kass-Hout P13.10-005 Predictors of Favorable Functional Outcome Following Acute Ischemic Stroke Secondary to M1/ICA Occlusion in the Extended Thrombectomy Time Window – Quinn Steiner, Thomas Andrew Reher, Qianqian Zhao, Alexey Samsonov, John W. Garrett, Nicole Bennett, Vivek Prabhakaran, Beverly Aagard-Kienitz, Bolanle Famakin P13.10-006 Cerebral Venous Sinus Thrombosis in the Setting of an AVM While on Anticoagulation: A Case Report – Milena Lobaina, Laura J. Wu, Hashem M. Shaltoni, Arun Singh Chhabra P13.10-007 Low NIHSS Large Vessel Occlusion: Impact of Treatment Modality on Early Outcomes – Sung Jeon, Sharon Poisson P13.10-008 Reducing Unnecessary Hospital Transfers for Patients Not Taken for Thrombectomy – Kelsey Duncan, Julie Fussner, Kelly M. Montgomery, Cathy A. Sila P13.10-009 Risk Factors, Treatments, and Outcomes of Ischemic Stroke Associated with Basilar Artery Occlusion – Mona Al Banna, Melissa Mariscal, Sweta Rao, Fadar Oliver Otite, Richa Sharma P13.10-010 Moyamoya Syndrome in the Setting of Sturge Weber: A Case Report – Aaisha Mozumder, Michael Gaub, Richard Cody Simon, Jonathan Fisher, Firas Kaddouh
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 13
11
Movement Disorders
Movement Disorders: PD Gut and Lung and PD Biomarkers 1 P13.11-001 Mediterranean Diet Impacts Gastrointestinal Symptoms and Modulates Gut Microbiota in People with Parkinson’s Disease – Carley Rusch, Matthew Beke, Lily Tucciarone, Carmelo Nieves, Maria Ukhanova, Massimiliano S. Tagliamonte, Volker Mai, Joon Hyuk Suh, Yu Wang, Shannon Chiu, Bhavana U. Patel, Adolfo Ramirez Zamora, Bobbi Langkamp-Henken P13.11-002 Proof of Concept Study of Prebiotics to Modulate Gut Microbiome in Parkinson’s Disease – Deborah Hall, Robin Voigt, Thaisa Cantu-Jungles, Bruce R. Hamaker, Shohreh Raeisi, Maliha Shaikh, Stefan Joshua Green, Phillip Andrew Engen, Bichum Ouyang, Ankur Naqib, Christopher Forsyth, Heather Rasmussen, Shahriar Sedghi, Christopher Goetz, Ali Keshavarzian P13.11-003 Effects of probiotic, prebiotic or synbiotic supplementation on Parkinson’s Disease: A systematic review with meta-analysis – Miguel Francisco Cabanillas Lazo, Milagros Del Pilar Pascual-Guevara, Carlos S. Mamani-García, Victor Andrés Velasquez Rimachi, Nicanor Mori, Carlos Alva-Diaz P13.11-004 Early biochemical changes in a-synuclein in the central and enteric nervous system in Parkinson’s disease – Virginia Gao, Lauren Komer, Juan Antonio Briano, Carl Crawford, Claire Henchcliffe, Andrea P. Lee, Jacqueline Burré P13.11-005 Genetic Overlap between Parkinson’s Disease and Inflammatory Bowel Disease – Xiaoying Kang, Alexander Ploner, Yunzhang Wang, Dylan Williams, Nancy Pedersen, Karin Wirdefeldt P13.11-006 Lifelong Constipation in Synucleinopathies: An Incident Cohort Study in Olmsted County, MN (1991-2010). – Pierpaolo Turcano, Emanuele Camerucci, Aidan Mullan, Cole Daniel Stang, Adil Bharucha, Delana Weis, Bradley F. Boeve, James H. Bower, J. Eric Ahlskog, Rodolfo Savica P13.11-007 Pyridostigmine as an Effective Treatment for Atonic Colon in Parkinson’s Disease – Ann Nguyen Ly, Mahrin Rahman, David D. Song P13.11-008 Respiratory Comorbidities in Patients With Parkinson’s Disease – Andrew Thach, Rajat Chandra, Jingjun Wang, Yifei Wang, Samuel Croset, Eric Pappert, Pinky Agarwal
12
Wednesday, April 6 8:00 a.m.–9:00 a.m.
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology and Neuro-otology Cases 1 P13.12-001 Acute Posterior Multifocal Placoid Pigment Epitheliopathy as the presenting feature of Sarcoid – Audrey Reynolds, Karen Curtin, Andrea Ryan, Conor Murphy, Eamonn Molloy, Justin Kinsella P13.12-002 Vestibular Paroxysmia Successfully Treated with N-acetylcysteine: A Case Report – Courtney Iser, Karissa Arca, David W. Dodick, Jamie Bogle P13.12-003 Recurrent Progressive Peripheral Vertigo: Revisiting Vestibular Paroxysmia – Bryan Paulo Lopez Canlas, Julia Morrow Kerrigan P13.12-004 Atypical Optic Neuritis Associated with golimumab – Smathorn Thakolwiboon, Praelada Wongsirimeteekul, Mirla L. Avila P13.12-005 A case of pediatric Idiopathic intracranial hypertension associated with aplastic anemia – Usama Tariq, Apoorva Jagadish, Rosario Maria S. Riel-Romero
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Inherited Muscle Disorders 2 P13.13-001 Strength is Associated with Functional Abilities and Changes over a 12 Month Period in Individuals with Facioscapulohumeral Dystrophy (FSHD) – Katy Eichinger, Michael McDermott, Kiley Higgs, Michaela Walker, Leann Lewis, William Martens, Doris G. Leung, Sabrina Sacconi, Karlien Mul, Valeria A. Sansone, Elena Carraro, Leo Hong-Li Wang, Perry Shieh, Bakri Elsheikh, Samantha Jo LoRusso, Nicholas Elwood Johnson, Russell Butterfield, Maria Chiara Frisoni, Alrabi Tawil, Jeffrey Statland
P13.13-003 A Concisely Recorded Ambulatory Assessment for Enhancing Real-World Outcomes Research in Duchenne Muscular Dystrophy: Development and Validation – Anna Mayhew, James Signorovitch, Volker Straub, Chiara Marini-Bettolo, Chiara Marini-Bettolo, Amritpal Sodhi, Adnan Manzur, Vandana Ayyar Gupta, Victoria Selby, Francesco Muntoni P13.13-004 High-throughput Variant Resolution Utilizing Deep Mutational Scanning in Sarcoglycanopathies – Conrad Weihl, Chengcheng Li, Jackson Wilborn, Jil Daw, Okechukwu Obidike, Katy Eichinger, Nicholas Elwood Johnson, Gabriel Haller P13.13-005 Preliminary Twelve-Month Functional Change in Limb Girdle Muscular DystrophyR9/2I – Jeffrey Statland, Kameron Bates, Han Xie, Lindsay N. Alfano, John Vissing, Tahseen Mozaffar, Katherine D. Mathews, Linda Pax Lowes, Matthew P. Wicklund, Conrad Weihl, Doris G. Leung, Peter B. Kang, Carla D. Zingariello, Urvi G. Desai, Erin DeSpain, Jessica St Romain, Douglas M. Sproule, Nicholas Elwood Johnson, The GRASP Consortium P13.13-006 Predicting Trajectories of Ambulatory Function in Duchenne Muscular Dystrophy (DMD) – Francesco Muntoni, James Signorovitch, Nathalie M. Goemans, Adnan Manzur, Nicolae Done, Henry Lane, Gautam Sajeev, Susan J. Ward, Craig McDonald P13.13-007 The Cognitive Profile of Congenital Myotonic Dystrophy and the Impact of Sleep Quality – Namita Patel, Kiera Berggren, Man Hung, Kameron Bates, Karen Ann Bax, Craig Gordon Campbell, Nicholas Elwood Johnson P13.13-008 Expanding the clinical spectrum of CLCN1 mutations – Nivedita Jerath P13.13-009 Novel KCNA1 Variant Associated Syndrome of Episodic Dystonia and Electrophysiologic Myokymia - A Case Report – Lauren Ashley Major, Robert Lebel, Steven M. Rothman, Ai Sakonju
P13.13-002 Reliability of Reachable Workspace (RWS) Measurement System in a Large, Multi-Site, International FSHD Clinical Study – Maya Hatch, Jay Han, Gregorij Kurillo, Leo Hong-Li Wang, Katy Eichinger, Michael McDermott, Kiley Higgs, Michaela Walker, Leann Lewis, William Martens, Doris G. Leung, Sabrina Sacconi, Karlien Mul, Valeria A. Sansone, Elena Carraro, Perry Shieh, Bakri Elsheikh, Samantha Jo LoRusso, Russell Butterfield, Nicholas Elwood Johnson, Alrabi Tawil, Jeffrey Statland
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
77
Poster Session 14
1
Autoimmune Neurology
Autoimmune Neurology: Neuromyelitis Optica Spectrum Disorder 1
Wednesday, April 6 11:45 a.m.–12:45 p.m.
2
Headache
Headache: Migraine Therapeutics 4
P14.1-001 Quantifying the Economic Burden of Hospitalization from Neuromyelitis Optica: Results of a Cross-sectional Survey – Dylan R. Rice, Kathryn Holroyd, Danielle Kei Pua, Michael Levy, Farrah J. Mateen, Shamik Bhattacharyya
P14.2-001 Combined Prophylactic Treatment of Chronic Migraine with OnabotulinumtoxinA and AntiCGRP Monoclonal Antibodies – Audrey Marie Blazek, Rima Dafer, Christopher P. Rhyne, Ivan Rocha Ferreria Da Silva
P14.1-002 Tumefactive Demyelinating Lesions due to NMO treated with Eculizumab – Kimberly O’Neill, Lauren Gluck
P14.2-002 A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1-Hour Post-Dose in the Pooled ACHIEVE I and ACHIEVE II Trials – Charles Iaconangelo, Daniel Serrano, Aubrey Manack Adams, Joel M. Trugman, Richard B. Lipton
Autoimmune Neurology: COVID-19 and Autoimmune Neurologic Disorders 2 P14.1-003 Multiple Cranial Neuropathies After COVID-19 Vaccination – Hemali Patel, George T. Savvides, Yin Allison Liu, Michelle Apperson P14.1-004 A Case of Transverse Myelitis After Moderna SARS-CoV-2 Vaccination – Bahram Rabbani, Danny Samkutty, Ahmad Al-Awwad, Nidhiben A. Anadani P14.1-005 A Case of an 83 Year Old Male with Acute Disseminated Encephalomyelitis-like Presentation Post COVID-19 Vaccination – Teye Aniefiok Umanah, Suman Bharath, Ming He P14.1-006 Severe Multifocal Cortical Encephalopathy Following COVID-19 Vaccination: A Case Report – Michael Saad, Xin Yang, Sabeena Iqbal Malik P14.1-007 Autoimmune gastrointestinal dysmotility following SARS-CoV-2 infection successfully treated with intravenous immunoglobulin – Mayra Montalvo Perero, Padmini Nallapaneni, Sara Hassan, Samuel Nurko, Julie Khlevner, Sean J. Pittock
P14.2-003 PREDICT: PREEMPT fixed-dose, fixed-site and follow the pain – Corrie Graboski, May Ong-Lam, Werner J. Becker, Julia Ma, Katherine Sommer, Ian Finkelstein P14.2-004 Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3, Randomized, Double-blind, Placebo-controlled Trial – Amanda Jones, Stewart J. Tepper, Richard B. Lipton, Herriot Tabuteau P14.2-005 Efficacy of memantine compared to sodium valproate as prophylactic treatment for migraine: A pilot clinical trial – Damaris Daniela Vazquez Guevara, Ildefonso Rodriguez-Leyva P14.2-006 Cardiovascular Safety of STS101, A Novel Investigational DHE Nasal Powder Product: Initial Data from the ASCEND Study – Alan M. Rapoport, Shannon Strom, Detlef Albrecht
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Neuropsychology and Remote Assessments 2 P14.3-001 Validation of MyCog: A Self-Administered Rapid Detection Tool for Cognitive Impairment in Everyday Clinical Settings – Zahra Hosseinian, Laura M. Curtis, Yusuke Shono, Saki Amagai, Julia N Yoshino Benavente, Michael Bass, Maria Varela Diaz, Stephanie Batio, Cindy Nowinski, Mr. Michael Wolf, Richard Gershon
78
2022 AAN Annual Meeting
P14.3-002 Quantification of Cognitive Impairments in Preclinical and Early Alzheimer’s Disease: A Proof of Concept Study to Investigate the Feasibility, Adherence and Preliminary Clinical Validity of Remote Smartphone Based Self-Assessments of Cognition, Function and Behavior – Thanneer Malai Perumal, Arnaud Marc Wolfer, Florian Lipsmeier, Michael Lindemann, Foteini Orfaniotou, Simone Rey, Irma Kurniawan, David Watson, Merce Boada Rovira, Kirsten I. Taylor P14.3-003 Figure-Ground Testing as an Accurate and Efficient Tool For Clinical Screening of Posterior Cortical Atrophy – Golnoush Akhlaghipour, Mario F. Mendez, Youssef I. Khattab, Oleg Yerokhin Yerstein P14.3-004 Predicting behind-the-wheel driving behavior in PD through motor and cognitive testing in outpatient clinics – Nikolaos Andronas, Elissaios Karageorgiou, Ion Beratis, Stella Fragkiadaki, Dionysia Kontaxopoulou, George Yannis, Leonidas Stefanis, Sokratis Papageorgiou P14.3-005 Characterization of Mild Cognitive Impairment with a Digital Cognitive Assessment Tool – Nandor K. Pinter, Erica S. Westphal, Mandy Spaltman, Maxwell Daniel Yargeau, Ryu Platinum Dorn, Sarah Harlock, Gijs Van Elswijk, Bela Ajtai, Ben Schmand, Willem Huijbers
4
MS and CNS Inflammatory Disease
MS Symptom Assessment & Management 3 P14.4-001 The Predictors of Fatigue in Multiple Sclerosis – Harriet Louisa Johanna Moore, Krishnan Padmakumari S Nair, Kathleen Baster, Rod Middleton P14.4-002 NODDI Microstructural Abnormalities in Normal-Appearing Gray Matter and White Matter Contribute to Cognitive Impairment in Multiple Sclerosis – Paolo Preziosa, Lorenzo Conti, Elisabetta Pagani, Olga Marchesi, Damiano Mistri, Andrea Falini, Maria Assunta Rocca, Massimo Filippi P14.4-003 A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity who are Treated With abobotulinumtoxin A – Salvatore Napoli, Donna Bradley, Dianna Sullivan, Olivia Parsons, Sarah B. Cardoso, Rachel ODonnell
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
There’s a smarter way to treat epilepsy. The RNS System is the only epilepsy therapy that… Delivers Personalized Neuromodulation Therapy Recognizes and responds to each patient’s unique brain patterns, providing personalized stimulation to prevent seizures before they start. Gives You A Window to the Brain® Records EEG data while patients live their normal lives, providing unprecedented visibility into real-world brain activity that can help you optimize patient treatment plans.
82% seizure reduction at ≥ 3 years
Life Changing Seizure Reductions Greatest reductions in seizure frequency seen in any published neuromodulation study for focal epilepsy.1, 2
WEBINAR
April 27th 3:30 – 4:30 PT
Learn more from the experts! Join us for a webinar to learn more about the RNS System, how to identify potential patients, and how to build successful connections with L4 Comprehensive Epilepsy Centers for effective patient management.
REGISTER
Learn More About the RNS System www.neuropace.com
1. Elliott, et al., Epilepsy Behav, 2011. 2. Salanova, et al., Neurology, 2015. Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at http://www.neuropace.com/safety/. ©2022 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are trademarks of NeuroPace, Inc. NP 220018 Rev1 / Rev. Date: 2022-02
NeuroPace® RNS® System Brief Statement Surgical Indication for Use
Implantation of the RNS® System and associated surgical procedure risks may
The RNS® System is an adjunctive therapy in reducing the frequency of seizures
cause, but are not limited to, infection, intracranial hemorrhage, tissue damage,
in individuals 18 years of age or older with partial onset seizures who have
temporary pain at the implant site, CSF leakage, seroma, and paralysis.
undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have
RNS® System and Therapy
frequent and disabling seizures (motor partial seizures, complex partial seizures
The safety and effectiveness has not been studied in pregnant women. The
and / or secondarily generalized seizures). The RNS® System has demonstrated safety
effects of long-term brain stimulation are not completely known. Strong
and effectiveness in patients who average 3 or more disabling seizures
electromagnetic interferences (EMI) can result in serious patient injury or
per month over the three most recent months (with no month with fewer than
death, damaged brain tissue, loss or change in symptom control, reoperation,
two seizures), and has not been evaluated in patients with less frequent
stimulation to turn on or off, a return of symptoms, or a momentary increase in
seizures.
stimulation felt by the patient. In addition EMI, such as security screening devices and radio frequency identification, can result in delivering the
Contraindications
programmed stimulation to the patient and appear as sensing artifacts on the
The RNS® System is contraindicated for patients at high risk for surgical
ECoG recordings. The RNS® System could interact with implanted cardiac
complications, with medical devices implanted that deliver electrical energy to
devices and result in inappropriate device response or device damage.
the brain, and those who are unable (or do not have the necessary assistance)
Additional surgical procedures can result from battery malfunction, electrical
to properly operate the NeuroPace® Remote Monitor or Magnet. For patients
short, open circuit, lead fracture, lead insulation failure, damage as a result of
with an implanted RNS® System the following medical procedures are contraindicated:
head trauma, or lead migration. Severe brain tissue damage can result from
• Electroconvulsive Therapy (ECT) • Transcranial Magnetic Stimulation (TMS) • Diathermy procedures (any treatment that uses highfrequency electromagnetic radiation, electric currents or ultrasonic waves to produce heat in body tissues)
exposure to battery chemicals if the Neurostimulator is ruptured or pierced due to outside forces. The patient must collect data from the Neurostimulator once a day and send data to the PDMS once a week. Medical Environment Electrolysis on the head and neck should be avoided. Prior to the administration of Extracorporeal Shock Wave Lithotripsy or high radiation
Warnings and Precautions
sources the administering physician should consult with the physician
The RNS® System is not compatible with non-NeuroPace leads and/or pulse
prescribing the RNS® System. Read the user manual to understand the steps to
generators. Electrical shock may occur with incorrect use of the Programmer
be taken before, during and after computerizedTomography (CT) scans.
or Remote Monitor. Do Not Resterilize and Do Not Reuse the implantable products.
Potential Adverse Events Serious adverse events occurring in ≥ 2.5% of patients and those of particular
MRI Safety Information
relevance reported during the RNS® System clinical studies include EEG monitoring, infection, change in seizures, medical device removal, death, device
RNS® Neurostimulator model RNS-320: An MRI scan may be safely performed
lead damage or revision, antiepileptic drug toxicity, hemorrhage, psychiatric
on patients with the RNS® System (with RNS Neurostimulator model RNS-320)
events, status epilepticus and seizure-related injury. Refer to the product
only under the specific conditions of safe use detailed in the MRI Guidelines for
labeling for a detailed disclosure of other reported adverse events.
the RNS® System. Scanning under different conditions may result in device damage or malfunction and serious patient risks including permanent brain
Rx Only. Refer to the product labeling for a detailed disclosure of specific
damage which may cause severe injury, coma, or death.
indications, contraindications, warnings, precautions and adverse events.
RNS® Neurostimulator model RNS-300M of the RNS® System is MR Unsafe.
DN 1014760 Rev 4
Having an MRI scan with a model RNS-300M neurostimulator implanted may
Rev. Date: 2020-03
result in serious injury or possible death. ©2022 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are trademarks RNS® System External Components: All external components and accessories
of NeuroPace, Inc. NeuroPace, Inc., 455 N. Bernardo Ave., Mountain View, CA
of the RNS® System such as the Magnet, RNS® Tablet, NeuroPace® Programmer,
94043. www.NeuroPace.com
NeuroPace® Remote Monitor, and Wand are MR Unsafe and can pose a
NP 220018 Rev. 1 Rev. Date: 2022-02
projectile hazard in the MR environment, and therefore, must be kept out of the MRI scanner room. Clinical Use The RNS® System should only be implanted at Comprehensive Epilepsy Centers by neurosurgeons with adequate experience in the implantation of subdural and stereotactic implantation of intraparenchymal electrodes and in the surgical treatment of intractable epilepsy. The RNS® System should only be used by neurologists and neurosurgeons with adequate experience in the management of intractable epilepsy and in the localization of epileptic foci. They must complete a NeuroPace® RNS® System training program and demonstrate specific expertise related to epilepsy, video-EEG monitoring, interpretation of electrocorticograms (ECoGs), the pharmacology of antiepileptic medications and selection of patients for epilepsy surgery. In some instances Neurologists who meet the experience and certification requirements but do not practice at Comprehensive Epilepsy Centers could be qualified by NeuroPace to provide post-implant programming.
Wednesday, April 6 11:45 a.m.–12:45 p.m.
Poster Session 14
P14.4-004 The humoral response to SARS-COV-2 vaccines in MS patients: Impact of DMT, lymphocyte count, immunoglobulins, and vaccine type – Hesham Ahmed Abboud, Collin Jakubecz, Sophia Woodson, Alessandro Serra P14.4-005 Persistently Impaired Antibody Response of Ocrelizumab-treated Multiple Sclerosis Patients to Third (“Booster”) mRNA Vaccine Against SARSCoV-2 – Pavle Repovic P14.4-006 Temporal Trends in Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated With Natalizumab, Ocrelizumab or Fumarates – Pavle Repovic, Jongchan Choi, Sunga Hong, Jennifer Umali Reola, Kelly Chun, Christos John Petropoulos, James D. Bowen, Peiqing Qian, Simon Evans, Rick Edmark, Jason P. Mendoza, Robin L. Avila, James Richard Heath, Jason D. Goldman
MS Neuroimaging 2 P14.4-007 TSPO-PET-measurable Microglial Activation Associates with Serum 3-hydroxykynurenine Levels in Multiple Sclerosis Patients – Maija Saraste, Markus Matilainen, Marcus Sucksdorff, Cecilia Rajda, Zsolt Galla, Laszlo Imre Vecsei, Laura Airas P14.4-008 Cerebral Blood Flow Dependency on Systemic Arterial Circulation in Progressive Multiple Sclerosis – Dejan Jakimovski, Brianna Gibney, Karen L. Marr, Deepa Ramasamy, Michael G. Dwyer, Niels Bergsland, Bianca WeinstockGuttman, Murali Ramanathan, Robert Zivadinov P14.4-009 Exploring in-vivo brain microstructural damage in multiple sclerosis through T1w/T2w-ratio mapping: a multicenter study – Monica Margoni, Elisabetta Pagani, Alessandro Meani, Loredana Storelli, Sarlota Mesaros, Jelena Drulovic, Frederik Barkhof, Hugo Vrenken, Antonio Gallo, Alvino Bisecco, Debora Pareto, Jaume Sastre-Garriga, Olga Ciccarelli, Marios Yiannakas, Jacqueline Palace, Paolo Preziosa, Maria Assunta Rocca, Massimo Filippi P14.4-010 Thalamic Volume Predicts Recovery from Cognitive Relapse – Zachary Weinstock, Michael G. Dwyer, Niels Bergsland, Dejan Jakimovski, Sarah Anne Morrow, Devon Conway, Tom Fuchs, Curtis Wojcik, Robert Zivadinov, Bianca WeinstockGuttman, Ralph H. B. Benedict
P14.4-011 Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome – Cassandre Landes-Chateau, Lydiane Mondot, Mikael Cohen, Celine Callier, Helene Zephir, Celine Louapre, Francoise Durand Dubief, Clarisse Carra-Dalliere, Eric Thouvenot, Emmanuelle Le Page, Aurelie Ruet, Eric Berger, Nathalie Derache, Pierre Clavelou, Thibault Moreau, Olivier Casez, Olivier F. Gout, Jerome De Seze, Jonathan Ciron, Sandrine Wiertlewski, Bertrand Bourre, Laurent Magy, Philippe Cabre, Jean Pelletier, Marc Debouverie, Bruno Stankoff, Alain Creange, Ombeline Fagniez, Corinne Pottier, Jean Philippe Neau, Jean-Phillippe Camdessanche, Carole Henry, Stephane Beltran, Anne Marie Guennoc, Ayman Poincaré Tourbah, Fatai Radji, Nathalie Morel, Karine Boyer, Abdullatif Al Khedr, Aksel Siva, Orhun H. Kantarci, Daniel Pelletier, Darin T. Okuda, Beverly AagardKienitz, SFSEP
5
Child Neurology and Developmental Neurology
Child Neurology: Neurovascular/Critical Care/Quality 3 P14.5-001 Reliability and Validity of a Novel Quick Neurologic Exam Tool for Assessing Patients in the Pediatric Intensive Care Unit (PICU) – Apirada Thongsing, Susan Erin Duberstein Coad, Michael Miksa P14.5-002 Use of intra-dural thrombolysis in a case of extensive pediatric Cerebral Sinus Venous Thrombosis (CSVT) and Venous infarction – Aya A. Ouf, Jaims Lim, Gull Sial, Kathleen Sellick, Renee Reynolds, Veetai Li, Leon A. Weinstock P14.5-003 Quantitative Cerebrovascular Reactivity Atlas In Children – Kenda Alhadid, Amanda Robertson, Kirsten Walker, Andrea Kassner, William J. Logan, Gabrielle A. DeVeber, Nomazulu Dlamini Child Neurology: Seizures/Genetic Syndromes 5 P14.5-004 Presence and Predictive Value of Midline Vertex Discharges on EEG in Children with Complex Febrile Seizures – Purva Choudhari, Alison M. Dolce, Andrea R. Lowden P14.5-005 A Case of CHD2 Epileptic Encephalopathy – Megan Bone, Kimberly Goodspeed, Dallas Armstrong
Information is accurate as of February 8, 2022, and is subject to change.
6
Research Methodology and Education
Teaching Across the Spectrum of Medical Education in Neurology 2 P14.6-001 Experiences with a virtual nationwide seminar series for neuroimmunology trainees – John Peters, John Corboy, Sarah E. Hopkins, Le Hua, Ahmed Z. Obeidat, Vijayshree Yadav, Erin Longbrake P14.6-002 Global Uptake of a Virtual Neurology Clinical Reasoning Conference: Live versus Asynchronous Learning – Valeria Roldan, Gabriela Figueiredo Pucci, Maria Jimena Aleman, Aaron L. Berkowitz P14.6-003 Fun with Physiology: Improving resident neurophysiology education with interactive quizzes – Jonathan Donnelly, Leila Saadatpour, Alejandro Tobon P14.6-004 Neurology and Child Neurology Training Program First Attempt Pass Data on the ABPN Certification Examinations – Dorthea Juul, Jaffar Khan, Larry R. Faulkner
7
Neuro Trauma and Critical Care
Neurocritical Care: Status Epilepticus, Brain Death and Cardiac Arrest 2 P14.7-001 Perspectives on the use of ancillary tests for determining neurological death: a survey of Canadian intensivists – Joel Neves Briard, Michael Yu, Livia Pinheiro Carvalho, Shane English, Frederick Daragon, Francois Lauzier, Alexis Turgeon, Sonny Dhanani, Lauralyn McIntyre, Sam Shemie, Greg Knoll, Dean Fergusson, Samantha Anthony, Matthew Weiss, Michael Chasse P14.7-002 Recognition of Unilateral Eye Opening as Spinal Motor Reflex in Brain Death – Eesha Oza, Nilufer Yalcin, Klepper A. Garcia, Manan Shah P14.7-003 Unilateral Spontaneous Pupillary Activity in Brain Death: A Case Report – Atef Kokash, Erafat Rehim, Tsneem Mbydeen, Preet M. Varade P14.7-004 Neurological Injury and Outcomes in Fentanylrelated Cardiac Arrest – Matheus Otero, Jonathan Shih, Edilberto Amorim De Cerquiera Filho P14.7-005 Diagnostic Accuracy of GCS Score compared to CRS-r for Consciousness – Greer Waldrop, Sachin Agarwal, Jerina Carmona, Kevin Doyle, Shivani Ghoshal, Soojin Park, David J. Roh, Qi Shen, Angela M. Velazquez, Athina Vrosgou, Jan Claassen
AAN.com/AM
81
Poster Session 14
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 3 P14.8-001 Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects – Dolly A Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Leslie Ruckle, Chad Orevillo, Philip Perera P14.8-002 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects – Dolly A Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Leslie Ruckle, Chad Orevillo, Philip Perera P14.8-003 Safety of a Second Dose of Diazepam Nasal Spray Within 4 Hours in Patients With Seizure Clusters: Final Results From a Long-Term, Phase 3, Open-Label, Repeat-Dose Safety Study – Gregory D. Cascino, Jay D. Desai, Daniel C. Tarquinio, James W. Wheless, Robert E. Hogan, Michael R. Sperling, Kore K. Liow, Sunita N. Misra, Adrian Rabinowicz, Enrique Carrazana Epilepsy and Clinical Neurophysiology (EEG): EEG 1 P14.8-004 Association of EEG Findings with Clinical Outcome in Patients with Encephalitis – Shirin Jamal Omidi, Rohini D. Samudralwar, Katherine Marie Johns Harris, Shivika Chandra, Rodrigo Hasbun P14.8-005 Meta-analysis of EEG Findings in Patients with PRES – Sihyeong Park, Arsalan Anwar, Sidra Saleem, Imran I. Ali P14.8-006 Utilization and findings of out-patient EEG in routine clinical care of patients with acute symptomatic seizure concern after acute stroke – Pradeep Chandan, Vineet Punia P14.8-007 Continuous EEG During ECMO: A Single-Center Retrospective Cohort Study – Jennifer Marie Olson, Brandon P. Foreman, Moshe Albert Mizrahi
Wednesday, April 6 11:45 a.m.–12:45 p.m.
9
Neuro-oncology
Neuro-oncology: Neuroimaging and Informatics 2 P14.9-001 Semi-Automated Longitudinal Lesion Tracking In PACS Reveals High Proportion of Metastatic Lesions Showing Mixed Response To Radiosurgery – Gabriel Ignacio Cassinelli Petersen, Tej Verma, Khaled Bousabarah, Leon Jekel, Sara Merkaj, Ryan C. Bahar, Sandra Abi Fadel, Ichiro Ikuta, MingDe Lin, Antonio M. P. Omuro, Mariam Aboian P14.9-002 Integration of Machine Learning Into Clinical Radiology Practice – Development of a Machine Learning Tool for Preoperative Glioma Grade Prediction – Sara Merkaj, Tal Zeevi, Khaled Bousabarah, Eve Kazarian, MingDe Lin, Andrej Pala, Gabriel Ignacio Cassinelli Petersen, Leon Jekel, Ryan C. Bahar, Niklas Joern Tillmanns, Jin Cui, Ichiro Ikuta, Richard A. Bronen, Sandra Abi Fadel, Malte Westerhoff, Antonio M. P. Omuro, Mariam Aboian P14.9-003 Cancer informatics survey of different grades and subtypes of glioma – Parampreet Kaur P14.9-004 Comparing Deep Learning and Classical Machine Learning Methods For Differentiating Primary CNS Lymphomas From Gliomas – A Systematic Review – Gabriel Ignacio Cassinelli Petersen, Julia Shatalov, Tej Verma, Waverly Rose Brim, Sara Merkaj, Ryan C. Bahar, Harry Subramanian, Jin Cui, Michele Hackley Johnson, Ajay Malhotra, Antonio M. P. Omuro, Mariam Aboian P14.9-005 Bias assessment of Artificial Intelligence papers in Glioma segmentation using TRIPOD – Avery Lum, Waverly Rose Brim, Harry Subramanian, Sam Payabvash, Ichiro Ikuta, MingDe Lin, Khaled Bousabarah, Michele Hackley Johnson, Ajay Malhotra, Mariam Aboian P14.9-006 Systematic Review of Machine Learning Models for Differentiation of Glioma from Brain Metastasis – Leon Jekel, Waverly Rose Brim, Gabriel Ignacio Cassinelli Petersen, Sara Merkaj, Harry Subramanian, Tal Zeevi, Sam Payabvash, Khaled Bousabarah, MingDe Lin, Jin Cui, Alexandria Brackett, Michele Hackley Johnson, Antonio M. P. Omuro, Bjorn Scheffler, Mariam Aboian P14.9-007 Differential Prevalence of Developmental Venous Anomalies in Glioma Subtypes – Jacob William Benson, Jerome J. Graber
82
2022 AAN Annual Meeting
10
Cerebrovascular Disease and Interventional Neurology
Interventional Neurology 3 P14.10-001 Outcomes in Acute Ischemic Stroke Patients with Metastatic Cancer Undergoing Mechanical Endovascular Revascularization: Analysis of the National Readmission Database – Hassan Osama Mostafa Aboul Nour, Ahmed Maraey, Mahmoud Khalil, Ahmed Elzanaty, Hadeer Rafat Elsharnoby, Daniel Miller, Stephan A. Mayer P14.10-002 Peri-embolization Use of Stent Retrievers as a Rescue Tool in Patients with Subarachnoid Hemorrhage – Abdallah Omar Amireh, Muhammad Nagy, Hassan M. Ali, Siddhart Kumar Mehta, Haralabos Zacharatos, Farah Yolanda Fourcand, Jawad F. Kirmani P14.10-003 Tachycardia is Associated with Mortality after Thrombectomy for Acute Ischemic Stroke – Penina Krieger, Amanda Jin Zhao, Leah Croll, Hannah Irvine, Jose L. Torres, Kara R. Melmed, Aaron S. Lord, Koto Ishida, Jennifer A. Frontera, Ariane Lewis P14.10-004 Effects of blood pressure management after endovascular thrombectomy on short term outcomes in patients with acute ischemic stroke – Jiping Zhou, Heba Samara, Ali Ebrahim, Jay Kinariwala, Wazim Mohamed P14.10-005 Novel Endovascular Method for Chronic Total Occlusion (CTO) of the Internal Carotid Artery (ICA) – Nicholas Ravindra Mulchan, Philip Yeung, Ambooj Tiwari, Jennifer A. Frontera, Ketevan Berekashvili, Jeffrey Farkas, Jose L. Torres, Matthew D. Sanger P14.10-006 Utility of IV thrombolysis and mechanical thrombectomy in nonagenarians with acute ischemic stroke – Tasha Ann Tombo, Anam Syed, Michael Wesolowski, Michael Joel Schneck P14.10-007 Reversible focal neurologic deficits as a complication of diagnostic cerebral angiogram – Anusha Mangalampalli, Sri Raghav Seshu Sista, Elias Samaha P14.10-008 Middle meningeal artery embolization performed through a transcarotid artery revascularization stent (TCAR) – Christopher Medina, Elie E. Dancour, Paul Wright P14.10-009 Hypoperfusion Intensity Ratio May Predict Cerebral Edema After Endovascular Thrombectomy – Caitlin Radnis, Anjali Asthana, Rima Dafer
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 14
P14.10-010 Anomalous Right Vertebral Artery Origin from the Right Common Carotid Artery: A Rare Angiographic Finding – Sara Habib, Ahmer Asif, Maria Shoaib, Sameera Siddiqui, Robert Alan Hamilton
11
Movement Disorders
Movement Disorders: PD Gut and Lung and PD Biomarkers 2 P14.11-001 No Accumulation of Glucosylceramide in PD Cerebrospinal Fluid – Tatsuro Mutoh, Yoshiki Niimi, Hisako Akiyama, Hirohisa Watanabe, Yoshio Hirabayashi P14.11-002 Poly (ADP-Ribose) and a–synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity – Fabrice Lucien, Eduardo E. Benarroch, Aidan Mullan, Farwa Ali, Bradley F. Boeve, Michelle M. Mielke, Ronald C. Petersen, Cole Daniel Stang, Emanuele Camerucci, Owen A Ross, Zbigniew K. Wszolek, David S. Knopman, James H. Bower, Wolfgang Singer, Rodolfo Savica
Movement Disorders: Tremor 1 P14.11-003 Type 2 Diabetes and the Risk of Parkinson’s Disease in an Essential Tremor Population – Julia Hendricks, Mary Taglieri, Mudit Gupta, Mihai Cosmin Sandulescu P14.11-004 WITHDRAWN P14.11-005 Patient-Specific Outcomes of Transcutaneous Afferent Patterned Stimulation with Varying Frequencies for Essential Tremor – Alexander Kent, Han Biehn Kim, Vedanshi Bhargava, Dhira Khosla, Kathryn Rosenbluth P14.11-006 Tremor and Quality of Life Following Thalamic Deep Brain Stimulation for Essential Tremor: 5-Year Outcomes. – Ka Loong Kelvin Au, Kelly E. Lyons, Michael T. Frassica, Binith Cheeran, Rajesh Pahwa P14.11-007 Low Initial Stimulation Amplitude Is Associated With Improved Tremor Outcome in Clinical Responders To VIM DBS For ET – Salman Ikramuddin, Rebecca Doran Butler, Jerrold L. Vitek, Lauren E. Schrock, Scott E. Cooper, Matthew Johnson, Joseph Y. Matsumoto
Wednesday, April 6 11:45 a.m.–12:45 p.m.
12
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology and Neuro-otology Cases 2 P14.12-001 An Unusual Case of Bilateral Orbital Hemorrhage – Sanem Pinar Uysal, Catherine Hassett, Dhimant Dani P14.12-002 An Unusual Case of Isolated Bilateral Papillitis – Molly Rachel Fensterwald, Angela Jinsook Oh, Perry Shieh, Samuel Spiegel P14.12-003 Postoperative Diffusion Restriction in Proximal Optic Nerve – Parth Pranav Parikh, Oana Maria Dumitrascu P14.12-004 Double trouble: A Unique Case of Herpes Zoster Ophthalmicus with Concomitant Abducens Nerve Palsy – Roberto Gomez, Anthony Fam, Machteld E. Hillen P14.12-005 A young female with acute onset visual disturbance: a case report – Jonathan Donnelly, Leila Saadatpour, Ali E. Kaabi, John E. Carter
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Inherited Muscle Disorders 3 P14.13-001 Cardiac MRI in Duchenne and Becker Muscular Dystrophy – Manu S S. G, Atchayaram Nalini, Ashita Barthur, Seena Vengalil, Saraswati Nashi P14.13-002 Prevalence and impact on quality of life of gastrointestinal and genitourinary symptoms in facioscapulohumeral muscular dystrophy – Michael Cole, June Kinoshita, Bridget Zimmerman, Katherine D. Mathews
P14.13-005 Evaluation of Total Binding Antibodies Against rAAVrh74 in Patients with Duchenne Muscular Dystrophy – Natalie Goedeker, Danielle A. Griffin, Sachi Dharia, Sourav Santra, Jesantha Coy, Nicole Yocum, Craig M. Zaidman P14.13-006 Understanding the patients’ journey to the diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a real-world retrospective data analysis – Chamindra G. Konersman, Kathryn Munoz, Richard A. Brook, Nathan Kleinman, Kelly Ditrapani, Bradley W. McEvoy, Alissa N. Peters, Trista Hardin, Chao-Yin Chen, Mark Stahl P14.13-007 Understanding Falls in FSHD – Enrico Bugiardini, Katy Eichinger, Michael George Hanna, Gita Ramdharry, Michael McDermott, Kiley Higgs, Michaela Walker, Leann Lewis, William Martens, Doris G. Leung, Sabrina Sacconi, Karlien Mul, Valeria A. Sansone, Elena Carraro, Leo Hong-Li Wang, Perry Shieh, Bakri Elsheikh, Samantha Jo LoRusso, Russell Butterfield, Nicholas Elwood Johnson, Maria Chiara Frisoni, Alrabi Tawil, Jeffrey Statland P14.13-008 Developmental changes of the axon initial segment in animal model of Duchenne Muscular Dystrophy – Samantha Lee Shallop, Tytus Bernas, Mathula Thangarajh P14.13-009 Facioscapulohumeral muscular dystrophy myopathologic dissection in 22 patients shows highly variable morphologic findings – Lisanne Hubregtse, Karlijn Bouman, Chéryane Lama, Saskia Lassche, Benno Kusters, Baptiste Periou, Francois Jerome Authier, Nicol Voermans, Edoardo Malfatti P14.13-010 Inherited Myopathy Plus: Double-Trouble from Rare Neuromuscular Disorders – Andre Granger, Grayson Bernard Beecher, Teerin Liewluck, Ruple S. Laughlin, Margherita Milone
P14.13-003 Prevalence of healthcare conditions and services used by patients with myotonic dystrophy (DM1 and DM2) prior to diagnosis; a real-world data analysis – John W. Day, Kathryn Munoz, Richard A. Brook, Bradley W. McEvoy, Li-Jung Tai, Kelly Ditrapani, Nathan Kleinman, Mohita Kumar, ChaoYin Chen, Mark Stahl P14.13-004 Development of Validated Clinical Outcome Assessments in Limb Girdle Muscular Dystrophy R1/2A – Nicholas Elwood Johnson, Kameron Bates, Han Xie, Lindsay N. Alfano, Conrad Weihl, Linda Pax Lowes, Matthew P. Wicklund, Katherine D. Mathews, Tahseen Mozaffar, Jessica St Romain, Erin DeSpain, Katy Eichinger, The GRASP Consortium
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
83
Poster Session 15
1
Autoimmune Neurology
Autoimmune Neurology: Neuromyelitis Optica Spectrum Disorder 2 P15.1-001 Inebilizumab Improves Pain Outcomes and Quality of Life in Neuromyelitis Optica Spectrum Disorder – Ho Jin Kim, Michael Smith, William Rees, Michele Gunsior, Eliezer Katz, Friedemann Paul P15.1-002 SAkuraBONSAI: A Prospective, Open-label Study of Satralizumab Investigating Novel Imaging, Biomarker, and Clinical Outcomes in Patients with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) – Anthony Traboulsee, Kazuo Fujihara, Ho Jin Kim, Romain Marignier, Kevin O’Connor, Robert C. Sergott, Heinz Wiendl, Jens Wuerfel, Scott S. Zamvil, Sean J. Pittock, Veronica Anania, Regine Buffels, Thomas Kuenzel, Sian Lennon-Chrimes, Jeffrey L. Bennett P15.1-003 Cognitive Impairment in Neuromyelitis Optica Spectrum Disorder (NMOSD) – Luka Vlahovic, Jamie C. McDonald, Jessica Hinman, Anna Tomczak, Christopher Lock, Gayle Deutsch, Lorene M. Nelson, May Han P15.1-004 Safety and Efficacy of Inebilizumab as Treatment for Newly Presenting Neuromyelitis Optica Spectrum Disorder – John William Lindsey, Evanthia Bernitsas, Dewei She, Eliezer Katz, Bruce A. C. Cree P15.1-005 Neuromyelitis optica / Neuromyelitis optica spectrum disorders: pattern of clinical presentation, radiological characteristics, and AQP4 serological status among Sudanese patients – Etedal Ahmed Ibrahim, Eiman Hamid P15.1-006 Long-term Efficacy and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease – Eleni Vasileiou, Paula Barreras, Angeliki Filippatou, Kathryn Fitzgerald, Michael Levy, Ellen M. Mowry, Peter A. Calabresi, Elias S. Sotirchos P15.1-007 Indirect Comparison Analysis of FDA-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder – Dean M. Wingerchuk, Sean J. Pittock, Michael Levy, Kazuo Fujihara, Ichiro Nakashima, Friedemann Paul, Adrian Kielhorn, Minying Royston, Imran Tanvir, Inar Zhang
84
2022 AAN Annual Meeting
Wednesday, April 6 5:30 p.m.–6:30 p.m.
2
Headache
Headache: Migraine Therapeutics 5 P15.2-001 Efficacy of Intravenous Valproic Acid and Oral Valproic Acid Tapers for Treatment of Pediatric Headaches in the Emergency Department – Scott Rosenthal, Emma Lynn Mazzio, Hannah Wellman, Jill Marks, Jerry Jewell, Sarah Guistolisi, Jan A. Martin, Ricka Messer, Rakesh Mistry, Marcy E. Yonker, Craig A. Press P15.2-002 The Efficacy of Transdiagnostic Cognitive Behavioral Therapy on Migraine Headache: A Randomized Clinical Trial – Negin Badihian, Forouzandeh Soleimanian Boroujeni, Shervin Badihian, Vahid Shaygannejad, Yousef Gorji P15.2-003 Exploratory Efficacy of INP104 by Migraine Attack Severity and Time of Dosing: Results From the Phase 3 STOP 301 Study – Brian D. Loftus, Michelle Murphy, Christopher J. Fitzpatrick, Sutapa Ray, Stephen Bevan Shrewsbury, Sheena K. Aurora P15.2-004 Celecoxib Oral Solution in the Acute Treatment of Migraine: Pooled Efficacy and Safety Results From 2 Randomized Placebo-controlled Trials – Stewart J. Tepper, Harvey Kushner, Mancia M. Ko, Todd Kunkel, Richard B. Lipton P15.2-005 Improvements in Disability, Migraine Frequency, and the Interictal Period with INP104: Results from the Phase 3 STOP 301 Study – Cynthia Emilie Armand, Dawn C. Buse, Robert Vann, Sutapa Ray, Stephen Bevan Shrewsbury, Sheena K. Aurora P15.2-006 Impact of Celecoxib Oral Solution on Symptomatic Improvements in the Acute Treatment of Migraine – Stewart J. Tepper, Harvey Kushner, Mancia M. Ko, Todd Kunkel, Richard B. Lipton
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Aspects 1 P15.3-001 The Diagnostic Utility of the Motor Perseveration Sign for the Identification of Mild Neurocognitive Disorder and Dementia – Brad Tyson, Puneet Kainth, Pinky Agarwal P15.3-002 Q-RUDAS: A Cognitive Test Adapted To The Indigenous Cuzco Quechua Language, Pilot Study – Nilton Custodio Capunay, Marco Moises Malaga, Enrique Choquenaira Imata, Victor Andrés Velasquez Rimachi, Aaron Rodriguez, Carlos AlvaDiaz, Rosa Montesinos
P15.3-003 A Review of Posterior Cortical Atrophy over 25 Years – Golnoush Akhlaghipour, Oleg Yerokhin Yerstein, Leila Parand, Li-Jung Liang, Adrienne Isaac, Youssef I. Khattab P15.3-004 WITHDRAWN P15.3-005 Prevalence of Comorbidities in a National Sample of Lewy Body Dementia Caregivers – Anna Moshkovich, Melissa Levin, Faizan Akram, Serena Hess, Jori Fleisher
4
MS and CNS Inflammatory Disease
MS Neuroimaging 3 P15.4-001 Contrast enhancement sources on postGadolinium “black-blood” 3D T1-weighted Turbo-Spin-Echo images in patients with multiple sclerosis. – Claudio Gobbi, Lucia Danieli, Daniela Distefano, Alessandro Cianfoni, Luca Roccatagliata, Emanuele Pravatà, Chiara Zecca P15.4-002 Predicting Treatment Response with MRI-Based Subtyping in Relapsing and Secondary Progressive MS – Arie Gafson, Phoebe Jiang, Changyu Shen, Dawei Liu, Rodrigo Perea, Douglas L. Arnold, Colm Elliott, Bing Zhu, Elizabeth Fisher, Olga Ciccarelli, Declan Chard, Frederik Barkhof, Arman Eshaghi, Shibeshih Belachew P15.4-003 Myelin Mapping in Trigeminal Neuralgia: Standardizing Conventional MR Images Enables Quantitative Comparison of Myelin Content – Meng Fei Li, Powell Chu, Peter Shih-Ping Hung, David J. Mikulis, Moji Hodaie P15.4-004 Assessment of cervical spinal cord volume in pediatric-onset multiple sclerosis – Saher Suleman, Matthew Harwood, Paul Kang, Ram Narendra Narayan, Jeremy Hughes P15.4-005 An imaging signature in choroid plexuses in pre-symptomatic multiple sclerosis – Vito Antonio Gerardo Ricigliano, Arya Yazdan Panah, Andrea Lazzarotto, Michel Bottlaender, Benedetta Bodini, Celine Louapre, Bruno Stankoff P15.4-006 Quantitative Analysis of MS Lesion in Cervical Spinal Cord (CSC) using Ultrahigh-b DWI (UHbDWI) – Kyle E. Jeong, Lubdha Shah, Sophie Lee, Bijaya Thapa, Nabraj Sapkota, Erica Bisson, Noel Carlson, Eun-Kee Jeong, John W. Rose
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 15
P15.4-007 Cerebrospinal Fluid Lymphocytic Pleocytosis is Associated With Enhanced Blood-Brain Barrier Breakdown at the Time of Multiple Sclerosis Diagnosis – Dinesh Keran Sivakolundu, Miriyam Kopyto, Katherine Hill, Hebatalla Elhusseiny, Robert K. Fulbright, David A. Hafler, Erin Longbrake P15.4-008 Automated MRI features of MS and common radiological mimickers – Moein Amin, Kunio Nakamura, Daniel Ontaneda P15.4-009 Longitudinal Assessment of Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis on Interferon beta-1a – Ka-Ho Wong, Rae E. Bacharach, Anette Fjeldstad, Julia Klein, M. Mateo Paz Soldan, John W. Rose P15.4-010 Examining Regional Brain Volume Differences in Radiologically Isolated Syndrome – Jeffrey Glaister, Melanie Guenette, Adelia Adelia, Scott Patten, Alexandre Prat, Roger Tam, Anthony Traboulsee, Shannon Kolind, Jiwon Oh
5
Child Neurology and Developmental Neurology
Child Neurology: SMA/DMD/Muscle 1 P15.5-001 Onasemnogene Abeparvovec in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with Three Copies of SMN2 – Kevin Strauss, Francesco Muntoni, Michelle A. Farrar, Kyoko Saito, Jerry R. Mendell, Laurent Servais, Hugh John McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Anne Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra Tauscher-Wisniewski, Bryan McGill, Thomas Macek P15.5-002 The RESTORE Registry: Real-World Assessments of Interventions and Long-Term Outcomes in Patients with Spinal Muscular Atrophy (SMA) – Richard Finkel, John W. Day, Darryl C. De Vivo, Eugenio Mercuri, Francesco Muntoni, Perry Shieh, Eduardo Tizzano, Isabelle Desguerre, Kyoko Saito, Melissa Menier, Nicole LaMarca, Fred Anderson, Omar Dabbous, Laurent Servais
Wednesday, April 6 5:30 p.m.–6:30 p.m.
P15.5-004 JEWELFISH: Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam – Claudia A. Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Janbernd Kirschner, Eugenio Mercuri, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Francis Warren, Mariacristina Scoto P15.5-005 Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial – Thomas O. Crawford, Basil T. Darras, John W. Day, Guochen Song, Georgios Nomikos, Amy Place, Doreen Barrett, Sanela Bilic, Janet ONeil, Nathalie Kertesz, Shaun Cote, Jagdish Patel, Yung Chyung
6
Neuro-rehabilitation
General Neuro-rehabilitation 1 P15.6-001 Loss of Regained or Spared Function after SCI (Neuroworsening): Evidence and Dimension – Markus Harrigan, Marcel Kopp, Juan Peng, YuYing Chen, Clayton Peterson, Jan M. Schwab P15.6-002 Nabiximols Efficacy in Multiple Sclerosis (MS) Spasticity: Treatment Effects on Spasticity Numeric Rating Scale (NRS) and Muscle Spasm Frequency in 2 Randomized Clinical Trials – Sajida Javaid, Fred D. Lublin, Jacqueline Ann Nicholas, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse, Daniel Checketts, Joshua R. Steinerman
7
Practice, Policy, and Ethics
Practice, Pitfalls, and Innovation 2 P15.7-001 Challenges in Deploying Low-Field and Ultra-Low Field MRI in Research, Clinical Care, Population Screening, and Direct-to-Consumer Use – Francis X. Shen, Susan Wolf, Michael Garwood, Duke Han, Judy Illes, W. Taylor Kimberly, Eran P. Klein, Karen Rommelfanger, Matthew Rosen, Kevin N. Sheth, Efrain Torres, Paul J. Tuite, John Thomas Vaughan P15.7-002 Updates and Improvements to the American Academy of Neurology Guideline Dissemination Practices – Sarah Tanveer, Sonja Potrebic, Mark Robert Keezer, Navdeep Sangha, Vishwanath Sagi, Scott A. Heller, Mia T. Minen, Anne Encarnacion Agraviador Constantino, Mark Douglas Johnson, Benzi Kluger, Kelly Sullivan, Scott Wessels P15.7-003 Hospital Teleneurology Role Leads to Significant Wait Time Reduction for Follow Up Appointments and Increased Access to Subspecialists – Matthew Hart, Sandeep Gill, Sukhraj Gill, Julianne Leah Gay, Scott M. Friedenberg, Anthony Noto P15.7-004 Patient Response to Telephonic follow up In Neurology: A Hospital Based Study – Anand Kumar, Varun Kumar Singh, Deepika Joshi, Abhishek Pathak, Rameshwar Nath Chaurasia, Vijaya Nath Mishra, Neha Lall, Pratishtha Sengar P15.7-005 Characterization of General Neurology Emergency Department Discharge Consultations: A Pilot Study into Potentially Avoidable Neurological ED Visits – Anik Amin
P15.6-003 Impact of Cerebral Small Vessel Disease on Neurological Outcomes Following Traumatic Brain Injury – Gary Robert Salomon, Kevin M. Barrett P15.6-004 Width of Tissue Bridges Predicts Neurologic Recovery 3 Months After Spinal Cord Injury: a Multi-Center Study – Dario Pfyffer, Andrew Craig Smith, Kenneth Arnold Weber, Christina Draganich, Jeffrey Berliner, Candace Tefertiller, Torsten Hothorn, Jan M. Schwab, Armin Curt, Patrick Freund
P15.5-003 The RESTORE Registry: Comparative Outcomes in Patients with Spinal Muscular Atrophy (SMA) in the United States Identified by Newborn Screening (NBS) or Clinical Diagnosis – Laurent Servais, Darryl C. De Vivo, Janbernd Kirschner, Eugenio Mercuri, Francesco Muntoni, Eduardo Tizzano, Susana Quijano-Roy, Kyoko Saito, Melissa Menier, Nicole LaMarca, Fred Anderson, Omar Dabbous, Richard S. Finkel
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
85
Poster Session 15
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 4 P15.8-001 Timing to Administration and Ease of Dosing of Diazepam Nasal Spray Rescue Therapy for Seizure Clusters: Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study – Jay D. Desai, Robert E. Hogan, James W. Wheless, Michael R. Sperling, Kore K. Liow, Daniel C. Tarquinio, Dennis J. Dlugos, Gregory D. Cascino, Sunita N. Misra, Adrian Rabinowicz, Enrique Carrazana P15.8-002 Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with FocalOnset and Generalized-Onset Seizures – Taoufik Alsaadi, Manuel Toledo, Fernando Ayuga Loro, Eugen Trinka, Tony Wu, Manoj Malhotra, Stella Leock Ngo, Antonio Gil-Nagel, Vicente Villanueva P15.8-003 Effectiveness and Tolerability of Brivaracetam by Reason for Initiation in Adults with Focal Seizures: Post-hoc Analysis of a Real-world, US Study – Heidi L. Henninger, Michael R. Sperling, Hamada Hamid Altalib, Hina N. Dave, Michael Gelfand, Roger J. Porter, Melinda S. Martin, Sami Elmoufti, Anne-Liv Schulz, Prashant Dongre, Jacqueline French Epilepsy and Clinical Neurophysiology (EEG): Epilepsy Co-morbidities 1 P15.8-004 Clinical Correlates of Cyclic Alternating Pattern of Encephalopathy (CAPE) – Crystal Jing Yu, Christine Smith, Taylor Maxwell Parker, Karly A. Landvay, Calvin Hu, Stephan Eisenschenk, Yue Wang, Maria J. Bruzzone, Carolina B. Maciel P15.8-005 The Management of Patients with Epilepsy Taking Anti-Epileptic Drugs Associated with Metabolic Bone Disease – Ma Su Su Aung, Shreeja Kadakia, Brian James Hanrahan P15.8-006 Seizure Incidence in Lung Transplant Patients – Maria Kristina Casanova Dorotan, Robert Bodroghy, Zachariah Dorey-Stein, Ching Tsao P15.8-007 Cognitive Deterioration in a Patient with Down Syndrome Presenting as Epileptic Encephalopathy – Annika Daya, Vinita J. Acharya, Jayant N. Acharya
86
2022 AAN Annual Meeting
Wednesday, April 6 5:30 p.m.–6:30 p.m.
9
Neuro-oncology
Observations in Neuro-oncology 1 P15.9-001 Clinical Reasoning: A 65-year-old Woman with Cancer History and Wrist Drop – Rebecca Merrill, Meaghan Puckett, William Patrick Morrow, Jason Powell, Eric Hsi, Rakhee Vaidya, Roy E. Strowd P15.9-002 Small Lymphocytic Lymphoma Causing Probable Vasculitic Neuropathy: A Distinctive Neurologic Manifestation of a Rare Hematologic Entity – Nishika Karbhari, Molly Perkins, Arati Gangadharan, Sean Soorena Zadeh, George Zanazzi P15.9-003 Erdheim-Chester Disease with Isolated CNS Involvement: A Case Report and Systematic Review of Literature – Anam Qamar Haque, Carlos Alberto Perez, Thejasvi Anantasagar Reddy, Rajesh K. Gupta P15.9-004 Anaplastic Pleomorphic Xanthoastrocytoma with Extracranial Bone Metastasis: A Case Report and Literature Review – Edith Jia-Jiun Yuan, Emily T. Lo, Tania Vartanians, Thomas Chen, Frances E. Chow P15.9-005 Brainstem Small Lymphocytic Lymphoma (SLL) Presenting as Serpiginous Small Vessel Enhancement and Peduncular Hallucinosis: A First Case Report – Brigitte Reina, Amy Chan P15.9-006 Erdheim-Chester Disease: A rare case with central nervous system involvement – José Maria Bandeira Costa, Joana Marques P15.9-007 A Fatal Case of Primary Diffuse Leptomeningeal Melanomatosis – Ramiro Gabriel Castro Apolo, Negar Moheb, Cleo Zarina Alejo Reyes, Sayyeda Zahra, Preet M. Varade
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Neuroimaging 2 P15.10-001 Associations of Intracranial Vascular Features on Non-contrast Enhanced MRA with Cognitive Impairment – Anders Gould, Zhensen Chen, Duygu Baylam Geleri, Niranjan Balu, Li Chen, Xu Peng, Kristi Pimentel, Gador Canton, Thomas Hatsukami, Chun Yuan P15.10-002 Clinical Utility of Intravascular Ultrasound (IVUS) in Carotid Artery Interventions – A systematic review and meta-analysis. – Awadh K. Pandit, Biswamohan Mishra, Venugopalan Y Vishnu, Shubham Misra, M.V.Padma Srivastava, Achal K. Srivastava, Shashank Sharad Kale P15.10-003 CT Perfusion Parameters for Early Prediction of Malignant Cerebral Edema in Hemispheric Infarction – Eesha Oza, Brian Alexander Tong, Dan Victor Giurgiutiu, Nilufer Yalcin, Klepper A. Garcia, Deepak Nag Ayyala, Askiel Bruno, Manan Shah P15.10-004 Deep medullary veins are associated with widespread brain structural abnormalities – Zi-Yue Liu, Feifei Zhai, Dong-Hui Ao, Fei Han, Ming-Li Li, Li-Xin Zhou, Jun Ni, Ming Yao, Shu-Yang Zhang, Li-Ying Cui, Zheng-Yu Jin, Yi-Cheng Zhu P15.10-005 Ultra High-field MRI Versus 1.5/3 T MRI in the Detection of Cerebrovascular Disease – David T. Krist, Rachael Tessem, Anant Naik, Tracy Kao, Victoria Andrea Blaiotta-Vazquez, Wael Ali Hassaneen Mostafa, Tracey Wszalek, Aaron Thomas Anderson, Paul Arnold P15.10-006 The Predictive Value of Multimodal Intraoperative Neuromonitoring Techniques for Periprocedural Preventive Interventions during Carotid Surgery – Brandon Trang Nguyen, Cara Joyce, Bernadette Aulivola, Michael Joel Schneck P15.10-007 Motor Tract Variations and Walking Recovery after Thalamic Hemorrhage: Analyses by Diffusion Tensor Tractography – Aki Arai P15.10-008 Unusual Multicompartmental Intracranial Hemorrhage After Tenecteplase Administration – Abdallah Omar Amireh, Muhammad Nagy, Hassan M. Ali, Haralabos Zacharatos, Siddhart Kumar Mehta, Farah Yolanda Fourcand, Jawad F. Kirmani P15.10-009 Illustration of exacerbating cortical superficial siderosis on close-up MRIs after resumption of anticoagulant therapy. – Bianca Oana Pîrlog, Augustin Gaudemer, Pierre Amarenco, Celine Guidoux
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 15
P15.10-010 Intracranial Hemorrhage due to Arteriovenous Malformations in Hepatic Cirrhosis – Maya Mounir Ramy, Kiely Whitham, Denny Joseph, Orlando Diaz, Tanu Garg
11
Movement Disorders
Movement Disorders: Atypical Movement Disorders 1 P15.11-001 Acute Parkinsonism Secondary to CHANTER Syndrome – Dharti Dua, Cody Magnuson, Amir Adeli P15.11-002 Iron accumulation correlates with disease severity in patients with Multiple System Atrophy – Daniel O. Claassen, Paula Trujillo Diaz, Jessie Iregui, Amy Wynn, Kilian Hett, James Silverman, Yan Yan, Hakmook Kang, David A. Stamler P15.11-003 Primary Familial Brain Calcification with Leukoencephalopathy Associated with a Novel Variant in PDGFB – Jack Shen, Alberto J. Espay, Emily J. Hill P15.11-004 Spectrum of Movement disorders of late-onset Niemann- Pick disease type C – Jasmine Parihar, Deepa Dash, Bhawana Aggarwal, Madhulika Kabra, Roopa Rajan, Deepti Vibha, Rajesh Kumar Singh, Rohit Bhatia, Neerja Gupta, Manjari Tripathi
Movement Disorders: Tremor 2 P15.11-005 Prospective, Multicenter, International Registry of Deep Brain Stimulation for Essential Tremor – P.R. Schuurman, Guenther Deuschl, Lilly Chen, Roshini Jain P15.11-006 Annual Health Care Costs Among Medicare Beneficiaries with Essential Tremor – Elan D. Louis, Kandice A. Kapinos P15.11-007 Increased Healthcare Cost and Mental Health Burden among Patients with Essential Tremor: A Retrospective Observational Study in A Large US Commercially Insured and Medicare Advantage Population – Dingwei Dai, Ali Samiian, Henriette Coetzer, Joaquim Fernandes
12
Wednesday, April 6 5:30 p.m.–6:30 p.m.
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology and Neuro-otology Research: Ocular Motor and Vestibular 1 P15.12-001 Effect of Convergence on the Horizontal VestibuloOcular Reflex in Normal Volunteers, Unilateral Acute and Subacute Peripheral Vestibulopathy and in One Patient with an Unilateral Pontine Tegmentum Lesion – Ammar Lamak Ujjainwala, Cal Dewar, Laurel Donaldson, Caroline Marie Rayburn, Emily Buenting, Jordan Noelle Boyle, Jorge C. Kattah P15.12-002 Delineating the anatomical basis of microsaccades using an ultrasensitive technique for detection of deficits in patients with MS – Christy Kathleen Sheehy, Eduardo Caverzasi, Christian Cordano, Ari Green P15.12-003 Mobile Integrated Cognitive Kit (MICK): A Digitized Visual Rapid Automatized Naming (RAN) Task for Concussion on the Sidelines – Scott Grossman, George Park, Lisena Hasanaj, Marc Balcer, Todd Hudson, John-Ross Rizzo, Janet C. Rucker, Steven Galetta, Laura J. Balcer P15.12-004 Quality of Life in Classical (infratentorial) Superficial Siderosis – Natallia Kharytaniuk, Amir Mazaheri, Menelaos Pavlou, David Werring, DorisEva Bamiou P15.12-005 Usefulness 3 tesla magnetic resonance imaging in the evaluation of central acute vestibular syndrome – Florencia Wainberg, Alfredo H. Laffue, Francisco Gualtieri
13
P15.13-004 Immune-mediated rippling muscle disease (iRMD): Clinical-electrophysiological-pathological spectrum and long-term outcomes – Grayson Bernard Beecher, Divyanshu Dubey, James Douglas Triplett, Teerin Liewluck, William J. Litchy, Margherita Milone P15.13-005 A comparison study of different imaging technologies in Inclusion Body Myositis – Anthony K. Ma, Bhaskar Roy P15.13-006 Less fatty infiltration of the quadriceps muscles in dysphagic inclusion body myositis – Kenichiro Taira, Madoka Mori-Yoshimura, Toshiyuki Yamamoto, Yasushi Oya, Ichizo Nishino, Yuji Takahashi P15.13-007 Anti (3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy: A Muscular Dystrophy Mimicker In Pediatric Patient – Rocio Delgado Diaz, Brenda Deliz Roldan, Alexandra M. Montalvo Acevedo, Ivonne Arroyo P15.13-008 Dysphagia in patients with Inclusion Body Myositis: A national inpatient sample-based study – Anthony K. Ma, Bhaskar Roy P15.13-009 Diagnostic delay and challenges in a case of sarcoid myositis – Maria Elisa Samaniego, Paul T. Twydell, Anvita Potluri P15.13-010 Improving Patient Outcomes through Standardized Protocols when prescribing Glucocorticoids. – Tiffany Chang, David Post, Neelam Goyal
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Acquired Myopathies 1 P15.13-001 Proteomic profiling of sporadic late-onset nemaline myopathy – Elie Naddaf, Surendra Dasari, Duygu Selcen, Cristine Charlesworth, Ken L. Johnson, Michelle L. Mauermann, Taxiarchis Kourelis P15.13-002 Atypical Presentations of Inclusion Body Myositis – Mazen S. Alamr, Marcus Vinicius Rocha Pinto, Elie Naddaf P15.13-003 Myopathies associated with large granular lymphocytic (LGL) leukemia – Pritikanta Paul, Margherita Milone, Min Shi, Mithun Shah, Teerin Liewluck
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
87
Thursday, April 7 8:00 a.m.–9:00 a.m.
Poster Session 16
1
Autoimmune Neurology
Autoimmune Neurology: NMOSD and MOGAD 3 P16.1-001 WITHDRAWN P16.1-002 Cerebral cortical encephalitis in Myelin Oligodendrocyte Glycoprotein Antibodyassociated Disease – Cristina Valencia Sanchez, John Chen, Jan-Mendelt Tillema, Claudia F. Lucchinetti, Mayra Montalvo Perero, Paul Martin Elsbernd, Alfonso Sebastian Lopez, Adrian Budhram, Elia Sechi, Amy Kunchok, Divyanshu Dubey, Sean J. Pittock, Eoin P. Flanagan P16.1-003 MOGAD in the Mountain West: Epidemiology and Outcomes in Pediatric and Adult Patients at Two Large Academic Referral Centers – Suzanne Liu, Melissa Wright, Ka-Ho Wong, Christopher Steven Mizenko, Ryan Kammeyer, Teri Schreiner, Robert Kadish, Tammy L. Smith, Jonathan Ross Galli, Julia Klein, John E. Greenlee, John W. Rose, M. Mateo Paz Soldan, Jeffrey L. Bennett, Joshua Bonkowsky, Lisa Kay Peterson, Amanda Lee Piquet, Stacey Clardy
Autoimmune Neurology: MOGAD 2 P16.1-004 MOG Antibody-Associated Disease Manifesting as MRI-Negative Encephalitis: A Case Report and Literature Review – David M. Anson, Akshaya Prabhakaran Sudha, Natalie Bartnik, Arpan Patel P16.1-005 A Case of MOGAD Optic Neuritis Initially Misclassified As CLIPPERS – Ethan Daniel ZerpaBlanco, Stan C. Kunigelis, Stacy Victoria Smith P16.1-006 A case of MOG antibody disorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis – Mark Keroles, Brian Rogers Stocksdale, Jessica P. Ng, Sahar Ahadi, Jeffrey E. Dunn
2
Headache
Headache: Advances in CGRP Inhibition for Precision Medicine 4 P16.2-001 Fremanezumab for Preventive Treatment in Migraine: The FINESSE Study – Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Torsten Kraya, Isabel Schauerte, Lars Neeb P16.2-002 Changes in Acute Headache Medication Use Among Patients With Chronic Migraine and Medication-Overuse Headache: An Exploratory Analysis of PROMISE-2 – Robert Cowan, Michael J. Marmura, H. Christoph Diener, Amaal J. Starling, Jack D. Schim, Joe Hirman, Thomas Brevig, Roger Cady P16.2-003 Timing and Location of Injection-site Adverse Events With Fremanezumab in Patients With Migraine: A Pooled Analysis of Phase 3 Studies – Holle Lee Dagny, Yoel Kessler, Verena Ramirez Campos, Xiaoping Ning, Joshua M. Cohen, Steve Barash, Tim Jürgens P16.2-004 Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Post-hoc Efficacy Analysis – Marc Ehrlich, Monika Maier Peuschel, Christian Sieder, Christian Hentschke, Uwe Reuter P16.2-005 Reductions in Acute Medication Use for Patients with Migraine Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis – Lynda Krasenbaum, Maurice Driessen, Michael Seminerio, Robert DiEgidio, Marc Tian P16.2-006 Effect of Erenumab on Patient-Reported Outcomes in Patients With Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study – Shuu-Jiun Wang, Artemio A. Roxas, Bibiana Saravia, Byung-kun Kim, Debashish Chowdhury, Naji J. Riachi, Sharon Mei Ling Tai, Surat Tanprawate, Tai Ngoc Tran, Yi Jing Zhao, Gabriel Paiva da Silva Lima, Shaloo Pandhi, Shihua Wen, Subhayan Mondal, Laurent Ecochard, Michal Arkuszewski
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Aspects 2 P16.3-001 A prospective observational study using questionnaires on the treatment needs of patients with dementia with Lewy bodies, their caregivers, and their physician in Japan – Yuta Manabe, Mamoru Hashimoto, Takuhiro Yamaguchi, Shunji Toya, Manabu Ikeda
88
2022 AAN Annual Meeting
P16.3-002 Creutzfeldt-Jakob disease predictors of survival: a 10 year experience from a reference center in Argentina – Santiago Crema, Micaela Hernandez, Juan Ignacio Castiglione, Ismael Calandri, Gustavo Sevlever, Ricardo F. Allegri P16.3-003 Exploring Gentrification’s Impact on the Cognitive Health of Older Black Adults – Ann Wachana, Sophia Aron, Holly E. Hinson, Raina Croff P16.3-004 Cognitive and Neuropsychiatric features of an Alzheimer ´s Disease Cohort in the Peruvian Population – Mario R. Cornejo Olivas, Pedro Mena, Maryenela Illanes-Manrique, Larry D. Adams, Elison Sarapura-Castro, Victoria Marca, Rosario Isasi, Sheila Castro Suarez, Gary W. Beecham, Koni Mejia, Jeffery M. Vance, Carla Manrique Enciso, Michael L. Cuccaro, Maria Meza-Vega, Margaret A. Pericak-Vance P16.3-005 Baseline Characteristics of the GRADUATE Studies: Phase III Randomized, PlaceboControlled Studies Investigating Subcutaneous Gantenerumab in Participants with Early Alzheimer’s Disease – Christopher Lane, Szofia S. Bullain, Angeliki Thanasopoulou, Paul Delmar, Merce Boada Rovira, Timo Grimmer, Diana Kerwin, Paulo Pacheco Fontoura, Monika Baudler, Geoffrey A. Kerchner, Rachelle Doody
4
MS and CNS Inflammatory Disease
MS Clinical Assessments & Outcome Measures P16.4-001 Temporal Mapping of Trigeminal Neuralgia Lesions to Symptom Onset in Multiple Sclerosis: When Do the Lesions Occur and What Do They Tell Us? – Sonam Dilwali, Ian Mark, Emmanuelle Waubant P16.4-002 Automatic rating of the neurological examination in multiple sclerosis: a proof of concept – Mikael Cohen, Christine Lebrun Frenay P16.4-003 Assessing treatment response in pediatric multiple sclerosis patients – Ermelinda De Meo, Massimo Filippi, Vincenzo Brescia Morra, Francesco Patti, Giorgia Teresa Maniscalco, Valentina Torri Clerici, Giuseppe Salemi, Marco Onofrj, Giacomo Lus, Marta Simone, Maria Trojano, Maria Pia Amato
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 16
P16.4-004 Spinal Cord Lesions and Brain Grey Matter Atrophy Independently Predict Clinical Worsening in Multiple Sclerosis: A 5-Year, Multicentre Study – Maria Assunta Rocca, Paola Valsasina, Alessandro Meani, Claudio Gobbi, Chiara Zecca, Frederik Barkhof, Menno M Schoonheim, Eva Strijbis, Hugo Vrenken, Antonio Gallo, Alvino Bisecco, Olga Ciccarelli, Marios Yiannakas, Alex Rovira, Jaume Sastre-Garriga, Jacqueline Palace, Lucy Matthews, Achim Gass, Philipp Eisele, Carsten Lukas, Barbara Bellenberg, Monica Margoni, Paolo Preziosa, Massimo Filippi P16.4-005 Evaluating the Impact of Administration of Ocrelizumab via Home Infusion on Safety and Patient Reported Outcomes – Britney Barrera, Haley Simpson, Eric Engebretson, Stefan Sillau, Brooke L. Valdez, Britney Barrera, Ryan Christopher Winger, Enrique Alvarez, Robert H. Gross, Amanda Lee Piquet, Teri Schreiner, John Corboy, Jinglan Pei, Timothy L. Vollmer, Kavita Nair P16.4-006 Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder – Elisabet Lopez-Soley, Sara Llufriu, Rocio Gomez, Jorge Maurino, Francisco Perez Miralles, Lucia Forero Diaz, Maria Sepúlveda, Carmen Calles, Maria Luisa Martinez Gines, Ines Gonzalez, Sabas Boyero, Lucía Romero-Pinel, Angel Perez Sempere, Virginia Meca Lallana, Luis Querol, Lucienne Costa Costa-Frossard Franca, Albert Saiz, Jose Meca Lallana, Elisabeth Solana P16.4-007 Evaluation of NEDA as a Predictor of Disease Progression in Patients With RMS and PPMS Treated With Ocrelizumab: Post-Hoc Analyses From the OPERA I/OPERA II and ORATORIO Trials – Xavier Montalban, Maria Pia Sormani, Harold Koendgen, Fabian Model, James Overell, HansMartin Schneble, Qing Wang, Dalia Rotstein P16.4-008 Estimating the profile of responders to treatment in the phase 3 EXPAND trial: do different patients show benefits on different outcomes? – Francesca Bovis, Ludwig Kappos, Sophie Arnould, Goeril Karlsson, Daniela Piani Meier, Maria Pia Sormani P16.4-009 High Efficacy Agents as First Line Treatment of Relapsing Forms of MS – Chiara Bellomo, Alexander Abud, Jonathan Cahill, Saima Chaudhry, Syed Rizvi P16.4-010 “The missing-piece sign” located in the cervical spinal cord in sDAVF – Jonathan Morena
5
Thursday, April 7 8:00 a.m.–9:00 a.m.
Child Neurology and Developmental Neurology
Child Neurology: SMA/DMD/Muscle 2 P16.5-001 Implementation of Spinal Muscular Atrophy Newborn Screening across the US – Mary K. Schroth, Maynard Friesz, Lisa Belter, Mary Curry, Jacqueline Glascock P16.5-002 MANATEE: A Study of RO7204239 in Combination with Risdiplam Treatment in Pediatric Patients with SMA – Tina Duong, Basil T. Darras, Jasper Morrow, Francesco Muntoni, Laurent Servais, Imogen Carruthers, Marianne Gerber, Heidemarie Kletzl, Carmen Martin, Becca Zhang, Renata Scalco, Eugenio Mercuri P16.5-003 Scurvy as a forgotten cause of pseudo-ataxia child; A Case Report with muscle pathology and musculoskeletal MRI findings. – Pitchamol Vilaisaktipakorn, Montida Veeravigrom P16.5-004 Health Care Resource Utilization in Spinal Muscular Atrophy Type 1 Patients in Japan: Results of a Global Caregiver Survey – Walter Toro Jimenez, Satoru Tanaka, Anish Patel, Omar Dabbous, Anastasiia Motrunich, Amir Amin, Mondher Toumi, Imen Touati, Kyoko Saito P16.5-005 Preferences Related to Treatment of Spinal Muscular Atrophy (SMA): Qualitative Study of SMA Caregivers and Health Care Professionals Treating SMA Types 1 and 2 in the United States – Anish Patel, Natalia Hawken-Hakimi, Samuel Aballea, Magdalena Bebrysz, Walter Toro Jimenez, Nicole LaMarca, Omar Dabbous, Mondher Toumi
6
Neuro-rehabilitation
General Neuro-rehabilitation 2 P16.6-001 Need for Medical Student Education in Rehabilitation and Post-Acute Care to Support Patients with Neurologic Illness and Injury – Dorothy Weiss Tolchin, Michael Young P16.6-002 Post Hoc Analysis of Nabiximols Efficacy by Concomitant Medication Use in 2 Enriched Placebo-Controlled Randomized Clinical Trials (RCTs) – Faria S. Amjad, Aaron L. Boster, Francisco Javier Carod-Artal, Robert Chinnapongse, Daniel Checketts, Peyman Adjamian, Joshua R. Steinerman
Information is accurate as of February 8, 2022, and is subject to change.
P16.6-003 Axial Diffusivity of the Left Anterior Limb of the Internal Capsule Associated with Slow Wave Sleep in Warfighters with Traumatic Brain Injury – Allen Bell, Brian Gerstenslager, Ping Hong Yeh, Rujirutana Srikanchana, Kimbra L. Kenney, John Ollinger, John Kent Werner P16.6-004 WITHDRAWN P16.6-005 Motor Cortex Inhibition: A Marker of Motor Function in Neurofibromatosis Type 1 – Alexander Doherty, David Huddleston, Hannah Jackson, Paul Horn, Donald Gilbert P16.6-006 Healthcare Resource Utilization and Costs Among Patients With Stroke-related Spasticity Before and After Treatment With OnabotulinumtoxinA – Lisa Bloudek, Kristen Migliaccio-Walle, David Oliveri, Amy Tung, Patrick J. Gillard
7
Practice, Policy, and Ethics
Practice, Pitfalls, and Innovation 3 P16.7-001 Optimizing Hypercoagulable Testing After Ischemic Stroke in the Acute Setting – Barbara S. Gordon-Kundu, Jennifer Picagli, Babar Khokhar P16.7-002 Identifying Gaps and Closing Loops: A Process Analysis of Neurology Resident Clinic Referrals – Devin Kyle Leslie, Santiago Diaz, Susan K. Dubois, Justin F. Rousseau P16.7-003 Real-World Healthcare Costs and Resource Utilization Among Patients Treated With Erenumab in the United States: A Retrospective Claims Database Study – Stewart J. Tepper, Todd J. Schwedt, Pamela Vo, Parth Joshi, Mrudula Glassberg, Ahmad Abdrabboh, Matias Ferraris, Santosh Tiwari, Jeffrey Thompson P16.7-004 B-Cell therapy Shared Medical Appointments (BCSMA) lead to faster time to treatment and less indirect care – Desiree Chizmadia, Deja Rose, Jennifer Stack, Ambar Liriano, Jessica Glaser, Mary R. Rensel P16.7-005 Where Does the Search End? A Cost Analysis of a Patient-Driven Work-Up of Potential Dysautonomia – Danielle M. Stember
AAN.com/AM
89
Thursday, April 7 8:00 a.m.–9:00 a.m.
Poster Session 16
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): EEG 2 P16.8-001 An EEG-Based Machine Learning Classifier To Differentiate Hippocampal-Coupled Sleep Spindles In Humans – Bryan Baxter, Sheraz Khan, Megan Thompson, Kristi Kwok, Bailey Driscoll, Rudra Patel, Matti Hamalainen, Catherine J Chu, Dara Sue Manoach P16.8-002 Localization of Inter-ictally Silent (IIS) Drug Resistant Focal Epilepsies (DRE) – Ifrah Zawar, Ping Liu, Richard C. Burgess, Andreas V. Alexopoulos, Vineet Punia P16.8-003 Benign Variants on Intracranial EEG- A Systemic Review. – Rawan Mahgoub, Ahmed S Taha, Efe Fakir, Rafeed Alkawadri P16.8-004 EEG Signatures of Delirium and Coma in Mechanically Ventilated ICU Patients – Shawniqua Williams Roberson, Kevin C. Zhang, Fei Ye, Pratik P Pandharipande, Nathan Brummel, Mayur Patel, James C. Jackson, E. Wesley Ely P16.8-005 Role of EEG in the diagnosis of spells of elevated intracranial pressure – Mohamed Nasser, Zubeda B. Sheikh P16.8-006 The Efficacy of CERIBELL in Acute Neurological Conditions in the Emergency Room – Iftekhar Ahmed, Ramya Chilappa P16.8-007 Cefalexin-Induced Electroencephalography Changes Mimicking Creutzfeldt-Jakob disease – Siobhan Delaney, Padraigin O’Sullivan, Jennifer Margaret Dineen, Brian McNamara, Orna O’Toole
9
Neuro-oncology
Observations in Neuro-oncology 2 P16.9-001 CNS Lymphoma Presenting as Cavernous Sinus Syndrome – Nathan Lightfoot, Bilaal Sirdar
P16.9-004 Methotrexate Induced CNS Neurotoxicity: Is It Always Leukoencephalopathy? – Syeda Manahil Haider Jeoffrey, Muhammad Taqi, Hisham Raza Alim Salahuddin P16.9-005 The Concomitant Incidence of Multiple Sclerosis and Primary CNS Tumors Leading to Treatment Dilemma. – Sandeep Gill, Muhammad Taimur Ahmad Malik P16.9-006 A Case of Myasthenia Gravis and Myositis after Immunotherapy and COVID Vaccine – Nelitza Ivemaris Rivera Vega, Karin Woodman P16.9-007 Efficacy and Safety of Amantadine in Cerebellar Mutism Syndrome - a Pediatric Case Series – Sarah Ghattas, Deborah M. Cassidy, Eileen Shieh, Gurcharanjeet Kaur
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Science 6 P16.10-001 Living with Children Improved Functional Recovery Post-Stroke – Dalton Akeim George, Antonio Bustillo, Adina Zeki Al Hazzouri, Scott Brown, Carolina Gutierrez, Chuanhui Dong, Kefeng Wang, Gillian L. Gordon-Perue, Erika Tatiana MarulandaLondono, Jose Gabriel Romano, Tatjana Rundek, Ralph L. Sacco, Hannah Gardener P16.10-002 Determination of Prevalence of Posterior Reversible Encephalopathy Syndrome (PRES) and Its Association with Cerebral Infarction, and Outcome in the Nationwide Inpatient Sample, 2016-2018 – Prabandh Reddy Buchhanolla, Shyamal Chandra Bir, Alexis Angelette, Annie Lewis, Sandeep Kandregula, Bharat Guthikonda, Vijayakumar Javalkar, Oleg Y. Chernyshev, Roger E. Kelley P16.10-003 Cerebral Hemodynamic Evaluation in Children with Sickle Cell Disease in India – Erum Khan, Bhakti Gajjar, Pranita Sharma, Pawan Jain, Vikas Goyal, Arvind Neral, Arvind Sharma, Sanjay Sharma, Vijay K. Sharma
Cerebrovascular Disease: Secondary Prevention P16.10-004 The Incidence and Clinical Outcomes of Acute Ischemic Strokes in Patients with Atrial Fibrillation on long term Oral Anticoagulation at OLSU-S – Junaid Ansari, Prabandh Reddy Buchhanolla, Amir Neshatfar, Arvin Parvathaneni, Rachel E. Triay, Alexandra Gaudet, Nimer Abushehab, Hugo Cuellar-Saenz, Roger E. Kelley, Vijayakumar Javalkar P16.10-005 Analysis of Ischemic Stroke Cases Eligible for Novel Treatment of Hypertriglyceridemia – Adam Peter Klein, Karen Yarbrough, Prachi Mehndiratta, Carolyn Cronin, John Cole, Marcella A. Wozniak, Steven J. Kittner, Seemant Chaturvedi P16.10-006 Cost effectiveness of smoking-cessation interventions following ischemic stroke and transient ischemic attack – Paul Wechsler, Ava L. Liberman, Daniel Restifo, Erika Lauren Abramson, Babak Navi, Hooman Kamel, Neal S. Parikh P16.10-007 Antiplatelets Versus Anticoagulants in Cervical Artery Dissection: A Meta-analysis – Abdulrahman Ibrahim Hagrass, Bashar Khaled Almaghary, Amira Abo Hegil Abo Ali, Mohammed Tarek Elgammal, Mohammed Al-kafarna, Aboalmagd Hamdallah, Sarah Makram Makram, Khaled Mohamed Ragab, Mohamed Abdelhady Abdelsadik Mostafa, Mohamed Fahmy Doheim P16.10-008 Morbidity and Mortality of Breakthrough Strokes in Patients on Novel Oral Anticoagulants – Christina Xia, Bhavya Narapureddy, Christina Delnero, Allen J. Hoste, Fiorella Guido, Hesham Masoud P16.10-009 Predictors of Very Early Stroke Recurrence in the POINT Trial Population – James R. Brorson, Natalie Monique Bourand P16.10-010 Larger Functional Shunts are associated with greater Cerebrovascular Disease Burden – Nancy Gadallah, Danisette Torres, Arifa Ghori, Laura Suhan, Spozhmy Panezai, Siddhart Kumar Mehta, Farah Yolanda Fourcand, Jawad F. Kirmani
P16.9-002 Two Rare Cases of Glioma in Total Spine with Metastases to Brain – Daniel Minsuk Oh, Pegah Kahaliardabili, Brooke Lauren Guerrero, Frances E. Chow P16.9-003 Isolated Oxaliplatin Induced Lhermitte’s sign in Rectal Cancer – Hadi Mohammad-Khanli
90
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 16
11
Movement Disorders
Movement Disorders: COVID, Telemedicine, and Community 2 P16.11-001 A pilot study on the effect of a community-based boxing program on Parkinson’s disease – Roshni A. Patel, Lucia Blasucci, Abhimanyu Mahajan P16.11-002 Clinical Trial Recruitment of Individuals with Parkinson’s Disease in a Community Setting: A Case Study – Sarah Ingersoll, Brian Alexander Cohn, Melissa Trieu, Kenneth Hayashida Movement Disorders: Atypical Movement Disorders 2 P16.11-003 Sensitivity and Specificity of the 2008 Diagnostic Criteria for Multiple System Atrophy – A Clinicopathological Study – Guillaume Lamotte, Farwa Ali, J. Eric Ahlskog, James H. Bower, Anhar Hassan, Bradley F. Boeve, William P. Cheshire, Dennis W. Dickson, Joseph E. Parisi, Keith A. Josephs, Ann M. Schmeichel, Phillip A. Low, Wolfgang Singer, Elizabeth A. Coon P16.11-004 Primary lateral sclerosis presenting as atypical parkinsonism: a clinical challenge – Aya Murakami, Shinsuke Fujioka, Shunsuke Koga, Kevin Bieniek, Masataka Nakamura, Yoshio Tsuboi, Melissa Murray, Zbigniew K. Wszolek, Dennis W. Dickson P16.11-005 Diversity of Ethnic Background among Progressive Supranuclear Palsy and its Predominant Variants – Juan Blas Couto, Susan Fox, Carmela Tartaglia, Gabor G. Kovacs, Anthony E. Lang P16.11-006 Brain-first Versus Body-first Synucleinopathies: A Population-based Cohort Study – Pierpaolo Turcano, Emanuele Camerucci, Aidan Mullan, Cole Daniel Stang, Delana Weis, Bradley F. Boeve, James H. Bower, J. Eric Ahlskog, Rodolfo Savica P16.11-007 Long-term follow-up of “brain-first/body-first” Lewy body diseases – Abhishek Lenka, David S. Goldstein P16.11-008 Manganese-Induced Parkinsonism - A Case Series – Butchi Raju Garuda, Gopi Seepana, Talabhaktula Sateesh Kumar, Arunakumari Upputuri
12
Thursday, April 7 8:00 a.m.–9:00 a.m.
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology and Neuro-otology Research: Ocular Motor and Vestibular 2 P16.12-001 Idiopathic Orbital Inflammatory Syndrome Masquerading as Isolate Nerve Palsy, A Case Series – Divya Nayar, Sehneet Grewal, Arvind Prabhu P16.12-002 VRDN-001: a Novel IGF-1R Monoclonal Antibody for Treatment of Thyroid Eye Disease: Adaptive Design Strategy for Clinical Development – Mark L. Moster, Barrett Katz P16.12-003 Migraine and Association of Benign Paroxysmal Positional Vertigo: A Large Tertiary University Medical Center Review – Sarah Goh, Natalia Murinova, Ami Zarrillo Cuneo, Daniel Krashin P16.12-004 Extracranial venous compression in persistent oscillating vertigo – Lindsey Randall, Jeffrey Riley P16.12-005 Tele-Neuro-Ophthalmology: An Update One Year Into The COVID-19 Pandemic – Adrienne Ng, Heather Moss, Kevin Lai, Melissa W. Ko
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Acquired Myopathies 2 P16.13-001 To compare the performance of various classification criteria in patients of idiopathic inflammatory myopathies in South Asian population. – Yogeesh P M, Vishnu VY, Padma Vasantha Hadakasira, Rohit Bhatia, Mamta Bhushan Singh, Roopa Rajan, Awadh K. Pandit, Rajesh Kumar Singh, Mehar Chand Sharma
P16.13-005 Dual energy X-ray absorptiometry to measure lean muscle mass in FSHD – Leo Hong-Li Wang, Anna Faino, Sarah J. Lowry, Katy Eichinger, Michael McDermott, Kiley Higgs, Michaela Walker, Leann Lewis, William Martens, Doris G. Leung, Sabrina Sacconi, Karlien Mul, Valeria A. Sansone, Perry Shieh, Bakri Elsheikh, Samantha Jo LoRusso, Russell Butterfield, Nicholas Elwood Johnson, Carmelo Messina, Alrabi Tawil, Jeffrey Statland P16.13-006 COL6A2 mutation (G733R) in an Argentine family with Bethlem myopathy diagnosed during adulthood – Micaela Kennedy, Jose M PastorRueda, Claudia Cejas, Fabio Adrian Barroso, Horacio Martinetto, Gustavo Sevlever P16.13-007 RBCK1-Associated Polyglucosan Body Myopathy Presenting with Mild Weakness and Pain: A Case Report – Sanket Aggarwal, Ryan David Jacobson, Richard Dineen, Peter Pytel P16.13-008 Glycogen Accumulation in GNE Myopathy – Andre Granger, Margherita Milone, Marcus Vinicius Rocha Pinto, Teerin Liewluck P16.13-009 Congenital cataracts, slow relaxation of handgrip, and electrical myotonia; mimicking myotonic dystrophy. – Melissa Cook, Georgios Manousakis, Teerin Liewluck, Pitcha Chompoopong P16.13-010 Importance of Muscle biopsy in a case of dysferlinopathy with novel gene mutation – Hasnain Arshad, Leila Darki, Said R. Beydoun
P16.13-002 Statin Associated Necrotizing Autoimmune Myositis and p-ANCA Vasculitis: A Rare Case Report – Chantal Bhan, Paul T. Twydell P16.13-003 Lower Extremity Muscle Fat Fraction in Myotonic Dystrophy Type 2 – Associations with Physical Performance – Diana Alejandra Madrid, Rebecca Knapp, Delanie Lynch, Paula R. Clemens, Ashley A. Weaver, Araya Puwanant P16.13-004 Hereditary myopathies in Mexican population: experience from a tertiary neuromuscular center. – Eunice Martínez Jiménez, Juan Carlos Lopez, Adib Jorge De Sarachaga, Anna Lisette Bazan, Elizabeth Leon, Edwin S. Vargas
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
91
TURN LIFE WITH LEMS INTO
WITH FIRDAPSE ® (AMIFAMPRIDINE)
“It’s so easy to do the simple things again. I can walk, take the stairs, and do things with the grandkids.” —Pat, managing her LEMS with FIRDAPSE. Individual results may vary.
The recommended first-line treatment for adults with Lambert-Eaton myasthenic syndrome (LEMS)1 Clinically proven to help patients maintain muscle strength and mobility2-4
Learn the hallmark signs of LEMS and the definitive diagnostic tests that can help you change the lives of undiagnosed patients. INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. SELECTED IMPORTANT SAFETY INFORMATION FIRDAPSE can cause seizures. Do not use FIRDAPSE in patients with a history of seizures, or with a hypersensitivity to amifampridine or another aminopyridine. Please see Brief Summary of full Prescribing Information on the next page. References: 1. Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020;54(1):56-63. 2. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma; 2021. 3. Shieh P, Sharma K, Korhman B, Oh SJ. Amifampridine phosphate (FIRDAPSE) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis. 2019;20(3):111-119. 4. Oh SJ, Scherbakova N, Kostera-Pruszczyk A, et al; LEMS Study Group. Amifampridine phosphate (FIRDAPSE®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717-725. FIRDAPSE® is a registered trademark of SERB. © 2022 Catalyst Pharmaceuticals, Inc. All Rights Reserved. Printed in USA. 22LEM0795 February 2022
FIRDAPSE treatment for up to 2 years (open-label, long-term safety phase of the study).
FIRDAPSE® (amifampridine) tablets for oral use BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION FOR FIRDAPSE INDICATIONS AND USAGE FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. DOSAGE AND ADMINISTRATION • The recommended starting dosage is 15 mg to 30 mg daily taken orally in divided doses (3 to 4 times daily) - Starting dosage is 15 mg daily for patients with renal impairment, hepatic impairment, and in known N-acetyltransferase 2 (NAT2) poor metabolizers • Dosage can be increased by 5 mg daily every 3 to 4 days • Dosage is not to exceed a maximum of 80 mg daily • The maximum single dose is 20 mg CONTRAINDICATIONS FIRDAPSE is contraindicated in patients with: • A history of seizures • Hypersensitivity to amifampridine phosphate or another aminopyridine. WARNINGS AND PRECAUTIONS Seizures FIRDAPSE can cause seizures. Seizures have been observed in patients without a history of seizures taking FIRDAPSE at the recommended doses, at various times after initiation of treatment, at an incidence of approximately 2%. Many of the patients were taking medications or had comorbid medical conditions that may have lowered the seizure threshold. Seizures may be dose-dependent. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures. Hypersensitivity In clinical trials, hypersensitivity reactions and anaphylaxis associated with FIRDAPSE administration have not been reported. Anaphylaxis has been reported in patients taking another aminopyridine; therefore, it may occur with FIRDAPSE. If anaphylaxis occurs, administration of FIRDAPSE should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: • Seizures • Hypersensitivity Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In controlled and uncontrolled trials (Study 1 and 2) in patients with LEMS, 63 patients were treated with FIRDAPSE, including 40 patients treated for more than 6 months, and 39 patients treated for more than 12 months. In an expanded access program, 139 patients with LEMS were treated with FIRDAPSE, including 102 patients treated for more than 6 months, 77 patients treated for more than 12 months, and 53 patients treated for more than 18 months. Study 1 was a double-blind, placebo-controlled, randomized discontinuation study in adults with LEMS. Following an initial open-label run-in phase (up to 90 days), patients were randomized to either continue FIRDAPSE treatment or transition to placebo for a 14-day double-blind phase. Following final assessments, patients were allowed to resume
During the open-label run-in phase of Study 1, 53 patients received FIRDAPSE for an average of 81 days at an average daily dosage of 50.5 mg/day. The average patient age was 52.1 years and 66% were female. There were 42 patients who had no prior exposure to FIRDAPSE at the initiation of this study. Table 1 shows adverse reactions with an incidence of 5% or greater occurring in the 42 LEMS patients newly initiated on treatment with FIRDAPSE during the run-in phase of the study. Table 1. Adverse Reactions in ≥5% of LEMS Patients Newly Treated with FIRDAPSE in Study 1 ADVERSE REACTION Paresthesia* Upper respiratory tract infection Abdominal pain Nausea Diarrhea Headache Elevated liver enzymes** Back pain Hypertension Muscle spasms Dizziness Asthenia Muscular weakness Pain in extremity Cataract Constipation Bronchitis Fall Lymphadenopathy
FIRDAPSE N=42 % 62 33 14 14 14 14 14 14 12 12 10 10 10 10 10 7 7 7 7
*Includes paresthesia, oral paresthesia, oral hypoesthesia **Includes elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT) Other Adverse Reactions In the overall population treated in Study 1 (n=53), including the double-blind phase and the 2-year open-label long-term safety phase, additional adverse reactions occurring in at least 5% of the patients included: dyspnea, urinary tract infection, gastroesophageal reflex, insomnia, peripheral edema, pyrexia, viral infection, blood creatine phosphokinase increase, depression, erythema, hypercholesterolemia, and influenza. These patients received an average daily dosage of 66 mg of FIRDAPSE. DRUG INTERACTIONS Drugs that Lower Seizure Threshold The concomitant use of FIRDAPSE and drugs that lower seizure threshold may lead to an increased risk of seizures. The decision to administer FIRDAPSE concomitantly with drugs that lower the seizure threshold should be carefully considered in light of the severity of the associated risks. Drugs with Cholinergic Effects The concomitant use of FIRDAPSE and drugs with cholinergic effects (e.g., direct or indirect cholinesterase inhibitors) may increase the cholinergic effects of FIRDAPSE and of those drugs and increase the risk of adverse reactions. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy. Physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the registry by calling 855-212-5856 (toll-free), using the Fax number 877-867-1874 (toll-free), by contacting the Pregnancy Coordinating Center at firdapsepregnancyregistry@ubc.com or by visiting the study website at www.firdapsepregnancystudy.com.
Risk Summary There are no data on the developmental risk associated with the use of FIRDAPSE in pregnant women. In animal studies, administration of amifampridine phosphate to rats during pregnancy and lactation resulted in developmental toxicity (increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development) at doses associated with maternal plasma drug levels lower than therapeutic drug levels (see Animal Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats prior to and during mating and continuing throughout organogenesis produced no adverse effects on embryofetal development. Plasma amifampridine exposure (AUC) at the highest dose tested is approximately 7 times that in humans at the maximum recommended human dose (MRHD) of 80 mg amifampridine/day. Oral administration of amifampridine phosphate (0, 9, 30, or 57 mg/kg/day) to pregnant rabbits throughout organogenesis produced no adverse effects on embryofetal development. The highest dose tested is approximately 7 times the MRHD (80 mg/day amifampridine) on a body surface area (mg/m2) basis.
effect and tolerability. The safety, efficacy, and pharmacokinetics of amifampridine have not been studied in patients with end-stage renal disease (CLcr <15 mL/min or patients requiring dialysis). No dosage recommendation for FIRDAPSE can be made for patients with end-stage renal disease. Hepatic Impairment The effects of FIRDAPSE have not been studied in patients with hepatic impairment. FIRDAPSE is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure. Therefore, initiate FIRDAPSE in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modification or discontinuation of FIRDAPSE for patients with hepatic impairment as needed based on clinical effect and tolerability. NAT2 Poor Metabolizers Exposure of FIRDAPSE is increased in patients who are N-acetyltransferase 2 (NAT2) poor metabolizers. Therefore, initiate FIRDAPSE in patients who are known NAT2 poor metabolizers at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modification of FIRDAPSE for patients who are known NAT2 poor metabolizers as needed based on clinical effect and tolerability. PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide). Risk of Seizures
Oral administration of amifampridine phosphate (0, 7.5, 22.5, or 75 mg/kg/day) to female rats throughout pregnancy and lactation resulted in an increase in stillbirths and pup deaths, reduced pup weight, and delayed sexual development in female pups at the mid and high doses tested. The no-effect dose (7.5 mg/kg/day amifampridine phosphate) for adverse developmental effects is associated with a plasma amifampridine exposure (AUC) less than that in humans at the MRHD.
Inform patients that FIRDAPSE can cause seizures, and to notify their healthcare provider if they experience a seizure.
Lactation Risk Summary
Instruct patients to take FIRDAPSE exactly as prescribed. Patients should carefully follow the dose escalation schedule provided by their healthcare provider to safely achieve the therapeutic dosage. Inform patients that the tablets may be divided in half at the score, if needed. Instruct patients not to take a double dose to make up for a missed dose.
There are no data on the presence of FIRDAPSE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FIRDAPSE and any potential adverse effects on the breastfed infant from FIRDAPSE or from the underlying maternal condition. In lactating rat, amifampridine was excreted in milk and reached levels similar to those in maternal plasma. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of FIRDAPSE did not include sufficient numbers of subjects aged 65 and over (19 of 63 patients in Studies 1 and 2) to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Hypersensitivity Instruct patients to inform their healthcare provider if they have signs or symptoms of hypersensitivity, and to seek emergency help if symptoms of anaphylaxis occur. FIRDAPSE Dosing
Drug Interactions Instruct patients to notify their healthcare provider prior to starting any new medication, including over-the-counter drugs. Pregnancy Instruct patients that if they are pregnant or plan to become pregnant while taking FIRDAPSE they should inform their healthcare provider. Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to FIRDAPSE during pregnancy and encourage them to enroll if they become pregnant while taking FIRDAPSE [see Use in Specific Populations (8.1) of full Prescribing Information]. Storage Advise patients to store FIRDAPSE at 68°F to 77°F (20°C to 25°C).
Renal Impairment Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment. Therefore, in patients with renal impairment, FIRDAPSE should be initiated at the lowest recommended starting dosage (15 mg/day), and patients should be closely monitored for adverse reactions. Consider dosage modification or discontinuation of FIRDAPSE for patients with renal impairment as needed based on clinical
Distributed by Catalyst Pharmaceuticals, Inc., Coral Gables, FL 33134. FIRDAPSE® is a registered trademark of SERB. Catalyst and the Catalyst logo are trademarks of Catalyst Pharmaceuticals, Inc. © 2022 Catalyst Pharmaceuticals, Inc. All Rights Reserved.
Poster Session 17
1
Autoimmune Neurology
Autoimmune Neurology: Clinical Observations 5 P17.1-001 Anti-hu Associated Encephalomyelitis as a presentation of Primary Extrapulmonary Small Cell Carcinoma of the Small Bowel – Vincent Trung Huu Ngo, Kasim Qureshi, Michael Meyers, Muhammad Farooq P17.1-002 A Tale of 2 Leukodystrophies in DOCK8 Deficiency, a Rare Primary Immunodeficiency – Ariane Soldatos, Irene CM Cortese, Anita M. Fletcher, Corina Gonzalez, Alexandra Freeman P17.1-003 Neurologic manifestations of Degos disease – Sasha Zivkovic, Tawfiq Al-Lahham, David Lacomis P17.1-004 Mast cell activation syndrome, Mannose binding lectin, Ehlers-Danlos syndrome, and Neuropsychiatric symptoms. – Ilene S. Ruhoy, Isabelle Brock, Anne Maitland
1
Neuromuscular and Clinical Neurophysiology (EMG)
Autonomic Disorders 1 P17.1-005 COVID-Long Haulers Can Develop POTS (Postural Orthostatic Tachycardia Syndrome) with Small Fiber Neuropathy and Abnormal Autonomic Testing – Christopher John Cantrell, Robert G. Wilson P17.1-006 Case series: A review of three patients with autonomic dysfunction and positive TS-HDS or FGFR3 antibodies – Raeann Bourscheid, Sonesh Dilip Amin, Peter Eric Hauer, Melissa M. Cortez, Kelsey Rachel Juster-Switlyk P17.1-007 Demonstrating New-onset or Worsened Sudomotor Function post COVID-19. – Aditi Vian Varma-Doyle, Nicole Villemarette-Pittman, Paul Andrew LeLorier, Noah Blackstone Reeves, John D. England
94
2022 AAN Annual Meeting
Thursday, April 7 11:45 a.m.–12:45 p.m.
2
Headache
Headache and Population Health 3 P17.2-001 Prescription Opioids in Patients With Migraine in Southern Israel: a Retrospective Database Analysis – Mohnnad Asla, Iso Peles, Mariya Abayev, Michal Gordon, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur, Gal Ifergane P17.2-002 Unmet Treatment Needs in Migraine Among Those Seeking Care from Neurologists or Headache Specialists: Results of the OVERCOME US study – Michael L. Reed, Elizabeth Johnston, Robert A. Nicholson, Dawn C. Buse, Anthony J Zagar, Sait Ashina, Susan Hutchinson, Robert E. Shapiro, Eric M. Pearlman, Richard B. Lipton P17.2-003 Perspectives From Members of an Online Community on Their Communications With Health Care Professionals About Migraine Treatment: A Social Listening Analysis – Edward Kim, Heather Lapidus Glassner, Jaclyn Klepper, Jessica Cirillo P17.2-004 Migraine Epidemiology in Southern Israel: A Retrospective Database Study – Iso Peles, Mohnnad Asla, Mariya Abayev, Michal Gordon, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur, Gal Ifergane P17.2-005 Employability, Work Difficulties and Factors Impacting Chronic Migraine Patients of Hawaii: Results of a Quality Improvement Survey – Michelle Stafford, Tracy Van, Rachel Gorenflo, Frances Tiffany Morden, Kara Ushijima, Ashley Ung, Emma Sage Inouye, Uiyeol Yoon, Vimala Sravanthi Vajjala, Enrique Carrazana, Kore K. Liow P17.2-006 Direct Health Care Costs of Patients Suffering With Migraine in Southern Israel: a Retrospective Database Analysis – Iso Peles, Mariya Abayev, Michal Gordon, Victor Novack, Rinat Ribalov, Tamar Lengil, Ron Maor, Mayera Elizur, Lynda Krasenbaum, Gal Ifergane
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Aspects 3 P17.3-001 Cerebellar infarcts are associated with a higher frequency of dementia and decreased performance in cognitive domains of memory, attention, and language. – Camilo Bermudez, Sheela Raghavan, Mary M. Machulda, Scott Przybelski, Ekaterina Hofrenning, Timothy Lesnick, David S. Knopman, Ronald C. Petersen, Petrice Mostardi Cogswell, Michelle M. Mielke, Prashanthi Vemuri, Clifford R. Jack, Jonathan Graff-Radford P17.3-002 Assessing the Impact of Older Driver Visual and Cognitive Impairment on Intersection Stopping Behavior – Guillermo Basulto-Elias, Ashirwad Barnwal, Anuj Sharma, Jennifer Merickel, Matthew Rizzo, Shauna Hallmark P17.3-003 Improvement of Quality of Life in Individuals with Cognitive Impairment After Spiritual Support Group – William G. Buxton, Traci Richelle Lyon, David Merrill, Verna R. Porter, Mihae Kim, Claudia Wong, Judy Weintraub, Jennifer Leigh Lisenby, Anne C. Galbraith P17.3-004 Bringing Art to Life: Growing Empathy Through Art Therapy, Life Story and Relationships – Daniel C. Potts, Neelum T. Aggarwal, Rebecca Mae Allen, Keisha Carden, Angel Duncan P17.3-005 INVOKE-2 - A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer’s Disease – Sam Jackson, Robert Paul, Aashka Joshi, Yijie Liao, Glenn Morrison, Abe Castro, Felix Leejia Yeh, Michael Ward
4
MS and CNS Inflammatory Disease
MS Epidemiology and Prognosis P17.4-001 Early Predictors of Disability in Paediatric Multiple Sclerosis: Evidence from a Multi-National Registry – Sifat Sharmin, Charles Malpas, Izanne Roos, Ibrahima Diouf, Raed Alroughani, Serkan Ozakbas, Guillermo Izquierdo Ayuso, Sara Eichau Madueño, Dana Horakova, Eva Havrdova, Francesco Patti, Murat Terzi, Cavit Boz, Bassem I. Yamout, Samia J. Khoury, Marco Onofrj, Alessandra Lugaresi, Ayse Altintas, Alexandre Prat, J M. Girard, Pierre Duquette, Maria Jose Marques de Sa, Danielle Spitareli, Youssef Sidhom, Riadh Gouider, Aysun Soysal, Recai Turkoglu, Maria Pia Amato, Yara D. Fragoso, Tomas Kalincik
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 17
P17.4-002 Early Treatment Can Postpone the Time to Disability Pension in Relapsing-Remitting Multiple Sclerosis – Malthe Faurschou Wandall-Holm, Mathias Buron, Tine Iskov Kopp, Finn Sellebjerg, Melinda Magyari P17.4-003 Trajectories of disability and relapse-rate in naïve patients on oral drugs: results from the Italian Multiple Sclerosis Register – Alessia Manni, Damiano Paolicelli, Giuseppe Lucisano, Pietro Iaffaldano, Riccardo Sansone, Luca Bollo, Francesco Patti, Carlo Pozzilli, Claudio Gasperini, Giovanna De Luca, Vincenzo Brescia Morra, Matilde Inglese, Giacomo Lus, Roberto Bergamaschi, Ilaria Pesci, Paola Gazzola, Patrizia Sola, Gioacchino Tedeschi, Massimo Filippi, Maria Pia Amato, Maria Trojano P17.4-004 The Impact of BMI on Brain Volume and Cognitive Function in RRMS: A Secondary Analysis – Aliza Ben-Zacharia, Malvin Janal, Abraham Brody, Jerry S. Wolinsky, Fred D. Lublin, Gary Raymond Cutter P17.4-005 Analysis of Fertility Characteristics in Patients with MS in NARCRMS Database – Celeste Fine, Amber Peskin, John Gamba, Toni Saldana-King, Raquel T. Brillante, Coraly Perez-Bajandas, Megan Vignos P17.4-006 Patterns of Healthcare Utilization and Expenditure among People with Multiple Sclerosis in the Age of Disease-Modifying Therapy: An Analysis of Claim Data from a Commercially Insured Population in the United States, 2010-2019 – Wen Zhu, Zongqi Xia P17.4-007 Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis – Tamara Castillo-Trivino, Rocio Gomez, Monica Borges, Jesus Manuel Martin Martinez, Javier Sotoca, Ana María Alonso Torres, Ana Belen Caminero Rodriguez, Laura Borrega Canelo, Jose Luis Sanchez Menoyo, Francisco BarreroHernandez, Carmen Calles, Luis Brieva Ruiz, Rosario Blasco Quilez, Julio Dotor Garcia-Soto, Maria Campo Amigo, Laura Navarro, Eduardo Aguera Morales, Moises Garces Redondo, Olga Carmona Codina, Gabaldon Torres Laura, Lucía Forero, Mariona Hervas Pujol, Jorge Maurino, Susana Sainz de la Maza P17.4-008 Younger Age at Multiple Sclerosis Onset Is Associated With Worse Outcomes at Age 50 – Gauruv Bose, Brian Curran Healy, Bonnie Glanz, Hrishikesh A. Lokhande, Mariann Polgar-Turcsanyi, Charles R.G. Guttmann, Rohit Bakshi, Howard L. Weiner, Tanuja Chitnis
Thursday, April 7 11:45 a.m.–12:45 p.m.
P17.4-009 A Practical Approach to Longitudinal Neurological Care of Adults With X-linked Adrenoleukodystrophy and Adrenomyeloneuropathy (X-ALD/AMN) – Alexandra Behar Kornbluh, Jennifer Lauren Orthmann Murphy P17.4-010 The Diagnosis and Treatment of Epilepsy in Patients with Multiple Sclerosis: a Case Series from Argentina – Melanie Lara Sanchez, Abril Marone, Mariano Marrodan, Jorge D. Correale
5
Child Neurology and Developmental Neurology
Child Neurology: SMA/DMD/Muscle 3 P17.5-001 Demographic and Clinical Profiles of Neonates Diagnosed with Spinal Muscular Atrophy (SMA) via the Kentucky Newborn Screening (NBS) Program: A Two-Year Experience – Arpita Lakhotia, David Toupin, Anna Rachele Thamann, Kelly Elaine Jackson, Darrin Sevier, Angela Crutcher, Sainan Wei, Vaneet Arora, Alexander Asamoah, William C. Robertson P17.5-002 Case of a novel genotypic homozygous missense mutation that disrupts oligomerization of SMN protein and causes severe SMA Type 0 – Sonia Ann Varghese, Yael Shiloh-Malawsky, Senyene Hunter, Elizabeth Jalazo, Cynthia Marion Powell, AG Matera, Zheng Fan P17.5-003 RAINBOWFISH: Preliminary Efficacy and Safety Data in Risdiplam-Treated Infants with Presymptomatic SMA – Richard S. Finkel, Michelle A. Farrar, Dmitry Vlodavets, Laurent Servais, Edmar Zanoteli, Mohammad A. F. Al-Muhaizea, Leslie Nelson, Alexandra Prufer, Yi Wang, Carolyn Fisher, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Laura Palfreeman, Renata Scalco, Enrico Silvio Bertini P17.5-004 The Burden of Spinal Muscular Atrophy Type 1 (SMA1) on Caregivers in the United States (US): First Results of a Global Survey – Walter Toro Jimenez, Anish Patel, Samuel Aballea, Anastasiia Motrunich, Omar Dabbous
6
Neuro-rehabilitation
General Neuro-rehabilitation 3 P17.6-001 The Development of Phelan-McDermid-specific anchors for the Clinical Global Impression Scales – Elizabeth M. Berry-Kravis, Sandeep Valluripalli Soorya, Alexander Kolevzon, Audrey Thurm, Nancy Jones
Neuromodulation for Rehabilitation 1 P17.6-002 Decoding Speech from Human Motor Cortex Using an Intracortical Brain Computer Interface – Daniel Rubin, Tommy Hosman, Anastasia Kapitonava, John D. Simeral, Sydney Cash, Leigh R. Hochberg
7
Practice, Policy, and Ethics
Ethics, Diversity & Research, Oh My... 1 P17.7-001 Gender Discrepancies in Neurologist Compensation – Melissa Yu, Shannon Ashley Merillat, Allison L. Weathers, David A. Evans, Becky Wolf, John Ney P17.7-002 Demographic and Subsequent Funding Trends in the AAN Research Program (1996-2021) – Daniela Arantxa Pimentel Maldonado, Tachira Tavarez, Alejandro Vargas, Gabriel M. Moreno, Raelle Tagge, Daniel Thomas Lackland, Bruce I. Ovbiagele P17.7-003 Examining National Representativeness of the Axon Registry – Andrew M. Wilson, Kavita Nair, Sarah M. Benish, Gregory J. Esper, Amanda Lien, Aristotle Mante, Karen Lundgren, Becky Schierman, John Ney P17.7-004 An Ethical Approach to Detecting Covert Consciousness – Michael Young, Yelena Bodien, Leigh R. Hochberg, Brian Edlow
P17.5-005 CSF IL-8 as a potential marker for gene therapy outcomes in Spinal Muscular Atrophy – Sumit Verma, Kelsey Perry, J. Christina Howell, Raj Razdan, Alice L. Dawson, William T. Hu
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
95
Poster Session 17
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Co-morbidities 2 P17.8-001 Occurrence of cognitive impairment in older adult patients with epilepsy – Jeongyeon Hwang, Kristen Lucas, Rohit Ajay Marawar P17.8-002 Patient-reported Outcomes in Mood, Fatigue, Sleep Disturbance, and Disability While on Brivaracetam Treatment: a Prospective Observational Study – Hamada Hamid Altalib, Jacqueline French, Michael R. Sperling, Heidi L. Henninger, Hina N. Dave, Michael Gelfand, Anne-Liv Schulz, Sami Elmoufti, Prashant Dongre, Melinda S. Martin P17.8-003 Time-course of Treatment-emergent Adverse Events Potentially Associated with Behavioral Disorders during Adjunctive Brivaracetam Treatment of Adults with Focal Seizures – Kimford J. Meador, Svetlana Dimova, Cedric Laloyaux, Xavier Nondonfaz, Florin Floricel, Sami Elmoufti, Pavel Klein P17.8-004 Barriers to Breastfeeding Counseling in Women with Epilepsy – Abrar Omar Al-Faraj, Jessica LeClair, Rebecca M. Summit, Deeya Modhwadiya, Isabelle Messina, Trudy Pang P17.8-005 Preferences and Experiences of Women with Epilepsy Regarding Sexual and Reproductive Health Care – Laura Anne Kirkpatrick, Elizabeth Ivy Harrison, Sonya Borrero, Anne R. Davis, Elizabeth Miller, Yoshimi Sogawa, Olivia Stransky, Mehret Birru, Alexandra Urban, Anne C. Van Cott, Traci Kazmerski P17.8-006 Quality of Life in People with Epilepsy: a Population-Based Study in the Detroit Metropolitan Area – Kristen Lucas, Maryam Jamil Syed, Rohit Ajay Marawar, Maysaa Merhi Basha, Deepti Zutshi P17.8-007 Factors Associated with Depression in Epilepsy Patients: a Population-Based Study in the Detroit Metropolitan Area – Kristen Lucas, Maryam Jamil Syed, Rohit Ajay Marawar, Maysaa Merhi Basha, Deepti Zutshi
Thursday, April 7 11:45 a.m.–12:45 p.m.
9
Infectious Disease
Infectious Disease: Peripheral Manifestations Take Center Stage in COVID-19 2 P17.9-001 Atypical Pharyngo-Cervico-Brachial Variant of GBS Associated with Covid-19 Antibodies – Butchi Raju Garuda, Gopi Seepana, Talabhaktula Sateesh Kumar, Arunakumari Upputuri P17.9-002 Bilateral facial nerve palsy associated with COVID-19 infections. – Karan Hingorani, Thomas Ryan Ford, Pria Anand, Michelle Kaku Infectious Disease: Bacteria, Fungi, and Parasites on the Mind and Body 2 P17.9-003 Neurosyphilis: a challenging diagnosis – Blibeche Hela, Khadija Sonda Moalla, Salma Sakka, Sawsan Daoud, Yosra Mzid, Nadia Bouattour, Mariem Damak, Nouha Farhat, Kheireddine Ben Mahfoudh, Chokri Abdellaziz Mhiri P17.9-004 CNS Tuberculosis Mimicking as Neurosarcoidosis: A Diagnostic Quandary – Jacob Lowery, Soukaina Noor, Laurel Officer
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Practice 1 P17.10-001 Decreasing Delayed Recognition, Diagnosis, & Treatment of Ischemic Posterior Circulation Strokes in The Emergency Department by Improving Triage Screening in Patients Presenting with Atypical Stroke Symptoms – Haley Ruth Hamer, Vanessa Pabon P17.10-002 Developing a Pilot Program to Increase Stroke Education Among Internal Medicine Residents – Gilad Muth, Rebecca Stainman, Triveni Abburi, Jeffrey Farkas, Richard Libman P17.10-003 Epidemiological Characteristics of Patients Received Therapeutic Hypothermia Following Acute Ischemic Stroke - a Nationwide Perspective – Greshaben Patel, David Pielykh, Aakash Baskar, Muhammad Imtiaz Tar, Chetna Dengri, Yogesh Kothari, Renu Renu, Sogut Turkmen Aksoy, Mohammed Rifat Shaik, Satish Tadepalli, Syed Nazeer Mahmood, Amit Munshi Sharma, Appala Suman Peela, Urvish K Patel, Shamik Shah
Cerebrovascular Disease: Systems of Care Research P17.10-005 Clinical pharmacy services as part of the Telehealth After Stroke Care in an underserved setting: a feasibility study – Yuliya Baratt, Hanlin Li, Neisha Patel, Kevin Strobino, Ian Kronish, Mitchell S. V. Elkind, Imama Ali Naqvi P17.10-006 Inclusion of Asymmetric Bilateral Weakness Optimizes VAN Pre-hospital LVO Triage – Aaisha Mozumder, Sujani Bandela, Lee Birnbaum P17.10-007 Evaluation of A Pre-hospital Stroke Assessment’s Ability to Identify Patients with Large Vessel Occlusion (LVO) – Samadhi Thavarajah, Zachary Langston, Adam Bayne Sarayusa, Shannon Sternberg, Ashley Pulido, Neel N. Shah P17.10-008 Completing the NIHSS Score Prior to CT Scan to Reduce Time to Acute Intervention for Stroke: A Quality Improvement Project – Paige Sutton, Kyle Darpel, Margie Campbell, Jessica Doyle Lee, Kara Jo Swafford P17.10-009 Impact of Patient Transfer to an External ICU Hospital for Post-Operative Monitoring after Endovascular Intervention – Ankita Tripathi, John Liang, Michael Graff Fara, Alexandra S. Reynolds, Danielle Wheelwright P17.10-010 Impact of Artificial Intelligence Stroke Software on Detection of LVO Transfer Patients – Irma Nora Duncan, Ermias Mekonnen Aytenfisu, Sohum Desai, Michael Machiorlatti, Wondwossen G. Tekle, Ameer Hassan
11
Movement Disorders
Movement Disorders: Ataxia and Tourette 1 P17.11-001 Beliefs about Tourette Syndrome in Adolescent Patients with Tics – Jessica Frey, Tracy Tholanikunnel, Heather Simpson, Irene Malaty P17.11-002 Mini-Child Tourette Syndrome Impairment Scale Scores in Functional versus Primary Tic Disorders – Travis Larsh, Steve Wu, Donald Gilbert
P17.10-004 Acute Ischemic Stroke in Young Adults – Narsis Aminian, Nehaal Ahmed, Vivien H. Lee
96
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 17
Movement Disorders: Dystonia and Botulinum Toxin 2 P17.11-003 Real-world Experience with Botulinum Toxin A for The Treatment of Hemifacial Spasm: A Study of 1138 Injections – Samantha Anne Gutierrez, Jeryl Ritzi Tan yu, Patrick Yalung, Roland Dominic Jamora P17.11-004 Real-world Botulinum Toxin Type A Treatment Patterns in Patients with Spasticity – Daniel Gratie, Daniel Mercer, Jae Hyun Lee, Patrick J. Gillard P17.11-005 Real-world Botulinum Toxin Type A Treatment Patterns in Patients with Cervical Dystonia – Daniel Gratie, Daniel Mercer, Jae Hyun Lee, Patrick J. Gillard P17.11-006 Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population – Pinky Agarwal, Richard L. Barbano, Henry Paul Moore, Marc Schwartz, Aleksej Zuzek, Atul T. Patel P17.11-007 Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians – H. A. Jinnah, Henrique Ballalai Ferraz, Stephanie Standal, Pooia Fattahi, Aleksej Zuzek, Nabilah Alibhai, Kate Merath P17.11-008 EEG analysis of social cognition in cervical dystonia – Rosalie Herings, Shameer Rafee, Sean O’Riordan, Michael Hutchinson, Richard Reilly
12
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology Research: Vision 1 P17.12-001 Deep Learning Can Accurately Distinguish Between True Papilledema and Optic Disc Drusen On Ocular Fundus Photographs – Valerie Biousse, Raymond Najjar, Kanchalika Sathianvichitr, Zhiqun Tang, Steffen Hamann, Clare Louise Fraser, J. Alexander Fraser, Mung Yan Lin, Caroline Vasseneix, Jason Peragallo, Fiona Evann Costello, Tien Y. Wong, Nancy J. Newman, Dan Milea P17.12-002 The Phase III REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON) – Nancy J. Newman, Patrick Yu-Wai-Man, Valerio Carelli, Prem S. Subramanian, Mark L. Moster, An-Guor Wang, Sean Donahue, Bart Peter Leroy, Valerie Biousse, Catherine Vignal-Clermont, Alfredo Sadun, Gema Rebolleda, Elizabeth Fortin, Rudrani Banik, Laure Blouin, Michel Roux, Magali Taiel, Jose-Alain Sahel
Thursday, April 7 11:45 a.m.–12:45 p.m.
P17.12-003 Neurofilament light chain levels differentiate between ischemic and inflammatory optic neuropathies – Shailee Samir Shah, Sara Mariotto, Elia Sechi, Sean J. Pittock, Eoin P. Flanagan, M. Tariq Bhatti, John Chen P17.12-004 A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis – Jeffrey L. Bennett, Nathan C. Grove, Ruth K. Johnson, Christopher Steven Mizenko, Joan DuPont, Brandie Wagner, Anne M. Lynch, Teresa Frohman, Elliot M. Frohman, Kenneth Shindler P17.12-005 Cerebrospinal Fluid Biomarkers in Idiopathic Intracranial Hypertension: An Exploratory SWATH Proteomics analysis. – Awadh K. Pandit, Shubham Misra, Rahul Chakraborty, Praveen Singh, Gyaninder Pal Singh, Swati Phuljhele, Achal K. Srivastava, Deepti Vibha, Ajay Garg, Dheeraj Mohania
13
Health Care Disparities
Racial Disparities in Neurologic Care P17.13-001 Health Disparities in African American Patients with Multiple Sclerosis: A Retrospective Chart Review Study – Elissa Dykes, William R. Meador, Surachat Ngorsuraches
P17.13-006 The Impact of Race and Ethnicity on Time to Diagnosis of Multiple Sclerosis: Preliminary Results – Jemima Akinsanya, Frances Andrada, Karan Divyam Kawatra, Jenifer Dwyer, Joan M. Ohayon, Daniel Reich, Irene CM Cortese, Shila Azodi
13
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular Disease: Inherited Muscle Disorders 5 P17.13-007 Mitochondrial myopathies diagnosed in adulthood: phenotypic spectrum and long-term outcomes – Grayson Bernard Beecher, Elie Naddaf P17.13-008 Adult Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) Diagnostic Challenge – Jory Liang, Jennifer A. Roggenbuck, Sarah Heintzman, Bakri Elsheikh, Adam Quick P17.13-009 DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC) for the Treatment of FSHD – Barbora Malecova, David Sala, Garineh Mary Melikian, Gulin Erdogan, Rachel Johns, Joanne Young, Erwann Ventre, Sole Gatto, Matthew Onorato, Adam Pavlicek, Orsolya Kiraly, Martin Koegler, Arthur A. Levin, Philipp Hadwiger, William M. Flanagan
P17.13-002 Racial differences in trust and risk disclosure preferences among older research volunteers screened for prodromal synucleinopathies – Carly Marshall, Isabelle Havis, Vikas Kotagal P17.13-003 Brain Barriers: Elucidating Complex LanguageBased Barriers to Neurological Care in LimitedEnglish Proficiency, Refugee, and Immigrant Populations – Alexandra Miner P17.13-004 Improving MD-Patient Communication: Patient satisfaction with communication during neurology outpatient consultation in Cross-Cultural Scenarios – Diana Andino, Anam Syed, Fady Mousa-Ibrahim, Sean D. Ruland P17.13-005 Racial Differences In Palliative Care Utilization And Impact On Inpatient Mortality Length Stay And Costs Among Patients With Ischemic Stroke – Mohammad Rauf A. Chaudhry, Kahtan Fadah, Danish Kherani, Baljinder Singh, Saqib A. Chaudhry, Mohammad Ghatali, Anantha Ramana Vellipuram, Paisith Piriyawat, Alberto Maud, Gustavo J. Rodriguez, Isabel Victoria NarvaezCorrea
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
97
Thursday, April 7 5:30 p.m.–6:30 p.m.
Poster Session 18
1
Autoimmune Neurology
Autoimmune Neurology: Clinical Observations 6 P18.1-001 Paraneoplastic Stiff Person Syndrome: Persistence of Symptoms is Common Despite Treatment of Underlying Malignancy – Alexandra Christina Simpson, Danielle Obando, Alexandra Balshi, Yujie Wang, Scott Douglas Newsome P18.1-002 Powassan Encephalitis: A Case Report from Long Island, New York, USA – Danielle Bazer, Matthew Orwitz, Nicholas Koroneos, Olga Syritsyna, Elizbieta Wirkowski P18.1-003 Combined central and peripheral demyelination syndrome after COVID-19 vaccination with brisk response to plasma exchange and steroids – William Hoffman, Morgan Christina Jordan, Francis Cloran, John H. Sladky P18.1-004 Characterization of Neurological Morbidity Associated with Anti-Thyroid Antibodies: Hashimoto’s Encephalopathy and Beyond – Mark Phillips Figgie, Hannah Marie Kelly, Nataliya Pyatka, Clara Chu, Hesham Ahmed Abboud
1
Neuromuscular and Clinical Neurophysiology (EMG)
Autonomic Disorders 2 P18.1-005 Autonomic dysfunction following COVID-19 infection: an early experience – Kamal Shouman, Greg S. Vanichkachorn, William P. Cheshire, Mariana Suarez, Shahar Shelly, Guillaume Lamotte, Paola Sandroni, Eduardo E. Benarroch, Sarah E. Berini, Jeremy K. Cutsforth-Gregory, Elizabeth A. Coon, Michelle L. Mauermann, Phillip A. Low, Wolfgang Singer P18.1-006 Mortality Risk Factors in Patients with Diabetic Autonomic Neuropathy: Insights from a Structured Clinical Documentation Toolkit – Alexandru C. Barboi, Bruce A. Chase, Katerina Markopoulou, Roberta Frigerio, Sylwia Pocica P18.1-007 Mycoplasma Pneumoniae Infection Associated with Autoimmune Small Fiber Neuropathy and Postural Orthostatic Tachycardia Syndrome (POTS) – Kamal R. Chemali, Andrew Sandefer
2
Global Health
Global Neurology P18.2-001 Accuracy of Automated Analyzers for the Estimation of CSF Cell Counts: A Systematic Review and Meta-Analysis – Greer Waldrop, Kaitlyn Cocuzzo, Colleen Louise Schneider, Carla Kim, Teddy G. Goetz, Mashina Chomba, Marie Smithgall, Kiran Thakur P18.2-002 Authorship Diversity in Cochrane Systematic Reviews of Stroke: Inequities in Global Representation – Vivek Bhat, Ahmad Ozair, Nishanth R. Subash, Shreyas Bellur, Fawaz AlMufti P18.2-003 International COVID-19 Vaccine Experience and Perceptions Survey in Patients with Myasthenia Gravis: An Interim Analysis – Yingkai Li, Srikanth Muppidi, Samantha Masterson, Wendi Huff, Tabitha Karatz, Jeff Guptill P18.2-004 Quality of Life in Epilepsy patients in India during Covid-19 pandemic. – Nirmal Surya, Ram Mohan R. Sankaraneni, Sanjay P. Singh P18.2-005 Socio-epidemiological Factors associated with the Incidence of Cerebrospinal Meningitis in Sub-Saharan Africa – Gabriel D. Pinilla Monsalve, Natalia Llanos Leyton, Maria Gonzalez-Velez, Jairo Alonso Quiñones P18.2-006 WITHDRAWN
3
Aging, Dementia, Cognitive, and Behavioral Neurology
Aging and Dementia: Clinical Aspects 4 P18.3-001 Learning to PERSEVERE: Feasibility and Efficacy of Peer Mentor Support and Caregiver Education in Lewy Body Dementia – Faizan Akram, Serena Hess, Melissa Levin, Danielle Dodson, Glenn Thurston Stebbins, Michelle HS Tosin, Bichum Ouyang, Joshua Chodosh, Jori Fleisher P18.3-002 Digital Driving Metrics Index Early Mobility Declines in Patients At Risk for Alzheimer’s Disease – Jennifer Merickel, Ruiqian Wu, Jun Ha Chang, Matthew Rizzo, Ying Zhang
P18.3-003 Huntingtin gene intermediate alleles influence the progression from Subjective Cognitive Decline to Mild Cognitive Impairment: a 15-year follow-up study – Salvatore Mazzeo, Silvia Bagnoli, Sonia Padiglioni, Filippo Emiliani, Assunta Ingannato, Giulia Giacomucci, Vittoria Conti, Camilla Ferrari, Sandro Sorbi, Benedetta Nacmias, Valentina Bessi P18.3-004 Combination of Antidepressants and Antipsychotics as Novel Treatment Options for Psychosis in Alzheimer’s Disease – Peihao Fan, Lirong Wang, Julia Kofler, Robert A. Sweet P18.3-005 TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease – Jennifer Zimmer, Paul R. Solomon, Cynthia Evans, Ming Lu, John R. Sims, Dawn A. Brooks, Mark A. Mintun
4
MS and CNS Inflammatory Disease
MS Digital Tools P18.4-001 DAMS-Net: A Domain Adaptive Lesion Segmentation Framework in Patients with Multiple Sclerosis from Multiple Imaging Centers – Dongnan Liu, Mariano Cabezas, Geng Zhan, Dongang Wang, Linda Ly, Kain Kyle, Heidi N. Beadnall, Helmut Butzkueven, Anneke Van Der Walt, Melissa Gresle, Katherine Buzzard, Tomas Kalincik, Jeannette Lechner-Scott, Bruce Taylor, Robert Hyde, Michael Barnett, Weidong Cai, Chenyu Wang P18.4-002 Social Networks in Pediatric-Onset Multiple Sclerosis are Associated with Less Negative Peer Pressure – Micky Bacchus, Wendy Sulina Vargas, Michael Glendinning, Seth Nathatn Levin, Kaho Onomichi, Philip De Jager, Brenda Banwell P18.4-003 haMSter: a Smartphone Application for Remote Patient Monitoring – Patrick Altmann, Markus Ponleitner, Fritz Leutmezer, Tobias Monschein, Paulus Stefan Rommer, Thomas Alois Berger, Gabriel Bsteh P18.4-004 Digital Performance Measures Show Sensitivity to Demographic and Disease Characteristics in a Multiple Sclerosis Cohort Utilizing the MS Care Connect Mobile App in a Real-world Setting – Ryan Metzger, Kelly Davis Garrett, Angelene Christensen, John F. Foley P18.4-005 User Perspectives on a Digital Therapeutic for Major Depressive Disorder in Multiple Sclerosis Patients: A Qualitative Study – Gina Kackloudis, Eliane Boucher, Eliane Boucher, Acacia C. Parks
98
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 18
P18.4-006 Reliability of Mobile Video Oculography in a prospective cohort of MS patients – Mikael Cohen, Solange Hesse, Kevin Polet, Sandrine Louchart de la Chapelle, Alain Pesce, Christine Lebrun Frenay P18.4-007 TELE MS: A Randomized Controlled Trial Investigating Remote Visits in People with Multiple Sclerosis – Patrick Altmann, Markus Ponleitner, Fritz Leutmezer, Paulus Stefan Rommer, Thomas Alois Berger, Gabriel Bsteh P18.4-008 Use of MyChart Messages and Telephone Calls in Patients with Multiple Sclerosis at an Academic Medical Center – Caralynn Li, Alena Makarova, Angela Aungst, Derrick Robertson P18.4-009 Evaluating Telemedicine Care in Patients with Neuroimmunological Disorders via a Questionnaire Based Survey – Huiam Mubarak, Minhwan Kim, Aimee Borazanci, Tejas Ranade, Ram Narendra Narayan, Michael Vincent Robers P18.4-010 Relationship of Superficial White Matter Integrity and Cognition in Early MS: A Machine Learning Study – Korhan Buyukturkoglu, Ceren Tozlu, Christopher Vergara, Valentina Fuentealba, Jacob Dahan, Amy Kuceyeski, James F. Sumowski, Carlos Guevara Oliva, Ranganatha Sitaram, Claire Riley, Pamela Guevara, Victoria Leavitt
5
Child Neurology and Developmental Neurology
Child Neurology: SMA/DMD/Muscle 4 P18.5-001 Pooled Safety Data from the Risdiplam Clinical Trial Development Program – Basil T. Darras, Claudia A. Chiriboga, Laurent Servais, Giovanni Baranello, Enrico Silvio Bertini, John W. Day, Nicholas Deconinck, Dirk Fischer, Nathalie M. Goemans, Janbernd Kirschner, Andrea Klein, Ricardo Masson, Maria Mazurkiewicz Beldzin, Yi Wang, Silvia Bader-Weder, Ksenija Gorni, Birgit Jaber, Tammy McIver, Renata Scalco, Eugenio Mercuri P18.5-002 Real-world Outcomes of Nusinersen Alone and Onasemnogene Abeparvovec (OA) Alone or with Prior Nusinersen in Pediatric Patients with Spinal Muscular Atrophy (SMA): Interim Analysis of a US Retrospective Chart Review Study – Omar Dabbous, Min Yang, Mihaela Georgieva, Walter Toro Jimenez, Nicole LaMarca, Anish Patel, Christopher Carley, Sandra P. Reyna
Thursday, April 7 5:30 p.m.–6:30 p.m.
P18.5-003 Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study of Nusinersen in Children with Spinal Muscular Atrophy (SMA) Who Received Onasemnogene Abeparvovec – John Brandsema, Julie Anne Parsons, Craig McDonald, Richard S. Finkel, Kathryn J. Swoboda, Ricardo Masson, Yingying Liu, Corinne Makepeace, Angela Paradis, Zdenek Berger, Joanne M. Wagner, Kathleen C. Somera-Molina P18.5-004 A Rare Case of Congenital Myasthenia Syndrome 11 Caused by a Novel Mutation in RAPSN Diagnosed with Rapid Whole Genome Sequencing (rWGS). – Graham Kiyoshi Reid, Apostolos Psychogios, Rachel Supinger, Kallol Kumar Set
6
Neuro-rehabilitation
Neuromodulation for Rehabilitation 2 P18.6-001 Teleintervention for Persisting Symptoms PostAcute COVID-19 Illness Using Transcranial Direct Current Stimulation (tDCS) – Tehila Eilam-Stock, Allan George, Matthew Lustberg, Robyn J. Wolintz, Lauren B. Krupp, Leigh Elkins Charvet
7
Practice, Policy, and Ethics
Ethics, Diversity & Research, Oh My... 2 P18.7-001 Patient Satisfaction of Teleneurology during COVID-19 Pandemic in Detroit – Bowen Song, Deepti Zutshi, Maryam Jamil Syed, Rohit Ajay Marawar, Maysaa Merhi Basha, Janaki Patel, Arshdeep Kaur P18.7-002 Neurology Resident Burnout and Wellness: A Quality Assessment Inventory Tool – Daniel Minsuk Oh, Jennifer S. Hui P18.7-003 Improving Seizure Management through Interprofessional Collaboration – Michael Miller Chang, Sylvia Bowditch, Caroline Wang, Kiran M. Kanth, Trishna Kantamneni, Roumelia Decontreaus, Carissa Reis, Lisa Eller, Daniel Aquino, Kendra Schomer, Katherine Park P18.7-004 Assessing the DEI needs of an Academic Neurology Department – Sonia Kaur Singh, Anjail Sharrief, Thy Nguyen
P18.6-002 Visual Field Defect Rehabilitation through Visual Restoration Therapy – Lakshmanan Sankaranarayanan, Guhan Ramamurthy, Lakshmi N. Ranganathan P18.6-003 Treating word finding difficulty in multiple sclerosis using high-definition transcranial direct current stimulation targeting the preSupplementary Motor Area – Hsueh-Sheng Chiang, Julie Fratantoni, Sven Vanneste, Michael Kraut, John Hart P18.6-004 Application of Principal Component and Discriminant Analyses on Hippocampal Neuromodulation During a Direct Reach Task – Richard Lee, Roberto Martin Del Campo Vera, Yelim Lee, Kuang-Hsuan Chen, Rinu Sebastian, Spencer Kellis, Brian Lee P18.6-005 Regaining control of movement following a spinal cord injury using Epidural Electrical Stimulation coupled with Task Specific Training – Srimathy Narasimhan, Shankar Balakrishnan P18.6-006 A Teleintervention Program for Multiple Sclerosis (MS) Mobility: Exercise with Transcranial Direct Current Stimulation (tDCS) – Giuseppina Pilloni, Marilyn Moffat, Lauren B. Krupp, Leigh Elkins Charvet
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
99
Thursday, April 7 5:30 p.m.–6:30 p.m.
Poster Session 18
8
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Others 2 P18.8-001 Effects of an Evidence-Based Continuous EEG Triage Protocol on Seizure Detection in Hospitalized Adults: A Quality Improvement Analysis – Brent Jacobus P18.8-002 A Case Report of Second Degree Heart Block and Sinus Pauses after VNS Placement in Refractory Epilepsy – Badria Munir, Farman Ali, Eric J. Seachrist P18.8-003 Trends in Antiseizure Medication Fills and Cost in Medicare Beneficiaries with Epilepsy – Samuel Waller Terman, Chun Chieh Lin, Brian Callaghan, James F. Burke P18.8-004 How Long is a Piece of String? A Retrospective Study of the Correlation Between Length of Stay in Epilepsy Monitoring Unit and Diagnostic Yield – Mohammad Hijaz Adenan, Mohamed Khalil, Kai Sheng Loh, Arif A. Shukralla, Stephen Klaus, Michael Owen Kinney, Hany El-Naggar, Norman Delanty P18.8-005 An Online, Interactive, Self-Paced, Case-Based Clinical Neurophysiology Curriculum for Neurology Residents – Valerie Jeanneret Lopez, Spencer Hutto, Monica B. Dhakar, Denise Fay Chen, Harshad Ladha, Ruba Al-Ramadhani, Muruvet Elkay, Rebecca E. Fasano, Panayiotis Mitsias, Ioannis Karakis P18.8-006 Petechiae: An Atypical Initial Presentation of Seizure – Shivanee Sodani, Musab Zorlu, Hasmik Amirjanyan, Swetha Ade, Ajay M. Tunguturi P18.8-007 Serving Los Angeles County Patients with Teleneurology, A Clinical Tool Here to Stay – Bo Carl Leung, Hasnain Arshad, Shawna W. Benard, Christianne N. Heck, Laura A. Kalayjian, Jonathan Kuo, Patricia Lee, George Nune
9
Infectious Disease
Infectious Disease: Bacteria, Fungi, and Parasites on the Mind and Body 3 P18.9-001 Disseminated Cytomegalovirus Infection with Meningoencephalitis in an Immunosuppressed Renal Transplant Patient – Jaspreet Johal, Ramiro Gabriel Castro Apolo, Negar Moheb, Hussam A. Yacoub P18.9-002 Nocardia Spinal Abscess in the Immunocompetent Patient – Jennifer Hannah Newman, Emily Casaletto, Caio Marconato Matias, Tzu-ying Chuang, Muhammad Athar P18.9-003 Central Nervous System Tuberculosis with SARSCoV-2 Infection: A Short Case-series from Sri Lanka – Shanindra Revanka De Alwis, Shiran Ajith Paranavitane, Senaka Bandusena, Arjuna Hirantha Fernando P18.9-004 To Report A Rare Case of Focal Cranial Nerve and Long Tract Neurologic Deficits associated with Legionnaire’s disease – Arshdeep Kaur, Shashwat Pokharel, Sabeena Iqbal Malik
9
Neuro-oncology
Molecular Determinants of Neurooncology 2 P18.9-005 Restoring Levels of a Tumor Suppressor to Treat Glioblastoma using an RNA Therapeutic Strategy – Rohan Rao, Donatien Kamdem Toukam, Debanjan Bhattacharya, Daewoo Han, Jingchu Huang, Andrew Steckl, Daniel Pomeranz Krummel, Soma Sengupta
10
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease: Clinical Practice 2 P18.10-001 Feeding tube dependence among older stroke patients with feeding tubes – Corey R. Fehnel, Yoojin Lee, Tom G. Travison, Sandeep Kumar, Bridget J. Perry, Julie Lima, Susan Mitchell
P18.10-003 Closing Gaps in Care of Patients with Embolic Stroke of Unknown Source: A Multi-disciplinary approach – Lamya Ibrahim, Muhammad Bilal Tariq, Mohammad Jamil Ahmad, Ijeoma Ekeruo, Munachi Nkiru Okpala, Nicole Gonzales, Anjail Sharrief P18.10-004 Acute Pain: A Consideration in Blood Pressure Management in Acute Ischemic Stroke in the Sickle Cell Patient – Joseph Frazee, Jon Alexander Karel
Cerebrovascular Disease: COVID-19 2 P18.10-005 Pediatric Cerebral Infarction associated with recent SARS-CoV-2 mild infection treated with intravenous thrombolysis and endovascular thrombectomy – Luis Guillermo Manrique, Anusha Mangalampalli, Deepak N. Reddy P18.10-006 Neuroimaging in COVID-19 Patients on Mechanical Ventilation Receiving Sedation: Insight Beyond Diagnosis – Saman Fatima, Sudheer Pachipala, Ayush Agarwal, Venugopalan Y Vishnu, Padma Vasantha Hadakasira P18.10-007 Cerebrovascular Manifestations of COVID-19 in Young Adults – Pranusha Pinna, Therese Dunne, Alejandro Vargas, Laurel Jean Cherian, Gabriela Trifan, Jose Biller, Ronald Alvarado Dyer, Ivan Da Silva P18.10-008 Patterns of Seeking Emergent Stroke Care During the COVID -19 Pandemic: A Nebraska Stroke Center Perspective – Mohammad Dibs, Michele Faulkner, Amna Sohail P18.10-009 Descriptive Analysis of Acute Ischemic Stroke in COVID-19 Patients Through The Course of COVID-19 Pandemic – Jay Liuhong Liu, Keval D. Shah, Amin Marji, Ayaz M. Khawaja P18.10-010 Acute stroke patients with low NIHSS did not delay hospital presentation during COVID – Ali E. Kaabi, Aaisha Mozumder, Sujani Bandela, Agnelio Silverio Cardentey, Lee Birnbaum
P18.10-002 Association Between Mean Platelet Volume And Severity Of Acute Ischaemic Stroke Assessed By Modified Rankin Scale – Dinesh Mohan Chaudhari, Charchit Gupta, Pushpendra Nath Renjen, Anjali Mishra
100
2022 AAN Annual Meeting
Publication Code Key Publication Code Example: P1.2-003 | P1 = Poster Session Number | 2 = Neighborhood | 003 = Poster Number
Poster Session 18
11
Movement Disorders
Movement Disorders: Ataxia and Tourette 2 P18.11-001 A systematic review of the spectrum and prevalence of non-motor symptoms in adults with progressive cerebellar ataxias – Naveed Malek, Yaqub Al Sami, Aram Aslanyan, Rajith Nilantha De Silva
12
Thursday, April 7 5:30 p.m.–6:30 p.m.
Neuro-ophthalmology/Neurootology
Neuro-ophthalmology Research: Vision 2 P18.12-001 The Impact of a Portable Artificial Vision Device (OrCam Read) on Vision-Related Quality-of-Life in Patients with Primary Brain Tumors and Low Vision – Tanvi Chokshi, Yin Allison Liu
P18.11-002 Tremor in Spinocerebellar Ataxia 12 (SCA12): Clinical and Electrophysiological Perspective – Achal K. Srivastava, Manpreet Kaur Kaur Narang, Roopa Rajan, Mohammed Faruq
P18.12-002 An Interprofessional Residency Education and Utilization of the Phone-adapted Panoptic Ophthalmoscope – Lauryn Currens, Goun Je, Richard Church, Kate Daniello, Francisco De la Serna, Jee-young Han, Adalia M. Jun-O’Connell
P18.11-003 Acute Cerebellar Ataxia after COVID-19 Infection in a 5-year-old Boy. – Kimberly O’Neill, Aparna Polavarapu Ramarao
P18.12-003 A Sneak into the science of the Sneaker colour- Is it truly related to Cerebral Dominance? – Harini Pavuluri, Ashalatha Radhakrishnan
P18.11-004 Unusual Presentation of Self Limiting Neonatal Seizures Along with Other Neurological Manifestations in Siblings Diagnosed with Spinocerebellar Ataxia Type 8 (SCA 8) – Shrikant Mishra, Shaweta Khosa, Julian Thomas, Gurveer Singh Khosa, Catherine Yim, Bhavesh Trikamji
P18.12-004 Association Between COVID-19 Vaccination and Optic Neuritis in Adults: A Vaccine Adverse Event Reporting System (VAERS) Study – Mustafa Jaffry, Kranthi Kiran Mandava, Sanjana Rosario, Kamel Jedidi, Nizar Souayah
P18.11-005 Progressive Ataxia and Palatal Tremor with MRI Evidence of Hypertrophic Olivary Degeneration – Jennifer Hislop, Rita Bhatia, Henry Paul Moore P18.11-006 Cerebellar Fit in an Adult with Chiari II Malformation – Austin Mefford, Milena Lobaina, Yi Shen, Laura J. Wu P18.11-007 Social media consumption in adolescents with tics – Jessica Frey, Tracy Tholanikunnel, Heather Simpson, Irene Malaty P18.11-008 Functional Tic Disorders in Children during the COVID-19 Pandemic – Amy Armstrong-Javors, Marisela E. Dy-Hollins, Evan Realbuto, Jeremiah M. Scharf
P18.12-005 Vision-Specific Quality of Life in Patients with Post-Acute Sequelae of COVID-19 (PASC) – Peyton Meyer, Lisena Hasanaj, Peyton Meyer, Steven Galetta, Sujata P. Thawani, Laura J. Balcer
13
P18.13-005 Can You See Me Now?: Understanding Health Outcomes in Telehealth Among Seniors – Sherline Sauveur, Sherline Sauveur, Chantale Octavia Branson P18.13-006 Pediatric Neurology Patient Disparities in Use of and Access to Rapid Telehealth Implementation during the COVID-19 Pandemic – Lindsey Morgan, Payal B. Patel, Jingyang Chen, John Jay Alexander, Edward J. Novotny, Mark Wainwright P18.13-007 Reassessing the Geographical Distribution of Neurologists in the United States – Kyra Curtis, Sama Elrahi, Josh Bilello, Prashant Kumar Rai P18.13-008 Measuring Ambulatory Neurologic Health Disparities with the Axon Registry – Richard T. Benson, Sarah M. Benish, Gregory J. Esper, Brett M. Kissela, Nicole Rosendale, Erika Tatiana Marulanda-Londono, Omotola A. Hope, Tammy Thu Ann Pham, Matthew T. Roe, Aracelis Torres, Amanda Lien, Steven Kaai Kauwe, Aristotle Mante, Karen Lundgren, Becky Schierman, Lyell K. Jones P18.13-009 Tightening up Acute Stroke Care in the Stroke Belt with Telestroke – Theresa Beth Sevilis, Mark McDonald, Amanda Avila, Gregory Wayne Heath, Mohammed N. Zaman, Thomas G. Devlin
Health Care Disparities
Disparities in Neurologic Care and Education P18.13-001 Attitudes, Beliefs and Experiences of an Academic Neurology Department Regarding Systemic Racism: University of Kentucky Neurology Residency Study – Thien Nguyen, Khawla M. Abusamra, Timothy James Ainger, Ima M. Ebong P18.13-002 Trends in Diversity at a Single US Adult Neurology Residency Program – Keiko Aun Fukuda, Mathura Ravishankar, Anne C. Van Cott, Paula R. Clemens, Sasha Zivkovic, Ajitesh Ojha P18.13-003 The Diversity of Graduate Medical Education Leadership in Neurology – Morgan Christina Jordan, Zahari Tchopev, Jeffrey C. McClean P18.13-004 Socioeconomic Bias in Ordering Toxicology Screens in Patients with an Acute Stroke – Fady Mousa-Ibrahim, Konrad Kubicki, Alexandria Cummuta, Christopher Richardson, Michael Joel Schneck, Garry Sigman
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
101
JOIN US
Our hope is to create a tomorrow where neurological disorders no longer limit human potential—to help preserve what makes people who they are
gene.com
© 2022 Genentech USA, Inc. All rights reserved. M-US-00014873(v1.0)
Experience PostersPOSTERS VIRTUALVirtual EXPERIENCE There will also be more than 470 abstracts exclusively presented as posters during the 2022 Annual Meeting Virtual Experience April 24-26. These posters will be available for the duration of the virtual meeting.
Virtual Experience Posters
Aging and Dementia P1.001 How did the Early COVID 19 Pandemic Lockdown Affect Care of Memory Disorder Patients?: Caregiver views – Krista Schoff, Nakul Katyal, Joel Isaac Shenker P1.002 Contribution of Vascular Risk Factors to Dementia and Dementia Risk Prediction Varies Across Mid- to Later-Life: The Framingham Heart Study – Emer McGrath, Alexa Beiser, Adrienne O’Donnell, Jayandra J. Himali, Matthew Pase, Claudia L. Satizabal, Sudha Seshadri P1.003 Person-centered Assessment in Early Alzheimer’s Disease – Alberto Villarejo Galende, Elena GarciaArcelay, Gerard Pinol-Ripoll, Antonio Del OlmoRodríguez, Felix Vinuela, Merce Boada Rovira, Emilo Franco Macias, Almudena Ibanez, Mario Riverol, Albert Puig-Pijoan, Pedro Abizanda, Rafael Arroyo Gonzalez, Miquel Baquero, Inmaculada Feria-Vilar, Mircea Balasa, Angel Berbel Garcia, Eloy Rodriguez-Rodriguez, Vieira Campos Alba, Guillermo Garcia-Ribas, Silvia Rodrigo-Herrero, Alberto Lleo, Eduardo Aguera Morales, Carmen Catalan Flores, Jorge Maurino P1.004 Prevalence and Cognitive Impact of Neuropathologies Across the Age Spectrum – Janice Xing-Yi Li, Hannah Nguyen, Kiana Scambray, S. Ahmad Sajjadi P1.005 Gene therapy for DRPLA model mice by AAVdelivered CRISPR / Cas9. – Shoichiro Ando, Taisuke Kato, Yuka Koike, Sachiko Hirokawa, Kenta Kobayashi, Shoji Tsuji, Osamu Onodera P1.006 Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial – Daniel Weintraub, Alberto J. Espay, Vibhash D. Sharma, Pierre Tariot, Victor Abler, Sanjeev Pathak, Srdjan Stankovic P1.007 Infratentorial Pathology in Frontotemporal Dementia Phenotypes – Mary Clare McKenna, Siobhan Hutchinson, Peter Bede
P1.008 Pallidal Functional Connectivity Changes Are Associated with Disgust Recognition in Pure Motor Amyotrophic Lateral Sclerosis – Veronica Castelnovo, Elisa Canu, Maria Antonietta Magno, Elena Gatti, Nilo Riva, Barbara Poletti, Vincenzo Silani, Massimo Filippi, Federica Agosta P1.009 Cortical Remodeling Across the Lifespan in Healthy Brain Reveals Structural Network Vulnerability to Neurodegeneration – Camilla Cividini, Federica Agosta, Silvia Basaia, Edoardo G. Spinelli, Veronica Castelnovo, Michela Leocadi, Davide Calderaro, Maria Antonietta Magno, Elisa Canu, Massimo Filippi P1.010 Functional Brain Connectome in Ventral and Dorsal Variants of Posterior Cortical Atrophy – Elisa Canu, Federica Agosta, Maria Antonietta Magno, Silvia Basaia, Camilla Cividini, Francesca Caso, Giuseppe Magnani, Maxime Montembeault, Richard Levy, Raffaella Migliaccio, Massimo Filippi P1.011 Updated US Prevalence Estimates Accounting for Racial and Ethnic Diversity for Trials and Therapies Targeting Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) and Mild AD Dementia – Cai Gillis, Mattia Gianinazzi, Mina Nejati, Nancy Maserejian P1.012 Subgroup Analyses of the Amyloid PET Substudies From EMERGE and ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Patients With Early Alzheimer’s Disease – Raj Rajagovindan, Tianle Chen, Hao Wu, Ying Tian, Laura Nisenbaum, Carmen Castrillo-Viguera, Ping He, Samantha Budd Haeberlein P1.013 Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment With Aducanumab Were Associated With Slowing in Clinical Decline – Raj Rajagovindan, Tianle Chen, Laura Nisenbaum, Ying Tian, Bharath Kumar Kandadi Muralidharan, Gersham Dent, Ping He, Carmen Castrillo-Viguera, Samantha Budd Haeberlein P1.014 Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE – Patrick Burkett, Kimberly Umans, Carmen Castrillo-Viguera, Derk Purcell, Jerome Barakos, Sami Fam, Samantha Budd Haeberlein, Karen Smirnakis
Information is accurate as of February 8, 2022, and is subject to change.
P1.015 Item-Level Analysis of Clinical Measures in Patients With Early Symptomatic Alzheimer’s Disease Following Treatment With High-Dose Aducanumab in the Phase 3 EMERGE Study – Sharon Cohen, Ping He, Mihaela Levitchi, Ryan Miller, Fiona Forrestal, Menglan Pang, Carmen Castrillo-Viguera, Judith Jaeger, Catherine Mummery, Anton P. Porsteinsson, Jeffrey Lee Cummings, Ying Tian, Lili Yang, Samantha Budd Haeberlein P1.016 ICARE AD-US: Design of a Prospective, SingleArm, Multicenter, Noninterventional, Real-World Study of Aducanumab in the United States – James E. Galvin, Jeffrey Lee Cummings, Mihaela Levitchi, Carl DeMoor, Alireza Atri, Verna R. Porter, Ivana Rubino P1.017 The Association of Vasomotor Symptoms During the Menopausal Transition and Cognition in Later Life – Amalia Peterson, Reena Gottesman, Eliza Cushman Miller, Sarah Tom P1.018 Quantitation of Nervous System Proteins NF-L, t-Tau, p-Tau181, Aß1-42, Aß1-40, GFAP and Inflammatory Cytokines IL-6, IL-10, TNFa in Alzheimer’s Disease Plasma. – Ahmed Chenna, Christos John Petropoulos, John Winslow P1.019 Masupirdine (SUVN-502), A Serotonin Receptor Sub-Type 6 Antagonist for the Potential Treatment of Agitation and Psychosis in Patients with Dementia of Alzheimer’s Type – Ramakrishna Nirogi, Rajesh Kumar Badange, Abdul Rasheed Mohammed, Santosh Kumar Pandey, Vijay Benade, Ramkumar Subramanian, Pradeep Jayarajan, Jyothsna Ravula, Satish Jetta, Venkat Jasti P1.020 Event-related potentials as biomarkers of cognitive performance in Alzheimer’s disease patients with cardiovascular risk factors – Anna Marin, Kylie Schiloski, Ana L. Vives-Rodriguez, Renée DeCaro, Andrew E. Budson, Katherine Turk P1.021 Hypertensive Disorders in Pregnancy and Future Development of Dementia: A Systematic Review and Meta-analysis – Aaron Ross Switzer, Eric E. Smith, Aravind Ganesh
AAN.com/AM
103
Virtual Experience Posters
P1.022 Changes of neuropsychiatric symptoms in patients with dementia during COVID-19 crisis : Telephone survey from the Yangcheon Dementia Reassurance Center – Soo-Hyun Kim, Hyunji Kim, Seungwon Chung, Hyung Ho Kim, Kee Duk Park, Geon Ha Kim, Sun Hee Hong, Jee Hyang Jeong, Geon Ha Kim P1.023 Investigating the Genetic Characteristics of Hippocampal Volume and Plasma Aß in a Chinese Community-Dwelling Population – Xinzhuang Yang, Mengyao Wan P1.024 Application of Appropriate Use Criteria for Cerebrospinal Fluid Testing for Alzheimer Disease Biomarkers: A Retrospective, Real-World Assessment in a Dementia Specialty Clinic – Taylor Krivanek, Seth Gale P1.025 Duration of Ice Hockey Play and Chronic Traumatic Encephalopathy Risk – Bobak Abdolmohamadi, Madeline Uretsky, Evan Nair, Nicole Saltiel, Raymond Nicks, Daniel Daneshvar, Victor E Alvarez, Bertrand Huber, Thor D. Stein, Ann C. McKee, Michael Alosco, Jesse B. Mez P1.026 Regional White Matter Hyperintensities and Relation to Cognition in Posterior Cortical Atrophy and Logopenic Progressive Aphasia – Nha Trang Thu Pham, Jonathan Graff-Radford, Mary M. Machulda, Anthony Spychalla, Christopher Schwarz, Matthew Senjem, Val John Lowe, Clifford R. Jack, Keith A. Josephs, Jennifer Louise Whitwell P1.027 Fatal Familial Insomnia presenting with gait ataxia, encephalopathy, and cachexia. Updating the diagnostic paradigm with recommendations for genetic screening and options for family counseling – Nara Michaelson P1.028 One Hundred Centenarians: Brain Pathology and Relationship to Dementia in The 90+ Study – Raumin Shawn Neuville, Chuching Ho, S. Ahmad Sajjadi, Roshni Biswas, Thomas J. Montine, Maria M. Corrada, Claudia Kawas P1.029 Retinal optical coherence tomography identifies early biomarkers for Alzheimer’s and Parkinson’s disease and cognitive decline – Sarah Shareef, Sayuri Sekimitsu, Yan Zhao, Tobias Elze, Ayellet Segre, Janey Wiggs, Nazlee Zebardast P1.030 White matter hyperintensities in frontotemporal lobar degeneration – Chloe Anastassiadis, Anna Vasilevskaya, Foad Taghdiri, Cristina Salvo, Carmela Tartaglia
104
2022 AAN Annual Meeting
Autoimmune Neurology P1.031 Aflibercept-induced recurrent cranial nerve neuritis affecting varying cranial nerves – Yifan Huang, Christian Gericke P1.032 Giant Cell Arteritis of the Superior Mesenteric Artery Presenting with Wernicke Encephalopathy from Thiamine Deficiency – Sarah Shapiro, Ludovica Farese, David Roman Renner P1.033 The Diagnostic Utility of Cerebral Angiography for Primary Central Nervous System Vasculitis: Analysis of Patients from a Tertiary Centre – Abhishek Gupta, Saiju Jacob P1.034 Atypical presentation of rare entity autoimmune autonomic ganglionopathy: Another potential cause of hypertensive crisis. – Baljinder Singh, Jananisree Ravichandran, Isabel Victoria Narvaez- Correa, Mohammad Rauf A. Chaudhry, Mohammad Ghatali, Paisith Piriyawat, Isabel Victoria Narvaez- Correa P1.035 Incidence of Skin Changes in Patients with Myasthenia Gravis Prescribed Mycophenolate mofetil or Azathioprine – Callee Brooks, Erin R. Dark, Stephanie Hwang, Stephanie Iyer, Anahit C. Mehrabyan P1.036 High-Resolution Manometry is Useful for Diagnosing Myasthenia Gravis with Mild Dysphagia – Kenjiro Kunieda, Yuichi Hayashi, Nobuaki Yoshikura, Akio Kimura, Ichiro Fujishima, Takayoshi Shimohata P1.037 Characterization of Neuronal Surface AntigenSpecific Immunostaining Pattern: Comparison between In-house and Commercial Brain Immunohistochemistry – Takahiro Iizuka, Naomi Nagata, Naomi Kanazawa, Atsuko Yanagida, Hiroki Suga, Juntaro Kaneko, Eiji Kitamura, Kazutoshi Nishiyama P1.038 Autoimmune limbic encephalitis mimicking progressive supranuclear palsy – Yoya Ono, Kazuhiro Higashida, Akio Kimura, Takayoshi Shimohata P1.039 IgG4-Mediated Chronic Inflammatory Demyelinating Polyneuropathy: A Severe Presentation of Contactin-1 Autoimmune Pathology – Magalie Carey, Katherine Wanda Zerebiec, Noah A. Kolb, Michael K. Hehir
P1.040 Oligosymptomatic anti-GABA A receptor encephalitis: a new diagnostic and therapeutic challenge – Iñigo Oyarzun Irazu, Antonio Cabrera Muras, Daniel Martínez Cóndor, Clea Gutierrez, Ivan Caballero, Borja Aguilera, Juan Manuel Garcia Sanchez, Alejandra Collia Fernandez, Josep O. Dalmau, Francesc R. Graus, Juan C. Garcia Monco Carra P1.041 Takotsubo’s Cardiomyopathy As A Result Of Guillain-Barre Syndrome: A Case Report And Review Of The Literature – Arnav Mahajan, Surasak Komonchan, Vathanyoo Plainetr, Pungjai Keandoungchun P1.042 Myelin oligodendrocyte glycoprotein antibodyassociated disease (MOGAD) with Coexistence of IgG to Glial Fibrillary Acidic Protein and NMDA Receptor – Nicole Khezri, Ellen Song P1.043 Mog-Antibody-Associated Disease: an Argentinian hospital-based study – Analisa Manin, Sara Palacios, Leandro Miguel Kim, Victoria Fernandez, Andres M. Villa P1.044 HLA-DR4-positive Vogt-Koyanagi-Harada (VKH) Syndrome: Review of pathophysiology and clinical correlation – Jacob Walter Loeffler, Esther H. Nie, May Han P1.045 Cost-Effectiveness of Eculizumab and Efgartigimod for the Treatment of generalized Myasthenia Gravis – Pei-Wen Lien, Foluso Agboola, Mrinmayee Joshi, Dmitriy Nikitin, Zaid K. Yousif, Shanikumar P. Patel, Vinura Withanawasam, Saira Jatoi, Eden Abera Gebre, Jeffrey A. Tice, Jonathan D. Campbell, Daniel Touchette P1.046 Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibodypositive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study – Ichiro Nakashima, Yo Hoshino, Kazumi Okamura, Hidekazu Kikui, Kazuo Fujihara P1.047 Opsoclonus Myoclonus Syndrome in Uterine Malignancy – Maithreyi Chappidi, Erik Von Burton P1.048 Mild encephalitis/encephalopathy with reversible splenial lesion after COVID-19 vaccination – Hiroya Ohara, Hironori Shimizu, Takehito Kasamatsu, Akihiro Kajita, Kenji Uno, Kazuma Sugie, Masako Kinoshita P1.049 Moderna COVID-19 Vaccine-Induced Immune Thrombosis of Central Retinal Artery –Report of a Case – Vai Hong Fong, Yung-Ray Hsu, Sin Yu Chow
Virtual Experience Posters
P1.050 Guillain-Barre Syndrome Following COVID-19 Vaccination: A Literature Review – Nasrin Jahan, Maha Hameed, Surya Suresh, Praveen Gowtham Varma Dasaraju, Harshadayani Jagadish Kumar, Biki Kumar Sah, Sujan Poudel P1.051 Dilemma in Differentiating Posterior Reversible Encephalopathy Syndrome and Lupus Cerebritis in Systemic Lupus Erythematosus with Multi-Organ Involvement: A Case Report – Pooja Patnaik, Alejandra Marcela Marquez, Giovanna Manzano, Anand Viswanathan P1.052 Bilateral Facial Weakness as Initial Presentation of Post COVID-19 Vaccination related Guillain Barré Syndrome – Khaled Gharaibeh, Taehong Lim, Ajaz Sheikh P1.053 Neurologic Immune-related Adverse Events of Immune Checkpoint Inhibitors – Chen Yan, Merry Huang, Carol Swetlik, Karlo Toljan, James Bena, Pauline Funchain, Marisa P. McGinley P1.054 Anti-N-Methyl-D-Aspartate Receptor Encephalitis In An Eleven Month Old Child with Atypical Presentation – Saraswati Nashi, Sumanth S, P.R. Srijithesh P1.055 An Atypical Case of anti-GFAP Astrocytopathy – Maxime Junior Jean, David J Sandness, Ryan Canissario, Lawrence M. Samkoff P1.056 An Unusual Case of CLIPPERS – Olivia Kingsford, Michael Vincent Robers P1.057 Giant Cell Arteritis and Area Postrema Syndrome: Where Do We Stand? – Rafael Gemaque Lima Bentes, William Souza Martins Ferreira, Matheus Alves Alves Da Silva, Barbara Maini Carvalho, Christiane Monteiro Siqueira Campos, Hennan Salzedas Teixeira, Carmen Lancelotti, Alex Baeta P1.058 Possible association of demyelination disease with new COVID19 infection – Lama Alshaikhmubarak, Bader Alonazy P1.059 Neurological Complications of COVID-19: GuillainBarre Syndrome Following Pfizer COVID-19 Vaccine – Sadia Waheed, Angel S. Bayas, Fawzi Hindi, Zufe Rizvi, Patricio S. Espinosa
Autonomic Disorders P1.060 Characterizing the natural history of progression in patients with Multiple System Atrophy – Miguel Angel Perez, Patricio Millar Vernetti, Jose M. Martinez, Michele Potashman, Irfan Qureshi, Victoria Wirtz, Gilbert J. L’Italien, Susan Durham, Judah Michael Ellison, Horacio C. Kaufmann P1.061 Use of Mayer Wave Activity to Identify Discordant Cardiovascular Autonomic Function during the Subacute Period of Spinal Cord Injury as a Potential Means to Identify Co-Occurring Traumatic Brain Injury – Michael F. La Fountaine, Thomas Bryce, Jill M. Wecht
Cognitive and Behavioral Neurology P1.062 Repetitive Transcranial Magnetic Stimulation improves neuropsychiatric manifestations in Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia – Amaar Marefi, Michaela Barbarosie, Roberta La Piana P1.063 Neuroanatomical Changes in Self-Reported Anxiety: A Cluster Analysis – Sanjana Sundara Raj Sreenath P1.064 Alzheimer’s Disease Cerebrospinal Fluid Biomarkers Differentiate Creutzfeldt-Jakob Disease from its Mimicker Autoimmune Encephalitis – Bryce Chang, Gregory S. Day, Jonathan Graff-Radford, Andrew McKeon, Eoin P. Flanagan, Alicia Algeciras-Schimnich, Ronald C. Petersen, David T. Jones, Michel Toledano, Wentao Li P1.065 Hippocampal Regional Abnormalities Contribute to Cognition in Multiple Sclerosis – Damiano Mistri, Laura Cacciaguerra, Elisabetta Pagani, Paola Valsasina, Alessandro Meani, Federica Esposito, Massimo Filippi, Maria Assunta Rocca P1.066 Mapping Topography and Network of Brain Injury in Patients with Disorders of Consciousness – Manoj Arachige, Thanh Phan, Udaya K. Seneviratne P1.067 Corticobasal Syndrome Associated with a Novel Lys694del Variant of the TBK1 gene – Kaitlin Seibert, Heather Smith, Allison Lapins, Peter Pytel, James A. Mastrianni
Information is accurate as of February 8, 2022, and is subject to change.
P1.068 Seeing Picasso Faces: About a Case of Prosopometamorphopsia – Claire Emmanuelle Delpirou Nouh, Venkataditya Dugyala, Ahmad Al-Awwad P1.069 Methotrexate-Induced Encephalopathy In A Patient With Relapsing Polychondritis – Mohammed Shan Uddin, Ajay Banga, Ariol Labrada, Roberto E. Sanchez P1.070 Neurocognitive And Psycho-emotional Disorders In Patients With Chiari Malformation Type I – Khristina Derevyanko P1.071 Mind Over Matter - or is it? Role of Right Temporoparietal Junction in Functional Neurologic Disorders – Areeba Siddiqui, Batool Akhlaq Hussain, Sanaz Attaripour P1.072 Developing a Preliminary Parkinson’s Disease Risk Estimator for Decline In Cognition Tool (pPREDICT) as a Practical and Pragmatic Tool to Estimate Risk of Cognitive Decline – Tara Carlisle, Kaitlin Olson, Nichole E. Carlson, Brianne Bettcher, Samantha K. Holden
Cerebrovascular Disease and Interventional Neurology P1.073 Prior Employment Status and Obesity Do Not Predict Post Stroke Fatigue – Zachary Cooper, Nadege Gilles, Jessica Rosemarie Sirizzotti, Steven R. Levine P1.074 Factors Associated with Anxiety after Hemorrhagic Stroke – Anlys Olivera, Sarah Ecker, Aaron S. Lord, Lindsey Gurin, Koto Ishida, Kara R. Melmed, Jose L. Torres, Barry M. Czeisler, Cen Zhang, Jennifer A. Frontera, Ariane Lewis P1.075 AMPA Receptor Modulation Mitigates PostStroke Damage Via Inhibition of Pro-inflammatory and Apoptotic Biomarkers in Experimental Model of Stroke – Himanshu Sharma, Reeta KH P1.076 A Risk Prediction Nomogram for Recurrent Stroke in Medically Treated Patients with Symptomatic Intracranial Atherosclerotic Disease – Xuan Tian, Linfang Lan, Lina Zheng, Hui Fang, Yuming Xu, Thomas Wai Hong Leung, Xinyi Leng
AAN.com/AM
105
Virtual Experience Posters
P1.077 Transradial Versus Transfemoral Access for Woven EndoBridge (WEB) Embolization of Intracranial Aneurysms: A Propensity-Score Matched Multicenter Study – Mahmoud Dibas, Nimer Adeeb, Jose Danilo Bengzon Diestro, Hugo Cuellar-Saenz, Ahmad Sweid, Sovann Vathana Lay, Adrien Guenego, Asala Aslan, Leonardo Renieri, Sri Hari Sundararajan, Guillaume Saliou, Markus Möhlenbruch, Robert W. Regenhardt, Justin E. Vranic, Ivan Lylyk, Paul Foreman, Jay Ashok Vachhani, Vedran Zupancic, Muhammad Ubaid Hafeez, Caleb Rutledge, Muhammad Waqas, Vincent Tutino, James D. Rabinov, Yifan Ren, Clemens M. Schirmer, Mariangela Piano, Anna Luisa Kühn, Caterina Michelozzi, Stéphanie Elens, Robert M Starke, Ameer Hassan, Arsalaan Salehani, Peter Sporns, Jesse Jones, MariosNikos Psychogios, Julian Spears, Boris Lubicz, Pietro Panni, Ajit Puri, Guglielmo Pero, Christoph J. Griessenauer, Hamed Asadi, Christopher Stapleton, Adnan H. Siddiqui, Andrew Ducruet, Felipe Albuquerque, Peter Tze Man Kan, Vladimir Kalousek, Pedro Lylyk, Srikanth Boddu, Jared Knopman, Mohammed Ali Aziz-Sultan, Nicola Limbucci, Pascal Jabbour, Christophe Cognard, Aman Patel, Adam A. Dmytriw P1.078 The Woven EndoBridge (WEB) device for the treatment of Intracranial Aneurysms: A Decade of Lessons Learned and Changes in Practice from the WorldwideWEB Consortium – Mahmoud Dibas, Nimer Adeeb, Jose Danilo Bengzon Diestro, Hugo Cuellar-Saenz, Ahmad Sweid, Sovann Vathana Lay, Adrien Guenego, Asala Aslan, Leonardo Renieri, Sri Hari Sundararajan, Guillaume Saliou, Markus Möhlenbruch, Robert W. Regenhardt, Justin E. Vranic, Ivan Lylyk, Paul Foreman, Jay Ashok Vachhani, Vedran Zupancic, Muhammad Ubaid Hafeez, Caleb Rutledge, Muhammad Waqas, Vincent Tutino, James D. Rabinov, Yifan Ren, Clemens M. Schirmer, Mariangela Piano, Anna Luisa Kühn, Stéphanie Elens, Stéphanie Elens, Robert M Starke, Ameer Hassan, Arsalaan Salehani, Peter Sporns, Jesse Jones, MariosNikos Psychogios, Julian Spears, Boris Lubicz, Pietro Panni, Ajit Puri, Guglielmo Pero, Christoph J. Griessenauer, Hamed Asadi, Christopher Stapleton, Adnan H. Siddiqui, Andrew Ducruet, Felipe Albuquerque, Peter Tze Man Kan, Vladimir Kalousek, Pedro Lylyk, Srikanth Boddu, Jared Knopman, Mohammed Ali Aziz-Sultan, Nicola Limbucci, Pascal Jabbour, Christophe Cognard, Aman Patel, Adam A. Dmytriw P1.079 Evaluating the Effect of Gender and Diabetes Mellitus on Stroke Severity – Jessica Rosemarie Sirizzotti, Zachary Cooper, Bernardus Willems, Nadege Gilles, Steven R. Levine
106
2022 AAN Annual Meeting
P1.080 Hemodynamics Features of Symptomatic Intracranial Atherosclerotic Disease Associated with Severity of Ipsilateral Cerebral Small Vessel Disease – Lina Zheng, Xuan Tian, Jill Abrigo, Xinyi Leng, Thomas Wai Hong Leung P1.081 Mobile Stroke Unit Patient Utilization: A SingleCenter Experience – Matthew Orwitz, Jason Mathew, Danielle Bazer P1.082 Endovascular Thrombectomy for Treatment of Acute Ischemic Stroke During Pregnancy and the Early Postpartum Period – Alis J. Dicpinigaitis, Chirag Gandhi, Fawaz Al-Mufti P1.083 Does Perfusion Computed Tomography Abnormalities in Patients with Transient Ischemic Attack Predict Subsequent Ischemic Stroke and Cardiovascular Event? – Aisha Abdulrazaq, Muhammad Fawad Ishfaq, Adnan I. Qureshi P1.084 Predicting Stroke Risk in Symptomatic Intracranial Atherosclerotic Disease: Stroke Mechanisms as Another Dimension beyond Arterial Luminal Stenosis – Xinyi Leng, Xueyan Feng, Lina Zheng, Xuan Tian, Thomas Wai Hong Leung P1.085 Causal Relationship Between Polycythemia Vera And Reversible Cerebral Vasoconstriction: A Case Report – Arnav Mahajan, Surasak Komonchan, Yodkhwan Wattanasen, Wuttipong Tirakotai P1.086 Adrenal Abnormalities and Stroke – Hamza Chaudhry, Tehniyat Baig, Hooman Kamel P1.087 Early and 30-day Clinical and Neuropsychological Effects of Iatrogenic Brain Infarcts in the ENACT Randomized-Controlled Trial – Aravind Ganesh, Mayank Goyal, Alexis Wilson, Johanna Maria Ospel, Andrew M. Demchuk, David J. Mikulis, Julien Poublanc, Timo Krings, Roberta Mary Anderson, Michael Tymianski, Michael D. Hill P1.088 Investigating a New Risk Factor of Subarachnoid Hemorrhage: Opium Use Disorder – Alireza Zandifar, Zahra Sadat Mortazavi, Luis Octavio Tierradentro Garcia, Jorge Du Ub Kim, Arastoo Vossough, Mohammad Saadatnia P1.089 Risk and Predictors of Relapse after Smoking Cessation in Patients with Ischemic Stroke and Transient Ischemic Attack – Neal S. Parikh, Cenai Zhang, Babak Navi, Hooman Kamel P1.090 Prescription Smoking-Cessation Medication Pharmacy Claims After Stroke and Transient Ischemic Attack – Neal S. Parikh, Yongkang Zhang, Daniel Restifo, Babak Navi, Hooman Kamel
P1.091 Preadmission Anti-hypertensive Agents May Affect Cerebral Vasospasm Risk in Aneurysmal Subarachnoid Hemorrhage – Elijah Malik PersadPaisley, Alizeh Shamshad, Saba S. Paracha, Christoph Stretz, Nicholas S. Potter, Linda C. Wendell, Bradford B. Thompson, Karen L. Furie, Jesse Menville, Ali Mahta P1.092 Thrombolysis for Acute Ischemic Stroke in Patients with versus without Pre-morbid Disability: A Meta-analysis – Benjamin Frank Beland, Fouzi Bala, Mohammed Almekhlafi, Aravind Ganesh P1.093 Low Fibrinogen Level as a Predictor of Hemorrhagic Transformation after Thrombolytic Therapy for Acute Ischemic Stroke – Alessandro Iliceto, Roger C. Cheng, Deviyani Mehta, Raymond Vincent Mirasol, Igor Rybinnik P1.094 Management of Early Neurologic Deterioration Due to Stroke Progression or Recurrence – Joontae Kim, Sura Ryu, Hyunsoo Kim, You-Ri Kang, Shina Kim P1.095 Spinal Dural Arteriovenous Fistula: A diagnostic conundrum for neurologists – Megan Weisenberg, Meghna Kumar-Pelayo P1.096 Could The “Modified 8 D’s of Stroke Care” Improve Sex Disparities in Door-to-Needle Time in Acute Ischemic Stroke? – Melika Jameie, Mana Jameie, Ghasem Farahmand, Saba Ilkhani, Zahra Ranjbar, Hannah Magrouni, Sanaz Heydari, Mojtaba Shahbazi, Maryam Kaeedi, Rozita Amiri, Fateme Alizadeh Boroujeni, Mahnaz Varedi, Bahareh Pourghaz, Mojdeh Ghabaee P1.097 Effects of Demographics and Socioeconomic Status on Opioid Use in Patients with Subarachnoid Hemorrhage – Kareem Joudi, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Karen L. Furie, Ali Mahta P1.098 Surpass Streamline for the Treatment of Heterogenous Size Intracranial Aneurysms: A Multicenter US Real-World Experience – Juan A. Vivanco-Suarez, Mudassir Farooqui, Milagros Galecio-Castillo, Cynthia Zevallos, Kimon Bekelis, Justin Singer, David J Altschul, Johanna Therese Fifi, Fawaz Al-Mufti, Bradley Gross, Brian Jankowitz, Peter Tze Man Kan, Margarita Rabinovich, Sarah Newman, Emanuele Orru, Ajay Wakhloo, Santiago Ortega Gutierrez P1.099 Characterizing Post-Operative Stroke in Patient’s Undergoing Neck Dissection – Derek Woodruff, Eric Goldstein
Virtual Experience Posters
P1.100 Effect of Decompression Craniectomy on Survival and Functional Outcome in Patients with COVID-19 and Malignant Infarct: A Retrospective Cohort Study and Review of Literature – Sudheer Pachipala, Saranya B. Gomathy, Ayush Agarwal, Venugopalan Y Vishnu, Awadh K. Pandit, Rohit Bhatia, Padma Vasantha Hadakasira P1.101 Can Inflammatory Markers Predict TOAST Subtypes in Young Onset Ischaemic Strokes? – Tara Hamilton, Shameer Rafee, Christopher McGuigan P1.102 Association Between Stroke Severity and Cardiac Troponins in Acute Stroke – Andrea Kuczynski, Grace Rzyczniak, Gee Hung Leo Cheong, Petra Famiyeh, Manav Vyas P1.103 Team-based Resident Training for Stroke Code Simulations Decreases Variations in Thrombolytic Door to Needle Times – Hyeyoung Seol, Peri Smith, Aidan Azher, Zafer Keser, Aditya Kumar, Shivika Chandra, Amanda L. Jagolino-Cole, Alicia Zha P1.104 Motor Impairment In Intracerebral Hemorrhage – Mariem Elfekih, Ines Bedoui, Bissene Douma, Zeineb Brahem, Hajer Derbali, Jamel Zaouali, Ridha Mrissa P1.105 A Case of Contrast-Induced Encephalopathy in The Setting of Acute Stroke Thrombolysis – Qasem N. Alshaer, Zaid R. Najdawi, Ryan B. Peterson, Nirav R. Bhatt P1.106 Endovascular Treatment of Acute Ischemic Stroke in Patients with versus without Pre-morbid Disability: A Meta-analysis – Benjamin Frank Beland, Fouzi Bala, Mohammed Almekhlafi, Eva Akshitkumar Mistry, Mayank Goyal, Aravind Ganesh P1.107 Physician Approaches to Imaging and Revascularization for Acutely Symptomatic Carotid Stenosis: Insights from the Hot Carotid qualitative study – Aravind Ganesh, Benjamin Frank Beland, Gordon Jewett, David JT Campbell, Malavika Varma, Ravinder Jeet Singh, Abdulaziz Sulaiman Al Sultan, John Wong, Bijoy Menon P1.108 Physician Approaches to Anti-thrombotic Therapies for Acutely Symptomatic Carotid Stenosis: Insights from the Hot Carotid Qualitative Study – Aravind Ganesh, Benjamin Frank Beland, Gordon Jewett, David JT Campbell, Malavika Varma, Ravinder Jeet Singh, Abdulaziz Sulaiman Al Sultan, John Wong, Bijoy Menon
P1.109 Direct Oral Anticoagulants and Antiepileptic Drug Combination on Risk of Ischemic Stroke and Major Bleeding – a territory-wide review – Bonaventure Ip, Ho Ko, Hiu Wo Chan, Carly Yeung, Brian Yiu, Alexander Yuk-Lun Lau, Grace LH Wong, Thomas Wai Hong Leung P1.110 A Large Lambl’s Excrescence Causing Embolic Stroke in a Young Patient: A Case Report and Review of Literature – Hadi Abou-El-Hassan, Yusra Azhar, Asad Ikram, Dmitry Belchenko, Tobias B. Kulik, Michel T. Torbey P1.111 Hemoglobin Levels And Cerebral Collaterals As Independent Predictors Of Functional Outcome In Acute Ischemic Stroke Cases With Large Vessel Occlusion (LVO) – Sankar Prasad Gorthi, Krithishree S., Prakashini K P1.112 Hypertensive Disorders in Pregnancy and Future Risk of Stroke and Hypertension: A Systematic Review and Meta-analysis – Aaron Ross Switzer, Eric E. Smith, Aravind Ganesh P1.113 Treatment Non-Adherence And Barriers To Treatment Adherence Among People Diagnosed With Stroke In A Tertiary Care Hospital Of South India. – Ashwini Naik, Jyothi Chakrabarty P1.114 On Evaluating The Potential Of Machine Learning For Effective Classification Of Ischemic And Hemorrhagic Stroke In Resource Limited Settings – Aman Bhardwaj, Yamini Antil, Aanchal Chadha, Padma Vasantha Hadakasira, Vinny P. Wilson, Amit Mehndiratta, Venugopalan Y Vishnu, Rahul Garg P1.115 Presumed Large Vessel Occlusion in Patients presenting with First-ever Ischemic Stroke at a Tertiary Teaching Hospital in Tanzania – Sarah Shali Matuja, Rashid Ali Ahmed, Patricia Munseri, Khuzeima Shabirhussein Khanbhai, Kezia Kodawa Tessua, Frederick Richard Lyimo, Gustavo J. Rodriguez, Alberto Maud, Mohammad Rauf A. Chaudhry, Mohamed Manji, Faheem Gulamabbas Sheriff P1.116 Supranuclear Oculomotor Palsy In Cerebral Venous Sinus Thrombosis: A Rare Occurrence – Varun Kumar Singh, Kumar Bismaya, Pratishtha Sengar, Pratishtha Sengar, Anand Kumar P1.117 Bow Hunter Syndrome: An intriguing case of posterior circulation stroke in obstetrics department – Neenu Alexander, Justin Cornelius
Information is accurate as of February 8, 2022, and is subject to change.
P1.118 The impact of prior multimorbidity on the longterm risk and costs of institutionalisation after stroke: a population-based study – Matthew Downer, Ramon Luengo-Fernandez, Linxin Li, Peter Rothwell P1.119 Critical Analysis Of Differentiation Between Ischemic And Hemorrhagic Stroke In Resource Limited Settings: A Systematic Review – Aman Bhardwaj, Padma Vasantha Hadakasira, Vinny P. Wilson, Amit Mehndiratta, Venugopalan Y Vishnu, Rahul Garg P1.120 Re-evaluating Risk Factors, Incidence, and Outcome of Aneurysmal and Non-aneurysmal Subarachnoid Hemorrhage – Alireza Zandifar, Zahra Sadat Mortazavi, Jorge Du Ub Kim, Luis Octavio Tierradentro Garcia, Seyedeh Zahra Tara, Arastoo Vossough, Mohammad Saadatnia P1.121 Contagion Effect of COVID-19 - Cerebral venous sinus thrombosis – Abhilash Thatikala, Hafsa Bareen Syeda, Shubham Biyani, Syeda Busmah Owais, Rucha Bahekar, Sukanthi Kovvuru, Sanjeeva Reddy Onteddu, Krishna Nalleballe P1.122 Subtle Neurological Symptoms as Early Signs of Watershed Infarction in COVID-19 Infection – Mohammad Amin Najafi, Alireza Zandifar, Mohsen Kheradmand, Luis Octavio Tierradentro Garcia, Jorge Du Ub Kim, Fariborz Khorvash, Arastoo Vossough, Mohammad Saadatnia P1.123 Factors Associated with Depression after Hemorrhagic Stroke – Janice Chou, Sarah Ecker, Anlys Olivera, Aaron S. Lord, Lindsey Gurin, Koto Ishida, Kara R. Melmed, Jose L. Torres, Barry M. Czeisler, Cen Zhang, Jennifer A. Frontera, Ariane Lewis P1.124 Predictors of Outcome in Patients with Concurrently-Diagnosed Ischemic and Hemorrhagic Stroke – Fransisca Indraswari, Janine Molino, Michael E. Reznik, Abdulrahman Bukhari, Christopher Leon Guerrero, Shawna M. Cutting P1.125 Diagnosis of Stroke and Prognosis of Interventions Using Imaging and Machine Learning – Kathleen Miao, Julia Miao P1.126 Initially Misdiagnosed Bilateral Medial Medullary Stroke – a Case Report – Isadora Versiani de Lemos, Priscila Santos Mageste, Matheus Castro, Alexandra Seide Cardoso, Mariana Soares de Freitas Tamy, Raimundo Marcial de Brito Neto, Vanessa Cristina Colares Lessa, Gabriel R. Freitas
AAN.com/AM
107
Virtual Experience Posters
P1.127 Central vs Local Stroke Adjudication in the IRIS Trial – Rachel Forman, Catherine Viscoli, Walter N. Kernan P1.128 Circulating Inflammatory Biomarkers and Enlarged Perivascular Spaces: the Framingham Heart Study – Oluchi Stella Ekenze, Adlin Pinheiro, Serkalem Demissie, Emelia Benjamin, Ramachandran Vasan, Charles S. DeCarli, Sudha Seshadri, Jose Rafael Romero P1.129 Mysterious case of recurrent cryptogenic strokes in a young female: A rare case of Parry Romberg Syndrome – Vijaya Lakshmi Valaparla, Xiangping Li, Chilvana V. Patel, Arun Singh Chhabra, Hashem M. Shaltoni, Anand Vilaschandra Patel P1.130 A comprehensive analysis of stroke risk factors by HIV serostatus in Uganda: Implications for stroke prevention in sub-Saharan Africa – Amir Abdallah Mbonde, Jonathan Chang, Kisekka Abdu Musubire, Samson Okello, Adrian Kayanja, Acan Moses, Nkwanga Jacob, Andrew Katende, Felicia Chow, Deanne Saylor, Cumara Barahona O’Carroll, Mark Siedner
Child Neurology and Developmental Neurology P1.131 Clinical Phenomenology of Functional Tics during the COVID-19 Pandemic – Jaclyn Martindale, Gregory Bryan Russell P1.132 Phenotype of Pathogenic Variant in the Gene NHLRC1 in Lafora Disease – Apirada Thongsing, Mohamad Abou Merhi Saifeddine, Daniel Lax P1.133 Exercise-Induced Rhabdomyolysis: Atypical Phenotype of a Dystrophinopathy – Anastasia Railean, Jaclyn Martindale P1.134 Associations Between Steroid Treatment and Clinical Outcomes Among Non-ambulatory Patients with Duchenne Muscular Dystrophy (DMD) – Craig McDonald, Oscar Mayer, Kan N. Hor, Jessica Marden, Jonathan Freimark, Henry Lane, Adina Zeling Zhang, Molly Frean, Claudio Santos, Richard Allen Able, James Signorovitch P1.135 Associations Between Deflazacort Versus Prednisone/Prednisolone and Markers of Disease Progression in Clinically Important Subgroups of Patients with Duchenne Muscular Dystrophy – Craig McDonald, Jessica Marden, Henry Lane, Adina Zeling Zhang, Ha Nguyen, Claudio Santos, Richard Allen Able, James Signorovitch
108
2022 AAN Annual Meeting
P1.136 Evaluation of 18,911 Individuals with Autism Reveals that Exome Analysis Provides Higher Diagnostic Rates and Reduced Time to Diagnosis than Traditional Testing Strategies – Amanda S. Lindy, Rebecca Torene, Kyle Retterer, Paul Stephen Kruszka P1.137 Efficacy and Safety of Onasemnogene abeparvovec in Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis – Aaron Rodriguez, Fabián Andrés Chávez Ecos, Sandra Chavez-Malpartida, Giancarlo Alvarado-Gamarra, Peggy C. Martinez Esteban, Carlos Alva-Diaz P1.138 Post Covid 19 Immune Mediated Neurological Manifestations in Children : A single centre study – Lokesh Saini, Deepthi Krishna, Sarbesh Tiwari, Daisy Khera, Prawin Kumar, Jagdish Prasad Goyal, Bharat Choudhary, Kuldeep Singh P1.139 Patient Factors Predictive of the Use of Genetic Testing in Infantile Spasms – Kenza El Marzouki, Senyene Hunter
Epilepsy/Clinical Neurophysiology (EEG) P1.140 Brivaracetam use in Hong Kong: a post-marketing cohort study – Wui Ho, Holy MH Chan, Sze Wai E. Yeung, Hoi Ki, Hiu Tung Lui, Lok Yiu Chan, Cheuk Nam Rachel Lo, Yun Hin Ian Leung, William C.Y. Leung, Chang Shek Kwan P1.141 Characteristics of Seizure-induced Reversible MRI Abnormalities in Status Epilepticus – Frederick P. Mariajoseph, Parveen Sagar, Subramanian Muthusamy, Shalini Amukotuwa, Udaya K. Seneviratne P1.142 Seizure-induced Reversible MRI Abnormalities in Single Seizures: Current Knowledge and Future Directions – Frederick P. Mariajoseph, Subramanian Muthusamy, Shalini Amukotuwa, Udaya K. Seneviratne P1.143 Distinguishing Quantitative EEG Correlates of Psychogenic Non-Epileptic Seizures versus Epilepsy – Josh Goldenberg, Syphong Dzuy Ha, Julie Roth, Judy Liu, W. Curt LaFrance, Andrew S. Blum, Jason B. Richards P1.144 Focal clonic movements elicited by electrical cortical stimulation of primary motor cortex – Neel Fotedar
P1.145 Using Semiology to Classify Epileptic Seizures versus Psychogenic Non-Epileptic Seizures - A Meta-Analysis – Subramanian Muthusamy, Udaya K. Seneviratne, Catherine Tuo-Wei Ding, Thanh Phan P1.146 Asystole after VNS battery change: a case report – Animesh Gupta, LynnMarie Jarratt P1.147 Effectiveness of epilepsy treatment with Cannabis Sativa derivatives in children with Dravet Syndrome – Systematic Review – Layne Nunes Lins, Hermila Guedes P1.148 Quality and publication rates of randomized blinded clinical trial abstracts presented at Annual Meetings of the American Epilepsy Society 20102019 – Sriram Sunil Kumar, Rohit Das P1.149 Assessment of COVID-19 Vaccination Status and Vaccine Tolerance in Patients with Epilepsy in the State of Kentucky – Rani Priyanka Vasireddy, Zabeen Kaizar Mahuwala, Meriem K. Bensalem Owen, Deb Jo McGrath, Beth Stivers P1.150 Comparison of Levetiracetam vs Carbamazepine in Epilepsy Patients: A Systematic Review – Jeremiah Wijaya, Fellisa Meliani, Rivaldo Steven Heriyanto, Rivaldo Steven Heriyanto, Gilbert Sterling Octavius P1.151 ELEVATE Study 410: Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients Aged =4 Years with Focal-Onset Seizures (FOS) or Generalized Tonic-Clonic Seizures (GTCS) – Pavel Klein, Omar Samad, Dinesh Kumar, Stella Leock Ngo, Manoj Malhotra P1.152 Assessment of Cognition (EpiTrack®) and Depression (Beck Depression Inventory-II) Following Perampanel (Monotherapy/First Adjunctive) in Patients with Epilepsy Enrolled in The ELEVATE Phase IV Study – Joon Kang, Omar Samad, Dinesh Kumar, Stella Leock Ngo, Manoj Malhotra P1.153 Functional Impairments are Common in Adults with Epilepsy and Psychogenic Non-epileptic Seizures – Venkat Prahas Suru, Noah Andrews, James Bena, Nancy R. Foldvary-Schaefer P1.154 Perampanel in Elderly Patients: An Overview of Data from Studies 307, 335, 412, 342, and 506 – Ilo E. Leppik, Robert T. Wechsler, Dae Won Seo, Takamichi Yamamoto, Anna Patten, Hugh Jiwoong Lee, Stella Leock Ngo, Manoj Malhotra
Virtual Experience Posters
P1.155 Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures Treated in Clinical Practice – Estevo Santamarina, Javier Abril, Xiana Rodríguez Osorio, Takamichi Yamamoto, Rob McMurray, Eugen Trinka, Wendyl J. D’Souza, Rosaria Renna, Vicente Villanueva P1.156 Knowledge and Attitude toward Epilepsy among the Final and Semi-Final Years Medical Students at University of Bahri, Sudan – Mohammed Nasir Mustafa, Lina Gafar Wedaalla, Tibyan Kamal Ahmed P1.157 Use of Non-Medical Practices in the Management of Epilepsy: Experience in a South Eastern Nigerian Clinic – Chukwuma Emmanuel Nwaze, Yvonne Emuobome Eghwrudjakpor, Christian Chidi Nduka, Udomba Ozioma Kosy, Jenny Oriaku Ojukwu, Nnenna Zinnah Aloziem, Opeyemi Jeremiah Ajayi, Emmanuel Odion Igue, Jovita Eghe Egharevba, Stephanie Chiemelie Metu, Samson Pamilerin Ogunbolu, Ngozi Glory Amadi, Obiamaka Maria Aghadiuno, Njoku Julie Chidimma, Adaeze Ruth Avah, Chinomso Daniel Ogumerem, Jemimah Onua, Ahunna Ugochi Nwogu, Chukwudi Amarachukwu Nwogu, Chinekwu Anyanwu P1.158 Patterns of medication use in patients with rare Mendelian pediatric epilepsies – Ella Nysetvold, Nivi Ahlawat, Kristina Cotter, Caitlin A. Nichols P1.159 Prevalence of Depression among Epilepsy patients in a Tertiary Care Hospital in Sri Lanka – Gimhani Ratnayake, Athula Dissanayake, Damith Liyanage, Wasana Senanayake P1.160 Correlation analysis between multi-dimensional scale for PDD and ADHD (MSPA) and WAIS-III in adult epilepsy – Hiromi Kanesaki, Rie S. Tsuburaya, Kozue Takada, Kazuaki Sato, Hiromitsu Tabata, Masako Kinoshita P1.161 Convulsive and Non-convulsive Status Epilepticus: Prevalence, Related Etiologies, Treatment, and Outcome. A retrospective Cohort Study in Saudi Arabia – Abdullah Saleh Alamri, Abdullah kabbani, Remah Alzayyat, Adel Al Rashidi, Fouad Ahmad Alsaadi, Shahad Alsheikh, Rawan Salim Alyami, Sultan Salem Alzahrani, Mohammed Ahmed Alshammari, Laila Osama Alibrahim P1.162 Programming of Electronic Medical Record for ACNS Standardized Critical Care EEG Terminology – Olga Selioutski, Anne C. Van Cott P1.163 On Demand EEG Education - a Novel, Appbased Teaching Method Focused on Interictal Epileptiform Discharge Identification – Jaden Daniel Barfuss, Fabio Augusto Nascimento E Silva, Erik P. Duhaime, M. Brandon Westover, Jin Jing
P1.164 Meta-analysis of 175 Patients with COVID-19 and Seizures, Status Epilepticus, or Cortical Myoclonus: An Individual Patient Data Analysis – Cristina Jageka, Amman Bhasin, Aditi Kappagantu, Helena Ann Brantz, Rooqash Ali, Brittany M Stopa, Saef Izzy, Ayaz M. Khawaja P1.165 Association of clinical variables with cyclic alternating pattern of encephalopathy (CAPE) – Rene Andrade-Machado, Jiping Zhou, Deepti Zutshi P1.166 Rhythmic Epileptic Discharges in Focal Cortical Dysplasia : an EEG-pathology Study – Yang Zheng, Wen-Jie Ming, Lv Jing, Yao Ding, Mei-Ping Ding
General Neurology P1.167 Diagnostic Approach to Cranial Nerve III Palsy – Meera Solanki, Kiran Iyer, Alexa Leah Noronha, Adriana Carola Mendez, Nataliya Ternopolska P1.168 DTI Abnormalities in Healthy E200K Carriers May Serve as an Early Biomarker for Genetic Creuzfeldt-Jakob Disease (gCJD) – Nurit Omer, Rawan Silbak, Noa Trabulus, Tamara Shiner, Orna Moore, Mali Gana-Weiss, Orly Goldstein, Tal Glinka, Avi Orr-Urtreger, Nir Giladi, Amgad Droby, Noa Bregman P1.169 Technology as Treatment: Use of Virtual Complementary and Integrative Therapies by Patients in Neurology – Mia T. Minen, Neil A. Busis, Steven Friedman, Maya Catherine Campbell, Ananya Sahu, Kazi Shafia Maisha, Quazi Ilham Hossain, Mia Soviero, Deepti Verma, Leslie Yao, Farng-Yang Foo, Jaydeep M. Bhatt, Laura J. Balcer, Steven Galetta, Sujata P. Thawani P1.170 Ischaemic Lumbrosacral Plexopathy following Infrarenal Aortic Thrombosis – Suzanne Kirstin Quigley, Emma Troy, Niamh Bermingham, Aisling Ryan P1.171 Bilateral facial paralysis as first clinical manifestation in HIV positive patient – Melissa Annette Morales Garcia, Jessica Abreu Garcia, Raymond Manuel Rivera Vergara, Cristina Alejandra Cruz, Marelisa Albelo Martinez, Jose Carlos Lopez Puebla, Gishlaine Alfonso, Valerie E. Wojna P1.172 A social media survey to understand where patients with neurologic conditions obtain information on pregnancy planning, pregnancy, and breastfeeding – Jenna Alys Brunn, Anita Valanju Shelgikar, Louise M. O’Brien
Information is accurate as of February 8, 2022, and is subject to change.
P1.173 Demographic Factors and Diagnoses Associated with Ambulatory Neurology Video Telehealth visit No-shows – Aashrai Sai Venkat Gudlavalleti, John Elliott, Rafah Asadi P1.174 White Matter Involvement in SPG76. A Retrospective MRI Analysis of 11 Subjects. – Abdulrahman Alkhalifa, Shihan Chen, Massimiliano Filosto, Elisa Cali, Henry Houlden, Wladimir Bocca Pinto, Afagh Alavi, Francesco Nicita, Stefano Tozza, Sirio Cocozza, Nicola Carboni, Nazli Basak, Bernard Brais, Guy A. Rouleau, Roberta La Piana P1.175 Assessing Patient Demand for Neurologists in the United States Using Google Trends – Nanda Krishnan Siva, Haig Pakhchanian, Rahul Raiker, Phonphanh Dedthanou, Shanawar Ali Waris, Darshan A. Dave P1.176 Methylmalonic Acidemia-Uncommonly Missed Diagnosis in Adults: The Usefulness of MMA for seizures/weakness/ataxia – Sonia Kalirao, Brianna Cocuzzo P1.177 Clinico-Radiological Profile and Treatment Outcomes in Hypertrophic Pachymeningitis: A Retrospective Study – Rajesh Kumar Singh, Manish Salunkhe, Ajay Garg, Ayush Agarwal, Animesh Das, Divya M. Radhakrishnan, Awadh K. Pandit, Rohit Bhatia, Padma Vasantha Hadakasira, Vinay Goel, Rishikesh Kumar, Achal K. Srivastava P1.178 Wernicke Encephalopathy (WE) In Young Healthy Teenagers – Irum Hina, Ehtesham Khalid P1.179 When to resect: Benign yet debilitating neurological symptoms related to rare cases of skull-based Epidermoid cysts. – Vanessa Dwairi, Priya Nidamanuri, Thandar Aung P1.180 Posterior Reversible Encephalopathy Syndrome with Spinal Cord Involvement (PRES-SCI) - a Case Report and Literature Review – Mathura Ravishankar, Alexandra Urban P1.181 A Unique Case of Whippets-Induced B12 Deficiency Manifesting as a Subacute BrownSequard Spinal Syndrome – Andrew Shenchi Kao, Sabeena Iqbal Malik P1.182 Frequency, Persistence, and Patient-reported Outcomes of Neurological Symptoms in Mild COVID-19: Results from the ALBERTA HOPE COVID-19 Trial – Aravind Ganesh, Ryan Edgar Rosentreter, Yushi Chen, Rahul Mehta, Graham Alexander McLeod, Miranda Wan, Jonathan Krett, Yasamin Mahjoub, Angela Lee, Ilan Schwartz, Luanne Metz, Eric E. Smith, Michael D. Hill
AAN.com/AM
109
Virtual Experience Posters
P1.183 Post Lumbar Puncture Spinal Epidural Venous Engorgement–A Potential Imaging Trap – Khaled Gharaibeh, Hira Pervez, Ajaz Sheikh P1.184 A Systematic Review Of Clinical Profile Of Cerebral Abscess In Post Covid Rhino Orbital Cerebral Mucormycosis – Amaravathi Markala, Justin Cornelius, Srujanitha Tadi, Manivannan Ramraj, Murugan Ponnaiah Kasirajan P1.185 A Young Man Suffered By Recurrent Headache and Visual Symptoms – Ning Su, Yan Zhou, Chenhui Mao, Li-Ying Cui, Yicheng Zhu, Jun Ni P1.186 Steroid-Responsive Ecchordosis Physaliphora Diagnosed as CLIPPERS: A Systematic Review of Literature and Case Report – Thejasvi Anantasagar Reddy, Carlos Alberto Perez, Anam Qamar Haque, Rohan S. Samant, Rajesh K. Gupta P1.187 Managing Rapid Sodium Correction: A Case of Osmotic Demyelination – Sara Grace Hubacek, Nelson Parks Douglass, Saurabh G. Shukla P1.188 Akinetic Mutism Resulting from Cerebral Fat Embolism from Underlying Hemoglobin SC Disease Crisis – Elsa Cassandra Rodriguez, William Remley, Cyra Mae Bunag, Varun Jain, Bhavana U. Patel P1.189 A rare case of Foster-Kennedy syndrome secondary to meningioma causing impaired venous drainage. – Sahil Naik, Satya Rashmit Durugu, Shivani Naik
Global Health P1.190 Socioeconomic Status and Cognitive Function in Children with HIV: Evidence from the HIVAssociated Neurocognitive Disorders in Zambia (HANDZ) Study – Esau G. Mbewe, Pelekelo Kabundula, Sylvia Mwanza-Kabaghe, Milimo Mweemba, Alexandra Buda, Heather Adams, Gretchen L. Birbeck, David Bearden P1.191 Validation of the NIH Toolbox Cognition Battery in Children with and without HIV Infection in Zambia – Pelekelo Kabundula, Esau G. Mbewe, Sylvia Mwanza-Kabaghe, Milimo Mweemba, Gretchen L. Birbeck, Heather Adams, David Bearden
Headache P1.192 Deep phenotyping using cranial autonomic symptoms in migraine and cluster headache – JrWei Wu, Chia-Chun Chiang, Shu-Ting Chen P1.193 Low Levels of Rimegepant in Breast Milk After a Single 75-mg Dose – Teresa Baker, Robert Croop, Lisa Kamen, David Stock, Andrea Ivans, Rajinder K. Bhardwaj, Matt Anderson, Jennifer Madonia, Joseph Stringfellow, Richard Bertz, Vladimir Coric, Thomas Wright Hale P1.194 Acute prolonged motor aura resembling ischemic stroke after COVID-19 vaccination (CoronaVac): the first case report – Wanakorn Rattanawong, Wasan Akaratanawat, Supatporn Tepmongkol, Aurauma Chutinet, Nijasri Charnnarong P1.195 Relation of Anxiety and Depression with Personal Protective Equipment Associated Headache in Healthcare Workers During COVID-19 Outbreak – Eva Saragih, Haflin S. Hutagalung, Khairul P. Surbakti P1.196 Three-Year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results from the LIBERTY Study – Uwe Reuter, Peter Goadsby, Michel D. Ferrari, Gabriel Paiva da Silva Lima, Subhayan Mondal, Shihua Wen, Tracy E. Stites, Michal Arkuszewski, Michel Lanteri-Minet, Shaloo Pandhi P1.197 Long-term Treatment with Galcanezumab in 29 Patients with Chronic Migraine: Results from the 3-year Continued Access Program of the REGAIN Study – Amnon Mosek, Lily Li, Hai-An Hsu, Angelo Camporeale, Gabriel Vainstein P1.198 Intravenous Ibuprofen for Acute Migraine Treatment: A Double-Blind Randomized PlaceboControlled Pilot Study – John Curran, Hsiangkuo Yuan, Scott Keith, Mary Hopkins, Stephen D. Silberstein P1.199 CGRP as a Marker of Headache Attributed to COVID-19 Infection – Esra Erdil, Esin Engin, Emine Nese Tuncer, Tulin Tanridag P1.200 A Case of ATP1A2 Familial Hemiplegic Migraine Presenting with Unilateral Encephalopathy and a Cytotoxic Corpus Callosum Lesion – Emma Troy, Audrey Reynolds, Brian McNamara, Aine P. Merwick P1.201 Prescription Patterns of Triptans in the Treatment of Migraine – Ariana Barreau, Nicholas Peterman, Bradley Kaptur, Kristine Carpenter
110
2022 AAN Annual Meeting
P1.202 Headache Apps Found in the Commercial Marketplace: A Systematic Analysis of Features and Characteristics – Ananya Sahu, Leslie Yao, Maya Catherine Campbell, Mia Soviero, Quazi Ilham Hossain, Deepti Verma, Erica Camacho, John Torous, Mia T. Minen P1.203 Adherence to the IHS Guidelines for Controlled Trials of Acute Treatment of Migraine Attacks with Parenteral NSAIDs – John Waters, John Curran, Hsiangkuo Yuan P1.204 Validation of diagnostic criteria for menstrual migraine – Iris Verhagen, Hermes Spaink, Britt Willemijn Hele Van Der Arend, Daphne Suzanne Van Casteren, Antoinentte Maassen Van Den Brink, G.M. Terwindt P1.205 Real-world evidence on HRQoL of therapyresistant migraine patients undergoing preventive treatment in an ambulatory care setting – Schirin Sulaiman, Hannah Maria Haneke, Valerie Kirchberger, Markus Jahn, Jan-Peter Jansen P1.206 Recurrent Thunderclap Headaches as a Presenting Symptom of Coccidioidal Meningitis – Olivia Kingsford, Madeline Louise Singer, Kerry Louise Knievel P1.207 MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days for Preventive Treatment of Migraine – Karissa Johnston, Gilbert J. L’Italien, Evan Popoff, Lauren Powell, Fiona O’Sullivan, Linda Harris, Robert Croop, Vladimir Coric, Richard B. Lipton P1.208 Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis – Evan Popoff, Lauren Powell, Karissa Johnston, Fiona O’Sullivan, Linda Harris, Chelsea Leroue, Robert Croop, Vladimir Coric, James Arthur Moren P1.209 Assessing Resident Opinions and Implementation of Quality Care for Headache Patients in Continuity Clinic – Aakash Bhargava, Ashish Adlakha, Riya Luhar P1.210 Presentation of headache and its management in the Emergency Department amongst a cohort of diverse reproductive age women – Crystal Jicha, Jelena M. Pavlovic
Virtual Experience Posters
Health Care Disparities P1.211 Impact of COVID-19 on Physical Activity, Diet, and Stroke Awareness in Homeless Individuals of Chicago – Joseph Dodson, Antonia Santos, Annabelle Volgman, Neelum T. Aggarwal P1.212 Proportion of Life in Canada and Stroke Incidence and Outcomes in Immigrants – Manav Vyas, Jiming Fang, Peter Austin, Moira Kapral P1.213 Race, Ethnic, and Language Differences in Clinic Follow-up After Stroke Admission – Laura Okonokhua, Jesus Roberto Varela, Laurel Jean Cherian, James Conners, Rima Dafer, Nicholas D. Osteraas, Sarah Song, Alejandro Vargas P1.214 Autoimmune encephalitis in the Philippines: a scoping review on the treatment gaps, challenges, and current state of care – Gerald Tangonan Pagaling, Christian Wilson Turalde, Roland Dominic Jamora P1.215 Influence of Race and Ethnicity on Adherence to Secondary Stroke Prevention Medications in an Integrated Managed Care Health System – William Patrick Neil, Bruce I. Ovbiagele P1.216 Snowball effect of COVID- 19 : Stroke Care Underutilization – Abhilash Thatikala, Hafsa Bareen Syeda, Shubham Biyani, Naren Raj Arulprakash, Khushboo Verma, Sen Sheng, Mudassar Kamran, Vishank Arun Shah, Sisira Yadala, Sanjeeva Reddy Onteddu, Krishna Nalleballe P1.217 A Cross-Sectional Analysis of Medical Crowdfunding Requests for Neurological Patients and Caregivers in Canada – Erin Balcom, Phillip Gregoire
History of Neurology P1.218 The expulsion of Augusta Dejerine-Klumpke from the Salpêtrière hospital: Pierre Marie’s revenge. – Leo Coutinho, Matheus Gomes Ferreira, Carlos Henrique Ferreira Camargo, Olivier Walusinski, Helio Afonso Ghizoni Teive
Infectious Disease P1.219 Antiviral therapy for Herpes Simplex Virus encephalitis: Systematic Review and Meta analysis of RCTs – Sri Harsha Boppana P1.220 “Long-hauler” impact of COVID-19 on brain microstructure: a 3-month follow-up study – Nick Teller, Jordan Chad, Eugenie Roudaia, Ali Hashemi, Haddas Grosbein, Asaf Gilboa, Maged Goubran, Ivy Cheng, Sandra E. Black, Rob Fowler, Chinthaka Heyn, Fuqiang Gao, Mario Masellis, Jennifer Rabin, Xiang Ji, Aravinthan Jegatheesan, Benjamin Lam, Allison Sekuler, Bradley MacIntosh, Simon James Graham, Jean Chen P1.221 Progressive Multifocal Leukoencephalopathy and Sphingosine 1-Phosphate Receptor Modulators Used in Multiple Sclerosis: An Updated Review of Literature – Durgesh Chaudhary, Samiksha Srivastava, Katherine Elizabeth Beard, Xue Bai, Sijin Wen, Syed Hassan Khalid, Shitiz K. Sriwastava, Robert P. Lisak P1.222 COVID-19-related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement. – Thanakit Pongpitakmetha, Pasin Hemachudha, Wanakorn Rattanawong, Poosanu Thanapornsangsuth, Thiravat Hemachudha P1.223 Spectrum of Acute Necrotizing Hemorrhagic Encephalitis in COVID-19 patients: A case series and Review – Rohan Sharma, Nidhi Kapoor, Krishna Nalleballe, Vishank Arun Shah, Shilpa Haldal, Sanjeeva Reddy Onteddu, Krishna C. Mylavarapu, Thomas Spradley, Lana Hasan, Murat Gokden, Manoj Kumar P1.224 PISA Syndrome in Subacute Sclerosing Pan Encephalitis: Case Report and Review of Literature – Amit Shankar Singh, Jeenendra Prakash Singhvi P1.225 Subarachnoid Hemorrhage and Cerebral Edema Caused by Disseminated Coccidiomycosis: A Case Report – Taylor Stuart Campbell, Trusha Mehta, Paul H. Janda, Aroucha Vickers, Alan Alexander Arismendez, Mckenzie Merritt P1.226 Neurological Spectrum Of Post Covid Rhino Orbital Cerebral Mucormycosis - An Observational Study in a Tertiary Care Centre in South India, Madurai – Justin Cornelius, Manivannan Ramraj, Murugan Ponnaiah Kasirajan, Amaravathi Markala, Srujanitha Tadi, Dhileeban Maharajan P, Neenu Alexander
Information is accurate as of February 8, 2022, and is subject to change.
P1.227 HSV-2 Vasculitis as a Cause of Ischemic Stroke and Intracerebral Hemorrhage: a Case Report – Lia Carolina Franco Castro, Shannon Hextrum, Aimee M. Aysenne P1.228 Neurognathostomiasis: Varied CNS Manifestations, A Report of Two Cases – Sridhar S, Saraswati Nashi, Dipti Baskar P1.229 Post-acute neurological sequalae of SARS-COV-2 infection – Alanna Mary Rose Balbi, Audrey Li, Marianna Shnayderman Yugrakh, Marla Hamberger, Melodie R. Winawer P1.230 Neuromelioidosis in the guise of a Demyelinating illness – Gimhani Ratnayake, Athula Dissanayake, Damith Liyanage, Pratheepa Kuganantharajah P1.231 Study of patterns of presentation in post COVID-19 mucormycosis – Shubham Dubey, Ayush Dubey P1.232 Herpes Zoster Associated Myelitis: Clinical and Radiographic Features – James Douglas Triplett, Michel Toledano, Lyell K. Jones P1.233 A Case of Cytotoxic Lesion of the Corpus Callosum Associated with Legionella Pneumonia – Megan Elizabeth Trenz, Thomas Michael Snyder
Movement Disorders P1.234 Demographics and Clinical Characteristics of Autosomal Dominant Spinocerebellar Ataxias in Canada: A Multi-center Study – Sohaila Abdullah Alshimemeri, Danah AboAlSamh, Lily Zhou, Sarah Furtado, Scott W. Kraft, Veronica A. Bruno, Antoine Duquette, Bernard Brais, Oksana Suchowersky, Renato Puppi Munhoz, Elizabeth Slow P1.235 A rapid, ultra-sensitive, RT-QuIC assay, with novel protocol, for MSA and PD using a single site skin biopsy and serum neurofilament light chain. – Diana Angelika Olszewska, Ivan MartinezValbuena, Naomi Visanji, Mario Sousa, Puja Bhakta, Anna Vasilevskaya, Chloe Anastassiadis, Carmela Tartaglia, Gabor G. Kovacs, Anthony E. Lang P1.236 Mindfulness based program for newly diagnosed Parkinson’s patients. – Azima Shaji, Nora Ko, Aaron C. W. Lasker, Alexa Leah Noronha, Yahnily Ocasio, Parampreet Kaur, Emma Muller, Adriana Carola Mendez
AAN.com/AM
111
Virtual Experience Posters
P1.237 Return of individual research reports in an observational study of Parkinson’s disease: Participant preferences and influences on future research participation – Taylor Myers, Ellen Wagner, Meghan Elizabeth Pawlik, Julia Marie Soto, Christopher Tarolli, Ruth Schneider, Jamie Lynn Adams, E. Ray Dorsey, Stella Jensen-Roberts P1.238 Unraveling the Potential of Specialized Allied Health Therapy in Parkinson’s Disease – Amir Hossein Talebi, Jan Ypinga, Marten Munneke, Bastiaan Roelof Bloem, Sirwan Darweesh P1.239 Longitudinal follow up of mood symptoms in cervical dystonia – Fiadhnait O’Keeffe, Andrew Moriarty, Sean O’Riordan, Michael Hutchinson P1.240 Treatment of Cervical Dystonia Using Shorter IncobotulinumtoxinA Injection Intervals Improves Patient-reported Outcomes in Those With Inadequate Benefits from Standard Intervals – Stuart H. Isaacson, David Charles, Cynthia L. Comella, Daniel D. Truong, Odinachi N. Oguh, Jennifer S. Hui, Eric Molho, Matthew A. Brodsky, Erin Furr-Stimming, Georg Comes, Michael Hast, Robert A. Hauser P1.241 Injections Of Incobotulinumtoxina at Intervals Less Than 10 Weeks are Effective and Safe for Cervical Dystonia Patients with Inadequate Benefit from Standard Injection Intervals – Cynthia L. Comella, Robert A. Hauser, Stuart H. Isaacson, Daniel D. Truong, Odinachi N. Oguh, Jennifer S. Hui, Eric Molho, Matthew A. Brodsky, Erin Furr-Stimming, Georg Comes, Michael Hast, David Charles P1.242 Association of behavioral activation system with dopaminergic striatum in Parkinson’s disease patients – Hidetomo Murakami, Masakazu Ozawa, Tomotaka Shiraishi, Tadashi Umehara, Shusaku Omoto, Yasuyuki Iguchi P1.243 Frontal Low Delta Spectral Power is Lower in Patients with Parkinson’s Disease than in Matched Controls – Adeel Ali Memon, Corina Catiul, Zachary Irwin, Jennifer Pilkington, Allen Joop, Raima A. Memon, Kimberly Wood, Svjetlana Miocinovic, Amy W. Amara P1.244 Effect of LRRK2 and GBA Mutations on Parkinson’s Disease Clinical Progression in Elderly Patients – Vincent Chang, Farnaaz Ataullah Sheikh, Dennis Hasenhuendl, Siyuan Fu, Sagari R. Bette, Stuart H. Isaacson P1.245 Functional Movement Disorders in Patients with Ehlers-Danlos Syndrome – Jason H. Margolesky, Dyanet Loreta Puentes, Danielle Spengler Shpiner, Henry Paul Moore, Corneliu C. Luca, Carlos Singer, Ihtsham Haq
112
2022 AAN Annual Meeting
P1.246 Structural and Functional Cerebellar Alterations in Parkinson’s Disease with Postural Instability and Gait Disorders – Elisabetta Sarasso, Andrea Gardoni, Silvia Basaia, M. Antonietta Volonte, Massimo Filippi, Federica Agosta P1.247 Motor Cerebro-Cerebellar Networks Breakdown Among Different Subtypes of Parkinson’s Disease – Silvia Basaia, Federica Agosta, Alessandro Francia, Camilla Cividini, Tanya Stojkovic, Iva Stankovic, Rosa De Micco, Luigi Albano, Elisabetta Sarasso, Andrea Gardoni, Roberta Balestrino, Vladana Markovic, Elka Stefanova, Vladimir S. Kostic, Massimo Filippi P1.248 Neuroimaging Correlates of Gait Abnormalities in Progressive Supranuclear Palsy – Irene Sintini, Kenton Kaufman, Hugo Botha, Stacy Loushin, Matthew Senjem, Robert I. Reid, Christopher Schwarz, Clifford R. Jack, Val John Lowe, Keith A. Josephs, Jennifer Louise Whitwell, Farwa Ali P1.249 Variation in mortality according to severity and phenotype in Progressive Supranuclear Palsy – Duncan Street, Zi Qi Kok, Timothy Rittman, James Rowe P1.250 Associations between Baseline Cognitive Function and Gait Outcomes after Treadmill Training in Parkinson disease – Raima M. Amin, Raima M. Amin, Andrew Humbert, Brenna Cholerton, Cyrus P. Zabetian, Ignacio Mata, Valerie Kelly P1.251 Long-term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson’s Disease Treated With Levodopa-Carbidopa Intestinal Gel by Baseline Hoehn & Yahr Stage: Analysis of the DUOGLOBE Study – Francesco Pontieri, Ray Chaudhuri, Jason Lamar Aldred, Paul M. Bourgeois, Thomas L. Davis, Esther Cubo Delgado, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Mihaela A. Simu, Lars Bergmann, Omar Ladhani, Tianming Gao, David G. Standaert, Norbert Kovacs P1.252 Amyloid beta deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort – Alexander Mihaescu, Mario Masellis, Ariel Graff-Guerrero, Mikaeel Valli, Carme Uribe, Maria Diez-Cirarda, Antonio Strafella P1.253 Success of Home-to-Home Tele-neuropsychology (TeleNP) in Deep Brain Stimulation (DBS) Candidacy Assessments of Multicultural PD Patients: State of Practice for COVID-19 and Beyond – Marina Sarno, Annelly Buré-Reyes, Scott Harcourt, Dayana Rodriguez, Wendy Gaztanaga, Ihtsham Haq, Bonnie E. Levin
P1.254 The real-world use of istradefylline for Parkinson’s disease: Post-marketing surveillance of safety and effectiveness in Japan – Makio Takahashi, Satoru Itou, Shuji Horiguchi, Yukie Tsuji P1.255 The Hidden Disease Burden and Treatment Experience of Patients with Essential Tremor: A Retrospective US Claims Analysis – Drew Campbell, Kelly E. Lyons, Gabriel M. Belfort P1.256 PRAX-944-221: A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor – Gabriel M. Belfort, Shane Raines, Ted Snyder, Bernard M. Ravina P1.257 PRAX-944-222: A Phase 2 Randomized, Doubleblind, Placebo-controlled Trial of PRAX-944 for the Treatment of Essential Tremor – Gabriel M. Belfort, Shane Raines, Ted Snyder, Bernard M. Ravina P1.258 Outcome Assessment in Early-Stage Parkinson’s Disease (PD) Clinical Trials: Are Legacy PatientReported Outcome (PRO) Instruments Fit for Purpose – Thomas Morel, Sophie Cleanthous, John Andrejack, Roger Barker, Geraldine Blavat, Babak Boroojerdi, William H. Brooks, Paul Burns, Stefan Cano, Casey Gallagher, Lesley Susan Gosden, Carroll Siu, Ashley R. Slagle, Kate Trenam, Natasha Ratcliffe, Karlin Schroeder P1.259 Neurogenetic Traits Outline Vulnerability to Cortical Disruption in Parkinson’s Disease – Silvia Basaia, Federica Agosta, Ibai Diez Palacio, Elisenda Bueicheku, Federico d’Oleire Uquillas, Manuel Delgado Alvarado, César CaballeroGaudes, Maria C. Rodriguez-Oroz, Tanya Stojkovic, Vladimir S. Kostic, Jorge Sepulcre, Massimo Filippi P1.260 Real Time Quaking Induced Conversion (RT-QuIC) for Skin Alpha-Synuclein Seeding Activity in Parkinson Disease Versus Controls – Steven Alexander Gunzler, Curtis Tatsuoka, Mohamed Elkasaby, Alexander Wang, Shu G. Chen, Zerui Wang, Wenquan Zou P1.261 An AAV Encoding Human ABCD1 Shows DoseResponsive Expression and Function Following Spinal Cord Delivery in a Rodent Model of Adrenomyeloneuropathy – Honggeun Park, Tony Del Rio, Vidyullatha Vasireddy, Tiffany Lutz, Carrie Ng, Yi Gong, Inge Dijkstra, Stephan Kemp, Casey Maguire, Sean W. Clark, David William Anderson, Karen Kozarsky
Virtual Experience Posters
P1.262 Olfaction and apathy in early Parkinson’s disease – Alfonso Enrique Martinez Nunez, Katie Latack, Miguel Situ-Kcomt, Abhimanyu Mahajan P1.263 Bilateral Alien Limb and the Spectrum of Creutzfeldt-Jakob Disease Phenomenology: A Case Series and Review of the Literature. – Dana Alyse Sugar, Neepa J. Patel P1.264 Striatal Dopaminergic Deficiency Contributes to Musculo-skeletal Pain in Parkinson’s Disease – Katarina Rukavina, Juliet Staunton, Magdalena Krbot Skoric, Nicola Mulholland, Ben Corcoran, Alexandra Rizos, K Ray Chaudhuri P1.265 Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease – Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili P1.266 Comparison Of Electrophysiologic And Ultrasound Guidance For Onabotulinum Toxin-A Injections In Focal Upper Extremity Spasticity And Dystonia – Alexandra Nmashie, Codrin I. Lungu, Mary Catherine George, Susan Shin, Barbara P. Karp, Winona Tse, Steven Frucht, Vivian Koo, Katharine Alter, Elaine Considine, Tianxia Wu, Gina Norato, Mark Hallett, David M. Simpson P1.267 Understanding Geo-demographics of Parkinson’s Disease Among African Americans – Khadar Haroun, Demetrius S. Geiger, Kevin James Lane, Chantale Octavia Branson P1.268 a-synuclein propagation via olfactory pathway induces olfactory bulb atrophy and widespread glucose hypometabolism in a non-human primate model. – Masanori Sawamura, Hirotaka Onoe, Hideo Tsukada, Norihito Uemura, Kaoru Isa, Tadashi Isa, Ryosuke Takahashi P1.269 Enhancing Pandemic-Sensitive Recruitment Strategies for a Remote, Randomized PlaceboControlled Trial for Fracture Prevention in Patients with Neurodegenerative Parkinsonisms – Nijee Sharma Luthra, Ethan G. Brown, Samuel Goldman, Jose-Rafael Pantoja Zuzuarregui, Trisha F. Hue, Chris Paul Schambach, Ian O. Bledsoe, Michael Schwarzschild, E. Ray Dorsey, Alberto J. Espay, Irene Litvan, Nikolaus McFarland, Kyle T. Mitchell, David G. Standaert, James Beck, Helen Rowbotham, Cheryl Meng, Jacque Perkins, Primi Ranola, Raymundo Picos, Dana Robertson Kriesel, Kenneth Ward Lyles, Steve Cummings, Caroline M. Tanner
P1.270 Estimating the meaningful within-patient change threshold for the MDS-UPDRS Part III – Stefano Zanigni, Dylan Trundell, Annabelle Monnet, Nima Shariati Fokalaei, Emma Moore, Evan Davies, Nathalie Pross, Gennaro Pagano, Tania Nikolcheva
P1.278 Long-term Outcomes for Mood, Anxiety and Apathy in Dystonia with Bilateral DBS Surgery – Emma Leone, Varun Jain, Rohini Manoj Kumar, Nivedita Jha, Lina Ly, Charles Jacobson, Kelly D. Foote, Michael S. Okun, Aparna Wagle-Shukla
P1.271 Incidence of Parkinson Disease in North America – Connie C. Marras, Eric Miklos Roberts, Caroline M. Tanner, Stephen K. Van Den Eeden, Rodolfo Savica, Web Ross, Brian Fiske, James Beck, Allison Wright Willis
P1.279 New-onset movement disorders after COVID-19 – Emilia M. Gatto, Natalia Gonzalez Rojas, Martin Cesarini, Javier Ziliani, Jose Etcheverry, Gustavo Da Prat de Magahlaes
P1.272 Long-term Motor and Non-Motor Symptom Benefits in Patients With Advanced Parkinson’s Disease Treated With Levodopa-Carbidopa Intestinal Gel: Final Analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study – Ray Chaudhuri, Norbert Kovacs, Francesco Pontieri, Jason Lamar Aldred, Paul M. Bourgeois, Thomas L. Davis, Esther Cubo Delgado, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Mihaela A. Simu, Lars Bergmann, Pavnit Kukreja, Omar Ladhani, Jia Jia, David G. Standaert P1.273 Differentiating the dopaminergic midbrain nuclei in early-stage Parkinson’s disease using quantitative susceptibility mapping and R2* relaxometry – Erind Alushaj, Nicholas HandfieldJones, Alan Kuurstra, Ravi Menon, Adrian Owen, Ali R. Khan, Penny MacDonald P1.274 Serum Insulin-like Growth Factor-1 as a biomarker for Parkinson’s Disease: A systematic review and meta-analysis. – Mariam Mostafa Alwerdani, Alaa Salah El-Sayed, Ahmed Hanbal, Esraa G. Sayed, Mustafa Mohammed Nasser, Mohamed Fahmy Doheim, Mohamed Mahmoud Salama P1.275 Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson’s disease – Natalie P. Witek, Jessica Joyce, Roshni A. Patel, Jacob Hawkins, Yuanqing Liu, Bichum Ouyang, Jeffrey A. Borgia, Jochen Reiser, Deborah Hall P1.276 Parkinson’s Disease in patients with Essential Tremor: a prospective clinical and functional neuroimaging assessment – Gabriel Sampaio Froehner, Carlos Henrique Ferreira Camargo, Giorgio Fabiani, Alex Meira, Rui Kleber MartinsFilho, Renato Puppi Munhoz, Helio Afonso Ghizoni Teive P1.277 Cutaneous Alpha-Synuclein, Dopamine Transporter Imaging, and Cardiac MIBG Scan in Multiple System Atrophy – Virgilio Gerald H. Evidente, Christopher H. Gibbons, Roy L. Freeman, Danica Luz Evidente, Todd D. Levine
Information is accurate as of February 8, 2022, and is subject to change.
P1.280 Imaging in Late-Onset GM2 Gangliosidosis: A Systematic Review – Elizabeth Haxton, Neha Godbole, Olivia Rowe, Florian Eichler, Eva-Maria Ratai, Christopher D. Stephen P1.281 Metabolomic markers of the kynurenine and polyamine pathways are altered in Parkinson’s disease independent of LRRK2 status – Grace Crotty, Yuan Ting Chang, Eric A. Macklin, Romeo Maciuca, Junhua Wang, Manuel Montalban, Sonnet Davis, Jamal Alkabsh, Rachit Bakshi, Xiqun Chen, Alberto Ascherio, Giuseppe Astarita, Sarah Huntwork-Rodriguez, Michael Schwarzschild
MS and CNS Inflammatory Disease P1.282 Deep Learning Prediction of Response to Disease Modifying Therapy in Primary Progressive Multiple Sclerosis – Jean-Pierre René Falet, Joshua Durso-Finley, Brennan Nichyporuk, Julien Schroeter, Francesca Bovis, Maria Pia Sormani, Doina Precup, Tal Arbel, Douglas L. Arnold P1.283 Analysis and Evaluation of Ponesimod Hepatic Safety Data – Andrea Vaclavkova, Verena Walter, Allitia DiBernardo, Maria Ait Tihyaty P1.284 Determining the Effectiveness of Double Inversion Recovery (DIR) Brain MRI Sequence in Detecting Upper Spinal Cord Lesions in Multiple Sclerosis Patients – Shivam Patel, Jaime Imitola, Leo Wolansky P1.285 Acute Disseminated Encephalomyelitis in a Puerto Rican patient with positive SARS-Cov-2: Casualty or Causality? – Melissa Annette Morales Garcia, Johnny A. Sanabria Lopez, Brenda Deliz Roldan P1.286 Analysis of Post-treatment Relapse Activity in the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide – Ludwig Kappos, Robert J. Fox, Michel Burcklen, Mark S. Freedman, Brian Hennessy, Antoine Stos, Philippe Linscheid, Andrea Vaclavkova, Hilke Kracker, Tatiana Sidorenko, Carlo Pozzilli
AAN.com/AM
113
Virtual Experience Posters
P1.287 Impact of the coronavirus SARS COV-2 (COVID19) pandemic on the quality of life and mood of patients with multiple sclerosis – Leila Cohen, Ricardo Alonso, Berenice Silva, Cecilia Pita, Natalia Ciufia, Orlando Garcea, Barbara Eizaguirre P1.288 Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial) – Marie Groth, Benjamin Ettle, Tobias Bopp, Tjalf Ziemssen P1.289 A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes – Ralph H. B. Benedict, Maria Pia Sormani, Marisa P. McGinley, Douglas L. Arnold, Amit Bar-Or, Robert A. Bermel, Pavan Bhargava, Declan Chard, Guy Gherardi, Roland G. Henry, Owain Howell, Beverly Aagard-Kienitz, Letizia M. Leocani, Catherine Lubetzki, Agne Kazlauskaite, Thomas Kuenzel, Xavier Montalban, Finn Sellebjerg, Giancarlo Comi, Licinio Manuel Craveiro, Helmut Butzkueven P1.290 A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis – Giancarlo Comi, Robert A. Bermel, Amit Bar-Or, Marisa P. McGinley, Douglas L. Arnold, Roland G. Henry, Ralph H. B. Benedict, Pavan Bhargava, Helmut Butzkueven, Declan Chard, Guy Gherardi, Owain Howell, Beverly Aagard-Kienitz, Letizia M. Leocani, Agne Kazlauskaite, Thomas Kuenzel, Xavier Montalban, Maria Pia Sormani, Finn Sellebjerg, Licinio Manuel Craveiro, Catherine Lubetzki P1.291 Ponesimod Shows Improved Effect on Brain Volume Compared with Other DMTs, A Model Based Meta-Analysis – Maria Ait Tihyaty, Matthew Zierhut, Alexander Keenan, Allitia DiBernardo P1.292 Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MSFatigue in Relapsing Multiple Sclerosis: MSFatigue and Ambulation Move at Their Own Pace – Frederik Barkhof, Maximilian Schuier, Ibrahim Turkoz, David J. Williamson, Alexander Keenan, Maria Ait Tihyaty
114
2022 AAN Annual Meeting
P1.293 Signatures of premature immunosenescence in patients with multiple sclerosis – Melanie Eschborn, Marc Pawlitzki, Timo Wirth, Christopher Nelke, Steffen Pfeuffer, Andreas SchulteMecklenbeck, Lisa Lohmann, Leoni Rolfes, Katrin Pape, Maria Eveslage, Stefan Bittner, Catharina Groß, Tobias Ruck, Heinz Wiendl, Sven G. Meuth, Luisa Hildegard Klotz P1.294 „Back to the roots - from Phenotype to Genotype in Monozygotic Twins discordant for Multiple Sclerosis“ – Claudia Janoschka, Marisol Herrera Rivero, Lisa Ann Gerdes, Kathrin Koch, Heinz Wiendl, Reinhard Hohlfeld, Monika Stoll, Luisa Hildegard Klotz P1.295 Novel EEG Biomarker to Distinguish Anti-NMDAR Encephalitis from Other Types of Autoimmune Encephalitis – Tomotaka Mizoguchi, Makoto Hara, Naotoshi Natori, Satoshi Hirose, Yuki Yokota, Takayoshi Akimoto, Satoko Ninomiya, Masaki Ishihara, Katsuhiko Ogawa, Hideto Nakajima P1.296 Cladribine Tablets in Patients With RelapsingRemitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICKMS and MASTER-2): Interim Baseline and Safety Review – Augusto A. Miravalle, Joshua D. Katz, Derrick Robertson, Julie Aldridge, Emily Evans, Danielle Harlow, Lori Lebson, Jacob Alexander Sloane, Ann D. Bass, Edward J. Fox P1.297 MRI Predictors of Upper Cervical Cord Grey Matter Atrophy in Multiple Sclerosis Patients – Raffaello Bonacchi, Elisabetta Pagani, Maria Assunta Rocca, Massimo Filippi P1.298 Cognitive Reserve Modulates the Impact of Structural Damage of the Frontal Lobe on Executive Functioning in Multiple Sclerosis – Lorenzo Conti, Paolo Preziosa, Elisabetta Pagani, Massimo Filippi, Maria Assunta Rocca P1.299 Lesion Location Matters in Multiple Sclerosis: Clinical and Cognitive Correlates of Juxtacortical and Subventricular Zone Lesions – Mor Gueye, Laura Cacciaguerra, Nicolò Tedone, Carmen Vizzino, Damiano Mistri, Elisabetta Pagani, Massimo Filippi, Maria Assunta Rocca P1.300 Resting State Effective Connectivity Abnormalities of the Papez Circuit Contribute to Explain Worse Cognitive Performances in Multiple Sclerosis Patients – Olga Marchesi, Raffaello Bonacchi, Paola Valsasina, Maria Assunta Rocca, Massimo Filippi
P1.301 Neurocognitive Impact Of Behçet’s Disease – Ines Bedoui, Bissene Douma, Mariem Elfekih, Jamel Zaouali, Ridha Mrissa P1.302 Investigating the impact of Fingolimod, Natalizumab and Glatiramer Acetate on Normal appearing grey matter and Normal appearing white matter on 3T MRI. – Samiksha Srivastava, Zena Azo, Vince Marceau, Alek Tasich, Fen Bao, Carla E. Santiago-Martinez, Jacob Rube, Evanthia Bernitsas P1.303 Immunological Subsets characterization in newly diagnosed RRMS – Emanuele D’Amico, Aurora Zanghi, Nunziatina Laura Parrinello, Francesco Di Raimondo, Francesco Patti P1.304 Sex-Related Differences in Upper Limb Motor Function in Healthy Subjects and Multiple Sclerosis Patients: A Multiparamentric MRI Study – Chiara Maspero, Raffaello Bonacchi, Elisabetta Pagani, Paola Valsasina, Alessandro Meani, Maria Assunta Rocca, Massimo Filippi P1.305 Disability Progression and Improvement Among Active and Nonactive Secondary Progressive Multiple Sclerosis Patients in Placebo Arms of Clinical Trials – Pengcheng Xun, Natalia Sadetsky, Kiren Kresa-Reahl, Sasha Bogdanovich, Arie Barlev, Crystal Watson P1.306 Motor Dysfunction in Relapsing-Remitting Multiple Sclerosis: Association with Structural Brain Damage and Cognitive Impairment – Damiano Mistri, Laura Cacciaguerra, Loredana Storelli, Alessandro Meani, Claudio Cordani, Maria Assunta Rocca, Massimo Filippi P1.307 AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod treated patients with secondary progressive multiple sclerosis – Benedict Rauser, Tjalf Ziemssen, Marie Groth, Tobias Bopp P1.308 Treatment Patterns of Active and Nonactive Secondary Progressive Multiple Sclerosis Patients in the United States – Dhanalakshmi Thirumalai, Crystal Watson, Natalia Sadetsky, Arie Barlev, Eddie Jones, Sasha Bogdanovich P1.309 Regional Gray Matter Atrophy and White Matter Microstructural Abnormalities Explain SexRelated Differences in Cognitive Performances in MS – Nicolò Tedone, Paolo Preziosa, Elisabetta Pagani, Carmen Vizzino, Damiano Mistri, Massimo Filippi, Maria Assunta Rocca
Virtual Experience Posters
P1.310 A Deep-Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging – Loredana Storelli, Matteo Azzimonti, Mor Gueye, Paolo Preziosa, Gioacchino Tedeschi, Nicola De Stefano, Patrizia Pantano, Massimo Filippi, Maria Assunta Rocca P1.311 Advanced Diffusion-Weighted Imaging Models Better Characterize White Matter Neurodegeneration and Clinical Outcomes in Multiple Sclerosis – Loredana Storelli, Elisabetta Pagani, Alessandro Meani, Paolo Preziosa, Massimo Filippi, Maria Assunta Rocca P1.312 Multiple Sclerosis Phenotypes Display Divergent Dynamic Functional Connectivity Abnormalities for Thalamic Sub-Regions – Paola Valsasina, Antonio Carotenuto, Milagros Hidalgo de la Cruz, Laura Cacciaguerra, Paolo Preziosa, Olga Marchesi, Maria Assunta Rocca, Massimo Filippi P1.313 Immune checkpoint inhibitors and multiple sclerosis – Sarah Conway, Danielle Kei Pua, Kathryn Holroyd, Kristin Marissa Galetta, Shamik Bhattacharyya P1.314 The White Matter Rounds Experience: The Importance of a Multidisciplinary International Network to Accelerate the Diagnostic Process for Adult Patients with Rare White Matter Disorders – Yutong Huang, Paul Giacomini, Rami Massie, Sunita Venkateswaran, Roberta La Piana, Anne-Marie Trudelle, Giulia Fadda, Maryam Sharifiandorche, Hayet Boudjani, Laurence Poliquin-Lasnier, Laura Airas, Alexander Saveriano, Myriam Levesque-Roy, Matthias G. Ziller, Elka Miller, Claudia Martinez-Rios, Jorge Davila, Nagwa Wilson, Erin Longbrake, Jack P. Antel, Bernard Brais, Genevieve Bernard, Carolina A.E. Rush, Roberta La Piana P1.315 Longitudinal Extensive Transverse Myelitis: rare immunotherapy related adverse effect vs COVID19-related immunization complication – Aimalohi Esechie, Xiang Fang, Pankhuri Banerjee, Prashant Kumar Rai, Neeharika Thottempudi P1.316 Two Cases of Neurological Complications After mRNA Vaccination for COVID-19 – Michaela L Malin, Jerry Lin, Morgan C. Roche, Rose Putnam Griffin P1.317 COVID-19 Experiences and Vaccination in People with Multiple Sclerosis – Jenna Alys Brunn, Galit Levi Dunietz, Andrew R. Romeo, Tiffany Braley P1.318 Evaluation of Adult Biotinidase Activity in Patients with Idiopathic Inflammatory Demyelinating Diseases – Aysegul Akkan Suzan, Ahmet Kasim Kilic
P1.319 Lowered COVID-19 mRNA vaccine antibody response in MS patients treated with B -cell depleting and S1P-receptor-targeting therapies compared to controls: interim analysis – Sarah Conway, Maria K. Houtchens, Bonnie Glanz, Taylor Jane Saraceno, Mariann Polgar-Turcsanyi, Patricia Gaitan-Walsh, Emily Caroline Casady, Sasha Winston-Khan, Talia Brianna Feldman, Eunnindy Dells Sanon, Gauruv Bose, Shrishti Saxena, Aimee Loven, Choudhury Fabliha Binte Yusuf, Anu Paul, Rohit Bakshi, Shamik Bhattacharyya, Kristin Marissa Galetta, Tamara B. Kaplan, Christopher Severson, Tarun Singhal, Lynn Stazzone, Jonathan D. Zurawski, Brian Curran Healy, Howard L. Weiner, Tanuja Chitnis P1.320 Primary Progressive Multiple Sclerosis: Retrospective Study of Incidence in Greater Manchester – Gagana Mallawaarachchi, Jack Grimshaw, Thomas Jackson, Joyutpal Das, David Rog P1.321 Plasma Neurofilament light levels are increased in people with Radiologically Isolated Syndrome – Raphael Schneider, Koroboshka Brand-Arzamendi, Timothy R. Lim, Jeffrey Glaister, Melanie Guenette, Suradech Suthiphosuwan, Raphael Schneider, Jiwon Oh P1.322 The Effect of Demographic Factors on Prescription of High-Efficacy Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis – Jack Grimshaw, Gagana Mallawaarachchi, Thomas Jackson, Joyutpal Das, David Rog P1.323 Phenotype and recovery from relapses in patients with Relapsing Remitting Multiple Sclerosis with their first DMT prescription: an Italian registry study – Emanuele D’Amico, Aurora Zanghi, Francesco Patti P1.324 COVID-19 vaccination uptake in a multi-ethnic urban sample of MS patients – Vito Pasquale Arena, Ilya Kister P1.325 Central Vein Sign and advanced diffusion MRI to differentiate demyelinating from comorbiditiesrelated white matter lesions in patients with multiple sclerosis – Caterina Lapucci, Francesco Tazza, Silvia Rebella, Luca Roccatagliata, Nicola Mavilio, Giacomo Boffa, Elvira Sbragia, Nicolo Bruschi, Elisabetta Mancuso, Maria Cellerino, Simona Schiavi, Matilde Inglese P1.326 MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 18-Month Results – Daniel Reich, Anthony Traboulsee, Sana Syed, Deborah Dukovic, Timothy J. Turner, Douglas L. Arnold
Information is accurate as of February 8, 2022, and is subject to change.
P1.327 Evaluating the Effect of BTK Inhibitor Tolebrutinib in Human Tri-culture – Ross C. Gruber, Anna Blazier, L Lee, Sean Ryan, Agnes Cheong, Evis Havari, Timothy J. Turner, Dimitry Ofengeim P1.328 Humoral and Cellular Responses to SARS-CoV-2 Vaccines in MS Patients on Ocrelizumab and Other Disease-modifying Therapies: A Prospective Study From NYU Multiple Sclerosis Care Center – Ilya Kister, Yury Patskovsky, Ryan Curtin, Iryna Voloshyna, Katherine Perdomo, Zoe Rimler, Jinglan Pei, Nicole Ferstler, Velmurugu Yogambigai, Samantha Tatenda Nyovanie, Mark Joseph Mulligan, Joseph Jae-Suk Kim, Ethan Tardio, Tamar Bacon, Lana Zhovtis Ryerson, Marie Ines Samanovic-Golden, Amber Cornelius, Catarina Raposo, Jessica Priest, Ryan Christopher Winger, Michelle Krogsgaard, Gregg Joshua Silverman P1.329 Preserved T-cell response in B-cell depleted patients following SARS-CoV-2 vaccination – Simon Faissner, Neele Heitmann, Ulas Ceylan, Ricarda Rohling, Marielena Bongert, Ilya Ayzenberg, Kerstin Hellwig, Stephanie Pfaender, Ralf Gold P1.330 Effect of therapeutic plasma exchange in treatment of severe multiple sclerosis relapse - a retrospective analysis – Radovan Bunganic, Sarka Blahutova, Kamila Revendova, Olga Zapletalova, Pavel Hradilek, Zuzana Cermakova, Radomira Hrdlickova, Aravind Ganesh, Ondrej Volny P1.331 Reliability and Acceptance of a SmartphoneBased Remote Monitoring App (dreaMS) for People with MS – Results of a Feasibility Study – Tim Woelfle, Silvan Pless, Andrea Wiencierz, Óscar Gabriel Reyes Pupo, Ludwig Kappos, Johannes Lorscheider, Yvonne Naegelin P1.332 Lymphocyte Depletion and Repopulation Following Subcutaneous or Intravenous Alemtuzumab in Patients with Progressive Multiple Sclerosis: SCALA Study Results – Breogan Rodriguez Acevedo, Carlos Nos, Darren Phillip Baker, Yanzhen Wu, Magdalena Chirieac, Chandravathi Vage, Xavier Montalban P1.333 Retinal microvascular network alterations in Tunisian Multiple Sclerosis patients: potential biomarkers of visual involvement and disease progression – Mrabet Saloua, Yousra Falfoul, Amira Souissi, Khaled El Matri, Mrabet Saloua, Asma Hassairi, Alya Gharbi, Imen Kacem, Leila ElMatri, Riadh Gouider
AAN.com/AM
115
Virtual Experience Posters
P1.334 Myelin content monitoring by diffusion biomarkers in a therapeutic trial with leriglitazone in men with adrenomyeloneuropathy – Vincent Perlbarg, Silvia Pascual, Bernardo Blanco, Magali Barbier, Elise Yazbeck, Dorothee Uriet, Julie Rachline, Uwe Meya, Marc Martinell, Damien Galanaud, Marc Engelen, Fanny Mochel P1.335 Strong T-cell activation in response to SARSCoV-2 vaccination in patients with multiple sclerosis on B-cell depleting therapies – Joyce Lei, Vanessa Kirschner, Grant Feuer, Michaela L Malin, Jiayuan Liu, Morgan C. Roche, Jerry Lin, Roberto Alfonso, Rose Putnam Griffin P1.336 Neurofilament Serum Levels Do Not Correlate with Symptom Burden in Stable, OcrelizumabTreated MS Patients Enrolled into SYMptom Burden on Ocrelizumab, a Longitudinal Study (SYMBOLS) – Madaline McCluskey, Cheongeun Oh, Rose-Marie Jungquist, Zoe Rimler, Elizabeth Douglas, Andrew Joseph Bouley, Ellen S. Lathi, Joshua D. Katz, Ilya Kister P1.337 Clinical and radiological spectrum of Anti Myelin oligodendrocyte glycoprotein antibody related neurological disorders- An ambispective observational study – Manish Salunkhe, Pranjal Gupta, Rohit Bhatia, Rajesh Kumar Singh, Manjari Tripathi, Padma Vasantha Hadakasira, Venugopalan Y Vishnu, Awadh K. Pandit, Ayush Agarwal, Arunmozhimaran Elavarasi, Bhargavi Ramanujam P1.338 Patient Practices and Experiences During COVID-19 Among Individuals Across the United States Enrolled in MS LifeLines Patient Support Program – Jacqueline Ann Nicholas, DeMauri Mackie, Halley Costantino, Lori Lebson, Emily H. Mulvihill, Amy L. Phillips P1.339 Single-cell transcriptional profile of brain macrophages in multiple sclerosis – Takahisa Mikami, Michael Levy P1.340 A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program – Jacqueline Ann Nicholas, DeMauri Mackie, Halley Costantino, Lori Lebson, Emily H. Mulvihill, Amy L. Phillips P1.341 Diagnosis disclosure in multiple sclerosis: Associations with psychosocial outcomes and group-based treatment strategies – Anne Kever, Claire Riley, Victoria Leavitt
116
2022 AAN Annual Meeting
P1.342 Challenges in a dynamic world: the importance of studying cognitive flexibility in Persons with Multiple Sclerosis – Maria Sol Román, Barbara Eizaguirre, Pablo Rubio, Ariadna Gatti, Lara Bardoneschi, Loana De Los Santos, Fernando Caceres, Sandra Vanotti P1.343 Serum NfL and GFAP biomarker analysis in early high versus low efficacy DMT paradigms for MS – Vanessa Fernanda Moreira Ferreira, Jonathan D. Zurawski, Brian Curran Healy, Shrishti Saxena, Anu Paul, Fermisk Saleh, Yanqing Liu, Mariann PolgarTurcsanyi, Harald Kropshofer, Howard L. Weiner, Tanuja Chitnis P1.344 Exploring the evolution of functional and structural damage along the visual pathway in multiple sclerosis related acute optic neuritis. – Simone Guerrieri, Marco Pisa, Francesca Sangalli, Vittorio Martinelli, Giancarlo Comi, Letizia Leocani P1.345 7T MRI leptomeningeal enhancement and brain atrophy are associated with alterations in the IL-23 metabolic pathway in patients with multiple sclerosis – Jonathan D. Zurawski, Renxin Chu, Youmna Jalkh, Shahamat Tauhid, Tanuja Chitnis, Howard L. Weiner, Clary B. Clish, Rohit Bakshi, Chao Wang P1.346 Impact of Covid-19: Preserving Services for Patients with Multiple Sclerosis during a Global Pandemic. – Stephen James Ramsay, Fiona Jane Magill, Grainne Goldsmith, Fiona Kennedy, Stella Elaine Hughes, Gavin V. McDonnell P1.347 IgG4-Related Disease as an Autoimmune Consequence of Alemtuzumab Therapy for Management of Multiple Sclerosis – Anna Tierney, David Nolan, Chris Van Vliet, Wai-Kuen Leong P1.348 Migrainous features of multiple sclerosis (MS) users of MS Care ConnectTM, a self-efficacy mHealth digital application – Amy L. Dix, John F. Foley, Katherine Sylvia Geist P1.349 Implementation of Medication Therapy Disease Management Pharmacist for Multiple Sclerosis Patients in a Community Based Neurology Setting – Muhammad Taimur Ahmad Malik, Melissa Sartori, Amanda Sharry-Rogers, Allison Cebulko, Jonathan Brady, Megan E. Esch
P1.350 Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of RelapsingRemitting Multiple Sclerosis in Canada – Soukaïna Mouallif, Kim A. Thomas, Nicholas Adlard, Philip Cooney, Francois Blanchette, Barkha Patel, Moogeh Baharnoori, Virender Bhan, Fraser M. Clift, Daniel Grima
Neuro Trauma and Sports Neurology P1.351 Relationship between Headache Characteristics and a Remote History of TBI in US Veterans: A 10 Year Retrospective Chart Review – Alec Michael Giakas, Guoshuai Cai, Alexandra Ross, Xiao M. Androulakis P1.352 Autonomic dysfunction after moderate-severe traumatic brain injury: symptom spectrum and clinical testing outcomes – Lucia M. Li, Ekawat Vichayanrat, Helen Lai, Martina Del Giovane, Valeria Iodice P1.353 BodyPump Training Associated Vertebral Artery Dissection - An Unreported Complication – Nurose Karim, Mark Douglas Johnson P1.354 Trajectories of Insomnia Following Traumatic Brain Injury – John Kent Werner, Bryson Hewins, Andrew Krystal, Jennifer Albrecht, Vincent F. Capaldi, Pratik Mukherjee, Sonia Jain, Ashlee McKeon, Michael Timothy Smith, Joseph T. Giacino, Raquel Gardner, Lindsay Nelson, Scott Graeme Williams, Jacob Collen, Shelly Sun, David Schnyer, Amy Markowitz, Geoffrey Manley, Emerson Wickwire
Neurocritical Care P1.355 Predictors of Opiate Utilization in the Treatment of Headache and Impact on 3-month Outcomes Following Subarachnoid Hemorrhage – Dana Klavansky, Sheshali Wanchoo, Amanda Lin, Richard E. Temes, Tania Jean Rebeiz P1.356 Management and Outcomes of Hospitalized Patients with Myasthenia Gravis Infected with COVID-19: A Literature Review – Omar Abbas, Gustavo A. Patino
Virtual Experience Posters
P1.357 The Association of Posterior Reversible Encephalopathy Syndrome with COVID-19: A Systematic Review – Aqeeb Ur Rehman, Sadaf Iftikhar, Muhammad Zain Ameer, Ahmad Nawaz, Muhammad Aemaz Ur Rehman, Hareem Farooq, Abyaz Asmar, Muhammad Ebaad Ur Rehman P1.358 Eye opening and blinking in post anoxic coma – Neel Fotedar, Hemani Ticku P1.359 The Effect of Dysnatremia in Aneurysmal Subarachnoid Hemorrhage on Patient Outcomes – Alexandra Helliwell, Ryan Snow, Christoph Stretz, Nicholas S. Potter, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Karen L. Furie, Ali Mahta P1.360 Remote Ischemic Peri-Conditioning and High-dose Fentanyl as an adjunct to Targeted Temperature Management in Hypoxic ischemic Brain Injury post Cardiac Arrest (RESURRECT) – Rajeshwar Kumar, Mahesh Pundlik Kate, Himani Khatter, Jeyaraj Durai Pandian P1.361 Seizure Incidence in Neonates with CHD – Juan Carlos Duran, Jennifer M. Bain P1.362 Severe Headache Trajectory Following Aneurysmal Subarachnoid Hemorrhage: The Association with Lower Sodium Levels – Robert Stephen Eisinger, Zachary Sorrentino, Brandon Lucke-Wold, Sonya Zhou, Brooke Barlow, Brian Hoh, Carolina B. Maciel, Katharina M. Busl P1.363 Initiation of EVD Weaning in 5 Simple Steps – Sachin Ajay Kothari, Mevish S. Siddiq, Scott Rahimi, Manan Shah, Klepper A. Garcia P1.364 Delirium and Older Age: Two Independent Predictors of Worse Outcome in Low-intermediate Grade Subarachnoid Hemorrhage – Anisha Not Applicable Baktha, Liqi Shu, Linda C. Wendell, Bradford B. Thompson, Karen L. Furie, Jesse Menville, Ali Mahta P1.365 Association of Hemoglobin Trend and Outcome in Aneurysmal Subarachnoid Hemorrhage: A Single Center Cohort Study – Asghar Shah, Ryan Snow, Christoph Stretz, Nicholas S. Potter, Linda C. Wendell, Bradford B. Thompson, Jesse Menville, Karen L. Furie, Ali Mahta P1.366 A Tiered Compensation Model for Neurocritical Care Advanced Practice Provider Advancement through Annual Educational and Procedural Competencies – Naresh Mullaguri, Anusha Battineni, Ryan Hakimi
P1.367 Splenium Stroke in a Postpartum Female Following Spinal Anesthesia: A Case Report – Elisha Danzig, Amandeep Dolla, Lucjan O. Lang
P1.377 Novel SCN4A sequence variation presenting as “EMG disease”: A Case Report – Vaishnavi Sharma, Oscar Soto
P1.368 Decompressive Craniectomy in Patients with Severe Cerebral Venous Sinus Thrombosis – Hadi Abou-El-Hassan, Joshua D. Bernstock, Saef Izzy, Ayaz M. Khawaja
P1.378 Prognostic Factors Affecting ALS Progression through Disease Tollgates – Brian Crum, Fatih Erenay, Kalyan Pasupathy, Haoran Wu, Osman Ozaltin, Qu-Ming He
P1.369 On Consciousness: A Look into Therapeutic Pathways for Comatose Patients – Rohan Yarlagadda
P1.379 Pregnancy course and Musk-positive myasthenia gravis: a single center case series – Yohei Harada, Margaret Bettin, Vern C. Juel, Donald B. Sanders, Lisa Hobson-Webb, Shruti M. Raja, Janice M. Massey
P1.370 Stroke as a cause of donor brain death and prognostic implication in heart transplantation – Takahisa Mikami, Shinobu Itagaki, Tomohiro Fujisaki, Toshiki Kuno, David P. Lerner, Joseph D. Burns, Anelechi Anyanwu
Neuroepidemiology P1.371 Incidence of Neurodegenerative Diseases in Elderly Koreans with and without the First Diagnosed Type 2 Diabetes – Hee-Cheol Kim, Hojun Lee, Byeong-Churl Jang P1.372 Estimated Rate of Familial Amyotrophic Lateral Sclerosis: A Systematic Review and MetaAnalysis – Julie Barberio, Cathy Lally, Varant Kupelian, William Dana Flanders
Neuromuscular and Clinical Neurophysiology (EMG) P1.373 Accelerated DNA Methylation Age of the TARDBP 3’UTR in the Motor Cortex is Associated with Age of Sporadic ALS Onset. – Takuma Yamagishi, Yuka Koike, Akihiro Sugai, Norikazu Hara, Junko Ito, Akio Yokoseki, Tomohiko Ishihara, Shintaro Tsuboguchi, Mari Tada, Takeshi Ikeuchi, Akiyoshi Kakita, Osamu Onodera P1.374 Neuromuscular Manifestations of COVID-19 – Billie Hsieh, Ashley Smith, Xiaojing Liu, Kristin Angelica Brown, Suur Biliciler, Thy Nguyen P1.375 The prevalence of V122I mutation in African American individuals with bilateral carpal tunnel syndrome. A pilot study. – Jeffrey Z. Shije, Maria Adela B. Bautista, Carmen Smotherman P1.376 Usefulness of quantitative susceptibility mapping in ALS – Robin Warner
Information is accurate as of February 8, 2022, and is subject to change.
P1.380 Natural History and Phenotypic Spectrum of LGMD-D1: Implications for Clinical Trials – Andrew Ross Findlay, Sarah Elizabeth Robinson, Michelle Seiffert, Stephanie Poelker, Andrew Ross Findlay P1.381 Fast Progression in Amyotrophic Lateral Sclerosis: Pathways and Biomarkers from Multi-Omics Analysis – Roland G. Huber, Crystal Jing Jing Yeo P1.382 LGMD D2 TNPO3 related : a wide clinical spectrum and pathogenetic mechanism – Roberta Marozzo, Giovanna Cenacchi, Corrado Angelini P1.383 Effect of 3,4-diaminopyridine phosphate in symptomatic SOD1-G93A mice – Swathi Beladakere Ramaswamy, John Stanford, Stanley J. Iyadurai, Raghav Govindarajan, Richard J. Barohn P1.384 Novel biomarkers for limb girdle muscular dystrophy (LGMD) – Diego Lopergolo, Gian Nicola Gallus, Sara Aguti, Silvia Bianchi, Simona Salvatore, Anna Rubegni, Gianna Berti, Patrizia Formichi, Alessandro Malandrini P1.385 An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis – Hacer Durmus, Arman Cakar, Hasan Demirci, Fatma Yesim Parman P1.386 A Case Series Describing Clinical Presentation and Diagnostic Workup in 3 Patients with AntiNeurofascin-155 (NF155) – Melody Badii, Ashley E. Anderson, Vivek Misra, Sheetal Shroff P1.387 Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions – Leona Ling, Steven M. Tyler, Christopher Beneduce, Julia Brown, Sujatha Kumar, Jay Duffner, William Avery
AAN.com/AM
117
Virtual Experience Posters
P1.388 Implications and Predictors of Variability of Disease Progression in Amyotrophic Lateral Sclerosis (ALS) – Muzammil Arif Din So Abdul Jabbar, Yang Guo, Erik P. J. Pioro, Savitha Ramasamy, Crystal Jing Jing Yeo
P1.399 Phenotype Genotype Characterization of FKRPrelated Muscular Dystrophy among Indian Patients – Gopikrishnan Unnikrishnan, Mainak Bardhan, Akshata Huddar, Seena Vengalil, Saraswati Nashi, Hansashree Padmanabha, Atchayaram Nalini
P1.389 Predicting Fast Progressors in Amyotrophic Lateral Sclerosis (ALS): A Machine Learning Approach – Muzammil Arif Din So Abdul Jabbar, Yang Guo, Erik P. J. Pioro, Savitha Ramasamy, Crystal Jing Jing Yeo
P1.400 CSF biomarkers evaluated by principal component analysis in a NurOwn Phase 3 clinical trial – James D. Berry, Merit E. Cudkowicz, Robert H. Brown, Revital Aricha, Ralph Kern, Anthony J. Windebank, Nathan P. Staff, Namita Goyal, Robert G. Miller, Jonathan S. Katz, Matthew Burford, Yossef Levy, Chaim Lebovits, Yael Gothelf, Bruno Boulanger, Munish Mehra, Stacy Lindborg
P1.390 Multimodal Neuroimaging Reveals Differential Gray and White Matter Degeneration in Hypoand Hypermetabolic Brain Regions of Patients with ALS-FTD – Erik P. J. Pioro, Venkateswaran Rajagopalan P1.391 Spastic Paraparesis in a Patient with Homozygous SPG7 mutation – Sabrina Bulancea, Adrian Marchidann, Daphne Robakis, James Christian Hiana P1.392 ACE-IIM : Evidence of Autonomic and Cardiac dysfunction in Idiopathic Inflammatory Myositis – M M. Samim, Atchayaram Nalini, Sathyaprabha Talakad, Ashita Barthur, Seena Vengalil, Saraswati Nashi P1.393 Single Center Experience of SORD Neuropathy in Turkey – Arman Cakar, Ayse Candayan, Hacer Durmus, Esra Battaloglu, Fatma Yesim Parman P1.394 Clinical Delineation of Myasthenia Gravis in the Kingdom of Bahrain – Mohamed Falah, Hussein ALhafnawi, Ahmed Jaradat, Eslam Hamdy Shosha, Ali Alhilly, Firas Alnidawi, Mariam Mohammed Alhammadi, Moiz Bakhiet, Fatema Mohamed Abdulla P1.395 Incidence of Zoster-Associated Limb Paresis (ZALP): A Population-Based Analysis from 20082016 – James Douglas Triplett, Michel Toledano, Lyell K. Jones P1.396 Use of Repetitive Nerve Stimulation in the Geisinger Health System Neurophysiology Laboratory – J. David Avila P1.397 Patient-reported pain experience during nerve conduction studies and needle electromyography – Freddy Paiz, Gil Midroni, Charles Kassardjian P1.398 Hepatic Steatosis in Patients with Spinal Muscular Atrophy (SMA) – Crystal Jing Jing Yeo, Alexis Levine, Basil T. Darras
118
2022 AAN Annual Meeting
P1.401 Outcomes in POEMS patients: A case series – Amna Ramzan, Doyle Yuan, Kristin Angelica Brown, Suur Biliciler, Kazim Ali Sheikh, Thy Nguyen P1.402 New Patient Access via Telehealth in Neuromuscular Medicine During COVID-19 – Shaida Khan, Jaya Raghav Trivedi P1.403 The Use of Blood Carbonate (HCO3-) and Base-Excess (SBE) in Predicting Non-Invasive Ventilation (NIV) Adaptation – Umberto Manera, Maria Claudia Torrieri, Michela Maria Bellocchia, Fulvia Ribolla, Antonio Canosa, Rosario Vasta, Gabriele Mora, Alessio Mattei, Cristina Moglia, Andrea Calvo, Adriano Chio
P1.408 Bioimpedence analysis, hand grip and neurophysiology in hereditary transthyretin amyloidosis with polyneuropathy – Vincenzo Di Stefano, Ewan Thomas, Valerio Giustino, Andrea Gagliardo, Antonino Lupica, Salvatore Iacono, Giuseppe Battaglia, Filippo Brighina P1.409 Impact of COVID-19 and vaccines in myasthenia gravis: experience from an Italian cohort – Antonino Lupica, Vincenzo Di Stefano, Salvatore Iacono, Pignolo Antonia, Martina Quartana, Andrea Gagliardo, Brigida Fierro, Filippo Brighina P1.410 SQSTM1 Gene Mutation Causing Slowly Progressive Motor Neuron Disease – Blake Kent Windham, Chandra Sekhar Mannyam, Saurabh G. Shukla P1.411 A unique presentation of Cerebrotendinous Xanthomatosis without tendinous xanthomas. – Patricia Lee, Said R. Beydoun, Leila Darki P1.412 Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy (REMOTE-CIPN): A Randomized Trial of a Novel Telemedicine Care Model – Noah A. Kolb, A. Gordon Smith, Kelsey Barrell, Joan Skelly, Zhi-Jian Chen, Kathleen Griffith, Joanna Brell, Christina Echeverria, Kathi Mooney
P1.404 Rare genetic mutation of TARDBP leading to intrafamilial clinical phenotype variability; from pathogenic variant to genetic features modifier – Imen Kacem, Ikram Sghaier, Nicola Ticozzi, Amira Nasri, Antonia Ratti, Amina Gargouri, Vincenzo Silani, Riadh Gouider
P1.413 Exploring Protein Changes in Cerebrospinal Fluid of Spinal Muscular Atrophy Patients PreNusinersen vs. Post-Nusinersen Treatment using Bayesian Machine Learning Algorithms – Tahereh Kamali, Katharine Hagerman, Tina Duong, Dana McDonnell, Sally Dunaway, Whitney Tang, Jacinda B. Sampson, John W. Day
P1.405 Is there any role of vitamin D in CrampFasciculation Syndrome? – Anthony Alexander Hanna, Lonni Shultz, Anza Memon, Iram Zaman
P1.414 Hyper nasal speech presenting as Miller Fischer Syndrome – Gopika Govindan Kutty, Shivani Naik, Zeng Yu Wang
P1.406 Brain Metabolic Changes in Amyotrophic Lateral Sclerosis with SOD1 Mutations – Antonio Canosa, Andrea Calvo, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zocco, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera, Marco Pagani, Adriano Chio P1.407 Mesial Temporal Enlargement in Adult-Onset Myotonic Dystrophy Type 1 – Faisal Fecto, Dana McDonnell, Jacinda B. Sampson, Bryon Mueller, Kelvin O. Lim, Jeffrey Wozniak, Katharine Hagerman, John W. Day
Neuro-oncology P1.415 Mycobacterial Meningitis as an Early Complication of Bacille Calmette-Guerin Intravesical Chemotherapy in the Setting of a Systemic Infection. – Madiha Tariq, Nathan Clarke, Merry Chen P1.416 Pretreatment Neutrophil-to-Lymphocyte/ Monocyte-to-Lymphocyte Ratio as Prognostic Biomarkers in Glioma Patients – Sher Ting Ting Chim, Paul Sanfilippo, Terence John O’Brien, Kate Drummond, Mastura Monif
Virtual Experience Posters
P1.417 Stem Cell Factor as a Novel Diagnostic Plasma Biomarker for Glioblastoma Multiforme Patients – Amirhosein Kefayat, Parvin Goli, Fatemeh Ghahremani, Alireza Amouheidari P1.418 Folic-targeted Gold Nanoclusters as a Novel Radiosensitizer for Enhancement of The Radiotherapy Efficacy in Glioblastoma-bearing Animals – Amirhosein Kefayat, Fatemeh Ghahremani, Parvin Goli P1.419 Rapidly Progressive Sensorineural Hearing Loss as a Presenting Feature of Metastatic Breast Cancer with Leptomeningeal Carcinomatosis and Positive Zic4 Antibodies – Aseel Alsalem, Sina Marzoughi, Tychicus Chen P1.420 Lest We Forget: Ammonia in Encephalopathic Cancer Patients – Alexander C. Ou, Ivo W. Tremont, Sudhakar Tummala P1.421 Case Report of Selumetinib as a Novel Therapy in an NF2-Associated Ependymoma – Nigel Blackwood, Christopher Paul Zetzmann, Christopher Ray Trevino P1.422 Primary Central Nervous System T-cell Lymphoma Mimicking Isolated CNS Angiitis in a Young Immunocompetent Woman – Badiee Aniss Moussa, Fatima Mallat, Georgette Dib, Zaher Chakhachiro, Ahmad Beydoun P1.423 Neurofibromatosis Type 1 and Metastatic Testicular Germ Cell Tumor – Sushant Puri, David Heron, Nikolas Andre Mata-Machado, Mary Lou Schmidt, Stefania Maraka P1.424 Awake Craniotomy vs General Anesthesia for Excision of Brain Tumors: First Case-control Study from a Low-and-middle-income Country – Jaleed Ahmed Gilani, Saqib Kamran Bakhshi, Erum Baig, Altaf Ali Laghari, Daniyal Aziz Khan, Syed Mazin Junaid, Karim Rizwan Nathani, Faraz Shafiq, Muhammad Shahzad Shamim, Saad Akhtar Khan, Syed Ather Enam P1.425 Is Cancer the Main Cause of Death in NonMalignant Meningiomas? – Hazem Maher Gawish, Khaled Ashraf Mohamed, Khaled Tarek Dardeer, Ramy Abdelnaby P1.426 Identification of Challenges Faced by Caregivers of Patients with Newly Diagnosed Gliomas – Julia Russell Gomez, Lauryn Hemminger, Sandhya Seshadri, Jennifer N. Serventi, Nimish A. Mohile, Benzi Kluger
P1.427 Deep learning for prediction of IDH mutation in gliomas- a meta-analysis of evaluation of diagnostic test performance with a Bayesian approach – Mert Karabacak, Burak Berksu Ozkara, Seren Mordag, Sotirios Bisdas P1.428 Natural history study of cutaneous neurofibromas in people with NF1: Research in Progress – Carlos Guillermo Romo, Joshua Roberts, Bronwyn Slobogean, Shannon Langmead, Xiobu Ye, Sewon Kang, Verena Staedtke, Jaishri Blakeley P1.429 Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients with Neurofibromatosis type 1: Research in Progress – Carlos Guillermo Romo, Jaishri Blakeley, Joshua Roberts, Shannon Langmead, Laura Fayad, Shivani Ahlawat P1.430 Baseline cognition in patients with benign and low grade brain tumors prior to RT – Sara Hardy, Michael T. Milano, Nimish A. Mohile, Alan Finkelstein, Michelle Janelsins P1.431 Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration as Harbingers of Merkel Cell Carcinoma with Unknown Primary: A Rare Case Presentation. – Chindo Bala Mallum, Ahmer Asif, Oleksandra Los, Evgeny Sidorov P1.432 Depression & Neurotoxicity in a Population of Brain Tumor Patients Treated with a Short Course of Prophylactic Levetiracetam – Matthew Jordan Goldman, Kaitlyn Melnick, Marcia Hodik, Yu Wang, Maryam Rahman, Jean E. Cibula P1.433 Alpelisib induced diabetes ketoacidosis and resultant status epilepticus – Sangeetha Poongunam Isaac, Eileen Montalvan, Mohammed Afraz Pasha, Udit Yadav
P1.436 Resident Simulation (SIM) Education for NeuroOphthalmology Examination Skills To assess resident baseline and post-simulation (SIM) learning sessions for neuro-ophthalmologic examination skills. – George Park, Scott Grossman, Lisena Hasanaj, Janet C. Rucker, Steven Galetta, Laura J. Balcer P1.437 Breastfeeding Nystagmus Secondary to Tullio’s Phenomenon – Caroline Menton, Brooke Hartenstein, Adam Shipley, Isabella Canut, Hannah M. Rosenblum, Charles Maitland P1.438 Real-World Cost and Utilization Analysis of Botulinum Toxin Agents in Blepharospasm: A National Retrospective Cohort Study – Rashid Kazerooni, Daniel Rootman, Robert Goldberg, Liza M. Cohen P1.439 All-Trans Retinoic Acid-Induced Pseudotumor Cerebri in Patients with Acute Promyelocytic Leukemia: A Review – Sahar Noorani, Alden P. Gregston, Melanie Truong-Le
Neuro-rehabilitation P1.440 Physiotherapy with Dual-Tasks Improves Cognition and Resting-State Functional Connectivity in Parkinson’s Disease with Postural Instability and Gait Disorders – Michela Leocadi, Elisa Canu, Elisabetta Sarasso, Andrea Gardoni, Silvia Basaia, Veronica Castelnovo, M. Antonietta Volonte, Massimo Filippi, Federica Agosta P1.441 Fragmentation of pre-hospital acute spinal cord injury care – Shawna Huckell, Clayton Peterson, H Francis Farhadi, Jan M. Schwab
Neuro-ophthalmology/Neuro-otology P1.434 Cassava Flour and Isolated Mydriasis – Ammar Abdulraheem Ah Jumah, Rami Al-Hader, Hassan Osama Mostafa Aboul Nour, Dace Zvirbulis P1.435 Neurosyphilis Presenting as Mimicker of Giant Cell Arteritis with Bilateral Papilledema – Yensea Mayra Costas Encarnacion, Janice Leon
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
119
Virtual Experience Posters
Technological Advances and Other Factors that Impact Care in Pain and Palliative Medicine P1.442 Cognitive Decline Overtime in Patients with Chronic Pain and Headache: a Systematic Review – Karen Dos Santos Ferreira, Ana Velly P1.443 Medical Aid in Dying: Perspective from a Tertiary Care Movement Center – Lisa Damron, Robert Hess, Kevin M. McGehrin, Jane Mello Reynolds, Ece Bayram, David Gerhard Coughlin, Irene Litvan P1.444 Features, Functionalities, and the Future of Commercial Pain Applications – Maya Catherine Campbell, Mia Soviero, Deepti Verma, Quazi Ilham Hossain, Leslie Yao, Ananya Sahu, Erica Camacho, John Torous, Mia T. Minen P1.445 Durability of 10-kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy: 18-Month Multicenter Randomized Controlled Trial Results – Erika Petersen, Thomas Stauss, James Scowcroft, Lisa Brooks, Judith White, Shawn Sills, Kasra Amirdelfan, Maged Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis Patterson, Vincent Galan, Richard Bundschu, Neel Mehta, Dawood Sayed, Shivanand Pramod Lad, David DiBenedetto, Khalid Sethi, Paul Wu, Charles E. Argoff, Christian Nasr, Rod Taylor, David Caraway, Nagy Mekhail P1.446 Acupuncture-induced Changes in Nociception, Measured by Pain-related Evoked Potentials: A Pilot Mechanistic Study – Alexandra Dimitrova, Alisha Harrington, Tab Memmott, Jonathan Sisley, Barry S. Oken P1.447 Virtual Neuropalliative Care Curriculum Improves Residents’ Confidence and Knowledge – Tarini Goyal, Laura Elizabeth Donovan, Alexander Frolov
A Pandemic & Its Promise of Progress P1.448 Lessons Learned From the COVID-19 Pandemic and Recommendations for Reducing NonCompliance in Clinical Research – Matthew Gooden, Gina Norato, Sandra Martin, Avindra Nath, Lauren N. Reoma P1.449 Brace Yourself: The Emotional Burden of Diagnosing a Chronic Neurological Illness on Neurologists and Patients – Anna Gershteyn, Julia Russell Gomez, Christopher Mooney, Margie Hodges Shaw, Benzi Kluger
120
2022 AAN Annual Meeting
P1.450 Strategies for Behavioral Research in Neurology: Lessons Learned During the COVID-19 Pandemic and Applications for the Future – Kazi Shafia Maisha, Mia T. Minen, Ami Zarrillo Cuneo
P1.459 Developing a NeuroTwitter Onboarding Curriculum for Neurologists, Trainees and Students: A Prospective Study – Aaron Simon Zelikovich, Joseph E. Safdieh, Matthew S. Robbins
P1.451 The practice of teleneurology in the Philippines during the COVID-19 pandemic – Gerald Tangonan Pagaling, Adrian Isidoro Espiritu, Marie Antoinette Dellosa, Carl Froilan Leochico, Paul Matthew Dimagniva Pasco
P1.460 Prediction of Stroke in Dizziness and Vision Change During Emergency Triage – Carla Nicole Wood, Abhinav Katti, Alan H. Yee, Don Noel
P1.452 Optimizing the “Stroke Alert” Activation Protocol for Hospitalized Patients – Lisa Surowiec, Tyler Kendrick Simons, Oriana Tascione, Leticia Tornes, Erika Tatiana Marulanda-Londono, Neeta Garg P1.453 Time Spent in the Electronic Health Record by Neurologists: Analyzing daily use inside and outside the clinic using EPIC Signal data – Oliver Nguyen, Kea Turner, Nate Apathy, Lisa J. Merlo, Tanja Magoc, Sue Feldman, Adolfo Ramirez Zamora, Irene Malaty P1.454 Patient Satisfaction and Access Metrics during Pre and Post COVID-19 Pandemic in a Rural Neurology Setting – Muhammad Taimur Ahmad Malik, Edward Stefanowicz
Research Methodology and Education P1.455 #NeuroTwitterNetwork #HowToNeuroTwitter Guide 2020-2021: Increasing Access to Resources For #FutureNeurologists – Aaron Simon Zelikovich, Eric Christopher Lawson, Giana Dawod, Dylan Franco Del Papa, Mikel Shea Ehntholt, Evan Kolesnick, Jaclyn Martindale, Oluwasinmisola Opeyemi, Alexandria Pecoraro, Stephanie Linet Reyes, Andrew Yoo, Aaron L. Berkowitz, Matthew S. Robbins P1.456 Social media and social networks in neurology and neuroscience education: current applications and potential implementation – Stefano Sandrone P1.457 Development and Implementation of a Comprehensive Suite of Neurology Electives for Medical Students – Alina Masters-Israilov, Harini Sarva, Joseph E. Safdieh P1.458 Predictors of Narrative Evaluation Quality of Undergraduate Medical Students – Robert Ian Thompson-Stone, Jennifer Pascoe, Christopher Mooney, Valerie Lang, Jaclyn Burch, Melanie Braun, Michael Kelly, Christopher Mooney
P1.461 Towards the improvement of neurology clerks’ narrative evaluations: a multi-pronged faculty development initiative – Robert Ian ThompsonStone, Stephen Joseph Powell, Spencer Dahl, Carly Eiduson, Benjamin Reinhardt, Christopher Mooney P1.462 Neurology Research Day Presentations by Residents: From Abstract to Publication – Chandrasekhar Sundarrajan, Shruti Veera Raghavan, Shilpa Chitnis, Marisara Dieppa, Steven Vernino, Lauren Phillips, Rohit Das P1.463 Development of an intensive preparedness initiative to better equip students participating in the MGH Youth Neurology Education and Research Program – Sarah Micucci, Madison Elizabeth Ellin, Nicte I. Mejia P1.464 @NMatch2022: The Expansion of a StudentLed Social Media-Based Initiative that supports Neurology and Child Neurology Residency Applicants – Gabriela Figueiredo Pucci, Tara Samiee, Natalie Sholl, Shreya Louis, Adnan Husein, Theandra Chioma Madu, Carolina Isabel Rodriguez Rivera, Jenny Rotblat P1.465 A Novel Interdisciplinary Education Tool on Neuromuscular Respiratory Failure – Rebecca DiBiase, Lauren Koffman
Sleep P1.466 Analyzing the Current State of Sleep Apps in the App Marketplace and in Literature: A Systematic Review. – Quazi Ilham Hossain, Deepti Verma, Leslie Yao, Ananya Sahu, Mia Soviero, Maya Catherine Campbell, Erica Camacho, John Torous, Mia T. Minen P1.467 REM Sleep Distribution and Timing in Hypersomnia – Margaret Blattner, Robert J. Thomas
Virtual Experience Posters
P1.468 Sleep-Wake Intracerebral Fluid Tracking (SWIFT) using Continuous Wave Functional Near- Infrared Spectroscopy (CW fNIRS): A Novel Approach to Visualizing TBI-Associated Neurodegeneration – Sean Young, John Kent Werner, Matthew C. Miller, Sara Lippa, Clara Scholl, William Coon, Monique Beaudoin, Joseph Angelo, Franck G. Amyot, Kimbra L. Kenney, John Kent Werner P1.469 Samelisant (SUVN-G3031), a Histamine-3(H3) Receptor Inverse Agonist in Animal Models of Sleep Disorders – Ramakrishna Nirogi, Anil Shinde, Abdul Rasheed Mohammed, Vinod Goyal, Santosh Kumar Pandey, Veera Raghava Chowda Palacharla, Ramkumar Subramanian, Renny Abraham, Jyothsna Ravula, Satish Jetta, Venkat Jasti P1.470 Patient Preference and Nocturnal Experience With Sodium Oxybate Treatment for Narcolepsy: Interim Data From RESTORE – Asim Roy, John Harsh, Akinyemi Ajayi, Thomas Patrick Stern, David J. Seiden, Jordan Scott Dubow P1.471 Allergic Contact Dermatitis to Silicone causing PAP Intolerance – Subhendu Rath, Neeraj Kaplish P1.472 Atypical Sleep-related Rhythmic Movement Disorder – Subhendu Rath, Qurratul ShamimUzzaman
Information is accurate as of February 8, 2022, and is subject to change.
AAN.com/AM
121